


**CUMULATIVE
SUPPLEMENT 8**
August 2026



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

46th EDITION

Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

46th EDITION

**Cumulative Supplement 8
August 2026**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	LEVOTHYROXINE SODIUM.....	vii
1.4	AVAILABILITY OF THE EDITION.....	viii
1.5	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	ix
1.6	CUMULATIVE SUPPLEMENT LEGEND.....	x

DRUG PRODUCT LISTS

Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Products Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

46th EDITION

**CUMULATIVE SUPPLEMENT 8
August 2026**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section

2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	App1 No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	–	RS

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2025</u>	<u>MAR 2026</u>	<u>JUN 2026</u>	<u>SEP 2026</u>	<u>DEC 2026</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	24120 2765 (11.5%)	24441 2813 (11.5%)	24637 2807 (11.4%)		
MULTISOURCE	21355 (88.5%)	21628 (88.5%)	21830 (88.6%)		
THERAPEUTICALLY EQUIVALENT	21260 (87.1%)	21534 (88.1%)	21763 (88.3%)		
NOT THERAPEUTICALLY EQUIVALENT	95 (0.4%)	94 (0.4%)	67 (0.3%)		

EXCEPTIONS ⁴	47 (0.2%)	47 (0.2%)	47 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	19	41	36
NUMBER OF APPLICANTS	1198	1198	1195

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABAMETAPIR

LOTION; TOPICAL
XEGLYZE

@ + LNHC 0.74% N206966 001 Jul 24, 2020 Apr CAHN

ABARELIX

POWDER; INTRAMUSCULAR
PLENAXIS

@ SPECIALITY EUROPEAN 100MG/VIAL N021320 001 Nov 25, 2003 Jan CDFR

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL
ACAMPROSATE CALCIUM

AB APPCO 333MG A218984 001 Mar 16, 2026 Mar NEWA

ACARBOSE

TABLET; ORAL
ACARBOSE

@ AVET LIFESCIENCES 25MG A202271 001 Feb 07, 2012 Jul DISC
@ 50MG A202271 002 Feb 07, 2012 Jul DISC
@ 100MG A202271 003 Feb 07, 2012 Jul DISC
@ NATCO PHARMA USA 25MG A091053 001 Jan 06, 2011 Mar CAHN
@ 50MG A091053 002 Jan 06, 2011 Mar CAHN
@ 100MG A091053 003 Jan 06, 2011 Mar CAHN

ACETAMINOPHEN

SOLUTION; INTRAVENOUS
ACETAMINOPHEN

AP1 APOTEX 1GM/100ML (10MG/ML) A205746 001 Apr 18, 2023 May CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL
BUTAPAP

AA ! MIKART 325MG; 50MG A089987 001 Oct 26, 1992 Mar CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA INGENUS PHARMS LLC 300MG; 50MG; 40MG A215047 001 Nov 17, 2021 Feb CAHN

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA ! ABHAI LLC 325MG; 50MG; 40MG A211106 001 Sep 26, 2018 Jun CHRS
@ STRIDES PHARMA INTL 325MG; 50MG; 40MG A040511 001 Aug 27, 2003 Jun DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

@ QUAGEN 325MG; 50MG; 40MG; 30MG A204649 001 Jul 08, 2020 Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA LANNETT CO INC 300MG; 5MG A207171 001 Jun 20, 2017 Mar CMFD
AA 300MG; 7.5MG A207171 002 Jun 20, 2017 Mar CMFD
AA 300MG; 10MG A207171 003 Jun 20, 2017 Mar CMFD
AA 325MG; 5MG A207172 001 Jun 22, 2017 Mar CMFD
AA 325MG; 7.5MG A207172 002 Jun 22, 2017 Mar CMFD
AA 325MG; 10MG A207172 003 Jun 22, 2017 Mar CMFD
@ STRIDES PHARMA INTL 325MG; 5MG A040655 001 Jan 19, 2006 Jan DISC
@ 325MG; 7.5MG A040656 001 Jan 19, 2006 Jan DISC
@ 325MG; 10MG A040355 001 May 31, 2000 Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA LANNETT CO INC 325MG; 5MG A207333 001 Sep 25, 2017 Feb CMFD
AA 325MG; 10MG A207333 002 Sep 25, 2017 Feb CMFD
PERCOCET
AA ! OZANTRI 325MG; 2.5MG A040330 001 Jun 25, 1999 Apr CAHN

TABLET; ORAL									
PERCOCET									
AA	!	325MG; 5MG	A040330	002	Jun 25, 1999	Apr	CAHN		
	@ +	325MG; 5MG	A085106	002		Apr	CAHN		
AA	!	325MG; 7.5MG	A040330	003	Nov 23, 2001	Apr	CAHN		
AA	!	325MG; 10MG	A040330	004	Nov 23, 2001	Apr	CAHN		
<u>ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE</u>									
TABLET; ORAL									
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN									
	@ MICRO LABS LTD INDIA	325MG; 37.5MG	A201952	001	Dec 14, 2012	Jun	DISC		
	@ SENORES PHARMS	325MG; 37.5MG	A078778	001	Apr 07, 2014	Jun	CAHN		
<u>ACETIC ACID, GLACIAL; HYDROCORTISONE</u>									
SOLUTION/DROPS; OTIC									
HYDROCORTISONE AND ACETIC ACID									
AT	COSETTE PHARMS NC	2%; 1%	A040609	001	Feb 06, 2006	May	CAHN		
<u>ACETYLCYSTEINE</u>									
INJECTABLE; INTRAVENOUS									
ACETADOTE									
AP	+! APOTEX	6GM/30ML (200MG/ML)	N021539	001	Jan 23, 2004	Jul	CAHN		
<u>ACLIDINIUM BROMIDE</u>									
POWDER, METERED; INHALATION									
TUDORZA PRESSAIR									
	+! AZURITY	0.4MG/INH	N202450	001	Jul 23, 2012	Jun	CAHN		
	+!	0.4MG/INH	N202450	001	Jul 23, 2012	Mar	CAHN		
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE</u>									
POWDER, METERED; INHALATION									
DUAKLIR PRESSAIR									
	+! AZURITY	0.4MG/INH; 0.012MG/INH	N210595	001	Mar 29, 2019	Jul	CAHN		
	+!	0.4MG/INH; 0.012MG/INH	N210595	001	Mar 29, 2019	Mar	CAHN		
<u>ACYCLOVIR</u>									
OINTMENT; TOPICAL									
ACYCLOVIR									
	@ COSETTE PHARMS NC	5%	A205591	001	Nov 13, 2017	May	CAHN		
TABLET; ORAL									
ACYCLOVIR									
	@ STRIDES PHARMA INTL	400MG	A074946	001	Nov 19, 1997	Jan	DISC		
	@	800MG	A074946	002	Nov 19, 1997	Jan	DISC		
<u>ACYCLOVIR SODIUM</u>									
INJECTABLE; INJECTION									
ACYCLOVIR SODIUM									
AP	HAINAN POLY	EQ 50MG BASE/ML	A218111	001	Jan 08, 2024	Jul	CAHN		
<u>ADAPALENE</u>									
SOLUTION; TOPICAL									
ADAPALENE									
AB	WAYLIS THERAP	0.1%	A203981	001	Sep 23, 2016	Jan	CAHN		
AB		0.1%	A204593	001	Jan 05, 2016	Jan	CAHN		
<u>ADAPALENE; BENZOYL PEROXIDE</u>									
GEL; TOPICAL									
ADAPALENE AND BENZOYL PEROXIDE									
AB	AUROBINDO PHARMA LTD	0.3%; 2.5%	A217384	001	Jul 22, 2026	Jul	NEWA		
AB	! SUN PHARMA CANADA	0.1%; 2.5%	A206959	001	Jan 24, 2018	Jun	CHRS		
EPIDUO									
	@ + GALDERMA LABS LP	0.1%; 2.5%	N022320	001	Dec 08, 2008	Jun	DISC		
<u>AFATINIB DIMALEATE</u>									
TABLET; ORAL									
AFATINIB DIMALEATE									
AB	APOTEX	EQ 20MG BASE	A210725	001	Jul 14, 2026	Jul	NFTG		
AB		EQ 30MG BASE	A210725	002	Jul 14, 2026	Jul	NFTG		
AB		EQ 40MG BASE	A210725	003	Jul 14, 2026	Jul	NFTG		
AB	HETERO LABS LTD V	EQ 20MG BASE	A210750	001	Jul 14, 2026	Jul	NFTG		
AB		EQ 30MG BASE	A210750	002	Jul 14, 2026	Jul	NFTG		
AB		EQ 40MG BASE	A210750	003	Jul 14, 2026	Jul	NFTG		

TABLET;ORAL

GILOTRIF

AB	+	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013	Jul CFTG
AB	+		EQ 30MG BASE	N201292	002	Jul 12, 2013	Jul CFTG
AB	+		EQ 40MG BASE	N201292	003	Jul 12, 2013	Jul CFTG

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

ALBUTEROL SULFATE

AB3		CIPLA	EQ 0.09MG BASE/INH	A219409	001	Apr 22, 2026	Apr NFTG
		VENTOLIN HFA					
AB3	+	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001	Apr CFTG

SYRUP;ORAL

ALBUTEROL SULFATE

@ COSETTE PHARMS NC

			EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	May CAHN
--	--	--	-----------------	---------	-----	--------------	----------

TABLET;ORAL

ALBUTEROL SULFATE

@ AIZANT

			EQ 2MG BASE	A210948	001	Mar 15, 2019	Jul DISC
			EQ 4MG BASE	A210948	002	Mar 15, 2019	Jul DISC
			EQ 2MG BASE	A072894	002	Jan 17, 1991	Jun DISC
AB		NATCO PHARMA USA	EQ 2MG BASE	A072894	002	Jan 17, 1991	Mar CAHN
			EQ 4MG BASE	A072894	001	Jan 17, 1991	Jun DISC
AB	!		EQ 4MG BASE	A072894	001	Jan 17, 1991	Mar CAHN
AB	!	ZYDUS PHARMS	EQ 4MG BASE	A208884	002	Oct 22, 2020	Jun CHRS

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL

ACLOVATE

@ + FOUGERA

			0.05%	N018707	001	Dec 14, 1982	Jul CAHN
--	--	--	-------	---------	-----	--------------	----------

OINTMENT;TOPICAL

ACLOVATE

@ + FOUGERA

			0.05%	N018702	001	Dec 14, 1982	Jul CAHN
--	--	--	-------	---------	-----	--------------	----------

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

>A>	AA	PRECISION DOSE INC	EQ 70MG BASE/75ML	A214523	001	Sep 02, 2026	Aug NEWA
-----	----	--------------------	-------------------	---------	-----	--------------	----------

TABLET, EFFERVESCENT;ORAL

BINOSTO

@ + RADIUS

			EQ 70MG BASE	N202344	001	Mar 12, 2012	Jun DISC
--	--	--	--------------	---------	-----	--------------	----------

ALISKIREN HEMIFUMARATE

TABLET;ORAL

TEKTURNA

AB	+	LXO IRELAND	EQ 150MG BASE	N021985	001	Mar 05, 2007	Jan CAHN
AB	+		EQ 300MG BASE	N021985	002	Mar 05, 2007	Jan CAHN

ALLOPURINOL

TABLET;ORAL

LOPURIN

AB		DR REDDYS	100MG	A071587	002	Apr 02, 1987	Jul CMS1
----	--	-----------	-------	---------	-----	--------------	----------

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

LOTRONEX

AB	+	LEGACY	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Jun CAHN
AB	+		EQ 1MG BASE	N021107	001	Feb 09, 2000	Jun CAHN

ALPELISIB

GRANULE;ORAL

VIJOICE

+! NOVARTIS

			50MG/PACKET	N218466	001	Apr 24, 2024	Apr CDPR
--	--	--	-------------	---------	-----	--------------	----------

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION;INTRAVENOUS

INFUVITE ADULT

AP	+	SANDOZ CANADA INC	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2 MG/ML;660 IU/ML;0.03	N021163	001	May 18, 2000	Apr CFTG
----	---	-------------------	---	---------	-----	--------------	----------

SOLUTION; INTRAVENOUS
INFUVITE ADULT

AP	+	MG/ML 2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML ; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2 MG/ML; 660 IU/ML; 30MCG/ML	N021163	002	Jun 16, 2003	Apr CFTG
----	---	--	---------	-----	--------------	----------

MULTIPLE VITAMINS INJECTION ADULT

AP	APOTEX	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML ; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2 MG/ML; 660 IU/ML; 0.03MG/ML	A210273	001	Apr 09, 2026	Apr NFTG
----	--------	--	---------	-----	--------------	----------

AP		2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML ; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2 MG/ML; 660 IU/ML; 30MCG/ML	A210672	001	Apr 09, 2026	Apr NFTG
----	--	---	---------	-----	--------------	----------

ALPRAZOLAMTABLET; ORAL
ALPRAZOLAM

	@	STRIDES PHARMA INTL	0.25MG	A090248	001	Sep 17, 2010	Jan DISC
	@		0.5MG	A090248	002	Sep 17, 2010	Jan DISC
	@		1MG	A090248	003	Sep 17, 2010	Jan DISC
	@		2MG	A090248	004	Sep 17, 2010	Jan DISC
AB		UNICHEM	0.25MG	A213204	001	Jul 13, 2026	Jul NEWA
AB			0.5MG	A213204	002	Jul 13, 2026	Jul NEWA
AB			1MG	A213204	003	Jul 13, 2026	Jul NEWA
AB			2MG	A213204	004	Jul 13, 2026	Jul NEWA

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

>D>	AB	ACTAVIS ELIZABETH	0.5MG	A078056	001	Feb 13, 2007	Aug DISC
>A>		@	0.5MG	A078056	001	Feb 13, 2007	Aug DISC
>D>	AB		1MG	A078056	002	Feb 13, 2007	Aug DISC
>A>		@	1MG	A078056	002	Feb 13, 2007	Aug DISC
>D>	AB		2MG	A078056	003	Feb 13, 2007	Aug DISC
>A>		@	2MG	A078056	003	Feb 13, 2007	Aug DISC
>D>	AB		3MG	A078056	004	Feb 13, 2007	Aug DISC
>A>		@	3MG	A078056	004	Feb 13, 2007	Aug DISC

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB		ONESOURCE	100MG	A211354	001	Feb 18, 2022	Jul CAHN
----	--	-----------	-------	---------	-----	--------------	----------

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

AA		POM PHARMA	50MG/5ML	A214178	001	Aug 20, 2021	Apr CAHN
----	--	------------	----------	---------	-----	--------------	----------

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

AB		POM PHARMA	100MG	A210215	001	Mar 10, 2020	Apr CAHN
	@	WATSON LABS INC	100MG	A208096	001	Dec 15, 2016	Jul DISC

AMBRISENTAN

TABLET; ORAL

AMBRISENTAN

@ SUN PHARM

@

5MG

10MG

A210784 001 Mar 28, 2019 May DISC

A210784 002 Mar 28, 2019 Jun DISC

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

@ GENUS LIFESCIENCES

! TARO PHARM INDS

AB !

0.1%

0.1%

0.1%

A076065 001 May 15, 2003 Jun DISC

A076229 001 May 31, 2002 Jun CTEC

A076229 001 May 31, 2002 Jun CHRS

AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

@ LEGACY

+!

@ LEGACY PHARMA

@ +

375MG/VIAL

500MG/VIAL

375MG/VIAL

500MG/VIAL

N020221 002 Sep 10, 1999 Jun CAHN

N020221 001 Dec 08, 1995 Jun CAHN

N020221 002 Sep 10, 1999 Mar CAHN

N020221 001 Dec 08, 1995 Mar CAHN

INJECTABLE; INJECTION								
ETHYOL								
	+	500MG/VIAL	N020221	001	Dec 08, 1995	Mar	CMFD	
<u>AMINOCAPROIC ACID</u>								
INJECTABLE; INJECTION								
AMINOCAPROIC ACID								
AP	ZENARA	250MG/ML	A215374	001	Aug 28, 2025	Mar	CAHN	
SOLUTION; ORAL								
AMINOCAPROIC ACID								
AA	APOZEAL PHARMS	0.25GM/ML	A213216	001	May 19, 2025	Jul	CAHN	
AA	CARNEGIE	0.25GM/ML	A214140	001	Jan 26, 2021	Feb	CAHN	
TABLET; ORAL								
AMINOCAPROIC ACID								
AB	CARNEGIE	500MG	A213928	001	Feb 12, 2021	Feb	CAHN	
AB		1GM	A213928	002	Feb 12, 2021	Feb	CAHN	
AB	RISING	500MG	A213944	001	Sep 14, 2022	May	CAHN	
AB		1GM	A213944	002	Sep 14, 2022	May	CAHN	
<u>AMINOPHYLLINE</u>								
SUPPOSITORY; RECTAL								
TRUPHYLLINE								
@	COSETTE PHARMS NC	250MG	A085498	001	Mar 23, 1983	May	CAHN	
@		500MG	A085498	002	Jan 03, 1983	May	CAHN	
<u>AMISULPRIDE</u>								
SOLUTION; INTRAVENOUS								
BARHEMSYS								
	+	LXO IRELAND	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020	Jun	CAHN
	+		10MG/4ML (2.5MG/ML)	N209510	002	Sep 01, 2020	Jun	CAHN
<u>AMITRIPTYLINE HYDROCHLORIDE</u>								
TABLET; ORAL								
AMITRIPTYLINE HYDROCHLORIDE								
AB	AUROBINDO PHARMA USA	10MG	A086009	002		Mar	CMFD	
AB		25MG	A086009	003		Mar	CMFD	
AB		50MG	A086009	001		Mar	CMFD	
AB		75MG	A086009	004		Mar	CMFD	
AB		100MG	A086009	005		Mar	CMFD	
AB		150MG	A086009	006		Mar	CMFD	
AB	RUBICON RESEARCH	10MG	A215376	001	May 01, 2023	May	CTEC	
AB		25MG	A215376	002	May 01, 2023	May	CTEC	
AB		50MG	A215376	003	May 01, 2023	May	CTEC	
AB		75MG	A215376	004	May 01, 2023	May	CTEC	
AB		100MG	A215376	005	May 01, 2023	May	CTEC	
AB		150MG	A215376	006	May 01, 2023	May	CTEC	
<u>AMLODIPINE BESYLATE</u>								
FOR SOLUTION; ORAL								
SDAMLO								
	+	BRILLIAN PHARMA	EQ 2.5MG BASE/BOT	N219531	001	Jul 24, 2025	Jan	CMFD
	+		EQ 5MG BASE/BOT	N219531	002	Jul 24, 2025	Jan	CMFD
	+		EQ 10MG BASE/BOT	N219531	003	Jul 24, 2025	Jan	CMFD
TABLET; ORAL								
AMLODIPINE BESYLATE								
AB	GRAVITI PHARMS	EQ 2.5MG BASE	A201380	003	Feb 17, 2026	Feb	NEWA	
@	STRIDES PHARMA	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Jun	DISC	
@		EQ 5MG BASE	A077516	002	Jul 11, 2007	Jun	DISC	
@		EQ 10MG BASE	A077516	003	Jul 11, 2007	Jun	DISC	
AB	TEVA PHARMS INC	EQ 2.5MG BASE	A219686	001	Jan 22, 2026	Jan	NEWA	
AB		EQ 5MG BASE	A219686	002	Jan 22, 2026	Jan	NEWA	
AB		EQ 10MG BASE	A219686	003	Jan 22, 2026	Jan	NEWA	
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM</u>								
TABLET; ORAL								
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM								
AB	APDM PHARMS	EQ 2.5MG BASE; EQ 10MG BASE	A207762	001	Jan 11, 2019	Jun	CAHN	
AB		EQ 2.5MG BASE; EQ 20MG BASE	A207762	002	Jan 11, 2019	Jun	CAHN	
AB		EQ 2.5MG BASE; EQ 40MG BASE	A207762	003	Jan 11, 2019	Jun	CAHN	
AB		EQ 5MG BASE; EQ 10MG BASE	A207762	004	Jan 11, 2019	Jun	CAHN	
AB		EQ 5MG BASE; EQ 20MG BASE	A207762	005	Jan 11, 2019	Jun	CAHN	
AB		EQ 5MG BASE; EQ 40MG BASE	A207762	006	Jan 11, 2019	Jun	CAHN	

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Jun CAHN
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Jun CAHN
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Jun CAHN
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Jun CAHN
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Jun CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	!	LUPIN PHARMS	EQ 10MG BASE;40MG	A078466	006	Jul 05, 2011	May CHRS
		LOTREL					
	@ +	SANDOZ	EQ 2.5MG BASE;10MG	N020364	002	Mar 03, 1995	May DISC
	@ +		EQ 5MG BASE;10MG	N020364	003	Mar 03, 1995	May DISC
	@ +		EQ 5MG BASE;20MG	N020364	004	Mar 03, 1995	May DISC
	@ +		EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006	May DISC
	@ +		EQ 10MG BASE;20MG	N020364	005	Jun 20, 2002	May DISC
	@ +		EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006	May DISC

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

>D>	@	TORRENT	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016	Aug CMFD
>A>	AB		EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016	Aug CMFD
>D>	@		EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016	Aug CMFD
>A>	AB		EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016	Aug CMFD
>D>	@		EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016	Aug CMFD
>A>	AB		EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016	Aug CMFD

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

@	LUPIN	EQ 5MG BASE;12.5MG;160MG	A200797	001	Jun 03, 2015	Jun DISC
@		EQ 5MG BASE;25MG;160MG	A200797	002	Jun 03, 2015	Jun DISC
@		EQ 10MG BASE;12.5MG;160MG	A200797	003	Jun 03, 2015	Jun DISC
@		EQ 10MG BASE;25MG;160MG	A200797	004	Jun 03, 2015	Jun DISC
@		EQ 10MG BASE;25MG;320MG	A200797	005	Jun 03, 2015	Jun DISC

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

TABLET;ORAL

WIDAPLIK

@ +	AZURITY	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Jun DISC
+	!	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	May CHRS
+		EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Mar CMFD
@ +		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Jun DISC
+		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Mar CMFD
@ +		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Jun DISC
+	!	EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Mar CMFD

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

@	LUPIN	EQ 5MG BASE;40MG	A201586	001	Jan 08, 2014	Jan DISC
@		EQ 5MG BASE;80MG	A201586	003	Jan 08, 2014	Jan DISC
@		EQ 10MG BASE;40MG	A201586	002	Jan 08, 2014	Jan DISC
@		EQ 10MG BASE;80MG	A201586	004	Jan 08, 2014	Jan DISC
	MYLAN	EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Feb CMFD
@		EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Jan DISC
		EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Feb CMFD
@		EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Jan DISC
		EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Feb CMFD
@		EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Jan DISC
!		EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Feb CMFD
@		EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Jan DISC

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

@	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Apr DISC
@		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Apr DISC
@		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Apr DISC
@		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Apr DISC

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

@ NUKEMED

30mCi-300mCi/8ML (3.75-37.5mCi/ML)

A204455 001 Apr 23, 2015 Apr DISC

! WA UNIV SCH MED

37.5mCi-800mCi/10ML (3.75-80mCi/ML)

A204506 002 Feb 13, 2026 Feb NFTG

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB PADAGIS ISRAEL

EQ 12% BASE

A075774 001 May 01, 2002 Jan CHRS

AB ! SUN PHARMA CANADA

EQ 12% BASE

A075883 001 Apr 10, 2003 Jan CHRS

AB ZYDUS LIFESCIENCES

EQ 12% BASE

A217815 001 Feb 12, 2026 Feb NEWA

LOTION;TOPICAL

AMMONIUM LACTATE

AB ZYDUS LIFESCIENCES

EQ 12% BASE

A217758 001 May 15, 2026 May NEWA

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

>A> AB CHARTWELL RX

250MG

A061926 001 Aug CAHN

>A> AB !

500MG

A061926 003 Aug CAHN

>D> AB TEVA

250MG

A061926 001 Aug CAHN

>D> AB !

500MG

A061926 003 Aug CAHN

FOR SUSPENSION;ORAL

AMOXICILLIN

>A> @ CHARTWELL RX

125MG/5ML

A061931 001 Aug CAHN

>A> AB

200MG/5ML

A065119 001 Dec 04, 2002 Aug CAHN

>A> AB !

250MG/5ML

A061931 002 Aug CAHN

>A> AB !

400MG/5ML

A065119 002 Dec 04, 2002 Aug CAHN

>D> @ TEVA

125MG/5ML

A061931 001 Aug CAHN

>D> AB

200MG/5ML

A065119 001 Dec 04, 2002 Aug CAHN

>D> AB !

250MG/5ML

A061931 002 Aug CAHN

>D> AB !

400MG/5ML

A065119 002 Dec 04, 2002 Aug CAHN

AMOXICILLIN PEDIATRIC

>A> AB CHARTWELL RX

50MG/ML

A061931 003 Dec 01, 1982 Aug CAHN

>D> AB TEVA

50MG/ML

A061931 003 Dec 01, 1982 Aug CAHN

TABLET;ORAL

AMOXICILLIN

>A> AB CHARTWELL RX

500MG

A065056 001 Sep 18, 2000 Aug CAHN

>A> AB !

875MG

A065056 002 Sep 18, 2000 Aug CAHN

>D> AB TEVA

500MG

A065056 001 Sep 18, 2000 Aug CAHN

>D> AB !

875MG

A065056 002 Sep 18, 2000 Aug CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN

>A> AB CHARTWELL RX

125MG

A064013 002 Sep 11, 1995 Aug CAHN

>A> AB !

250MG

A064013 001 Dec 22, 1992 Aug CAHN

>D> AB TEVA

125MG

A064013 002 Sep 11, 1995 Aug CAHN

>D> AB !

250MG

A064013 001 Dec 22, 1992 Aug CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>A> AB CHARTWELL RX

200MG/5ML;EQ 28.5MG BASE/5ML

A065089 001 May 25, 2004 Aug CAHN

>A> AB !

400MG/5ML;EQ 57MG BASE/5ML

A065089 002 May 25, 2004 Aug CAHN

>A> AB !

600MG/5ML;EQ 42.9MG BASE/5ML

A065162 001 Mar 12, 2004 Aug CAHN

>D> AB MICRO LABS

600MG/5ML;EQ 42.9MG BASE/5ML

A217805 001 Dec 08, 2023 Aug DISC

>A> @

600MG/5ML;EQ 42.9MG BASE/5ML

A217805 001 Dec 08, 2023 Aug DISC

>D> AB MICRO LABS LTD INDIA

200MG/5ML;EQ 28.5MG BASE/5ML

A205187 001 May 21, 2021 Aug DISC

>A> @

200MG/5ML;EQ 28.5MG BASE/5ML

A205187 001 May 21, 2021 Aug DISC

>D> AB

400MG/5ML;EQ 57MG BASE/5ML

A205187 002 May 21, 2021 Aug DISC

>A> @

400MG/5ML;EQ 57MG BASE/5ML

A205187 002 May 21, 2021 Aug DISC

>D> AB TEVA

200MG/5ML;EQ 28.5MG BASE/5ML

A065089 001 May 25, 2004 Aug CAHN

>D> AB !

400MG/5ML;EQ 57MG BASE/5ML

A065089 002 May 25, 2004 Aug CAHN

>D> AB !

600MG/5ML;EQ 42.9MG BASE/5ML

A065162 001 Mar 12, 2004 Aug CAHN

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>A> AB CHARTWELL RX

500MG;EQ 125MG BASE

A065101 001 Oct 30, 2002 Aug CAHN

>A> AB

875MG;EQ 125MG BASE

A065096 001 Oct 29, 2002 Aug CAHN

>D> AB DEVA HOLDING AS

500MG;EQ 125MG BASE

A209992 001 Sep 15, 2023 Aug CAHN

>D> AB

875MG;EQ 125MG BASE

A209991 001 Sep 15, 2023 Aug CAHN

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>A>	AB	REGCON HOLDINGS	500MG;EQ 125MG BASE	A209992	001	Sep 15, 2023	Aug CAHN
>A>	AB		875MG;EQ 125MG BASE	A209991	001	Sep 15, 2023	Aug CAHN
>D>	AB	TEVA	500MG;EQ 125MG BASE	A065101	001	Oct 30, 2002	Aug CAHN
>D>	AB	TEVA PHARMS USA	875MG;EQ 125MG BASE	A065096	001	Oct 29, 2002	Aug CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>A>		CHARTWELL RX	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005	Aug CAHN
>A>		!	400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005	Aug CAHN
>D>		TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005	Aug CAHN
>D>		!	400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		! SANDOZ	1GM;EQ 62.5MG BASE	A090227	001	Apr 21, 2010	Jan CTEC
		AUGMENTIN XR					
AB	+	US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	Jan CMFD

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

@	INGENUS PHARMS LLC	5MG	A213763	001	Aug 24, 2020	Feb CAHN
@		10MG	A213763	002	Aug 24, 2020	Feb CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

@	EUROFARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Feb CAHN
@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Feb CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

@	COSETTE PHARMS NC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		May CAHN
---	-------------------	---------------------------	---------	-----	--	----------

APALUTAMIDE

TABLET;ORAL

APALUTAMIDE

AB		ZYDUS LIFESCIENCES	60MG	A217113	001	Mar 17, 2025	May CAHN
----	--	--------------------	------	---------	-----	--------------	----------

APREPITANT

EMULSION;INTRAVENOUS

APONVIE

	+	HERON THERAPS INC	32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Mar CTEC
AB	+		32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Feb CFTG
		APREPITANT					
	+	AZURITY	130MG/18ML (7.2MG/ML)	N218754	001	Jun 16, 2026	Jun NEWA
	@	MYLAN	32MG/4.4ML (7.2MG/ML)	A218851	001	Mar 05, 2026	Mar DISC
AB			32MG/4.4ML (7.2MG/ML)	A218851	001	Mar 05, 2026	Feb NFTG

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

@	TEVA PHARMS USA	EQ 0.015MG BASE/2ML	A200293	001	Nov 09, 2021	Jun DISC
---	-----------------	---------------------	---------	-----	--------------	----------

ARIPIPRAZOLE

TABLET;ORAL

ARIPIPRAZOLE

@	APOTEX	2MG	A078583	001	Jul 24, 2015	Apr DISC
@		5MG	A078583	002	Jul 24, 2015	Apr DISC
@		10MG	A078583	003	Jul 24, 2015	Apr DISC
@		15MG	A078583	004	Jul 24, 2015	Apr DISC
@		20MG	A078583	005	Jul 24, 2015	Apr DISC
@		30MG	A078583	006	Jul 24, 2015	Apr DISC

TABLET, ORALLY DISINTEGRATING;ORAL

ARIPIPRAZOLE

>D>	AB	AUROBINDO PHARMA	10MG	A216208	001	Feb 18, 2026	Aug DISC
>A>		@	10MG	A216208	001	Feb 18, 2026	Aug DISC
	AB		10MG	A216208	001	Feb 18, 2026	Feb NEWA
>D>	AB		15MG	A216208	002	Feb 18, 2026	Aug DISC

TABLET, ORALLY DISINTEGRATING;ORAL
ARIPIPIRAZOLE

>A>	@	15MG	A216208	002	Feb 18, 2026	Aug DISC
AB		15MG	A216208	002	Feb 18, 2026	Feb NEWA

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB	COREPHARMA	50MG	A201514	001	Mar 25, 2019	Jan CMFD
AB		150MG	A201514	002	Mar 25, 2019	Jan CMFD
AB		250MG	A201514	003	Mar 25, 2019	Jan CMFD
	@ LUPIN	50MG	A200751	001	Nov 28, 2016	Jun DISC
	@	150MG	A200751	003	Nov 28, 2016	Jun DISC
	@	200MG	A200751	004	Nov 28, 2016	Jun DISC
	@	250MG	A200751	005	Nov 28, 2016	Jun DISC

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

AP	INGENUS PHARMS LLC	1MG/ML	A209315	001	Nov 15, 2018	Feb CAHN
	@	2MG/ML	A209315	002	Jan 14, 2021	Feb CAHN
AP	J MOLNER	1MG/ML	A210802	001	Nov 13, 2018	Jun CAHN

ARTICAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYKLX

@ +	AM GENOMICS	EQ 8% BASE	N218643	001	Aug 15, 2025	Feb DISC
@ +	THEA PHARMA	EQ 8% BASE	N218643	001	Aug 15, 2025	Apr CAHN

ASCORBIC ACID

SOLUTION;INTRAVENOUS

ASCORBIC ACID

AP	STIRA	25,000MG/50ML (500MG/ML)	A220172	001	Jul 30, 2026	Jul NEWA
>A>	! ZYDUS PHARMS	2,500MG/5ML (500MG/ML)	A220873	001	Aug 20, 2026	Aug NFTG
>A>	!	5,000MG/10ML (500MG/ML)	A220873	002	Aug 20, 2026	Aug NFTG
>A> AP		25,000MG/50ML (500MG/ML)	A220873	003	Aug 20, 2026	Aug NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS

INFUVITE PEDIATRIC

AP	+! SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001	Apr CFTG
AP	+! SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	002	Jan 29, 2004	Apr CFTG
AP	APOTEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	A210671	001	Apr 21, 2026	Apr NFTG
AP	APOTEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	A210456	001	Apr 21, 2026	Apr NFTG

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

PLENVU

>A>	+! NORGINE	7.54GM;140GM;2.2GM;48.11GM;5.2 GM;9GM	N209381	001	May 04, 2018	Aug CAHN
-----	------------	---------------------------------------	---------	-----	--------------	----------

FOR SOLUTION;ORAL
PLENVU

>D>	+	!	SALIX	7.54GM;140GM;2.2GM;48.11GM;5.2	N209381	001	May 04, 2018	Aug CAHN
				GM;9GM				

ASENAPINE MALEATETABLET;SUBLINGUAL
SAPHRIS

AB	+		ABBVIE	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Mar CAHN
AB	+			EQ 5MG BASE	N022117	001	Aug 13, 2009	Mar CAHN
AB	+	!		EQ 10MG BASE	N022117	002	Aug 13, 2009	Mar CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

>D>	@		GENUS	325MG;200MG	A040116	001	Apr 25, 1996	Aug CAHN
	@		INGENUS PHARMS LLC	325MG;200MG	A040832	001	Jan 07, 2010	May CAHN
>A>	@		ZETA PHARMS	325MG;200MG	A040116	001	Apr 25, 1996	Aug CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@ EPIC PHARMA LLC
PERCODAN

@ + ENDO OPERATIONS

325MG;4.8355MG

325MG;4.8355MG

A040910 001 Jul 16, 2020 Apr DISC

N007337 007 Aug 05, 2005 Apr DISC

ATENOLOL

TABLET;ORAL

ATENOLOL

AB IPCA LABS LTD

AB

AB

25MG

50MG

100MG

A077877 001 Dec 27, 2006 Jan CMFD

A077877 002 Dec 27, 2006 Jan CMFD

A077877 003 Dec 27, 2006 Jan CMFD

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB ! UNICHEM

TENORETIC 100

@ + TWI PHARMS

TENORETIC 50

@ + TWI PHARMS

100MG;25MG

100MG;25MG

50MG;25MG

A213302 002 Nov 25, 2020 Apr CHRS

N018760 001 Jun 08, 1984 Apr DISC

N018760 002 Jun 08, 1984 Apr DISC

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB CREEKWOOD PHARMS

AB

AB

AB

AB

AB

AB

EQ 10MG BASE

EQ 18MG BASE

EQ 25MG BASE

EQ 40MG BASE

EQ 60MG BASE

EQ 80MG BASE

EQ 100MG BASE

A218875 001 Jun 16, 2026 Jun NEWA

A218875 002 Jun 16, 2026 Jun NEWA

A218875 003 Jun 16, 2026 Jun NEWA

A218875 004 Jun 16, 2026 Jun NEWA

A218875 005 Jun 16, 2026 Jun NEWA

A218875 006 Jun 16, 2026 Jun NEWA

A218875 007 Jun 16, 2026 Jun NEWA

SOLUTION;ORAL

ATONCY

+! MAP77

EQ 4MG BASE/ML

N220320 001 Mar 20, 2026 Mar NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

>D> AB MICRO LABS LTD INDIA

>A> @

>D> AB

>A> @

>D> AB

>A> @

>D> AB

>A> @

AB UMEDICA

AB

AB

AB

EQ 10MG BASE

EQ 10MG BASE

EQ 20MG BASE

EQ 20MG BASE

EQ 40MG BASE

EQ 40MG BASE

EQ 80MG BASE

EQ 80MG BASE

EQ 10MG BASE

EQ 20MG BASE

EQ 40MG BASE

EQ 80MG BASE

A205945 001 Nov 07, 2019 Aug DISC

A205945 001 Nov 07, 2019 Aug DISC

A205945 002 Nov 07, 2019 Aug DISC

A205945 002 Nov 07, 2019 Aug DISC

A205945 003 Nov 07, 2019 Aug DISC

A205945 003 Nov 07, 2019 Aug DISC

A205945 004 Nov 07, 2019 Aug DISC

A205945 004 Nov 07, 2019 Aug DISC

A213853 001 Aug 19, 2020 Jun CTEC

A213853 002 Aug 19, 2020 Jun CTEC

A213853 003 Aug 19, 2020 Jun CTEC

A213853 004 Aug 19, 2020 Jun CTEC

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LYPQOZET

@	PHARMOBEDIENT	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Jul	DISC
@		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Jul	DISC
@		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Jul	DISC
@		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Jul	DISC

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

AP	+	ACCORD HLTHCARE	0.4MG/ML (0.4MG/ML)	N214652	001	Sep 29, 2020	Jul	CMFD
----	---	-----------------	---------------------	---------	-----	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

AT1		EDENBRIDGE PHARMS	1%	A219013	001	Apr 15, 2026	Apr	NEWA
AT1		GLAND	1%	A219996	001	Jul 31, 2026	Jul	NEWA

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	!	LEGACY	0.025MG;1MG	N017744	002		Jun	CAHN
---	---	--------	-------------	---------	-----	--	-----	------

MOTOFEN HALF-STRENGTH

@		LEGACY	0.025MG;0.5MG	N017744	001		Jun	CAHN
---	--	--------	---------------	---------	-----	--	-----	------

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@		QUAGEN	0.025MG;2.5MG	A085762	001		Apr	CAHN
@			0.025MG;2.5MG	A210571	001	Aug 31, 2018	Feb	CAHN

AURANOFIN

CAPSULE; ORAL

RIDAURA

+	!	LEGACY	3MG	N018689	001	May 24, 1985	Jun	CAHN
---	---	--------	-----	---------	-----	--------------	-----	------

AXITINIB

TABLET; ORAL

AXITINIB

@		APOTEX	1MG	A211650	001	Oct 30, 2025	Apr	DISC
---	--	--------	-----	---------	-----	--------------	-----	------

@			5MG	A211650	002	Oct 30, 2025	Apr	DISC
---	--	--	-----	---------	-----	--------------	-----	------

INLYTA

+		PF PRISM CV	1MG	N202324	001	Jan 27, 2012	Apr	CTEC
---	--	-------------	-----	---------	-----	--------------	-----	------

+	!		5MG	N202324	002	Jan 27, 2012	Apr	CTEC
---	---	--	-----	---------	-----	--------------	-----	------

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

>A>	AP		ADAPTIS	100MG/VIAL	A207518	001	Sep 29, 2016	Aug	CAHN
-----	----	--	---------	------------	---------	-----	--------------	-----	------

	@		AMNEAL	100MG/VIAL	A211549	001	Feb 03, 2022	Apr	DISC
--	---	--	--------	------------	---------	-----	--------------	-----	------

>D>	AP		SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Aug	CAHN
-----	----	--	-----------------	------------	---------	-----	--------------	-----	------

AZATHIOPRINE

TABLET; ORAL

IMURAN

@	+	LEGACY	25MG	N016324	002		Jun	CAHN
---	---	--------	------	---------	-----	--	-----	------

AB		+	!	50MG	N016324	001		Jun	CAHN
----	--	---	---	------	---------	-----	--	-----	------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

AZILSARTAN MEDOXOMIL

AB			LUPIN	EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Apr	CMFD
----	--	--	-------	-------------------	---------	-----	--------------	-----	------

AB				EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Apr	CMFD
----	--	--	--	-------------------	---------	-----	--------------	-----	------

EDARBI

AB		+		AZURITY	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Apr	CTEC
----	--	---	--	---------	-------------------	---------	-----	--------------	-----	------

AB		+	!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Apr	CTEC
----	--	---	---	--	-------------------	---------	-----	--------------	-----	------

AZITHROMYCININJECTABLE; INJECTION
AZITHROMYCIN

AP	!	EUGIA PHARMA	EQ 500MG BASE/VIAL	A203294	001	Jun 19, 2015	Jul CHRS
AP		HAINAN POLY	EQ 500MG BASE/VIAL	A203412	001	Oct 09, 2018	Jul CAHN
		ZITHROMAX					
	@ +	PFIZER	EQ 500MG BASE/VIAL	N050733	001	Jan 30, 1997	Jul DISC
		TABLET; ORAL					
		AZITHROMYCIN					
	@	CARLSBAD	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb CAHN
AB			EQ 600MG BASE	A211068	001	May 08, 2020	Feb CAHN
	@	STRIDES PHARMA	EQ 250MG BASE	A215772	001	Jul 15, 2022	Jun DISC
	@		EQ 500MG BASE	A215773	001	Jul 12, 2022	Jun DISC

AZTREONAMINJECTABLE; INJECTION
AZACTAM

	@	LABS DELBERT	500MG/VIAL	N050580	001	Dec 31, 1986	May CAHN
AP	+	!	1GM/VIAL	N050580	002	Dec 31, 1986	May CAHN
AP	+	!	2GM/VIAL	N050580	003	Dec 31, 1986	May CAHN
		AZTREONAM					
	@	HIKMA	1GM/VIAL	A207069	001	Feb 05, 2026	Feb DISC
AP			1GM/VIAL	A207069	001	Feb 05, 2026	Jan NEWA
	@		2GM/VIAL	A207069	002	Feb 05, 2026	Feb DISC
AP			2GM/VIAL	A207069	002	Feb 05, 2026	Jan NEWA

BACITRACINOINTMENT; OPHTHALMIC
BACITRACIN

	@	PADAGIS US	500 UNITS/GM	A061212	001		Mar DISC
--	---	------------	--------------	---------	-----	--	----------

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEOINTMENT; OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	@	PADAGIS US	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062166	002		Mar DISC
--	---	------------	--	---------	-----	--	----------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEOINTMENT; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

	!	BAUSCH AND LOMB INC	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A064068	001	Oct 30, 1995	May CAHN
--	---	---------------------	--	---------	-----	--------------	----------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATEOINTMENT; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	!	BAUSCH AND LOMB INC	400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A064064	001	Oct 30, 1995	May CAHN
	@	PADAGIS US	400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A060764	002		Mar DISC

BACITRACIN ZINC; POLYMYXIN B SULFATEOINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

	!	BAUSCH AND LOMB	500 UNITS/GM; 10,000 UNITS/GM	A064046	001	Jan 26, 1995	Mar CTEC
	!	BAUSCH AND LOMB INC	500 UNITS/GM; 10,000 UNITS/GM	A064046	001	Jan 26, 1995	May CAHN
	@	PADAGIS US	500 UNITS/GM; 10,000 UNITS/GM	A065022	001	Feb 27, 2002	Mar DISC

BACLOFENGRANULE; ORAL
LYVISPAH

	@ +	STRIDES PHARMA INTL	5MG/PACKET	N215422	001	Nov 22, 2021	Apr CDFR
	@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Apr CDFR
	@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Apr CDFR

GRANULES; ORAL
LYVISPAH

	@ +	STRIDES PHARMA INTL	5MG/PACKET	N215422	001	Nov 22, 2021	Jan CAHN
	@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Jan CAHN
	@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Jan CAHN

INJECTABLE; INTRATHECAL							
BACLOFEN							
>A>	AP	MAIA PHARMS INC	0.05MG/ML	A210048	003	Jan 15, 2021	Aug CMS1
SOLUTION; ORAL							
OZOBAX							
>D>		@ + METACEL PHARMS LLC	5MG/5ML	N208193	001	Sep 18, 2019	Aug CAHN
>A>		@ + ROSEMOUNT	5MG/5ML	N208193	001	Sep 18, 2019	Aug CAHN
OZOBAX DS							
>D>	AA	+! METACEL PHARMS LLC	10MG/5ML	N208193	002	Oct 12, 2023	Aug CAHN
>A>	AA	+! ROSEMOUNT	10MG/5ML	N208193	002	Oct 12, 2023	Aug CAHN
TABLET; ORAL							
BACLOFEN							
	AB	HIBROW HLTHCARE	5MG	A211555	003	Nov 30, 2021	May CTEC
	AB		10MG	A211555	001	Feb 01, 2019	May CTEC
	AB		20MG	A211555	002	Feb 01, 2019	May CTEC
>D>	AB	MICRO LABS	5MG	A217687	001	Nov 08, 2023	Aug DISC
>A>		@	5MG	A217687	001	Nov 08, 2023	Aug DISC
>D>	AB		10MG	A217687	002	Nov 08, 2023	Aug DISC
>A>		@	10MG	A217687	002	Nov 08, 2023	Aug DISC
>D>	AB		20MG	A217687	003	Nov 08, 2023	Aug DISC
>A>		@	20MG	A217687	003	Nov 08, 2023	Aug DISC
	AB	RUBICON RESEARCH	5MG	A209102	001	Nov 28, 2017	Jan CHRS
<u>BALOXAVIR MARBOXIL</u>							
TABLET; ORAL							
BALOXAVIR MARBOXIL							
	AB	NORWICH	40MG	A217449	001	Jun 17, 2026	Jun NFTG
	AB		80MG	A217449	002	Jun 17, 2026	Jun NFTG
XOFLUZA							
	AB	+ GENENTECH INC	40MG	N210854	002	Oct 24, 2018	Jun CFTG
	AB	+!	80MG	N210854	003	Mar 18, 2021	Jun CFTG
<u>BALSALAZIDE DISODIUM</u>							
CAPSULE; ORAL							
BALSALAZIDE DISODIUM							
	AB	CARNEGIE	750MG	A219422	001	Apr 03, 2025	Feb CAHN
<u>BAXDROSTAT</u>							
TABLET; ORAL							
BAXFENDY							
		+ ASTRAZENECA AB	1MG	N219878	001	May 15, 2026	May NEWA
		+!	2MG	N219878	002	May 15, 2026	May NEWA
<u>BECLOMETHASONE DIPROPIONATE; FORMOTEROL FUMARATE; GLYCOPYRROLATE</u>							
AEROSOL, METERED; INHALATION							
TRIMBOW							
		+! CHIESI	0.086MG/INH; 0.0049MG/INH; 0.010	N219622	001	May 14, 2026	May NEWA
		+!	6MG/INH 0.172MG/INH; 0.0049MG/INH; 0.010	N219622	002	May 14, 2026	May NEWA
			6MG/INH				
<u>BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE</u>							
TABLET; ORAL							
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
		@ APOTEX	5MG; 6.25MG	A078794	001	Aug 21, 2014	Mar DISC
		@	10MG; 12.5MG	A078794	002	Aug 21, 2014	Mar DISC
		@	20MG; 12.5MG	A078794	003	Aug 21, 2014	Mar DISC
		@	20MG; 25MG	A078794	004	Aug 21, 2014	Mar DISC
	AB	! SANDOZ	20MG; 25MG	A076631	004	Feb 11, 2004	Jan CHRS
LOTENSIN HCT							
	AB	+ VALIDUS PHARMS	20MG; 25MG	N020033	003	May 19, 1992	Jan CHRS
<u>BENDAMUSTINE HYDROCHLORIDE</u>							
SOLUTION; INTRAVENOUS							
BENDAMUSTINE HYDROCHLORIDE							
		+! AVYXA HOLDINGS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Mar CAHN
		+! DR REDDYS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Apr CMFD

BENZONATATECAPSULE;ORAL
BENZONATATE

AA	ASCENT PHARMS INC	150MG	A211518	002	Feb 22, 2019	Apr	CMFD
AA	MARKSANS PHARMA	100MG	A220298	001	Mar 30, 2026	Mar	NEWA
AA		200MG	A220298	002	Mar 30, 2026	Mar	NEWA
AA	! THEPHARMANETWORK LLC	150MG	A040627	003	Sep 24, 2014	Apr	CTEC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATEGEL;TOPICAL
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

	@ ACTAVIS LABS UT INC	2.5%;EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jul	DISC
AB		3.75%;EQ 1.2% BASE	A208757	001	Aug 07, 2026	Jul	NEWA

BENZPHETAMINE HYDROCHLORIDETABLET;ORAL
BENZPHETAMINE HYDROCHLORIDE

AA	AVET LIFESCIENCES	50MG	A202061	001	Jan 27, 2012	Jun	CMFD
----	-------------------	------	---------	-----	--------------	-----	------

BEPOTASTINE BESILATESOLUTION/DROPS;OPHTHALMIC
BEPOTASTINE BESILATE

@	APOTEX	1.5%	A206066	001	Mar 05, 2019	Apr	DISC
---	--------	------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATECREAM;TOPICAL
BETAMETHASONE DIPROPIONATE

AB	AUROBINDO PHARMA LTD	EQ 0.05% BASE	A219348	001	Jan 26, 2026	Jan	NEWA
AB	COSETTE PHARMS NC	EQ 0.05% BASE	A210217	001	Oct 12, 2018	May	CAHN
AB	+! FOUGERA	EQ 0.05% BASE	N019137	001	Jun 26, 1984	Jul	CAHN

LOTION;TOPICAL
BETAMETHASONE DIPROPIONATE

AB	COSETTE PHARMS NC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	May	CAHN
@		EQ 0.05% BASE	A071882	001	Jun 06, 1988	May	CAHN

OINTMENT;TOPICAL
BETAMETHASONE DIPROPIONATE

>A> AB	+! FOUGERA	EQ 0.05% BASE	N019141	001	Sep 04, 1984	Aug	CAHN
>D> AB	+! FOUGERA PHARMS INC	EQ 0.05% BASE	N019141	001	Sep 04, 1984	Aug	CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENESUSPENSION;TOPICAL
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	COSETTE PHARMS NC	0.064%;0.005%	A210765	001	May 11, 2020	May	CAHN
----	-------------------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATEAEROSOL, FOAM;TOPICAL
BETAMETHASONE VALERATE

@	INGENUS PHARMS LLC	0.12%	A207144	001	May 24, 2017	Feb	CAHN
---	--------------------	-------	---------	-----	--------------	-----	------

LUXIQ							
@ +	QUAGEN	0.12%	N020934	001	Feb 28, 1999	Jul	CAHN

CREAM;TOPICAL
BETA-VAL

AB	COSETTE PHARMS NC	EQ 0.1% BASE	N018642	001	Mar 24, 1983	May	CAHN
	BETAMETHASONE VALERATE						

AB	+! FOUGERA	EQ 0.1% BASE	N018861	001	Aug 31, 1983	Jul	CAHN
----	------------	--------------	---------	-----	--------------	-----	------

LOTION;TOPICAL
BETA-VAL

@	COSETTE PHARMS NC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	May	CAHN
---	-------------------	--------------	---------	-----	--------------	-----	------

	BETAMETHASONE VALERATE						
--	------------------------	--	--	--	--	--	--

AB	+! FOUGERA	EQ 0.1% BASE	N018866	001	Aug 31, 1983	Jul	CAHN
----	------------	--------------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL
BETA-VAL

AB	COSETTE PHARMS NC	EQ 0.1% BASE	A070069	001	Dec 19, 1985	May	CAHN
----	-------------------	--------------	---------	-----	--------------	-----	------

	BETAMETHASONE VALERATE						
--	------------------------	--	--	--	--	--	--

AB	+! FOUGERA	EQ 0.1% BASE	N018865	001	Aug 31, 1983	Jul	CAHN
----	------------	--------------	---------	-----	--------------	-----	------

BETAXOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
BETAXOLOL HYDROCHLORIDE

AT	EUROFARMA	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Feb CAHN
----	-----------	--------------	---------	-----	--------------	----------

BEXAROTENECAPSULE;ORAL
BEXAROTENE

>D> AB	HIKMA	75MG	A203663	001	Jun 16, 2020	Aug DISC
>A>	@	75MG	A203663	001	Jun 16, 2020	Aug DISC

BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM

TABLET;ORAL

BIXLENVO SUNLENCA STARTER PACK (COPACKAGED)

>A>	+!	GILEAD SCIENCES INC	EQ 75MG BASE, EQ 50MG BASE; EQ 300MG BASE	N221443	001	Aug 27, 2026	Aug NEWA
-----	----	---------------------	---	---------	-----	--------------	----------

BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM

TABLET;ORAL

BIXLENVO

>A>	+!	GILEAD SCIENCES INC	EQ 75MG BASE;EQ 50MG BASE	N221104	001	Aug 27, 2026	Aug NEWA
-----	----	---------------------	---------------------------	---------	-----	--------------	----------

BIMATOPROSTSOLUTION/DROPS;TOPICAL
BIMATOPROST

@	APOTEX	0.03%	A201894	001	Dec 01, 2014	Apr DISC
---	--------	-------	---------	-----	--------------	----------

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB	INGENUS PHARMS LLC	140MG;125MG;125MG	A217511	001	Jul 03, 2023	Feb CAHN
----	--------------------	-------------------	---------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB	MICRO LABS	5MG	A218303	001	Mar 09, 2026	Feb NEWA
AB		10MG	A218303	002	Mar 09, 2026	Feb NEWA
	@ NATCO PHARMA USA	5MG	A075831	001	Dec 14, 2005	Mar CAHN
	@	10MG	A075831	002	Dec 14, 2005	Mar CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	2.5MG;6.25MG	A217922	001	Jan 21, 2026	Jan NEWA
AB		5MG;6.25MG	A217922	002	Jan 21, 2026	Jan NEWA
AB		10MG;6.25MG	A217922	003	Jan 21, 2026	Jan NEWA
AB	UNIQUE PHARM	2.5MG;6.25MG	A219489	001	Mar 24, 2026	Mar NEWA
AB		5MG;6.25MG	A219489	002	Mar 24, 2026	Mar NEWA
AB		10MG;6.25MG	A219489	003	Mar 24, 2026	Mar NEWA

BIVALIRUDININJECTABLE;INTRAVENOUS
BIVALIRUDIN

AP	HAINAN POLY	250MG/VIAL	A213078	001	May 28, 2021	Jul CAHN
----	-------------	------------	---------	-----	--------------	----------

BORTEZOMIBINJECTABLE;INTRAVENOUS, SUBCUTANEOUS
BORTEZOMIB

@	CAPLIN ONE LABS	3.5MG/VIAL	A203654	001	Jul 26, 2022	Mar DISC
AP		3.5MG/VIAL	A203654	001	Jul 26, 2022	Jan CAHN

BOSENTANTABLET, FOR SUSPENSION;ORAL
BOSENTAN

AB	ZYDUS PHARMS	32MG	A213981	001	Feb 17, 2026	Feb NEWA
----	--------------	------	---------	-----	--------------	----------

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

AB	+	PF PRISM CV	EQ 400MG BASE	N203341	003	Oct 27, 2017	Jun CFTG
		BOSUTINIB MONOHYDRATE					
AB		MSN	EQ 400MG BASE	A209624	001	Jun 12, 2026	Jun NFTG

>A> BREPOCITINIB TOSYLATE

>A> TABLET; ORAL

>A> LISRAYA

>A>	+	!	PRIOVANT THERAP	EQ 30MG BASE	N220106	001	Aug 27, 2026	Aug NEWA
-----	---	---	-----------------	--------------	---------	-----	--------------	----------

BREXANOLONE

SOLUTION; INTRAVENOUS

ZULRESSO

@	+	SAGE THERAP SUPERNUS	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jun CAHN
---	---	----------------------	---------------------	---------	-----	--------------	----------

BRIGATINIB

TABLET; ORAL

ALUNBRIG

	+	!	TAKEDA PHARMS USA	90MG	N208772	002	Apr 28, 2017	Jan CHRS
	+			180MG	N208772	003	Oct 02, 2017	Jan CHRS

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AT	!	BAUSCH AND LOMB INC	0.2%	A076260	001	May 28, 2003	May CAHN
AB		GLAND	0.1%	A219219	001	Mar 11, 2026	Feb NEWA
AB		MANKIND PHARMA	0.1%	A220398	001	Apr 16, 2026	Apr NEWA
AB		MICRO LABS	0.1%	A218558	001	May 07, 2026	Apr NEWA
>D>	@	UPSHER SMITH LABS	0.1%	A217599	001	Jul 30, 2025	Aug CMFD
>A>	AB		0.1%	A217599	001	Jul 30, 2025	Aug CMFD
>D>	@		0.15%	A216772	001	Jun 12, 2024	Aug CMFD
>A>	AT		0.15%	A216772	001	Jun 12, 2024	Aug CMFD

BRIMONIDINE TARTRATE; CARBACHOL

SOLUTION/DROPS; OPHTHALMIC

YUVEZZI

+	!	VISUS	0.1%; 2.75%	N220142	001	Jan 28, 2026	Jan NEWA
---	---	-------	-------------	---------	-----	--------------	----------

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

AB		GLAND	0.2%; EQ 0.5% BASE	A219166	001	Jun 11, 2026	Jun NEWA
AB		SABA ILAC SANAYIVE	0.2%; EQ 0.5% BASE	A217934	001	Jul 01, 2026	Jun NEWA

BRIVARACETAM

SOLUTION; INTRAVENOUS

BRIVARACETAM

AP		HAINAN POLY	50MG/5ML (10MG/ML)	A218249	001	Feb 23, 2026	Feb NFTG	
AP		MICRO LABS	50MG/5ML (10MG/ML)	A214880	001	Feb 23, 2026	Feb NFTG	
AP		MSN	50MG/5ML (10MG/ML)	A214924	001	Feb 23, 2026	Feb NFTG	
AP		SHANDONG	50MG/5ML (10MG/ML)	A219766	001	Jul 13, 2026	Jul NEWA	
		BRIVIACT						
AP	+	!	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	Feb CFTG

SOLUTION; ORAL

BRIVARACETAM

AA		ALKEM LABS LTD	10MG/ML	A219772	001	Feb 23, 2026	Feb NEWA
AA		AUROBINDO PHARMA	10MG/ML	A220288	001	Aug 10, 2026	Jul NEWA
AA		INDOCO	10MG/ML	A220385	001	Feb 23, 2026	Feb NEWA
AA		LUPIN	10MG/ML	A220164	001	Feb 23, 2026	Feb NEWA
AA		MSN	10MG/ML	A214922	001	Feb 19, 2026	Feb NFTG
AA		REGCON HOLDINGS	10MG/ML	A220385	001	Feb 23, 2026	Mar CAHN
AA		ZHEJIANG POLY PHARM	10MG/ML	A218494	001	Feb 23, 2026	Feb NEWA

BRIVIACT

AA	+	!	UCB INC	10MG/ML	N205838	001	May 12, 2016	Feb CFTG
----	---	---	---------	---------	---------	-----	--------------	----------

TABLET; ORAL

BRIVARACETAM

AB		APOTEX	10MG	A214875	001	Feb 23, 2026	Feb NEWA
AB			25MG	A214875	002	Feb 23, 2026	Feb NEWA
AB			50MG	A214875	003	Feb 23, 2026	Feb NEWA

TABLET; ORAL
BRIVARACETAM

AB		75MG	A214875	004	Feb 23, 2026	Feb NEWA
AB		100MG	A214875	005	Feb 23, 2026	Feb NEWA
AB	AUROBINDO PHARMA LTD	10MG	A214848	003	Jul 13, 2026	Jul NEWA
AB		25MG	A214848	004	Jul 13, 2026	Jul NEWA
AB		50MG	A214848	001	Jan 06, 2023	Jan CMFD
AB		75MG	A214848	005	Jul 13, 2026	Jul NEWA
AB		100MG	A214848	002	Jan 06, 2023	Jan CMFD
>D> AB	CENTAUR PHARMS PVT	10MG	A220470	001	Feb 23, 2026	Aug DISC
>A>	@	10MG	A220470	001	Feb 23, 2026	Aug DISC
AB		10MG	A220470	001	Feb 23, 2026	Feb NEWA
>D> AB		25MG	A220470	002	Feb 23, 2026	Aug DISC
>A>	@	25MG	A220470	002	Feb 23, 2026	Aug DISC
AB		25MG	A220470	002	Feb 23, 2026	Feb NEWA
>D> AB		50MG	A220470	003	Feb 23, 2026	Aug DISC
>A>	@	50MG	A220470	003	Feb 23, 2026	Aug DISC
AB		50MG	A220470	003	Feb 23, 2026	Feb NEWA
>D> AB		75MG	A220470	004	Feb 23, 2026	Aug DISC
>A>	@	75MG	A220470	004	Feb 23, 2026	Aug DISC
AB		75MG	A220470	004	Feb 23, 2026	Feb NEWA
>D> AB		100MG	A220470	005	Feb 23, 2026	Aug DISC
>A>	@	100MG	A220470	005	Feb 23, 2026	Aug DISC
AB		100MG	A220470	005	Feb 23, 2026	Feb NEWA
AB	SCIEGEN PHARMS	10MG	A219952	001	Jul 01, 2026	Jun NEWA
AB		25MG	A219952	002	Jul 01, 2026	Jun NEWA
AB		50MG	A219952	003	Jul 01, 2026	Jun NEWA
AB		75MG	A219952	004	Jul 01, 2026	Jun NEWA
AB		100MG	A219952	005	Jul 01, 2026	Jun NEWA
AB	SUNSHINE	10MG	A214748	001	Jun 09, 2022	Jan CMFD
AB		25MG	A214748	002	Jun 09, 2022	Jan CMFD
AB		50MG	A214748	003	Jun 09, 2022	Jan CMFD
AB		75MG	A214748	004	Jun 09, 2022	Jan CMFD
AB		100MG	A214748	005	Jun 09, 2022	Jan CMFD
>A> AB	ZHEJIANG JUTAI PHARM	25MG	A220136	001	Sep 08, 2026	Aug NEWA
>A> AB		50MG	A220136	002	Sep 08, 2026	Aug NEWA
>A> AB		100MG	A220136	003	Sep 08, 2026	Aug NEWA
AB	ZYDUS PHARMS	10MG	A214501	001	Oct 03, 2022	May CMFD
AB		25MG	A214501	002	Oct 03, 2022	May CMFD
AB		50MG	A214501	003	Oct 03, 2022	May CMFD
AB		75MG	A214501	004	Oct 03, 2022	May CMFD
AB		100MG	A214501	005	Oct 03, 2022	May CMFD

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

@ J MOLNER EQ 0.09% ACID A202030 001 Jan 09, 2013 Jul CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

@ + PHARMOBEDIENT 2MG/5ML; 10MG/5ML; 30MG/5ML A088811 001 Jun 07, 1985 Jan DISC

BUDESONIDE

SUSPENSION; INHALATION

PULMICORT RESPULES

AN	+	ASTRAZENECA	0.25MG/2ML	N020929	001	Aug 08, 2000	Jan CHRS
AN	+		0.5MG/2ML	N020929	002	Aug 08, 2000	Jan CHRS

BUDESONIDE; FORMOTEROL FUMARATE

AEROSOL, METERED; INHALATION

SYMBICORT AEROSPHERE

+! ASTRAZENECA 0.08MG/INH; 0.0048MG/INH N216579 002 Apr 27, 2026 Apr NEWA

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE

AB	TEVA PHARMS USA INC	0.08MG/INH; 0.0045MG/INH	A212212	001	Apr 23, 2026	Apr NEWA
AB		0.16MG/INH; 0.0045MG/INH	A212212	002	Apr 23, 2026	Apr NEWA

BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATEAEROSOL, METERED; INHALATION
BREZTRI AEROSPHERE

+	!	ASTRAZENECA AB	0.16MG/INH;0.0048MG/INH;0.018MG/INH	N212122	002	Apr 27, 2026	Apr	NEWA
---	---	----------------	-------------------------------------	---------	-----	--------------	-----	------

BUMETANIDEINJECTABLE; INJECTION
BUMETANIDE

AP		ANTHEA PHARMA	0.25MG/ML	A220427	001	Feb 26, 2026	Feb	NEWA
		TABLET; ORAL						
		BUMETANIDE						
AB		MSN	0.5MG	A215362	001	Feb 05, 2026	Jan	NEWA
AB			1MG	A215362	002	Feb 05, 2026	Jan	NEWA
AB			2MG	A215362	003	Feb 05, 2026	Jan	NEWA

BUPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE

AP		ANTHEA PHARMA	0.25%	A220493	001	Apr 22, 2026	Apr	NEWA
AP			0.5%	A220493	002	Apr 22, 2026	Apr	NEWA
AP			0.75%	A220493	003	Apr 22, 2026	Apr	NEWA
	@	MEITHEAL	0.25%	A216039	001	Jun 23, 2023	Jul	DISC
	@		0.25%	A216040	001	Dec 27, 2023	Jul	DISC
	@		0.5%	A216039	002	Jun 23, 2023	Jul	DISC
	@		0.5%	A216040	002	Dec 27, 2023	Jul	DISC
	@		0.75%	A216040	003	Dec 27, 2023	Jul	DISC

BUPRENORPHINEFILM, EXTENDED RELEASE; TRANSDERMAL
BUTRANS

AB	+	KNOA PHARMA	5MCG/HR	N021306	001	Jun 30, 2010	May	CAHN
AB	+		7.5MCG/HR	N021306	005	Jun 30, 2014	May	CAHN
AB	+		10MCG/HR	N021306	002	Jun 30, 2010	May	CAHN
AB	+		15MCG/HR	N021306	004	Jul 25, 2013	May	CAHN
AB	+	!	20MCG/HR	N021306	003	Jun 30, 2010	May	CAHN

SOLUTION, EXTENDED RELEASE; SUBCUTANEOUS
BRIXADI

	+	!	BRAEBURN	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023	Mar	CHRS
	+	!		16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023	Mar	CHRS
	+	!		24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023	Mar	CHRS
	+	!		32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023	Mar	CHRS
	+	!		64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023	Mar	CHRS
	+	!		96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023	Mar	CHRS

BUPRENORPHINE HYDROCHLORIDETABLET; SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

	@	QUAGEN	EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun	CAHN
	@		EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun	CAHN
>D>	!	RUBICON RESEARCH	EQ 4MG BASE	A090279	003	Jul 10, 2026	Aug	CHRS
>A>			EQ 4MG BASE	A090279	003	Jul 10, 2026	Aug	CHRS
	!		EQ 4MG BASE	A090279	003	Jul 10, 2026	Jul	NFTG
	!		EQ 12MG BASE	A090279	004	Jul 10, 2026	Jul	NFTG

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	EQ 2MG BASE; EQ 0.5MG BASE	A219850	001	Jan 21, 2026	Jan	NEWA
AB			EQ 4MG BASE; EQ 1MG BASE	A219850	002	Jan 21, 2026	Jan	NEWA
AB			EQ 8MG BASE; EQ 2MG BASE	A219850	003	Jan 21, 2026	Jan	NEWA
AB			EQ 12MG BASE; EQ 3MG BASE	A219850	004	Jan 21, 2026	Jan	NEWA

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

>D>	AB		MICRO LABS	75MG	A207403	001	Apr 17, 2020	Aug	DISC
>A>		@		75MG	A207403	001	Apr 17, 2020	Aug	DISC
>D>	AB			100MG	A207403	002	Apr 17, 2020	Aug	DISC
>A>		@		100MG	A207403	002	Apr 17, 2020	Aug	DISC
	AB		SENORES PHARMS	75MG	A075584	001	Feb 07, 2000	Feb	CAHN

TABLET; ORAL

BUPROPION HYDROCHLORIDE						
AB		100MG	A075584	002	Feb 07, 2000	Feb CAHN
TABLET, EXTENDED RELEASE; ORAL						
BUPROPION HYDROCHLORIDE						
AB3	AUROBINDO PHARMA LTD	150MG	A216051	001	Jul 21, 2026	Jul NEWA
AB3		300MG	A216051	002	Jul 21, 2026	Jul NEWA
AB1	MACLEODS PHARMS	100MG	A218567	001	Jun 23, 2026	Jun NEWA
AB1		150MG	A218567	002	Jun 23, 2026	Jun NEWA
AB1		200MG	A218567	003	Jun 23, 2026	Jun NEWA
AB1	YICHANG HUMANWELL	100MG	A220529	001	May 04, 2026	Apr NEWA
AB1		150MG	A220529	002	May 04, 2026	Apr NEWA
AB1		200MG	A220529	003	May 04, 2026	Apr NEWA

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

AUVELITY

+	AXSOME	105MG; 30MG	N215430	002	Apr 30, 2026	Apr NEWA
---	--------	-------------	---------	-----	--------------	----------

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CONTRAVE

+	! AZURITY	90MG; 8MG	N200063	001	Sep 10, 2014	Jul CAHN
---	-----------	-----------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUCAPSOL

	EPIC PHARMA LLC	5MG	A218628	004	Apr 29, 2026	Apr NFTG
TABLET; ORAL						
BUSPIRONE HYDROCHLORIDE						
	EPIC PHARMA LLC	2.5MG	A208972	006	May 13, 2026	May NEWA
AB		5MG	A208972	001	Apr 16, 2019	May CTEC
AB		7.5MG	A208972	002	Apr 16, 2019	May CTEC
AB		10MG	A208972	003	Apr 16, 2019	May CTEC
		12.5MG	A208972	007	May 13, 2026	May NEWA
AB		15MG	A208972	004	Apr 16, 2019	May CTEC
AB		30MG	A208972	005	Apr 16, 2019	May CTEC
AB	INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Jul CTEC
AB		7.5MG	A209696	002	May 03, 2018	Jul CTEC
AB		10MG	A209696	003	May 03, 2018	Jul CTEC
AB		15MG	A209696	004	May 03, 2018	Jul CTEC
AB		30MG	A209696	005	May 03, 2018	Jul CTEC
	@ MYLAN	7.5MG	A076008	002	Jul 08, 2013	Feb DISC

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

>A>	AP	ADAPTIS	6MG/ML	A210931	001	Apr 18, 2019	Aug CAHN
	@	MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Jun DISC
	@	PRAXGEN	6MG/ML	A205106	001	Sep 21, 2018	Jul CAHN
>D>	AP	SHILPA	6MG/ML	A210931	001	Apr 18, 2019	Aug CAHN

BUTABARBITAL SODIUM

TABLET; ORAL

SODIUM BUTABARBITAL

>A>	@	WEST WARD	30MG	A085418	002		Aug CMS1
-----	---	-----------	------	---------	-----	--	----------

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	RENATA	0.5MG	A220309	001	Jun 15, 2026	Jun NEWA
----	--------	-------	---------	-----	--------------	----------

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

CABENUVA KIT

+	VIIIV HLTHCARE	400MG/2ML (200MG/ML); 600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021	May CHRS
---	----------------	--	---------	-----	--------------	----------

CABOZANTINIB S-MALATE

TABLET; ORAL

CABOMETYX

>D>	+	EXELIXIS INC	EQ 20MG BASE	N208692	001	Apr 25, 2016	Aug CFTG
>A>	AB	+	EQ 20MG BASE	N208692	001	Apr 25, 2016	Aug CFTG
>D>		+	EQ 40MG BASE	N208692	002	Apr 25, 2016	Aug CFTG
>A>	AB	+	EQ 40MG BASE	N208692	002	Apr 25, 2016	Aug CFTG
>D>		+!	EQ 60MG BASE	N208692	003	Apr 25, 2016	Aug CFTG
>A>	AB	+!	EQ 60MG BASE	N208692	003	Apr 25, 2016	Aug CFTG
>A>		CABOZANTINIB S-MALATE					
>A>	AB	MSN	EQ 20MG BASE	A213878	001	Aug 14, 2026	Aug NFTG
>A>	AB		EQ 40MG BASE	A213878	002	Aug 14, 2026	Aug NFTG
>A>	AB		EQ 60MG BASE	A213878	003	Aug 14, 2026	Aug NFTG

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

! MIKART

100MG; 1MG

A040590 001 Sep 16, 2005 Mar CAHN

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

AT	!	COSETTE PHARMS NC	0.005%	A078468	001	Mar 24, 2011	May CAHN
----	---	-------------------	--------	---------	-----	--------------	----------

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCITONIN-SALMON

AP		ZYDUS PHARMS	200 IU/ML	A215864	001	Mar 04, 2026	Feb NEWA
		SPRAY, METERED; NASAL					
		MIACALCIN					
	@ +	ALLIED	200 IU/SPRAY	N020313	002	Aug 17, 1995	Jun CAHN
	@ +	SAPTALIS PHARMS	200 IU/SPRAY	N020313	002	Aug 17, 1995	Jul CAHN

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB		HUMANWELL PURACAP	0.25MCG	A219796	001	Feb 27, 2026	Feb NEWA
AB			0.5MCG	A219796	002	Feb 27, 2026	Feb NEWA

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

@ LUPIN

667MG

A202127 001 Jul 09, 2015 Mar DISC

TABLET; ORAL

CALCIUM ACETATE

@ PADAGIS US

667MG

A091561 001 Apr 13, 2011 Mar DISC

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10%

AP		SQUARE PHARMS PLC	100MG/ML	A217463	001	Sep 29, 2025	May CMFD
	@		100MG/ML	A217463	001	Sep 29, 2025	Mar DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S

AP		FRESENIUS KABI USA	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	A210332	001	Mar 28, 2022	May CMFD
----	--	--------------------	---	---------	-----	--------------	----------

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	+	OTSUKA ICU MEDCL	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017608	001		May CHRS
----	---	------------------	---	---------	-----	--	----------

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS

CALCIUM GLUCONATE

AP		CAPLIN	1GM/10ML (100MG/ML)	A218840	001	May 04, 2026	Apr NEWA
AP			5GM/50ML (100MG/ML)	A218840	002	May 04, 2026	Apr NEWA
AP			10GM/100ML (100MG/ML)	A218840	003	May 04, 2026	Apr NEWA
	+	HQ SPCLT PHARMA	10GM/100ML (100MG/ML)	N210906	004	Nov 18, 2025	May NEWA

SOLUTION; INTRAVENOUS
CALCIUM GLUCONATE

>A>	AP	NIVAGEN	1GM/10ML (100MG/ML)	A213071	001	Oct 14, 2022	Aug CAHN
>A>	AP		5GM/50ML (100MG/ML)	A213071	002	Oct 19, 2023	Aug CAHN
>A>	AP		10GM/100ML (100MG/ML)	A213071	003	Apr 30, 2024	Aug CAHN
>D>	AP	NIVAGEN PHARMS INC	1GM/10ML (100MG/ML)	A213071	001	Oct 14, 2022	Aug CAHN
>D>	AP		5GM/50ML (100MG/ML)	A213071	002	Oct 19, 2023	Aug CAHN
>D>	AP		10GM/100ML (100MG/ML)	A213071	003	Apr 30, 2024	Aug CAHN
CALCIUM GLUCONATE IN SODIUM CHLORIDE							
>A>	AP	MILLA PHARMS	1GM/50ML (20MG/ML)	A219037	001	Aug 28, 2026	Aug NEWA
>A>	AP		2GM/100ML (20MG/ML)	A219037	002	Aug 28, 2026	Aug NEWA

CANAGLIFLOZIN

TABLET; ORAL

CANAGLIFLOZIN							
AB		APOTEX	100MG	A210449	001	Apr 14, 2026	Apr NFTG
AB			300MG	A210449	002	Apr 14, 2026	Apr NFTG
	@	AUROBINDO PHARMA LTD	100MG	A210386	001	Apr 20, 2026	Apr DISC
AB			100MG	A210386	001	Apr 20, 2026	Apr NEWA
	@		300MG	A210386	002	Apr 20, 2026	Apr DISC
AB			300MG	A210386	002	Apr 20, 2026	Apr NEWA
INVOKANA							
AB		+ JANSEN PHARMS	100MG	N204042	001	Mar 29, 2013	Apr CFTG
AB		+!	300MG	N204042	002	Mar 29, 2013	Apr CFTG

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE							
	@	PHARMOBEDIANT	32MG;12.5MG	A090704	002	Dec 04, 2012	Jul DISC
AB		SENORES PHARMS	16MG;12.5MG	A202965	001	Jun 03, 2013	Jan CAHN
AB			32MG;12.5MG	A202965	002	Jun 03, 2013	Jan CAHN
AB			32MG;25MG	A202965	003	Jun 03, 2013	Jan CAHN

CANGRELOR

POWDER; INTRAVENOUS

CANGRELOR							
AP		MSN	50MG/VIAL	A213703	001	Jun 04, 2026	May NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE							
AB		! DR REDDYS	500MG	A204345	002	Dec 04, 2020	Jan CHRS
		XELODA					
	@ +	CHEPLAPHARM	150MG	N020896	001	Apr 30, 1998	Jan DISC
	@ +		500MG	N020896	002	Apr 30, 1998	Jan DISC

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL							
	@	COSETTE PHARMS NC	12.5MG	A074433	001	Feb 13, 1996	May CAHN
	@		12.5MG	A074462	001	Feb 13, 1996	May CAHN
	@		12.5MG	A074483	001	Feb 13, 1996	May CAHN
	@		25MG	A074433	002	Feb 13, 1996	May CAHN
	@		25MG	A074462	002	Feb 13, 1996	May CAHN
	@		25MG	A074483	002	Feb 13, 1996	May CAHN
	@		50MG	A074433	003	Feb 13, 1996	May CAHN
	@		50MG	A074462	003	Feb 13, 1996	May CAHN
	@		50MG	A074483	003	Feb 13, 1996	May CAHN
	@		100MG	A074433	004	Feb 13, 1996	May CAHN
	@		100MG	A074462	004	Feb 13, 1996	May CAHN
	@		100MG	A074483	004	Feb 13, 1996	May CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE							
	@	COSETTE PHARMS NC	25MG;15MG	A074827	001	Dec 29, 1997	May CAHN
	@		25MG;25MG	A074827	002	Dec 29, 1997	May CAHN
	@		50MG;15MG	A074827	004	Dec 29, 1997	May CAHN
	@		50MG;25MG	A074827	003	Dec 29, 1997	May CAHN

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

>A>	@	APPCO	200MG	A214328	001	Aug 16, 2021	Aug CAHN
>D>	@	RK PHARMA	200MG	A214328	001	Aug 16, 2021	Aug CAHN
>D>		EPITOL					
>D>	AB	TEVA	200MG	A070541	001	Sep 17, 1986	Aug DISC
>A>	@		200MG	A070541	001	Sep 17, 1986	Aug DISC

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB		INGENUS PHARMS LLC	100MG	A216404	001	Dec 02, 2022	Feb CAHN
AB			200MG	A216404	002	Dec 02, 2022	Feb CAHN
AB			400MG	A216404	003	Dec 02, 2022	Feb CAHN

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		ALEMBIC	12.5MG; 200MG; 50MG	A218535	001	Feb 05, 2026	Jan NEWA
AB			18.75MG; 200MG; 75MG	A218535	002	Feb 05, 2026	Jan NEWA
AB			25MG; 200MG; 100MG	A218535	003	Feb 05, 2026	Jan NEWA
AB			31.25MG; 200MG; 125MG	A218535	004	Feb 05, 2026	Jan NEWA
AB			37.5MG; 200MG; 150MG	A218535	005	Feb 05, 2026	Jan NEWA
AB			50MG; 200MG; 200MG	A218535	006	Feb 05, 2026	Jan NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

@	SUN PHARM INDS	25MG; 100MG	A077828	001	Aug 23, 2007	Feb DISC
@		50MG; 200MG	A077828	002	Aug 23, 2007	Feb DISC

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

>D>	@	GENUS	4MG	A040442	001	Mar 19, 2003	Aug CAHN
	@		4MG	A040442	001	Mar 19, 2003	Jul DISC
AB		LEADING	6MG	A215476	001	Dec 19, 2024	Jun CTEC
AB	!	MIKART	6MG	A207484	001	May 31, 2016	Jun CTEC
	!	MISSION PHARMACAL	4MG	A090756	001	May 27, 2011	Jul CTEC
AA	!		4MG	A090756	001	May 27, 2011	Jul CHRS
>A>	@	ZETA PHARMS	4MG	A040442	001	Mar 19, 2003	Aug CAHN

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

	@	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	May CAHN
	@		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	May CAHN
	@		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May CAHN
	@		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May CAHN
	@	NOVAST LABS	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Feb DISC
	@		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Feb DISC
	@		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Feb DISC
	@		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Feb DISC
>D>	AP	QILU PHARM HAINAN	50MG/5ML (10MG/ML)	A219999	001	Feb 04, 2026	Aug DISC
>A>	@		50MG/5ML (10MG/ML)	A219999	001	Feb 04, 2026	Aug DISC
	AP		50MG/5ML (10MG/ML)	A219999	001	Feb 04, 2026	Jan NEWA
>D>	AP		150MG/15ML (10MG/ML)	A219999	002	Feb 04, 2026	Aug DISC
>A>	@		150MG/15ML (10MG/ML)	A219999	002	Feb 04, 2026	Aug DISC
	AP		150MG/15ML (10MG/ML)	A219999	002	Feb 04, 2026	Jan NEWA
>D>	AP		450MG/45ML (10MG/ML)	A219999	003	Feb 04, 2026	Aug DISC
>A>	@		450MG/45ML (10MG/ML)	A219999	003	Feb 04, 2026	Aug DISC
	AP		450MG/45ML (10MG/ML)	A219999	003	Feb 04, 2026	Jan NEWA
>D>	AP		600MG/60ML (10MG/ML)	A219999	004	Feb 04, 2026	Aug DISC
>A>	@		600MG/60ML (10MG/ML)	A219999	004	Feb 04, 2026	Aug DISC
	AP		600MG/60ML (10MG/ML)	A219999	004	Feb 04, 2026	Jan NEWA

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

AP		SOMERSET THERAPS LLC	EQ 0.25MG BASE/ML	A219529	001	May 27, 2026	May NEWA
----	--	----------------------	-------------------	---------	-----	--------------	----------

CARFILZOMIBPOWDER; INTRAVENOUS
CARFILZOMIB

AP	MSN	60MG/VIAL	A209526	001	Jul 20, 2026	Jul	NEWA
----	-----	-----------	---------	-----	--------------	-----	------

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

CARIPRAZINE HYDROCHLORIDE

@	AUROBINDO PHARMA LTD	EQ 1.5MG BASE
@		EQ 3MG BASE
@		EQ 6MG BASE

A213982	001	Dec 16, 2025	Jan	DISC
A213982	002	Dec 16, 2025	Jan	DISC
A213982	003	Dec 16, 2025	Jan	DISC

VRAYLAR

+	ABBVIE	EQ 1.5MG BASE
+		EQ 3MG BASE
+		EQ 6MG BASE

N204370	001	Sep 17, 2015	Jan	CTEC
N204370	002	Sep 17, 2015	Jan	CTEC
N204370	004	Sep 17, 2015	Jan	CTEC

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	INGENUS PHARMS LLC	350MG	A040823	001	Oct 22, 2008	Feb	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

CARMUSTINEINJECTABLE; INJECTION
CARMUSTINE

@	INGENUS PHARMS LLC	100MG/VIAL
---	--------------------	------------

A211011	001	Jun 21, 2022	May	CAHN
---------	-----	--------------	-----	------

CARVEDILOL

TABLET; ORAL

CARVEDILOL

@	ALLIED	3.125MG
@		6.25MG
@		12.5MG
@		25MG
@	LUPIN	3.125MG
@		6.25MG
@		12.5MG
@		25MG
@	SCIEGEN PHARMS	3.125MG
@		6.25MG
@		12.5MG
@		25MG

A077316	001	Sep 05, 2007	Jun	CAHN
A077316	002	Sep 05, 2007	Jun	CAHN
A077316	003	Sep 05, 2007	Jun	CAHN
A077316	004	Sep 05, 2007	Jun	CAHN
A078217	001	Sep 05, 2007	Feb	DISC
A078217	002	Sep 05, 2007	Feb	DISC
A078217	003	Sep 05, 2007	Feb	DISC
A078217	004	Sep 05, 2007	Feb	DISC
A077316	001	Sep 05, 2007	Jul	CAHN
A077316	002	Sep 05, 2007	Jul	CAHN
A077316	003	Sep 05, 2007	Jul	CAHN
A077316	004	Sep 05, 2007	Jul	CAHN

CASPOFUNGIN ACETATEPOWDER; INTRAVENOUS
CASPOFUNGIN ACETATE

AP	!	GLAND	50MG/VIAL	A207092	001	Sep 29, 2017	May	CHRS
AP	!		70MG/VIAL	A207092	002	Sep 29, 2017	May	CHRS
	@	HENGRUI PHARMA	50MG/VIAL	A200833	001	Jun 28, 2018	May	DISC
	@		70MG/VIAL	A200833	002	Jun 28, 2018	May	DISC

CEFAZOLIN SODIUMPOWDER; INTRAVENOUS
CEFAZOLIN SODIUM

+	HQ SPCLT PHARMA	EQ 3GM BASE/VIAL
---	-----------------	------------------

N211413	002	Mar 08, 2024	Feb	NEWA
---------	-----	--------------	-----	------

CEFEPIME HYDROCHLORIDE; ZIDEACTAMPOWDER; INTRAVENOUS
ZAYNICH

+	WOCKHARDT BIO AG	EQ 2GM BASE/VIAL; 1GM/VIAL
---	------------------	----------------------------

N220787	001	May 29, 2026	May	NEWA
---------	-----	--------------	-----	------

CEFIXIME

CAPSULE; ORAL

CEFIXIME

AB		AUROBINDO PHARMA LTD	400MG	A217607	001	Mar 23, 2026	Mar	NEWA
----	--	----------------------	-------	---------	-----	--------------	-----	------

FOR SUSPENSION; ORAL

CEFIXIME

AB		FDC LTD	100MG/5ML	A218691	001	May 14, 2026	May	NEWA
AB			200MG/5ML	A218691	002	May 14, 2026	May	NEWA

TABLET;ORAL

CEFIXIME

! FDC LTD

400MG

A206358 001 Dec 17, 2024 Jan CMFD

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS

CEFTAROLINE FOSAMIL

AP APOTEX

400MG/VIAL

A208075 001 Sep 21, 2021 Jan CMFD

AP 600MG/VIAL

A208075 002 Sep 21, 2021 Jan CMFD

TEFLARO

AP +! ABBVIE

400MG/VIAL

N200327 001 Oct 29, 2010 Jan CTEC

AP +! 600MG/VIAL

N200327 002 Oct 29, 2010 Jan CTEC

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

@ SANDOZ INC

EQ 1GM BASE/VIAL

A065204 001 May 03, 2005 Apr DISC

@ EQ 2GM BASE/VIAL

A065204 002 May 03, 2005 Apr DISC

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

>D> @ DEVA HOLDING AS

EQ 250MG BASE/VIAL

A210197 001 Jan 12, 2024 Aug CAHN

>D> @ EQ 500MG BASE/VIAL

A210197 002 Jan 12, 2024 Aug CAHN

>D> @ EQ 1GM BASE/VIAL

A210197 003 Jan 12, 2024 Aug CAHN

>D> @ EQ 2GM BASE/VIAL

A210197 004 Jan 12, 2024 Aug CAHN

>A> @ REGCON HOLDINGS

EQ 250MG BASE/VIAL

A210197 001 Jan 12, 2024 Aug CAHN

>A> @ EQ 500MG BASE/VIAL

A210197 002 Jan 12, 2024 Aug CAHN

>A> @ EQ 1GM BASE/VIAL

A210197 003 Jan 12, 2024 Aug CAHN

>A> @ EQ 2GM BASE/VIAL

A210197 004 Jan 12, 2024 Aug CAHN

CELECOXIB

CAPSULE;ORAL

CELECOXIB

@ ALLIED

50MG

A078857 001 May 30, 2014 Jun CAHN

@ 100MG

A078857 002 Feb 11, 2015 Jun CAHN

@ 200MG

A078857 003 Feb 11, 2015 Jun CAHN

@ 400MG

A078857 004 Feb 11, 2015 Jun CAHN

@ SENORES PHARMS

50MG

A078857 001 May 30, 2014 Jul CAHN

@ 100MG

A078857 002 Feb 11, 2015 Jul CAHN

@ 200MG

A078857 003 Feb 11, 2015 Jul CAHN

@ 400MG

A078857 004 Feb 11, 2015 Jul CAHN

CEPHALEXIN

FOR SUSPENSION;ORAL

CEPHALEXIN

AB AUROBINDO PHARMA

EQ 125MG BASE/5ML

A213568 001 Jun 09, 2026 May NEWA

AB EQ 250MG BASE/5ML

A213568 002 Jun 09, 2026 May NEWA

TABLET;ORAL

CEPHALEXIN

AB TEVA

EQ 250MG BASE

A063024 002 Jan 12, 1989 Jun CTEC

AB ! EQ 500MG BASE

A063024 001 Jan 12, 1989 Jun CTEC

CETIRIZINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

QUZYTIR

+! ESTEVE

10MG/ML (10MG/ML)

N211415 001 Oct 04, 2019 Apr CAHN

SOLUTION;ORAL

CETIRIZINE HYDROCHLORIDE

AA RUBICON RESEARCH

5MG/5ML

A220335 001 Feb 25, 2026 Feb NEWA

@ TIME CAP LABS

5MG/5ML

A078757 001 Aug 28, 2009 Mar CAHN

CETRORELIX ACETATE

POWDER;SUBCUTANEOUS

CETRORELIX ACETATE

AP EPIC PHARMA LLC

EQ 0.25MG BASE/VIAL

A218740 001 Apr 29, 2026 May CAHN

AP HUMANWELL

EQ 0.25MG BASE/VIAL

A218740 001 Apr 29, 2026 Apr NEWA

@ TEVA PHARMS INC

EQ 0.25MG BASE/VIAL

A215737 001 Aug 12, 2022 Jul DISC

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB	ZYDUS LIFESCIENCES	30MG	A220267	001	Mar 11, 2026	Feb NEWA
----	--------------------	------	---------	-----	--------------	----------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB	+ BARR	5MG	A084768	001		Mar CRLD
AB	+	10MG	A083116	001		Mar CRLD
AB	+!	25MG	A084769	001		Mar CRLD
LIBRIUM						
AB	+ BAUSCH	5MG	A085461	001		Feb CAHN
AB	+	10MG	A085472	001		Feb CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

PERIDEX

AT	+! SOLVENTUM	0.12%	N019028	001	Aug 13, 1986	May CAHN
----	--------------	-------	---------	-----	--------------	----------

CHLOROTHIAZIDE

SUSPENSION;ORAL

DIURIL

@ +	SALIX PHARMS	250MG/5ML	N011870	001		Jan DISC
-----	--------------	-----------	---------	-----	--	----------

CHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

CHLOROTHIAZIDE AND RESERPINE

@	HIKMA	250MG;0.125MG	A088365	002	Dec 22, 1983	Jul CMS1
---	-------	---------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	APOZEAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017	Jul CAHN
@	PADAGIS US	4MG/5ML;5MG/5ML;60MG/5ML	A204627	001	Apr 29, 2014	Mar DISC

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AA	! GENUS	30MG/ML	A214542	001	Jun 02, 2021	Mar CTEC
AA	!	100MG/ML	A214542	002	Jun 02, 2021	Mar CTEC
AA	RUBICON	30MG/ML	A216678	001	Oct 10, 2025	Mar CTEC
AA		100MG/ML	A216678	002	Oct 10, 2025	Mar CTEC
AA	RUBICON RESEARCH	30MG/ML	A216678	001	Oct 10, 2025	May CAHN
AA		100MG/ML	A216678	002	Oct 10, 2025	May CAHN

SONAZINE

>D> AA	SAPTALIS PHARMS	30MG/ML	A080983	004		Aug CAHN
AA		30MG/ML	A080983	004		Mar CMFD
>D> AA		100MG/ML	A080983	005		Aug CAHN
AA		100MG/ML	A080983	005		Mar CMFD
>A> AA	SCIEGEN PHARMS	30MG/ML	A080983	004		Aug CAHN
>A> AA		100MG/ML	A080983	005		Aug CAHN

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

>D> AP	DEVA HLDING	25MG/ML	A218229	001	Sep 24, 2024	Aug CAHN
AP	MSN	25MG/ML	A216092	001	Jan 26, 2026	Jan NEWA
>A> AP	REGCON HOLDINGS	25MG/ML	A218229	001	Sep 24, 2024	Aug CAHN

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Jan CAHN
AB		25MG	A212630	002	Nov 29, 2021	Jan CAHN
AB		50MG	A212630	003	Nov 29, 2021	Jan CAHN
AB		100MG	A212630	004	Nov 29, 2021	Jan CAHN
AB		200MG	A212630	005	Nov 29, 2021	Jan CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB	! ALKEM LABS LTD	50MG	A213412	002	Feb 11, 2020	Mar CHRS
@	COSETTE PHARMS NC	50MG	A088651	001	May 30, 1985	May CAHN
AB	INGENUS PHARMS LLC	25MG	A206904	001	Mar 30, 2017	May CAHN

TABLET;ORAL
CHLORTHALIDONE

AB		50MG	A206904	002	Mar 30, 2017	May CAHN
AB	MACLEODS PHARMS	25MG	A212229	001	Jul 01, 2026	Jun NEWA
AB		50MG	A212229	002	Jul 01, 2026	Jun NEWA
	THALITONE					
	@ + CASPER PHARMA LLC	25MG	N019574	002	Feb 12, 1992	Jun DISC

CHLORZOXAZONE

TABLET;ORAL
CHLORZOXAZONE

AA	SENORES PHARMS	500MG	A210961	001	Jan 22, 2024	Jan CAHN
----	----------------	-------	---------	-----	--------------	----------

CHOLESTYRAMINE

POWDER;ORAL
CHOLESTYRAMINE

AB	AIPING PHARM INC	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Jun CMFD
AB		EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Jun CMFD
AB	MICRO LABS	EQ 4GM RESIN/PACKET	A219318	001	Mar 05, 2026	Feb NEWA
AB	PHARMOBEDIENT	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Jan CAHN
AB		EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Jan CAHN
	CHOLESTYRAMINE LIGHT					
AB	ZYDUS PHARMS	EQ 4GM RESIN/PACKET	A202902	002	Apr 25, 2017	Mar NEWA

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL
FENOFIBRIC ACID

>D>	AB	MICRO LABS	EQ 45MG FENOFIBRIC ACID	A213450	001	Jun 16, 2020	Aug DISC
>A>		@	EQ 45MG FENOFIBRIC ACID	A213450	001	Jun 16, 2020	Aug DISC
>D>	AB		EQ 135MG FENOFIBRIC ACID	A213450	002	Jun 16, 2020	Aug DISC
>A>		@	EQ 135MG FENOFIBRIC ACID	A213450	002	Jun 16, 2020	Aug DISC

CHROMIC CHLORIDE

INJECTABLE;INJECTION
CHROMIC CHLORIDE

AP	SOMERSET THERAPS LLC	EQ 0.004MG CHROMIUM/ML	A218538	001	Nov 18, 2024	Feb CAHN
----	----------------------	------------------------	---------	-----	--------------	----------

CICLESONIDE

AEROSOL, METERED;INHALATION
ALVESCO

+	!	AZURITY	0.08MG/INH	N021658	002	Jan 10, 2008	Jun CAHN
+	!		0.16MG/INH	N021658	003	Jan 10, 2008	Jun CAHN

AEROSOL, METERED;NASAL
ZETONNA

@	+	AZURITY	0.037MG/INH	N202129	001	Jan 20, 2012	Jun CAHN
@	+		0.037MG/INH	N202129	001	Jan 20, 2012	Mar CAHN

SPRAY, METERED;NASAL
OMNARIS

+	!	AZURITY	0.05MG/SPRAY	N022004	001	Oct 20, 2006	Jun CAHN
+	!		0.05MG/SPRAY	N022004	001	Oct 20, 2006	Mar CAHN

CICLOPIROX

CREAM;TOPICAL
CICLOPIROX

AB	COSETTE PHARMS NC	0.77%	A078463	001	Dec 20, 2010	May CAHN
	LOPROX					

AB	+	!	EUROFARMA	0.77%	N018748	001	Dec 30, 1982	Feb CAHN
----	---	---	-----------	-------	---------	-----	--------------	----------

SOLUTION;TOPICAL
CICLOPIROX

@	COSETTE PHARMS NC	8%	A078233	001	Sep 18, 2007	May CAHN
---	-------------------	----	---------	-----	--------------	----------

SUSPENSION;TOPICAL
LOPROX

AB	+	!	EUROFARMA	0.77%	N019824	001	Dec 30, 1988	Feb CAHN
----	---	---	-----------	-------	---------	-----	--------------	----------

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
CIMETIDINE HYDROCHLORIDE

@	HOSPIRA	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997	May CAHN
---	---------	-------------------	---------	-----	--------------	----------

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

@	HETERO LABS LTD V	EQ 30MG BASE	A209403	001	Oct 07, 2020	Feb DISC
@		EQ 60MG BASE	A209403	002	Oct 07, 2020	Feb DISC
@		EQ 90MG BASE	A209403	003	Oct 07, 2020	Feb DISC
@	STEVENS J	EQ 30MG BASE	A204364	001	Dec 02, 2021	Feb CPOT
@		EQ 60MG BASE	A204364	002	Dec 02, 2021	Feb CPOT
@		EQ 90MG BASE	A204364	003	Dec 02, 2021	Feb CPOT
@	SUN PHARM	EQ 60MG BASE	A207008	002	Oct 11, 2018	Jul DISC

>A> CIZEPOFOL

>A> EMULSION; INTRAVENOUS

>A> CYPSEDO

>A>	+!	HAISCO	50MG/20ML (2.5MG/ML)	N220482	001	Aug 27, 2026	Aug NEWA
-----	----	--------	----------------------	---------	-----	--------------	----------

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

@	J MOLNER	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Jul CAHN
---	----------	--------------	---------	-----	--------------	----------

SOLUTION/DROPS; OTIC

CIPROFLOXACIN HYDROCHLORIDE

AB		ALEMBIC THERAP	EQ 0.2% BASE	A217887	001	Nov 05, 2024	May CAHN
----	--	----------------	--------------	---------	-----	--------------	----------

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	AMNEAL	EQ 250MG BASE	A075939	002	Jun 09, 2004	Mar DISC
@		EQ 500MG BASE	A075939	003	Jun 09, 2004	Mar DISC
@		EQ 750MG BASE	A075939	004	Jun 09, 2004	Mar DISC
@	HIKMA	EQ 250MG BASE	A076558	002	Jun 09, 2004	Jun DISC
@		EQ 500MG BASE	A076558	003	Jun 09, 2004	Jun DISC
@		EQ 750MG BASE	A076558	004	Jun 09, 2004	Jun DISC

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	@	HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb DISC
AP		PIRAMAL	EQ 2MG BASE/ML	A212432	001	Mar 11, 2022	Apr CMFD
AP			EQ 10MG BASE/ML	A212432	002	Mar 11, 2022	Apr CMFD

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP		HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Apr CMFD
AP			EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Apr CMFD
	@	HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Feb DISC
	@		EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Feb DISC

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

AB	+!	ALMATICA	EQ 30MG BASE	N215428	001	Jan 31, 2022	Mar CFTG
AB		AUROBINDO PHARMA LTD	EQ 30MG BASE	A219985	001	Mar 13, 2026	Mar NFTG

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@	AMNEAL PHARMS NY	EQ 10MG BASE	A077289	001	Nov 30, 2006	Feb DISC
@		EQ 20MG BASE	A077289	002	Nov 30, 2006	Feb DISC
@		EQ 40MG BASE	A077289	003	Nov 30, 2006	Feb DISC
@	COSETTE PHARMS NC	EQ 10MG BASE	A077048	001	Nov 16, 2004	May CAHN
@		EQ 20MG BASE	A077048	002	Nov 16, 2004	May CAHN
@		EQ 40MG BASE	A077048	003	Nov 16, 2004	May CAHN

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL; VAGINAL

PHEXX

	+!	EVOFEM INC	1%; 1.8%; 0.4%	N208352	001	May 22, 2020	May CTNA
--	----	------------	----------------	---------	-----	--------------	----------

CLADRIBINE

TABLET; ORAL

CLADRIBINE

AB		HOPEWELL PHARMA	10MG	A215547	001	Mar 27, 2026	Mar NEWA
----	--	-----------------	------	---------	-----	--------------	----------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

@	COSETTE PHARMS NC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Jun CAHN
@		EQ 300MG BASE	A063029	002	Aug 05, 2005	Jun CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	@	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Apr DISC
	@	APPCO	EQ 75MG BASE/5ML	A207047	001	May 11, 2018	May CAHN
	@	PADAGIS US	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Mar DISC

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

EVOCLIN

@ +	QUAGEN	1%	N050801	001	Oct 22, 2004	Jul CAHN
-----	--------	----	---------	-----	--------------	----------

CREAM;VAGINAL

CLEOCIN

>D> AB	+	PFIZER	EQ 2% BASE	N050680	002	Mar 02, 1998	Aug CHRS
>A> AB	+		EQ 2% BASE	N050680	002	Mar 02, 1998	Aug CHRS
		CLINDAMYCIN PHOSPHATE					
>D> AB		FOUGERA PHARMS	EQ 2% BASE	A065139	001	Dec 27, 2004	Aug CHRS
>A> AB	!		EQ 2% BASE	A065139	001	Dec 27, 2004	Aug CHRS

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB1		AUROBINDO PHARMA LTD	EQ 1% BASE	A218942	001	Mar 18, 2026	Mar NEWA
AB1		SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001	Jul 29, 2020	Feb CAHN

SOLUTION;TOPICAL

CLINDA-DERM

@	PADAGIS US	EQ 1% BASE	A063329	001	Sep 30, 1992	Mar DISC
---	------------	------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

AT	@	INGENUS PHARMS LLC	EQ 1% BASE	A064108	001	Sep 27, 1996	Feb CAHN
		RISING	EQ 1% BASE	A218300	001	Mar 23, 2026	Mar NEWA

SWAB;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		RISING	EQ 1% BASE	A218300	001	Mar 23, 2026	Jul CDFR
		CLINDETS					
	@	PERRIGO CO	EQ 1% BASE	A064136	001	Sep 30, 1996	Mar DISC

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

VELTIN

AB2	+	CHARTWELL RX	1.2%;0.025%	N050803	001	Jul 16, 2010	Jun CAHN
-----	---	--------------	-------------	---------	-----	--------------	----------

CLOBAZAM

FILM;ORAL

SYMPAZAN

+	COSETTE	5MG	N210833	001	Nov 01, 2018	Jun CAHN
+		10MG	N210833	002	Nov 01, 2018	Jun CAHN
+	!	20MG	N210833	003	Nov 01, 2018	Jun CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

@	INGENUS PHARMS LLC	0.05%	A206805	001	Jul 31, 2017	May CAHN
---	--------------------	-------	---------	-----	--------------	----------

OLUX

@ +	QUAGEN	0.05%	N021142	001	May 26, 2000	Jul CAHN
-----	--------	-------	---------	-----	--------------	----------

OLUX E

@ +	QUAGEN	0.05%	N022013	001	Jan 12, 2007	Jul CAHN
-----	--------	-------	---------	-----	--------------	----------

CREAM;TOPICAL

CLOBETASOL PROPIONATE

@	COSETTE PHARMS NC	0.05%	A074139	001	Aug 03, 1994	Jun CAHN
---	-------------------	-------	---------	-----	--------------	----------

TEMOVATE

>A>	@ +	FOUGERA	0.05%	N019322	001	Dec 27, 1985	Aug CAHN
>D>	@ +	FOUGERA PHARMS	0.05%	N019322	001	Dec 27, 1985	Aug CAHN
		TEMOVATE E					
>A>	@ +	FOUGERA	0.05%	N020340	001	Jun 17, 1994	Aug CAHN
>D>	@ +	FOUGERA PHARMS	0.05%	N020340	001	Jun 17, 1994	Aug CAHN

GEL; TOPICAL									
CLOBETASOL PROPIONATE									
	@	ENCUBE	0.05%	A208881	001	Mar 06, 2017	May	CAHN	
>D>	AB	! FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	Aug	CHRS	
>A>	AB		0.05%	A075368	001	Feb 15, 2000	Aug	CHRS	
>D>	AB	PADAGIS US	0.05%	A075027	001	Oct 31, 1997	Aug	CHRS	
>A>	AB	!	0.05%	A075027	001	Oct 31, 1997	Aug	CHRS	
OINTMENT; TOPICAL									
CLOBETASOL PROPIONATE									
AB		COSETTE PHARMS NC	0.05%	A074089	001	Feb 16, 1994	May	CAHN	
TEMOVATE									
>A>	@ +	FOUGERA	0.05%	N019323	001	Dec 27, 1985	Aug	CAHN	
>D>	@ +	FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Aug	CAHN	
SOLUTION; TOPICAL									
CLOBETASOL PROPIONATE									
	@	COSETTE PHARMS NC	0.05%	A074331	001	Dec 15, 1995	Jun	CAHN	
TEMOVATE									
>A>	@ +	FOUGERA	0.05%	N019966	001	Feb 22, 1990	Aug	CAHN	
>D>	@ +	FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990	Aug	CAHN	
SPRAY; TOPICAL									
CLOBETASOL PROPIONATE									
	@	PADAGIS US	0.05%	A090898	001	Jun 16, 2011	Mar	DISC	
<u>CLOCORTOLONE PIVALATE</u>									
CREAM; TOPICAL									
CLOCORTOLONE PIVALATE									
>D>	AB	TARO	0.1%	A206370	001	Apr 21, 2020	Aug	CHRS	
>A>	AB	!	0.1%	A206370	001	Apr 21, 2020	Aug	CHRS	
CLODERM									
>D>	AB	+! LEGACY	0.1%	N017765	001		Aug	CHRS	
>A>	AB	+	0.1%	N017765	001		Aug	CHRS	
	AB	+!	0.1%	N017765	001		Jun	CAHN	
<u>CLOFARABINE</u>									
SOLUTION; INTRAVENOUS									
CLOFARABINE									
	@	INGENUS PHARMS LLC	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018	May	CAHN	
	@	PHARMOBEDIENT	20MG/20ML (1MG/ML)	A208860	001	Nov 06, 2017	May	DISC	
<u>CLOMIPHENE CITRATE</u>									
TABLET; ORAL									
CLOMID									
AB	!	COSETTE	50MG	A075528	001	Aug 30, 1999	Jul	CTNA	
CLOMIPHENE CITRATE									
AB		ASCENT PHARMS INC	50MG	A220673	001	May 15, 2026	May	NEWA	
AB		RUBICON RESEARCH	50MG	A216545	001	Nov 12, 2024	May	CAHN	
<u>CLOMIPRAMINE HYDROCHLORIDE</u>									
CAPSULE; ORAL									
CLOMIPRAMINE HYDROCHLORIDE									
>D>	AB	IXORA LIFESCIENCE	25MG	A211364	001	Feb 07, 2020	Aug	CAHN	
>D>	AB		50MG	A211364	002	Feb 07, 2020	Aug	CAHN	
>D>	AB		75MG	A211364	003	Feb 07, 2020	Aug	CAHN	
>A>	AB	LEADING	25MG	A211364	001	Feb 07, 2020	Aug	CAHN	
>A>	AB		50MG	A211364	002	Feb 07, 2020	Aug	CAHN	
>A>	AB		75MG	A211364	003	Feb 07, 2020	Aug	CAHN	
	@	TP ANDA HOLDINGS	25MG	A210653	001	Apr 03, 2020	Jul	DISC	
	@		50MG	A210653	002	Apr 03, 2020	Jul	DISC	
	@		75MG	A210653	003	Apr 03, 2020	Jul	DISC	
<u>CLONAZEPAM</u>									
TABLET; ORAL									
CLONAZEPAM									
AB		CHARTWELL RX	0.5MG	A074925	001	Sep 30, 1997	Jan	CMFD	
AB			1MG	A074925	002	Sep 30, 1997	Jan	CMFD	
AB			2MG	A074925	003	Sep 30, 1997	Jan	CMFD	
	@	QUAGEN	0.5MG	A074940	001	Oct 30, 1997	Apr	CAHN	
	@		1MG	A074940	002	Oct 30, 1997	Apr	CAHN	
	@		2MG	A074940	003	Oct 30, 1997	Apr	CAHN	
		RUBICON RESEARCH	0.25MG	A075468	004	Jun 12, 2026	Jul	NFTG	

TABLET, ORALLY DISINTEGRATING;ORAL									
CLONAZEPAM									
AB	RUBICON RESEARCH	0.125MG	A216988	001	May 21, 2026	May	NEWA		
AB		0.25MG	A216988	002	May 21, 2026	May	NEWA		
AB		0.5MG	A216988	003	May 21, 2026	May	NEWA		
AB		1MG	A216988	004	May 21, 2026	May	NEWA		
AB		2MG	A216988	005	May 21, 2026	May	NEWA		
<u>CLONIDINE</u>									
SYSTEM;TRANSDERMAL									
CLONIDINE									
@	DIFGEN PHARMS	0.1MG/24HR	A076157	001	Aug 18, 2009	Feb	CAHN		
@		0.2MG/24HR	A076157	002	Aug 18, 2009	Feb	CAHN		
@		0.3MG/24HR	A076157	003	Aug 18, 2009	Feb	CAHN		
TABLET, EXTENDED RELEASE;ORAL									
NEXICLON XR									
	ROSEMOUNT	EQ 0.17MG BASE	N022500	001	Dec 03, 2009	Mar	CAHN		
@		EQ 0.26MG BASE	N022500	002	Dec 03, 2009	Mar	CAHN		
<u>CLONIDINE HYDROCHLORIDE</u>									
SOLUTION;ORAL									
QLONILIK									
+	CMP DEV LLC	0.05MG/ML	N221094	001	Jul 29, 2026	Jul	NEWA		
TABLET;ORAL									
CLONIDINE HYDROCHLORIDE									
!	TP ANDA HOLDINGS	0.05MG	A070923	004	Apr 06, 2026	Mar	NFTG		
<u>CLORAZEPATE DIPOTASSIUM</u>									
CAPSULE;ORAL									
CLORAZEPATE DIPOTASSIUM									
@	NATCO PHARMA USA	3.75MG	A071509	001	Oct 19, 1987	Mar	CAHN		
@		7.5MG	A071510	001	Oct 19, 1987	Mar	CAHN		
@		15MG	A071511	001	Oct 19, 1987	Mar	CAHN		
<u>COBICISTAT</u>									
TABLET;ORAL									
TYBOST									
@ +	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Mar	DISC		
<u>COBICISTAT; DARUNAVIR ETHANOLATE</u>									
TABLET;ORAL									
PREZCOBIX									
+	JANSSEN PRODS	150MG;EQ 675MG BASE	N205395	002	Mar 21, 2025	Mar	CHRS		
TABLET, FOR SUSPENSION;ORAL									
PREZCOBIX PED									
+	JANSSEN PRODS	90MG;EQ 600MG BASE	N220092	001	Feb 27, 2026	Feb	NEWA		
<u>CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>									
SYRUP;ORAL									
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE									
AA	!	PAI HOLDINGS	10MG/5ML;5MG/5ML;6.25MG/5ML	A040660	001	Dec 07, 2006	May	CAHN	
<u>CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE</u>									
SYRUP;ORAL									
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE									
AA	!	COSETTE PHARMS NC	10MG/5ML;6.25MG/5ML	A200386	001	Jun 29, 2012	May	CAHN	
<u>COLCHICINE</u>									
CAPSULE;ORAL									
COLCHICINE									
AB	MICRO LABS	0.6MG	A212880	001	Feb 17, 2026	Feb	NEWA		
TABLET;ORAL									
COLCHICINE									
AB	MACLEODS PHARMS	0.6MG	A210633	001	Feb 13, 2026	Feb	NEWA		
<u>COLCHICINE; PROBENECID</u>									
TABLET;ORAL									
PROBENECID AND COLCHICINE									
AB	INGENUS PHARMS LLC	0.5MG;500MG	A040618	001	May 13, 2008	May	CAHN		

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

+ PFIZER

5GM/SCOOPFUL

N017563 003 Sep 22, 1995 May CTEC

+!

5GM/PACKET

N017563 004 Sep 22, 1995 May CTEC

COLESTIPOL HYDROCHLORIDE

@ IMPAX LABS

5GM/SCOOPFUL

A077277 001 May 02, 2006 May DISC

@

5GM/PACKET

A077277 002 May 02, 2006 May DISC

TABLET; ORAL

COLESTIPOL HYDROCHLORIDE

>A> AB MACLEODS PHARMS

1GM

A220012 001 Sep 15, 2025 Aug CAHN

>D> AB PHARMOBEDIENT

1GM

A220012 001 Sep 15, 2025 Aug CAHN

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP ! XELLIA PHARMS APS

EQ 150MG BASE/VIAL

A205356 001 May 29, 2015 May CHRS

COLY-MYCIN M

@ + PH HEALTH

EQ 150MG BASE/VIAL

N050108 002 May DISC

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

VAPRISOL

@ APOTEX

20MG/4ML (5MG/ML)

N021697 001 Dec 29, 2005 Jul CAHN

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+! APOTEX

20MG/100ML (0.2MG/ML)

N021697 002 Oct 08, 2008 Jul CAHN

COPPER HISTIDINATE

POWDER; SUBCUTANEOUS

ZYCUBO

+! SENTYNL THERAPS INC

2.9MG/VIAL

N211241 001 Jan 12, 2026 Jan NEWA

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

>D> AN MICRO LABS

10MG/ML

A213658 001 Apr 29, 2022 Aug DISC

>A> @

10MG/ML

A213658 001 Apr 29, 2022 Aug DISC

CROTAMITON

CREAM; TOPICAL

EURAX

+! JOURNEY

10%

N006927 001 Apr CMFD

LOTION; TOPICAL

CROTAN

! LEGACY

10%

A087204 001 Jun CAHN

! LEGACY PHARMA

10%

A087204 001 Apr CTEC

!

10%

A087204 001 Apr CHRS

EURAX

@ + JOURNEY

10%

N009112 003 Apr DISC

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE

@ AMNEAL

EQ 0.4MG COPPER/ML

A217287 001 Jan 26, 2026 Mar DISC

AP EQ 0.4MG COPPER/ML

A217287 001 Jan 26, 2026 Jan NEWA

AP STIRA

EQ 0.4MG COPPER/ML

A217626 001 Apr 30, 2024 Apr CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP ASPIRO

1MG/ML

A219820 001 Jul 08, 2026 Jun NEWA

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB AIPING PHARM INC

7.5MG

A072854 003 May 13, 2026 May NEWA

CYCLOPENTOLATE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
PENTOLAIR

AT	BAUSCH AND LOMB INC	1%	A040075	001	Apr 29, 1994	May CAHN
----	---------------------	----	---------	-----	--------------	----------

CYCLOPHOSPHAMIDEINJECTABLE; INJECTION
CYCLOPHOSPHAMIDE

>D>	@	HAINAN POLY	500MG/VIAL	A218632	001	Dec 26, 2024	Aug CMFD
>A>	AP		500MG/VIAL	A218632	001	Dec 26, 2024	Aug CMFD
	@		500MG/VIAL	A218632	001	Dec 26, 2024	Jan DISC
>D>	@		1GM/VIAL	A218632	002	Dec 26, 2024	Aug CMFD
>A>	AP		1GM/VIAL	A218632	002	Dec 26, 2024	Aug CMFD
	@		1GM/VIAL	A218632	002	Dec 26, 2024	Jan DISC
>D>	@		2GM/VIAL	A218632	003	Dec 26, 2024	Aug CMFD
>A>	AP		2GM/VIAL	A218632	003	Dec 26, 2024	Aug CMFD
	@		2GM/VIAL	A218632	003	Dec 26, 2024	Jan DISC

CYCLOSPORINECAPSULE; ORAL
CYCLOSPORINE

AB1	ONESOURCE	25MG	A216046	001	Aug 02, 2022	Jul CAHN
AB1		50MG	A216046	002	Aug 02, 2022	Jul CAHN
AB1		100MG	A216046	003	Aug 02, 2022	Jul CAHN

EMULSION;OPHTHALMIC
CYCLOSPORINE

AB	JIANGSU ANBISON	0.05%	A219288	001	Jun 01, 2026	May NEWA
AB	TWI PHARMS	0.05%	A209064	001	Jan 21, 2026	Jan NEWA

INJECTABLE; INJECTION
CYCLOSPORINE

@	PADAGIS US	50MG/ML	A065151	001	Oct 07, 2003	Mar DISC
---	------------	---------	---------	-----	--------------	----------

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	ST JOHN PHARM	2MG/5ML	A209108	001	Oct 16, 2018	Jan CAHN
----	---------------	---------	---------	-----	--------------	----------

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

	@	ANVI	4MG	A087129	001		Mar CAHN
AA		INGENUS PHARMS LLC	4MG	A205087	001	Sep 23, 2015	Feb CAHN
	@	STRIDES PHARMA INTL	4MG	A087129	001		Jun CAHN

CYSTEINE HYDROCHLORIDESOLUTION; INTRAVENOUS
ELCYS

>D>	@ +	EXELA PHARMA	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023	Aug CMFD
>A>	+	!	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023	Aug CMFD

DACOMITINIB

TABLET; ORAL

VIZIMPRO

@ +	PFIZER	15MG	N211288	001	Sep 27, 2018	Jul DISC
@ +		30MG	N211288	002	Sep 27, 2018	Jul DISC
@ +		45MG	N211288	003	Sep 27, 2018	Jul DISC

DALBAVANCIN HYDROCHLORIDE

POWDER; INTRAVENOUS

DALBAVANCIN HYDROCHLORIDE

AP	BE PHARMS	EQ 500MG BASE/VIAL	A219604	001	Jun 04, 2026	May NEWA
AP	LONG GROVE PHARMS	EQ 500MG BASE/VIAL	A218602	001	Feb 26, 2026	Feb NEWA

DAPAGLIFLOZIN

TABLET; ORAL

DAPAGLIFLOZIN

AB	AIZANT	5MG	A211523	001	Apr 06, 2026	Mar NFTG
AB		10MG	A211523	002	Apr 06, 2026	Mar NFTG
AB	AJANTA PHARMA LTD	5MG	A211482	001	Apr 06, 2026	Mar NFTG
AB		10MG	A211482	002	Apr 06, 2026	Mar NFTG
AB	ALEMBIC	5MG	A211560	001	Apr 06, 2026	Mar NFTG
AB		10MG	A211560	002	Apr 06, 2026	Mar NFTG
AB	ALKEM LABS LTD	5MG	A211545	001	Apr 06, 2026	Mar NFTG

TABLET; ORAL

DAPAGLIFLOZIN

AB		10MG	A211545	002	Apr 06, 2026	Mar	NFTG
AB	AUROBINDO PHARMA	5MG	A211468	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211468	002	Apr 06, 2026	Mar	NFTG
AB	BIOCON PHARMA	5MG	A211470	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211470	002	Apr 06, 2026	Mar	NFTG
AB	CIPLA	5MG	A211535	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211535	002	Apr 06, 2026	Mar	NFTG
AB	INVENTIA	5MG	A211156	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211156	002	Apr 06, 2026	Mar	NFTG
AB	LUPIN	5MG	A211531	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211531	002	Apr 06, 2026	Mar	NFTG
AB	MACLEODS PHARMS	5MG	A211506	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211506	002	Apr 06, 2026	Mar	NFTG
AB	MICRO LABS	5MG	A211467	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211467	002	Apr 06, 2026	Mar	NFTG
AB	MSN	5MG	A211478	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211478	002	Apr 06, 2026	Mar	NFTG
AB	SANDOZ	5MG	A211312	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211312	002	Apr 06, 2026	Mar	NFTG
AB	TEVA PHARMS USA	5MG	A211541	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211541	002	Apr 06, 2026	Mar	NFTG
AB	ZYDUS PHARMS	5MG	A211582	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211582	002	Apr 06, 2026	Mar	NFTG
FARXIGA							
AB	+ ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Mar	CFTG
AB	+!	10MG	N202293	002	Jan 08, 2014	Mar	CFTG

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

AB	ALKEM LABS LTD	5MG; 500MG	A211563	001	Apr 06, 2026	Mar	NFTG
AB		5MG; 1GM	A211563	002	Apr 06, 2026	Mar	NFTG
AB		10MG; 500MG	A211563	003	Apr 06, 2026	Mar	NFTG
AB		10MG; 1GM	A211563	004	Apr 06, 2026	Mar	NFTG
AB	AUROBINDO PHARMA	5MG; 500MG	A211489	001	Apr 06, 2026	Mar	NFTG
AB		5MG; 1GM	A211489	002	Apr 06, 2026	Mar	NFTG
AB		10MG; 500MG	A211489	003	Apr 06, 2026	Mar	NFTG
AB		10MG; 1GM	A211489	004	Apr 06, 2026	Mar	NFTG
AB	CIPLA	5MG; 1GM	A211595	001	Apr 06, 2026	Mar	NFTG
AB	CIPLA LTD	5MG; 500MG	A211536	001	Apr 06, 2026	Mar	NFTG
AB		10MG; 500MG	A211536	002	Apr 06, 2026	Mar	NFTG
AB		10MG; 1GM	A211536	003	Apr 06, 2026	Mar	NFTG
AB	LUPIN	5MG; 500MG	A211579	001	Apr 06, 2026	Mar	NFTG
AB		5MG; 1GM	A211579	002	Apr 06, 2026	Mar	NFTG
AB		10MG; 500MG	A211579	003	Apr 06, 2026	Mar	NFTG
AB		10MG; 1GM	A211579	004	Apr 06, 2026	Mar	NFTG
AB	MACLEODS PHARMS	5MG; 500MG	A211559	001	Apr 06, 2026	Mar	NFTG
AB		5MG; 1GM	A211559	002	Apr 06, 2026	Mar	NFTG
AB		10MG; 500MG	A211559	003	Apr 06, 2026	Mar	NFTG
AB		10MG; 1GM	A211559	004	Apr 06, 2026	Mar	NFTG
AB	MICRO LABS	5MG; 500MG	A211466	001	Apr 06, 2026	Mar	NFTG
AB		5MG; 1GM	A211466	002	Apr 06, 2026	Mar	NFTG
AB		10MG; 500MG	A211466	003	Apr 06, 2026	Mar	NFTG
AB		10MG; 1GM	A211466	004	Apr 06, 2026	Mar	NFTG
AB	MSN	5MG; 500MG	A211479	001	Apr 06, 2026	Mar	NFTG
AB		5MG; 1GM	A211479	002	Apr 06, 2026	Mar	NFTG
AB		10MG; 500MG	A211479	003	Apr 06, 2026	Mar	NFTG
AB		10MG; 1GM	A211479	004	Apr 06, 2026	Mar	NFTG
AB	SUN PHARM	5MG; 1GM	A211491	001	Apr 06, 2026	Mar	NFTG
AB		10MG; 500MG	A211491	002	Apr 06, 2026	Mar	NFTG
AB		10MG; 1GM	A211491	003	Apr 06, 2026	Mar	NFTG
AB	TEVA PHARMS USA INC	2.5MG; 1GM	A211583	001	Apr 06, 2026	Mar	NFTG
AB		5MG; 500MG	A211583	002	Apr 06, 2026	Mar	NFTG
AB		5MG; 1GM	A211583	003	Apr 06, 2026	Mar	NFTG
AB		10MG; 500MG	A211583	004	Apr 06, 2026	Mar	NFTG
AB		10MG; 1GM	A211583	005	Apr 06, 2026	Mar	NFTG
XIGDUO XR							
AB	+ ASTRAZENECA AB	2.5MG; 1GM	N205649	005	Jul 28, 2017	Mar	CFTG
AB	+	5MG; 500MG	N205649	001	Oct 29, 2014	Mar	CFTG
AB	+	5MG; 1GM	N205649	002	Oct 29, 2014	Mar	CFTG
AB	+	10MG; 500MG	N205649	003	Oct 29, 2014	Mar	CFTG

TABLET, EXTENDED RELEASE;ORAL
XIGDUO XR

AB	+	10MG;1GM	N205649	004	Oct 29, 2014	Mar CFTG
----	---	----------	---------	-----	--------------	----------

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE

AB	!	MSN	10MG;EQ 5MG BASE	A211533	001	Apr 06, 2026	Mar NFTG
AB		TORRENT	10MG;EQ 5MG BASE	A211537	001	Apr 06, 2026	Mar NFTG

DAPSONE

GEL;TOPICAL

DAPSONE

AB		ALEMBIC	5%	A213414	001	Jun 25, 2026	Jun NEWA
	@	CHARTWELL RX	5%	A215087	001	Oct 31, 2023	May CAHN
	@		7.5%	A212657	001	Nov 01, 2023	May CAHN
AB		COSETTE PHARMS NC	5%	A210178	001	Mar 31, 2022	May CAHN

TABLET;ORAL

DAPSONE

AB		MACLEODS PHARMS	25MG	A218335	001	Jul 08, 2026	Jun NEWA
AB			100MG	A218335	002	Jul 08, 2026	Jun NEWA
AB		ZYDUS LIFESCIENCES	25MG	A220103	001	Feb 26, 2026	Feb NEWA
AB			100MG	A220103	002	Feb 26, 2026	Feb NEWA

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

	@	HENGRUI PHARMA	500MG/VIAL	A212022	001	Aug 22, 2019	Jan DISC
--	---	----------------	------------	---------	-----	--------------	----------

>A> DARAXONRASIB

TABLET;ORAL

RASONQUE

>A>	+	REVOLUTION MEDICINES	100MG	N220910	001	Aug 26, 2026	Aug NEWA
>A>	+	!	150MG	N220910	002	Aug 26, 2026	Aug NEWA

DASIGLUCAGON HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS

ZEGALOGUE

	@ +	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Feb DISC
--	-----	----------------	---	---------	-----	--------------	----------

ZEGALOGUE (AUTOINJECTOR)

	@ +	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Feb DISC
--	-----	----------------	---	---------	-----	--------------	----------

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

	@	INGENUS PHARMS LLC	50MG/VIAL	A210984	001	Sep 16, 2019	Jun CAHN
>A>	AP	NIVAGEN	50MG/VIAL	A212117	001	Dec 07, 2020	Aug CAHN
>D>	AP	NIVAGEN PHARMS INC	50MG/VIAL	A212117	001	Dec 07, 2020	Aug CAHN
	@	NOVAST LABS	50MG/VIAL	A210984	001	Sep 16, 2019	Feb DISC

DEFERIPRONE

TABLET;ORAL

FERRIPROX

	@ +	CHIESI	500MG	N021825	001	Oct 14, 2011	Apr DISC
--	-----	--------	-------	---------	-----	--------------	----------

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DEFEROXAMINE MESYLATE

	@	HIKMA	500MG/VIAL	A078086	001	May 30, 2007	Mar DISC
	@		2GM/VIAL	A078086	002	May 30, 2007	Mar DISC

DEFLAZACORT

SUSPENSION;ORAL

DEFLAZACORT

AB		BIOCON PHARMA	22.75MG/ML	A220709	001	May 28, 2026	Jun CAHN
AB		CARNEGIE	22.75MG/ML	A220709	001	May 28, 2026	May NEWA
AB		SUN PHARM INDS INC	22.75MG/ML	A219930	001	Jan 27, 2026	Jan NEWA

DEHYDRATED ALCOHOLSOLUTION; INTRA-ARTERIAL
ABLYSINOL

	@ +	BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018	Jan CAIN
AP	+	!	99% (5ML)	N207987	002	Jun 21, 2018	Jan CAIN

DEHYDRATED ALCOHOL

AP		ACCORD HLTHCARE	99% (5ML)	A217845	001	Jun 23, 2025	Jan CAIN
AP		BRECKENRIDGE	99% (5ML)	A219444	001	Jun 23, 2025	Jan CAIN
AP		INGENUS PHARMS LLC	99% (5ML)	A219569	001	Jul 09, 2025	Jan CAIN
AP		XGEN PHARMS	99% (5ML)	A219400	001	Jun 23, 2025	Jan CAIN

SOLUTION; INTRAVENOUS

DEHYDRATED ALCOHOL

	+	!	BE PHARMS	98% (5ML)	N214988	001	Oct 23, 2025	Jun CAHN
	+	!	ROYAL PHARMS	98% (5ML)	N214988	001	Oct 23, 2025	Jan CAIN

DESFLURANE

LIQUID; INHALATION

DESFLURANE

	@		SHANGHAI HENGRUI	100%	A208234	001	Feb 26, 2018	Jun DISC
			SUPRANE					
	+	!	BAXTER HLTHCARE	100%	N020118	001	Sep 18, 1992	Jun CTEC

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

	@		HERITAGE	10MG	A207433	001	May 05, 2016	Jan DISC
	@			25MG	A207433	002	May 05, 2016	Jan DISC
	@			50MG	A207433	003	May 05, 2016	Jan DISC
	@			75MG	A207433	004	May 05, 2016	Jan DISC
	@			100MG	A207433	005	May 05, 2016	Jan DISC
	@			150MG	A207433	006	May 05, 2016	Jan DISC
AB			INGENUS PHARMS LLC	10MG	A204963	001	Dec 26, 2017	Feb CAHN
AB				25MG	A204963	002	Dec 26, 2017	Feb CAHN
AB				50MG	A204963	003	Dec 26, 2017	Feb CAHN
AB				75MG	A204963	004	Dec 26, 2017	Feb CAHN
AB		!		100MG	A204963	005	Dec 26, 2017	Jul CHRS
AB				100MG	A204963	005	Dec 26, 2017	Feb CAHN
AB				150MG	A204963	006	Dec 26, 2017	Feb CAHN

NORPRAMIN

	@ +		VALIDUS PHARMS	10MG	N014399	007	Feb 11, 1982	Jul DISC
	@ +			25MG	N014399	001		Jul DISC
	@ +			50MG	N014399	003		Jul DISC
	@ +			75MG	N014399	004		Jul DISC
	@ +			100MG	N014399	005		Jul DISC
	@ +			150MG	N014399	006		Jul DISC

DESLORATADINE

TABLET; ORAL

DESLORATADINE

AB			NATCO PHARMA USA	5MG	A078351	001	Feb 10, 2012	May CMFD
	@			5MG	A078351	001	Feb 10, 2012	Mar CAHN

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

AP		+	!	J MOLNER	0.004MG/ML	N018938	001	Mar 30, 1984	Jun CAHN
	@				0.015MG/ML	N018938	002	Apr 25, 1995	Jun CAHN

DESMOPRESSIN ACETATE

AP			CAPLIN	0.004MG/ML	A219981	001	Feb 27, 2026	Feb NEWA
----	--	--	--------	------------	---------	-----	--------------	----------

SOLUTION; ORAL

DESMODA

	+	!	ETON	0.05MG/ML	N219873	001	Feb 25, 2026	Feb NEWA
--	---	---	------	-----------	---------	-----	--------------	----------

SPRAY, METERED; NASAL

DESMOPRESSIN ACETATE

>D>	AB		!	BAUSCH	0.01MG/SPRAY	A074830	001	Jan 25, 1999	Aug DISC
>A>		@			0.01MG/SPRAY	A074830	001	Jan 25, 1999	Aug DISC

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	ANNORA PHARMA	0.15MG,N/A;0.02MG,0.01MG	A219670	001	Jul 07, 2026	Jun NEWA
AB		0.15MG;0.03MG	A219761	001	Mar 18, 2026	Mar NEWA

DESONIDE

AEROSOL, FOAM; TOPICAL

VERDESO

@ + GENUS

0.05%

N021978 001 Sep 19, 2006 Apr CAHN

CREAM; TOPICAL

DESONIDE

AB	COSETTE PHARMS NC	0.05%	A074027	001	Sep 28, 1992	May CAHN
----	-------------------	-------	---------	-----	--------------	----------

LOTION; TOPICAL

DESONIDE

@ ENCUBE

0.05%

A207855 001 Sep 28, 2017 May CAHN

@ VERTICE

0.05%

A207855 001 Sep 28, 2017 Apr CAHN

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

>D> AB	ACTAVIS MID ATLANTIC	0.25%	A205082	001	Sep 04, 2015	Aug DISC
--------	----------------------	-------	---------	-----	--------------	----------

>A>	@	0.25%	A205082	001	Sep 04, 2015	Aug DISC
-----	---	-------	---------	-----	--------------	----------

@ COSETTE PHARMS NC

0.25%

A209595 001 Mar 04, 2020 Jun CAHN

AB	SCIEGEN PHARMS	0.05%	A203787	001	Jan 06, 2017	Apr CMFD
----	----------------	-------	---------	-----	--------------	----------

AB		0.25%	A203234	001	Jun 12, 2015	Apr CMFD
----	--	-------	---------	-----	--------------	----------

GEL; TOPICAL

DESOXIMETASONE

@ PADAGIS US

0.05%

A077552 001 Jan 09, 2006 Mar DISC

OINTMENT; TOPICAL

DESOXIMETASONE

@ COSETTE PHARMS NC

0.25%

A206740 001 Dec 23, 2016 Jun CAHN

@ ENCUBE

0.25%

A208101 001 Feb 25, 2016 May CAHN

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB	PLATINUM	EQ 50MG BASE	A204805	001	May 07, 2019	Mar CAHN
----	----------	--------------	---------	-----	--------------	----------

AB		EQ 100MG BASE	A204805	002	May 07, 2019	Mar CAHN
----	--	---------------	---------	-----	--------------	----------

AB	YICHANG HUMANWELL	EQ 25MG BASE	A220460	001	Mar 10, 2026	Feb NEWA
----	-------------------	--------------	---------	-----	--------------	----------

AB		EQ 50MG BASE	A220460	002	Mar 10, 2026	Feb NEWA
----	--	--------------	---------	-----	--------------	----------

AB		EQ 100MG BASE	A220460	003	Mar 10, 2026	Feb NEWA
----	--	---------------	---------	-----	--------------	----------

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

+! HIKMA

1MG/ML

A088252 001 Sep 01, 1983 Jan CRLD

SUSPENSION; INTRAOCULAR

DEXYCU KIT

@ + EYEPOINT PHARMS

9%

N208912 001 Feb 09, 2018 Jul DISC

TABLET; ORAL

DEXAMETHASONE

PANGEA

0.25MG

A088149 001 Apr 28, 1983 Mar CMFD

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

! BAUSCH AND LOMB INC

EQ 0.1% PHOSPHATE

A040069 001 Jul 26, 1996 May CAHN

@ CAPLIN

EQ 0.1% PHOSPHATE

A088771 001 Jan 16, 1985 Jan CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	BAUSCH AND LOMB INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064063	001	Jul 25, 1994	May CAHN
----	---------------------	---------------------------------------	---------	-----	--------------	----------

@ PADAGIS US

0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062938 001 Jul 31, 1989 Mar DISC

SUSPENSION/DROPS; OPHTHALMIC

DEXASPORIN

AT	BAUSCH AND LOMB INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064135	001	Sep 13, 1995	May CAHN
----	---------------------	---------------------------------------	---------	-----	--------------	----------

DEXAMETHASONE; TOBRAMYCINSUSPENSION/DROPS;OPHTHALMIC
TOBRAMYCIN AND DEXAMETHASONE

AB	BAUSCH AND LOMB INC	0.1%;0.3%	A064134	001	Oct 27, 1999	May CAHN
----	---------------------	-----------	---------	-----	--------------	----------

DEXMEDETOMIDINE HYDROCHLORIDEFILM;BUCCAL, SUBLINGUAL
IGALMI

+ BIOXCEL EQ 0.18MG BASE

N215390 002 Apr 05, 2022 Jan CHRS

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	BAXTER HLTHCARE CORP	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A208103	001	Apr 15, 2026	Apr NEWA
	@ CAPLIN	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	Apr DISC
AP		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	Jan CAHN
AP	DR REDDYS	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A220315	001	Feb 25, 2026	Feb NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A220315	002	Feb 25, 2026	Feb NEWA
	@ HENGRUI PHARMA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jun DISC
	@ KNACK	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A218675	001	Mar 09, 2026	May DISC
AP		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A218675	001	Mar 09, 2026	Feb NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	5MG	A202580	002	Aug 25, 2015	Mar CMS1
	@	10MG	A202580	003	Aug 25, 2015	Mar CMS1
	@	15MG	A202580	004	Aug 25, 2015	Mar CMS1
	@	20MG	A202580	005	Dec 21, 2015	Mar CMS1
	@	25MG	A202580	006	May 04, 2021	Mar CMS1
	@	35MG	A202580	007	May 04, 2021	Mar CMS1
	@	40MG	A202580	008	Aug 25, 2015	Mar CMS1
AB	PLATINUM	5MG	A078992	001	Nov 23, 2021	Apr CAHN
AB		10MG	A078992	002	Nov 23, 2021	Apr CAHN
AB		15MG	A078992	003	Nov 18, 2013	Apr CAHN
AB		30MG	A078992	004	Nov 18, 2013	Apr CAHN
AB		20MG	A078992	005	Nov 23, 2021	Apr CAHN
AB		40MG	A078992	006	Nov 23, 2021	Apr CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE;ORAL

AZSTARYS

+	COMMAVE SUB	EQ 5.2MG BASE;EQ 26.1MG BASE	N212994	001	May 07, 2021	May CAHN
+		EQ 7.8MG BASE;EQ 39.2MG BASE	N212994	002	May 07, 2021	May CAHN
+	!	EQ 10.4MG BASE;EQ 52.3MG BASE	N212994	003	May 07, 2021	May CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

@	QUAGEN	5MG	A206735	001	Jan 27, 2016	Apr CAHN
@		10MG	A206735	002	Jan 27, 2016	Apr CAHN
@		15MG	A206735	003	Jan 27, 2016	Apr CAHN
@	STRIDES PHARMA INTL	5MG	A205673	001	Oct 31, 2017	Jan DISC
@		10MG	A205673	002	Oct 31, 2017	Jan DISC
@		15MG	A205673	003	Oct 31, 2017	Jan DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	COSETTE PHARMS NC	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012	May CAHN
AA	HETERO LABS LTD III	15MG/5ML;6.25MG/5ML	A218264	001	Mar 12, 2026	Mar NEWA
AA	RUBICON RESEARCH	15MG/5ML;6.25MG/5ML	A220869	001	Jun 23, 2026	Jun NEWA

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB	SUN PHARM	20MG;10MG	A204196	001	Jun 03, 2026	May NEWA
	NUDEXTA					
AB	+! OTSUKA AMERICA PHARM	20MG;10MG	N021879	001	Oct 29, 2010	May CAHN

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION;ORAL, RECTAL

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM

>A> AA	ADAPTIS	66%;10%	A214201	001	Jun 27, 2022	Aug CAHN
>D> AA	ANDA REPOSITORY	66%;10%	A214201	001	Jun 27, 2022	Aug CAHN
>A> AA	GUARDIAN DRUG	66%;10%	A214201	001	Jun 27, 2022	Aug CAHN

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

AP	BAXTER HLTHCARE CORP	10MG/2ML (5MG/ML)	A219882	001	Jul 28, 2026	Jul NEWA
	!	20MG/4ML (5MG/ML)	A219882	002	Jul 28, 2026	Jul NFTG
AP	LUPIN	10MG/2ML (5MG/ML)	A220365	001	Jul 27, 2026	Jul NEWA

TABLET;ORAL

DIAZEPAM

@	STRIDES PHARMA INTL	2MG	A077749	001	Mar 31, 2006	Jan DISC
@		5MG	A077749	002	Mar 31, 2006	Jan DISC
@		10MG	A077749	003	Mar 31, 2006	Jan DISC

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB	ONESOURCE	25MG	A210078	001	Dec 03, 2019	Jul CAHN
	ZIPSOR					
AB	+! ASSERTIO SPECLTY	25MG	N022202	001	Jun 16, 2009	Feb CAHN
AB	+! COSETTE	25MG	N022202	001	Jun 16, 2009	Jun CAHN

FOR SOLUTION;ORAL

CAMBIA

AB	+! ASSERTIO SPECLTY	50MG	N022165	001	Jun 17, 2009	Feb CAHN
AB	+! COSETTE	50MG	N022165	001	Jun 17, 2009	Jun CAHN

TABLET;ORAL

DICLOFENAC POTASSIUM

AB	INGENUS PHARMS LLC	50MG	A215585	001	Oct 08, 2021	Feb CAHN
AB	RISING	50MG	A075463	001	Jul 26, 1999	Jun CAHN

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB	ALEMBIC	3%	A212351	001	Jul 27, 2022	Jun CTEC
@	AMNEAL	3%	A200936	001	Oct 28, 2013	Mar DISC
	SOLARAZE					
@ +	FOUGERA	3%	N021005	001	Oct 16, 2000	Jul CAHN

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

AB	AUROBINDO PHARMA USA	100MG	A076152	001	Dec 13, 2001	Jul CMFD
AB	INGENUS PHARMS LLC	100MG	A216275	001	Sep 23, 2022	Feb CAHN

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DICLOXACILLIN SODIUM

>A> AB	CHARTWELL RX	EQ 250MG BASE	A062286	001	Jun 03, 1982	Aug CAHN
>A> AB	!	EQ 500MG BASE	A062286	002	Jun 03, 1982	Aug CAHN
>D> AB	TEVA	EQ 250MG BASE	A062286	001	Jun 03, 1982	Aug CAHN
>D> AB	!	EQ 500MG BASE	A062286	002	Jun 03, 1982	Aug CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

AB	RUBICON RESEARCH	10MG	A216515	001	Jul 17, 2026	Jul NEWA
----	------------------	------	---------	-----	--------------	----------

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

>D> AB	AUROBINDO PHARMA USA	20MG	A040317	001	Sep 07, 1999	Aug CHRS
>A> AB	!	20MG	A040317	001	Sep 07, 1999	Aug CHRS

		TABLET;ORAL					
		DICYCLOMINE HYDROCHLORIDE					
>D>	AB	! WATSON LABS	20MG	A085223	001	Jul 30, 1986	Aug CHRS
>A>	AB		20MG	A085223	001	Jul 30, 1986	Aug CHRS
<u>DIFAMILAST</u>							
		OINTMENT;TOPICAL					
		ADQUEY					
		+! ACROTECH BIOPHARMA	1%	N219474	001	Feb 12, 2026	Feb NEWA
<u>DIFELIKEFALIN ACETATE</u>							
		SOLUTION;INTRAVENOUS					
>A>		DIFELIKEFALIN ACETATE					
>A>	AP	QILU PHARM HAINAN	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	A220919	001	Aug 31, 2026	Aug NFTG
		KORSUVA					
>D>		+! VIFOR INTL	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021	Aug CFTG
>A>	AP	+!	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021	Aug CFTG
<u>DIFLUPREDNATE</u>							
		EMULSION;OPHTHALMIC					
		DIFLUPREDNATE					
	AB	ALEMBIC	0.05%	A213774	001	Jan 26, 2026	Jan NEWA
>D>	AB	CIPLA	0.05%	A211776	001	Aug 09, 2021	Aug DISC
>A>	@		0.05%	A211776	001	Aug 09, 2021	Aug DISC
<u>DIGOXIN</u>							
		INJECTABLE;INJECTION					
		LANOXIN					
AP		+! AZURITY	0.25MG/ML	N009330	002		Jul CAHN
AP		+!	0.25MG/ML	N009330	002		Mar CAHN
		LANOXIN PEDIATRIC					
		+! AZURITY	0.1MG/ML	N009330	004		Jul CAHN
		+!	0.1MG/ML	N009330	004		Mar CAHN
		TABLET;ORAL					
		DIGOXIN					
		@ SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	May DISC
		@	0.25MG	A076363	002	Jan 31, 2003	May DISC
<u>DIHYDROERGOTAMINE MESYLATE</u>							
		INJECTABLE;INJECTION					
		DIHYDROERGOTAMINE MESYLATE					
		@ PADAGIS US	1MG/ML	A040475	001	Apr 28, 2003	Mar DISC
<u>DILTIAZEM HYDROCHLORIDE</u>							
		CAPSULE, EXTENDED RELEASE;ORAL					
		CARDIZEM CD					
AB3		+ BAUSCH	360MG	N020062	005	Aug 24, 1999	Jul CHRS
		DILTIAZEM HYDROCHLORIDE					
AB3		MACLEODS PHARMS	120MG	A218744	001	Feb 27, 2026	Feb NEWA
AB3			180MG	A218744	002	Feb 27, 2026	Feb NEWA
AB3			240MG	A218744	003	Feb 27, 2026	Feb NEWA
AB3			300MG	A218744	004	Feb 27, 2026	Feb NEWA
AB3			360MG	A218744	005	Feb 27, 2026	Feb NEWA
AB3		! NOVAST LABS	360MG	A208783	005	Jun 14, 2019	Jul CHRS
		TABLET;ORAL					
		DILTIAZEM HYDROCHLORIDE					
>A>	@	ADAPTIS	30MG	A211596	001	Nov 18, 2019	Aug CAHN
>A>	@		60MG	A211596	002	Nov 18, 2019	Aug CAHN
>A>	@		90MG	A211596	003	Nov 18, 2019	Aug CAHN
>A>	@		120MG	A211596	004	Nov 18, 2019	Aug CAHN
>D>	@	EDENBRIDGE PHARMS	30MG	A211596	001	Nov 18, 2019	Aug CAHN
>D>	@		60MG	A211596	002	Nov 18, 2019	Aug CAHN
>D>	@		90MG	A211596	003	Nov 18, 2019	Aug CAHN
>D>	@		120MG	A211596	004	Nov 18, 2019	Aug CAHN
AB		ZYDUS LIFESCIENCES	30MG	A219253	001	Aug 08, 2025	May CMFD
	@		30MG	A219253	001	Aug 08, 2025	Jan DISC
AB			60MG	A219253	002	Aug 08, 2025	May CMFD
	@		60MG	A219253	002	Aug 08, 2025	Jan DISC
AB			90MG	A219253	003	Aug 08, 2025	May CMFD
	@		90MG	A219253	003	Aug 08, 2025	Jan DISC

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE							
AB		120MG	A219253	004	Aug 08, 2025	May	CMFD
	@	120MG	A219253	004	Aug 08, 2025	Jan	DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE							
	@ MYLAN	120MG	A210531	001	Aug 17, 2020	Mar	DISC
	@	240MG	A210531	002	Aug 17, 2020	Mar	DISC

DIMETHYL SULFOXIDE

SOLUTION;INTRAVESICAL

DIMETHYL SULFOXIDE							
AT	RENOVA PHARMS	50%	A220173	001	Jul 07, 2026	Jul	CAHN
AT	STIRA	50%	A220173	001	Jul 07, 2026	Jun	NEWA
RIMSO-50							
AT	+! MYLAN INSTITUTIONAL	50%	N017788	001		Jun	CTEC

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE							
AA	ANNORA PHARMA	12.5MG/5ML	A219470	001	Jun 17, 2026	Jun	NEWA
AA	+! PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982	Jun	CTEC

DISULFIRAM

TABLET;ORAL

DISULFIRAM							
	@ NATCO PHARMA USA	250MG	A203916	001	Mar 04, 2015	Mar	CAHN
	@	500MG	A203916	002	Mar 04, 2015	Mar	CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM							
	@ LUPIN	EQ 125MG VALPROIC ACID	A078790	001	Jul 29, 2008	May	DISC
	@	EQ 250MG VALPROIC ACID	A078790	002	Jul 29, 2008	May	DISC
	@	EQ 500MG VALPROIC ACID	A078790	003	Jul 29, 2008	May	DISC

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM							
	@ COSETTE PHARMS NC	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Jun	CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE							
AP	HAINAN POLY	EQ 12.5MG BASE/ML	A216131	001	Dec 21, 2022	Jul	CAHN

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL							
>A>	AP	ADAPTIS	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	Aug CAHN
>A>	AP		80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	Aug CAHN
>A>	AP		160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	Aug CAHN
	@	GUANGDONG SUNHO	20MG/ML (20MG/ML)	A213768	001	May 13, 2025	Jul DISC
	@		80MG/4ML (20MG/ML)	A213768	002	May 13, 2025	Jul DISC
	@	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Feb CAHN
	@		80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Feb DISC
AP			80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Feb CAHN
	@		160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Feb DISC
AP			160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Feb CAHN
>D>	AP	SHILPA	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	Aug CAHN
>D>	AP		80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	Aug CAHN
>D>	AP		160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	Aug CAHN

SOLUTION;INTRAVENOUS

BEIZRAY							
	+! ZHUHAI	20MG/ML (20MG/ML)	N218711	002	Dec 10, 2025	Jul	NEWA

DOFETILIDECAPSULE;ORAL
DOFETILIDE

>A>	AB	ANDAS 5 HOLDING	0.125MG	A212496	001	Jul 29, 2026	Aug CAHN
>A>	AB		0.25MG	A212496	002	Jul 29, 2026	Aug CAHN
>A>	AB		0.5MG	A212496	003	Jul 29, 2026	Aug CAHN
	@	APPCO	0.125MG	A215323	001	Apr 14, 2022	Jun CAHN
	@		0.25MG	A215323	002	Apr 14, 2022	Jun CAHN
	@		0.5MG	A215323	003	Apr 14, 2022	Jun CAHN
	@	INGENUS PHARMS LLC	0.125MG	A212410	001	Dec 27, 2019	Feb CAHN
	@		0.25MG	A212410	002	Dec 27, 2019	Feb CAHN
	@		0.5MG	A212410	003	Dec 27, 2019	Feb CAHN
>D>	AB	INNOGENIX INC	0.125MG	A212496	001	Jul 29, 2026	Aug CAHN
	AB		0.125MG	A212496	001	Jul 29, 2026	Jul NEWA
>D>	AB		0.25MG	A212496	002	Jul 29, 2026	Aug CAHN
	AB		0.25MG	A212496	002	Jul 29, 2026	Jul NEWA
>D>	AB		0.5MG	A212496	003	Jul 29, 2026	Aug CAHN
	AB		0.5MG	A212496	003	Jul 29, 2026	Jul NEWA
	@	STRIDES PHARMA INTL	0.125MG	A208519	001	Oct 09, 2018	Jan DISC
	@		0.25MG	A208519	002	Oct 09, 2018	Jan DISC
	@		0.5MG	A208519	003	Oct 09, 2018	Jan DISC

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

@	LUPIN	23MG	A202782	001	Oct 30, 2015	Feb DISC
@	STRIDES PHARMA	5MG	A078662	001	May 31, 2011	Jun DISC
@		10MG	A078662	002	May 31, 2011	Jun DISC

DORAVIRINE; ISLATRAVIR

TABLET;ORAL

IDVYNZO

+	!	MSD	100MG;0.25MG	N216964	001	Apr 20, 2026	Apr NEWA
---	---	-----	--------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT2		ALEMBIC THERAP	EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	May CAHN
>D>	@	RUBICON RESEARCH	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008	Aug CMFD
>A>	AT1		EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008	Aug CMFD

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIIN HYDROCHLORIDE

>D>	AB	IXORA LIFESCIENCE	EQ 10MG BASE	A211619	001	Mar 09, 2021	Aug CAHN
>D>	AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Aug CAHN
>D>	AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Aug CAHN
>D>	AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Aug CAHN
>D>	AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Aug CAHN
>A>	AB	LEADING	EQ 10MG BASE	A211619	001	Mar 09, 2021	Aug CAHN
>A>	AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Aug CAHN
>A>	AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Aug CAHN
>A>	AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Aug CAHN
>A>	AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Aug CAHN
>D>	AB	MICRO LABS	EQ 10MG BASE	A217688	001	Jun 27, 2023	Aug DISC
>A>	@		EQ 10MG BASE	A217688	001	Jun 27, 2023	Aug DISC
>D>	AB		EQ 25MG BASE	A217688	002	Jun 27, 2023	Aug DISC
>A>	@		EQ 25MG BASE	A217688	002	Jun 27, 2023	Aug DISC
>D>	AB		EQ 50MG BASE	A217688	003	Jun 27, 2023	Aug DISC
>A>	@		EQ 50MG BASE	A217688	003	Jun 27, 2023	Aug DISC
>D>	AB		EQ 75MG BASE	A217688	004	Jun 27, 2023	Aug DISC
>A>	@		EQ 75MG BASE	A217688	004	Jun 27, 2023	Aug DISC
>D>	AB		EQ 100MG BASE	A217688	005	Jun 27, 2023	Aug DISC
>A>	@		EQ 100MG BASE	A217688	005	Jun 27, 2023	Aug DISC
	@	PH HEALTH	EQ 150MG BASE	A071422	006	Nov 09, 1987	Jul DISC
	AB	UNIQUE	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar CAHN
	AB		EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar CAHN
	AB		EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar CAHN
	AB		EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar CAHN
	AB		EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar CAHN
	AB	!	VELZEN PHARMA PVT	A211618	001	Mar 01, 2021	Jul CHRS

CREAM; TOPICAL							
DOXEFIN HYDROCHLORIDE							
AB	SUN PHARMA CANADA	5%		A213919	001	Apr 28, 2026	Apr NEWA
<u>DOXERCALCIFEROL</u>							
INJECTABLE; INJECTION							
DOXERCALCIFEROL							
AP	@ CAPLIN	4MCG/2ML (2MCG/ML)		A200926	001	Feb 04, 2014	Apr DISC
		4MCG/2ML (2MCG/ML)		A200926	001	Feb 04, 2014	Jan CAHN
	@	2MCG/ML (2MCG/ML)		A200926	002	Sep 04, 2014	Apr DISC
		2MCG/ML (2MCG/ML)		A200926	002	Sep 04, 2014	Apr NEWA
	@ EUGIA PHARMA	4MCG/2ML (2MCG/ML)		A213717	002	Jan 24, 2022	Mar DISC
	@ HIKMA	4MCG/2ML (2MCG/ML)		A091101	001	Aug 30, 2013	Mar DISC
<u>DOXORUBICIN HYDROCHLORIDE</u>							
INJECTABLE, LIPOSOMAL; INJECTION							
DOXORUBICIN HYDROCHLORIDE							
AB	QILU PHARM HAINAN	20MG/10ML (2MG/ML)		A219881	001	Feb 03, 2026	Jan NEWA
AB		50MG/25ML (2MG/ML)		A219881	002	Feb 03, 2026	Jan NEWA
<u>DOXYCYCLINE</u>							
CAPSULE; ORAL							
DOXYCYCLINE							
AB	AIPING PHARM INC	40MG		A219978	001	Oct 01, 2025	Jan CAHN
	@ COSETTE PHARMS NC	EQ 50MG BASE		A204446	001	May 28, 2015	Jun CAHN
	@	EQ 75MG BASE		A204446	002	May 28, 2015	Jun CAHN
	@	EQ 100MG BASE		A204446	003	May 28, 2015	Jun CAHN
<u>DOXYCYCLINE HYCLATE</u>							
INJECTABLE; INJECTION							
DOXYCYCLINE HYCLATE							
AP	@ AVET LIFESCIENCES	EQ 100MG BASE/VIAL		A203276	001	Feb 19, 2026	Feb DISC
		EQ 100MG BASE/VIAL		A203276	001	Feb 19, 2026	Feb NEWA
AP	HAINAN POLY	EQ 100MG BASE/VIAL		A217685	001	Jun 21, 2024	Jul CAHN
AP		EQ 200MG BASE/VIAL		A217685	002	Jun 21, 2024	Jul CAHN
AP	PHARMOBEDIENT	EQ 100MG BASE/VIAL		A217078	001	Feb 21, 2025	Jun CAHN
TABLET; ORAL							
DOXYCYCLINE HYCLATE							
	@ APOTEX	EQ 75MG BASE		A209243	001	Apr 15, 2019	Jan DISC
	@	EQ 150MG BASE		A209243	002	Apr 15, 2019	Jan DISC
	@ ARTHUR GRP	EQ 100MG BASE		A212487	001	Mar 30, 2022	Jul CAHN
TABLET, DELAYED RELEASE; ORAL							
DORYX							
	@ + MAYNE PHARMA	EQ 80MG BASE		N050795	004	Apr 11, 2013	Apr DISC
	@ +	EQ 200MG BASE		N050795	005	Apr 11, 2013	Apr DISC
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE</u>							
TABLET, DELAYED RELEASE; ORAL							
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE							
	@ PHARMOBEDIENT	10MG; 10MG		A207825	001	Jul 06, 2020	Jun DISC
<u>DRONABINOL</u>							
CAPSULE; ORAL							
DRONABINOL							
	@ RHODES	2.5MG		A078292	001	Jun 27, 2008	May CAHN
	@	5MG		A078292	002	Jun 27, 2008	May CAHN
	@	10MG		A078292	003	Jun 27, 2008	May CAHN
SOLUTION; ORAL							
SYNDROS							
	@ + WELLHOUSE PHARMA	5MG/ML		N205525	001	Mar 23, 2017	Jan CAHN
<u>DRONEDARONE HYDROCHLORIDE</u>							
TABLET; ORAL							
DRONEDARONE HYDROCHLORIDE							
	@ LUPIN	EQ 400MG BASE		A205904	001	Jan 31, 2024	Mar DISC
MULTAQ							
	+! SANOFI AVENTIS US	EQ 400MG BASE		N022425	001	Jul 01, 2009	Mar CTEC

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

+	!	ALMATICA	EQ 80MG BASE	N219131	001	Feb 27, 2026	Feb NEWA
+			EQ 90MG BASE	N219131	002	Feb 27, 2026	Feb NEWA
+			EQ 120MG BASE	N219131	003	Feb 27, 2026	Feb NEWA

DUTASTERIDECAPSULE;ORAL
DUTASTERIDE

AB		ONESOURCE	0.5MG	A204262	001	Nov 20, 2015	Jul CAHN
----	--	-----------	-------	---------	-----	--------------	----------

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDECAPSULE;ORAL
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

>D>	AB	PH HEALTH	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Aug DISC
>A>		@	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Aug DISC

ECONAZOLE NITRATECREAM;TOPICAL
ECONAZOLE NITRATE

AB		AUROBINDO PHARMA USA	1%	A210364	001	Apr 18, 2018	Mar CMFD
AB		ENCUBE	1%	A076574	001	Dec 17, 2004	Jun CMFD

EDARAVONESOLUTION;INTRAVENOUS
EDARAVONE

	@	DR REDDYS	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr DISC
	@	GLAND	60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr DISC
	@	PHARMOBEDIENT	30MG/100ML (0.3MG/ML)	A217565	001	Oct 31, 2024	Jun DISC
	@		60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Jun DISC
	!		60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Apr CTEC
AP		ZYDUS PHARMS	30MG/100ML (0.3MG/ML)	A218349	001	Jul 22, 2026	Jul NEWA
		RADICAVA					
	@ +	SHIONOGI	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr CAHN
	@ +		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr DISC
AP	+		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr CAHN

SUSPENSION;ORAL

RADICAVA ORS

	+	!	SHIONOGI	105MG/5ML	N215446	001	May 12, 2022	Apr CAHN
--	---	---	----------	-----------	---------	-----	--------------	----------

EFAVIRENZTABLET;ORAL
EFAVIRENZ

	@	PHARMOBEDIENT	600MG	A204869	001	Mar 12, 2018	Jul DISC
--	---	---------------	-------	---------	-----	--------------	----------

EFINACONAZOLESOLUTION;TOPICAL
EFINACONAZOLE

>D>	AB	ALEMBIC	10%	A212027	001	Feb 23, 2026	Aug DISC
>A>		@	10%	A212027	001	Feb 23, 2026	Aug DISC
	AB		10%	A212027	001	Feb 23, 2026	Feb NEWA
	AB	NIVAGEN PHARMS INC	10%	A211969	001	Jun 21, 2021	Mar CAHN

ELETRIPTAN HYDROBROMIDETABLET;ORAL
ELETRIPTAN HYDROBROMIDE

	@	CARLSBAD	EQ 20MG BASE	A209680	001	Jul 13, 2020	Feb CAHN
	@		EQ 40MG BASE	A209680	002	Jul 13, 2020	Feb CAHN

ELEXACFTOR, IVACFTOR, TEZACFTOR; IVACFTOR

GRANULE;ORAL

TRIKAFTA (COPACKAGED)

+		VERTEX PHARMS INC	80MG, 60MG, 40MG;59.5MG	N217660	001	Apr 26, 2023	Apr CDFR
+	!		100MG, 75MG, 50MG;75MG	N217660	002	Apr 26, 2023	Apr CDFR

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

@ CIPLA

EQ 84MG BASE

A212369 001 Dec 10, 2024 Feb DISC

ELTROMBOPAG OLAMINE

TABLET;ORAL

ELTROMBOPAG OLAMINE

AB	ACTAVIS LABS FL	EQ 50MG ACID	A208815	001	Jun 17, 2026	Jun NEWA
AB	AIZANT	EQ 12.5MG ACID	A220660	001	Apr 28, 2026	Apr NEWA
AB		EQ 25MG ACID	A220660	002	Apr 28, 2026	Apr NEWA
AB		EQ 50MG ACID	A220660	003	Apr 28, 2026	Apr NEWA
AB		EQ 75MG ACID	A220660	004	Apr 28, 2026	Apr NEWA
AB	AMNEAL	EQ 12.5MG ACID	A212884	001	Jan 14, 2026	Jan NEWA
AB		EQ 25MG ACID	A212884	003	Jan 14, 2026	Jan NEWA
AB		EQ 50MG ACID	A212884	002	Jan 14, 2026	Jan NEWA
AB		EQ 75MG ACID	A212884	004	Jan 14, 2026	Jan NEWA
AB	BIOCON PHARMA	EQ 12.5MG ACID	A220660	001	Apr 28, 2026	May CAHN
AB		EQ 25MG ACID	A220660	002	Apr 28, 2026	May CAHN
AB		EQ 50MG ACID	A220660	003	Apr 28, 2026	May CAHN
AB		EQ 75MG ACID	A220660	004	Apr 28, 2026	May CAHN
AB	DR REDDYS	EQ 12.5MG ACID	A219121	001	Mar 16, 2026	Mar NEWA
AB		EQ 25MG ACID	A219121	002	Mar 16, 2026	Mar NEWA
AB		EQ 50MG ACID	A219121	003	Mar 16, 2026	Mar NEWA
AB		EQ 75MG ACID	A219121	004	Mar 16, 2026	Mar NEWA
AB	HIKMA	EQ 12.5MG ACID	A220033	001	Apr 08, 2026	Apr CAHN
AB		EQ 25MG ACID	A220033	002	Apr 08, 2026	Apr CAHN
AB		EQ 50MG ACID	A220033	003	Apr 08, 2026	Apr CAHN
AB		EQ 75MG ACID	A220033	004	Apr 08, 2026	Apr CAHN
AB	MSN	EQ 12.5MG ACID	A220250	001	Jan 14, 2026	Jan NEWA
AB		EQ 25MG ACID	A220250	002	Jan 14, 2026	Jan NEWA
AB		EQ 50MG ACID	A220250	003	Jan 14, 2026	Jan NEWA
AB		EQ 75MG ACID	A220250	004	Jan 14, 2026	Jan NEWA
AB	SOMERSET THERAPS LLC	EQ 12.5MG ACID	A219638	001	Jan 14, 2026	Jan NEWA
AB		EQ 25MG ACID	A219638	002	Jan 14, 2026	Jan NEWA
AB		EQ 50MG ACID	A219638	003	Jan 14, 2026	Jan NEWA
AB		EQ 75MG ACID	A219638	004	Jan 14, 2026	Jan NEWA
AB	TEVA PHARMS USA	EQ 12.5MG ACID	A209938	001	Jul 13, 2026	Jul NEWA
AB		EQ 25MG ACID	A209938	002	Jul 13, 2026	Jul NEWA
AB		EQ 75MG ACID	A209938	003	Jul 13, 2026	Jul NEWA
AB	ZENARA	EQ 12.5MG ACID	A220033	001	Apr 08, 2026	Mar NEWA
AB		EQ 25MG ACID	A220033	002	Apr 08, 2026	Mar NEWA
AB		EQ 50MG ACID	A220033	003	Apr 08, 2026	Mar NEWA
AB		EQ 75MG ACID	A220033	004	Apr 08, 2026	Mar NEWA
AB	ZYDUS PHARMS	EQ 12.5MG ACID	A216281	001	Jan 14, 2026	Jan NEWA
AB		EQ 25MG ACID	A216281	002	Jan 14, 2026	Jan NEWA
AB		EQ 50MG ACID	A216281	003	Jan 14, 2026	Jan NEWA
AB		EQ 75MG ACID	A216281	004	Jan 14, 2026	Jan NEWA

ELUXADOLINE

TABLET;ORAL

ELUXADOLINE

	@ AUROBINDO PHARMA	75MG	A213511	001	Jun 02, 2026	Jun DISC
AB		75MG	A213511	001	Jun 02, 2026	May NEWA
	@	100MG	A213511	002	Jun 02, 2026	Jun DISC
AB		100MG	A213511	002	Jun 02, 2026	May NEWA
	VIBERZI					
	+ ABBVIE	75MG	N206940	001	May 27, 2015	Jun CTEC
AB	+	75MG	N206940	001	May 27, 2015	May CTEC
AB	+	75MG	N206940	001	May 27, 2015	May CTEC
	+!	100MG	N206940	002	May 27, 2015	Jun CTEC
AB	+!	100MG	N206940	002	May 27, 2015	May CTEC
AB	+!	100MG	N206940	002	May 27, 2015	May CTEC

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE

	@ APOTEX	200MG;EQ 25MG BASE;EQ 25MG BASE	A214095	001	Jan 30, 2026	Jul DISC
AB		200MG;EQ 25MG BASE;EQ 25MG BASE	A214095	001	Jan 30, 2026	Jan NFTG

TABLET;ORAL
ODEFSEY

	+	!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Jul CTEC
AB		+	!	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Jan CFTG

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE

AB			LAURUS	200MG;EQ 25MG BASE;300MG	A220232	001	Mar 04, 2026	Feb NEWA
----	--	--	--------	--------------------------	---------	-----	--------------	----------

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

	@		LUPIN	200MG;EQ 25MG BASE	A213926	001	Dec 13, 2024	Mar DISC
AB			MACLEODS PHARMS	200MG;EQ 25MG BASE	A214216	001	Apr 07, 2026	Mar NEWA
>A> AB			NATCO	200MG;EQ 25MG BASE	A214173	001	Aug 26, 2026	Aug NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

	@		PHARMOBEDIANT	200MG;300MG	A206436	001	Apr 09, 2018	Jun DISC
--	---	--	---------------	-------------	---------	-----	--------------	----------

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

	@		COSETTE PHARMS NC	5MG;12.5MG	A075727	001	Sep 18, 2001	Jun CAHN
	@			10MG;25MG	A075727	002	Sep 18, 2001	Jun CAHN

ENLICITIDE DECANOATE

TABLET;ORAL
LIPFENDRA

	+	!	MSD	EQ 20MG BASE	N220848	001	Jul 15, 2026	Jul NEWA
--	---	---	-----	--------------	---------	-----	--------------	----------

ENSIFENTRINE

SUSPENSION;INHALATION
OHTUVAYRE

	+	!	MSD	3MG/2.5ML	N217389	001	Jun 26, 2024	Apr CAHN
--	---	---	-----	-----------	---------	-----	--------------	----------

ENSITRELVIR

TABLET;ORAL
XOCOVA

	+	!	SHIONOGI	125MG	N220442	001	May 29, 2026	May NEWA
--	---	---	----------	-------	---------	-----	--------------	----------

ENTECAVIR

TABLET;ORAL
ENTECAVIR

	@		PHARMADAX	0.5MG	A212106	001	Aug 10, 2020	Mar CAHN
	@			1MG	A212106	002	Aug 10, 2020	Mar CAHN

ENZALUTAMIDE

TABLET;ORAL
ENZALUTAMIDE

AB			SANDOZ	40MG	A216068	001	Apr 20, 2026	Apr NFTG
AB				80MG	A216068	002	Apr 20, 2026	Apr NFTG
			XTANDI					
AB		+	ASTELLAS	40MG	N213674	001	Aug 04, 2020	Apr CFTG
AB		+	!	80MG	N213674	002	Aug 04, 2020	Apr CFTG

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS
EPHEDRINE SULFATE

AP			BAXTER HLTHCARE CORP	50MG/ML (50MG/ML)	A216740	001	Jul 08, 2026	Jun NEWA
	@		CIVICA	50MG/ML (50MG/ML)	A215593	001	Dec 23, 2025	Jun DISC
AP2			FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A219991	001	Mar 19, 2026	Mar NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

@	APOTEX	0.05%	A090919	001	Oct 31, 2011	Apr DISC
!	SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Apr CTEC

EPINEPHRINESOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
EPINEPHRINE

	+	!	BAXTER HLTHCARE CORP	1MG/ML (1MG/ML)	N220626	001	Mar 30, 2026	Mar NEWA
	+	!		30MG/30ML (1MG/ML)	N220626	002	Mar 30, 2026	Mar NEWA
AP	+	!	BPI LABS	1MG/ML (1MG/ML)	N205029	005	Mar 04, 2024	May CFTG
AP			DEVA HLDING	1MG/ML (1MG/ML)	A217426	001	Jul 31, 2026	Jul NEWA
AP			HIKMA	1MG/ML (1MG/ML)	A220562	001	May 29, 2026	May NFTG

SOLUTION;INTRAVENOUS

EPINEPHRINE

@	+		HOSPIRA	1MG/10ML (0.1MG/ML)	N209359	001	Nov 05, 2019	Jun DISC
---	---	--	---------	---------------------	---------	-----	--------------	----------

EPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

	+	!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N218475	002	Mar 16, 2026	Mar NEWA
@	+			EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N218475	001	Feb 28, 2025	Jun DISC

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

SOLUTION;INJECTION

FLAVALTA

	+	!	DEPROCO	EQ 0.017MG BASE/1.7ML (EQ 0.01MG BASE/ML);34MG/1.7ML (20MG/ML)	N216564	001	Mar 19, 2026	Mar NEWA
--	---	---	---------	--	---------	-----	--------------	----------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

@	+		WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Apr CRLD
---	---	--	----------------------	--------------	---------	-----	--	----------

EPLERENONE

TABLET;ORAL

EPLERENONE

>A>	@		ANDAS 5 HOLDING	25MG	A203896	001	Feb 02, 2017	Aug CAHN
>A>	@			50MG	A203896	002	Feb 02, 2017	Aug CAHN
>D>	@		INNOGENIX	25MG	A203896	001	Feb 02, 2017	Aug CAHN
	@			25MG	A203896	001	Feb 02, 2017	May CAHN
>D>	@			50MG	A203896	002	Feb 02, 2017	Aug CAHN
	@			50MG	A203896	002	Feb 02, 2017	May CAHN

EPLONTERSEN SODIUM

SOLUTION;SUBCUTANEOUS

WAINUA

	+	!	ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	002	Apr 15, 2026	Apr NEWA
--	---	---	----------------	---	---------	-----	--------------	----------

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

@			MEITHEAL	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Jun DISC
@				EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Jun DISC

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP			HAINAN POLY	2MG/ML	A209864	001	Jan 25, 2019	Jul CAHN
AP				75MG/100ML	A209864	002	Jan 25, 2019	Jul CAHN

ERGOALCIFIEROL

CAPSULE;ORAL

ERGOALCIFIEROL

AA	!	ONESOURCE	50,000 IU	A090455	001	Aug 03, 2010	Jul CAHN
----	---	-----------	-----------	---------	-----	--------------	----------

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL

ERGOMAR

+! PANGEA

2MG

A087693	001	Feb 24, 1983	Jul CRLD
---------	-----	--------------	----------

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS

ERIBULIN MESYLATE

AP		FORMOSA LABS	1MG/2ML (0.5MG/ML)	A219054	001	Mar 16, 2026	Mar NEWA
AP		NATCO	1MG/2ML (0.5MG/ML)	A217085	001	Jun 01, 2026	May NEWA
AP		XGEN PHARMS	1MG/2ML (0.5MG/ML)	A219054	001	Mar 16, 2026	Mar CAHN

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

>A>	AB	ADAPTIS	EQ 25MG BASE	A211960	001	Nov 05, 2019	Aug CAHN
>A>	AB		EQ 100MG BASE	A211960	002	Nov 05, 2019	Aug CAHN
>A>	AB		EQ 150MG BASE	A211960	003	Nov 05, 2019	Aug CAHN
>D>	AB	SHILPA	EQ 25MG BASE	A211960	001	Nov 05, 2019	Aug CAHN
>D>	AB		EQ 100MG BASE	A211960	002	Nov 05, 2019	Aug CAHN
>D>	AB		EQ 150MG BASE	A211960	003	Nov 05, 2019	Aug CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYTHROMYCIN

AB		CARNEGIE	250MG	A062746	001	Dec 22, 1986	Feb CAHN
----	--	----------	-------	---------	-----	--------------	----------

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

AT	!	BAUSCH AND LOMB INC	0.5%	A064067	001	Jul 29, 1994	May CAHN
		ILOTYCIN					
	@ +	DISTA	0.5%	N050368	001		Jul CRLD

SOLUTION;TOPICAL

ERYTHROMYCIN

@ ENCUBE

2%

A208100	001	Nov 20, 2017	May CAHN
---------	-----	--------------	----------

TABLET;ORAL

ERYTHROMYCIN

AB		CARNEGIE	250MG	A061621	001		Feb CAHN
AB			500MG	A061621	002		Feb CAHN

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

AB		CARNEGIE	250MG	A062298	001		Feb CAHN
AB			333MG	A062298	003	Mar 29, 1982	Feb CAHN
AB	!		500MG	A062298	002		Feb CAHN

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

@ COSETTE PHARMS NC

EQ 125MG BASE/5ML

A062169	001	Oct 17, 1990	Jun CAHN
---------	-----	--------------	----------

@

EQ 250MG BASE/5ML

A062169	002	Oct 17, 1990	Jun CAHN
---------	-----	--------------	----------

ERYTHROMYCIN ETHYLSUCCINATE

TABLET;ORAL

E.E.S. 400

@ CARNEGIE

EQ 400MG BASE

A061905	001		Feb CAHN
---------	-----	--	----------

BX	!		EQ 400MG BASE	A061905	002	Aug 12, 1982	Feb CAHN
----	---	--	---------------	---------	-----	--------------	----------

ERYTHROMYCIN ETHYLSUCCINATE

BX	!	CARNEGIE	EQ 400MG BASE	A061904	001		Feb CAHN
----	---	----------	---------------	---------	-----	--	----------

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

MICRO LABS

EQ 5MG BASE

A091655	001	Apr 22, 2026	Aug DISC
---------	-----	--------------	----------

@

EQ 5MG BASE

A091655	001	Apr 22, 2026	Aug DISC
---------	-----	--------------	----------

AB			EQ 5MG BASE	A091655	001	Apr 22, 2026	Apr NEWA
----	--	--	-------------	---------	-----	--------------	----------

>D>	AB		EQ 10MG BASE	A091655	002	Apr 22, 2026	Aug DISC
-----	----	--	--------------	---------	-----	--------------	----------

TABLET;ORAL

ESCITALOPRAM OXALATE

>A>	@	EQ 10MG BASE	A091655	002	Apr 22, 2026	Aug DISC
AB		EQ 10MG BASE	A091655	002	Apr 22, 2026	Apr NEWA
>D>	AB	EQ 20MG BASE	A091655	003	Apr 22, 2026	Aug DISC
>A>	@	EQ 20MG BASE	A091655	003	Apr 22, 2026	Aug DISC
AB		EQ 20MG BASE	A091655	003	Apr 22, 2026	Apr NEWA

ESLICARBAZEPINE ACETATE

TABLET;ORAL

ESLICARBAZEPINE ACETATE

AB	AUROBINDO PHARMA	200MG	A216481	001	Aug 05, 2026	Jul NEWA
AB		400MG	A216481	002	Aug 05, 2026	Jul NEWA
AB		600MG	A216481	003	Aug 05, 2026	Jul NEWA
AB		800MG	A216481	004	Aug 05, 2026	Jul NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

@	CISEN	EQ 20MG BASE	A213158	001	Sep 22, 2020	May DISC
@		EQ 40MG BASE	A213158	002	Sep 22, 2020	May DISC

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

>D>	AP	DEVA HOLDING AS	EQ 40MG BASE/VIAL	A207181	001	Mar 06, 2017	Aug CAHN
	AP	! HAINAN POLY	EQ 40MG BASE/VIAL	A215732	001	Feb 10, 2022	Jul CAHN
>A>	AP	REGCON HOLDINGS	EQ 40MG BASE/VIAL	A207181	001	Mar 06, 2017	Aug CAHN

ESTRADIOL

CREAM;VAGINAL

ESTRACE

AB	+! ABBVIE	0.01%	A086069	001	Jan 31, 1984	Mar CAHN
----	-----------	-------	---------	-----	--------------	----------

GEL;TRANSDERMAL

ESTRADIOL

AB	SOLARIS PHARMA CORP	0.1% (0.25GM/PACKET)	A217863	001	Jul 12, 2024	Feb CAHN
AB		0.1% (0.5GM/PACKET)	A217863	002	Jul 12, 2024	Feb CAHN
AB		0.1% (0.75GM/PACKET)	A217863	003	Jul 12, 2024	Feb CAHN
AB		0.1% (1GM/PACKET)	A217863	004	Jul 12, 2024	Feb CAHN
AB		0.1% (1.25GM/PACKET)	A217863	005	Jul 12, 2024	Feb CAHN
AB	XIROMED	0.1% (0.25GM/PACKET)	A211783	001	Aug 10, 2022	Jan CAHN
AB		0.1% (0.5GM/PACKET)	A211783	002	Aug 10, 2022	Jan CAHN
AB		0.1% (1GM/PACKET)	A211783	003	Aug 10, 2022	Jan CAHN

GEL, METERED;TRANSDERMAL

ESTRADIOL

AB	ENCUBE	0.06% (1.25GM/ACTIVATION)	A218214	001	May 11, 2026	May NEWA
AB	LONG GROVE PHARMS	0.06% (1.25GM/ACTIVATION)	A215096	001	Feb 02, 2026	Jan NEWA
	@ PADAGIS US	0.06% (1.25GM/ACTIVATION)	A215096	001	Feb 02, 2026	Jun DISC
AB		0.06% (1.25GM/ACTIVATION)	A215096	001	Feb 02, 2026	May CAHN

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

+	MILLCENT MFG PR	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan CAHN
+!		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan CAHN

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL

COMBIPATCH

+	NOVEN PHARMS INC	0.05MG/24HR;0.14MG/24HR	N020870	001	Aug 07, 1998	Mar CHRS
---	------------------	-------------------------	---------	-----	--------------	----------

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

@	LUPIN LTD	1MG	A091124	001	Sep 13, 2011	Apr DISC
@		2MG	A091124	002	Sep 13, 2011	Apr DISC
@		3MG	A091124	003	Sep 13, 2011	Apr DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28							
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL							
AB	!	XIROMED	0.05MG;1MG	A204704	001	Feb 09, 2016	Apr CHRS
		KELNOR 1/50					
	@	WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Apr DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

	SYSTEM;TRANSDERMAL						
	TWIRLA						
	+	AGILE	0.01MG/24HR;0.04MG/24HR	N204017	001	Feb 14, 2020	Jun CPOT
	TABLET;ORAL						
	QUARTETTE						
AB	+	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar CAHN
	TABLET;ORAL-28						
	MYZILRA						
	@	PH HEALTH	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A077502	001	Nov 23, 2011	Apr DISC

ETHINYL ESTRADIOL; NORELGESTROMIN

SYSTEM;TRANSDERMAL							
GWYN LO							
+	VIATRIS SPECIALTY	0.02MG/24HR;0.22MG/24HR	N219990	001	Jul 28, 2026	Jul NEWA	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28						
GILDAGIA						
@	PH HEALTH	0.035MG;0.4MG	A078376	001	Nov 06, 2012	Apr DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET;ORAL						
	GILDESS 24 FE						
	@	PH HEALTH	0.02MG;1MG	A090293	001	Dec 01, 2014	Apr DISC
	LO JUNEL FE						
AB		TEVA PHARMS INC	0.01MG,0.01MG;1MG,N/A	A219324	001	Jun 22, 2026	Jun NEWA
	LO LOESTRIN FE						
AB	+	APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jun CTEC
	TABLET, ORALLY DISINTEGRATING;ORAL						
	FEMLYV						
	+	MILLCENT MFG PR	0.02MG;1MG	N218718	001	Jul 22, 2024	Jun CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28						
PREVIFEM						
@	PH HEALTH	0.035MG;0.25MG	A076334	001	Jan 09, 2004	Apr DISC

ETHOSUXIMIDE

	CAPSULE;ORAL						
	ETHOSUXIMIDE						
	@	HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012	Apr DISC
AB		ONESOURCE	250MG	A211928	001	Feb 19, 2019	Jul CAHN

ETODOLAC

TABLET;ORAL						
ETODOLAC						
AB	AUROBINDO PHARMA LTD	400MG	A214872	001	Jul 15, 2026	Jul NEWA
AB		500MG	A214872	002	Jul 15, 2026	Jul NEWA
@	SENORES PHARMS	400MG	A074839	001	Jul 11, 1997	Jan CAHN

ETOPOSIDE

CAPSULE;ORAL						
ETOPOSIDE						
AB	! MYLAN	50MG	A075635	001	Sep 19, 2001	Jan CTEC
VEPESID						
AB	+ ONESOURCE SPECIALTY	50MG	N019557	001	Dec 30, 1986	Jan CMFD
INJECTABLE;INJECTION						
ETOPOSIDE						
	@ NATCO PHARMA USA	20MG/ML	A203507	001	Nov 20, 2017	Mar CAHN
	@	20MG/ML	A204927	001	Oct 31, 2017	Mar CAHN

INJECTABLE; INTRAVENOUS

AVOPEF

+! AVYXA HOLDINGS

100MG/5ML (20MG/ML)

N220200

001

Feb 13, 2026

Feb NEWA

SOLUTION; INTRAVENOUS

AVOPEF

+! AVYXA HOLDINGS

100MG/5ML (20MG/ML)

N220200

001

Feb 13, 2026

Mar CDFR

+!

500MG/25ML (20MG/ML)

N220200

002

Jun 24, 2026

Jun NEWA

EVEROLIMUS

TABLET; ORAL

EVEROLIMUS

AB ! ALKEM LABS LTD

1MG

A214138

004

Nov 26, 2021

May CHRS

AB APOTEX

2.5MG

A218488

001

May 12, 2026

May NEWA

AB 5MG

A218488

002

May 12, 2026

May NEWA

AB 7.5MG

A218488

003

May 12, 2026

May NEWA

AB 10MG

A218488

004

May 12, 2026

May NEWA

AB EUGIA PHARMA

0.25MG

A219533

001

Feb 25, 2026

Feb NEWA

AB 0.5MG

A219533

002

Feb 25, 2026

Feb NEWA

AB 0.75MG

A219533

003

Feb 25, 2026

Feb NEWA

AB 1MG

A219533

004

Feb 25, 2026

Feb NEWA

AB I3 PHARMS

0.25MG

A219464

001

Jun 30, 2026

Jun NEWA

AB 0.5MG

A219464

002

Jun 30, 2026

Jun NEWA

AB 0.75MG

A219464

003

Jun 30, 2026

Jun NEWA

AB 1MG

A219464

004

Jun 30, 2026

Jun NEWA

@ PH HEALTH

2.5MG

A207934

001

Dec 09, 2019

Jan DISC

@ 5MG

A207934

002

Dec 09, 2019

Jan DISC

@ 7.5MG

A207934

003

Dec 09, 2019

Jan DISC

@ 10MG

A207934

004

Dec 09, 2020

Jan DISC

ZORTRESS

AB + NOVARTIS

1MG

N021560

004

Aug 10, 2018

May CHRS

TABLET, FOR SUSPENSION; ORAL

EVEROLIMUS

AB BIOCON PHARMA

2MG

A217216

001

Jan 09, 2026

Jan NEWA

AB 3MG

A217216

002

Jan 09, 2026

Jan NEWA

AB 5MG

A217216

003

Jan 09, 2026

Jan NEWA

EXEMESTANE

TABLET; ORAL

EXEMESTANE

@ EIRGEN

25MG

A200898

001

Jul 28, 2014

Jul CAHN

EZETIMIBE

TABLET; ORAL

EZETIMIBE

>D> AB WATSON LABS INC

10MG

A200831

001

Jun 12, 2017

Aug DISC

>A> @ 10MG

A200831

001

Jun 12, 2017

Aug DISC

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

@ WATSON LABS INC

10MG; 10MG

A202968

001

Apr 26, 2017

Feb DISC

@ 10MG; 20MG

A202968

002

Apr 26, 2017

Feb DISC

@ 10MG; 40MG

A202968

003

Apr 26, 2017

Feb DISC

@ 10MG; 80MG

A202968

004

Apr 26, 2017

Feb DISC

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

@ APOTEX

125MG

A091480

001

Jul 22, 2011

Jul DISC

@ 250MG

A091480

002

Jul 22, 2011

Jul DISC

@ 500MG

A091480

003

Jul 22, 2011

Jul DISC

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

AB CARNEGIE

40MG/5ML

A217137

001

Jul 07, 2023

Feb CAHN

AB CONTRACT PHARMACAL

40MG/5ML

A219603

001

Mar 09, 2026

Feb NEWA

INJECTABLE; INJECTION

FAMOTIDINE

AP LUPIN

10MG/ML

A217432

001

May 12, 2026

May NEWA

SOLUTION; INTRAVENOUS

FAMOTIDINE

@ + SAGENT

20MG/5ML (4MG/ML)

N219935 001 Jul 16, 2025 Jul DISC

@ +

40MG/10ML (4MG/ML)

N219935 002 Jul 16, 2025 Jul DISC

@ +

200MG/50ML (4MG/ML)

N219935 003 Jul 16, 2025 Jul DISC

TABLET; ORAL

FAMOTIDINE

AB VKT PHARMA

20MG

A215630 001 Jan 07, 2022 Jan CAHN

AB 40MG

A215630 002 Jan 07, 2022 Jan CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

PEPCID RPD

@ + MERCK

20MG

N020752 001 May 28, 1998 Jun CRLD

@ +

40MG

N020752 002 May 28, 1998 Jun CRLD

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

IBUPROFEN AND FAMOTIDINE

AB ZYDUS LIFESCIENCES

26.6MG; 800MG

A218684 001 Feb 20, 2025 Feb CAHN

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

@ INGENUS PHARMS LLC

67MG

A207564 001 Apr 19, 2019 May CAHN

@

134MG

A207564 002 Apr 19, 2019 May CAHN

@

200MG

A207564 003 Apr 19, 2019 May CAHN

>D> AB RHODES PHARMS

67MG

A075753 001 Sep 03, 2002 Aug DISC

>A> @

67MG

A075753 001 Sep 03, 2002 Aug DISC

>D> AB 134MG

A075753 002 Apr 09, 2002 Aug DISC

>A> @ 134MG

A075753 002 Apr 09, 2002 Aug DISC

>D> AB 200MG

A075753 003 Apr 09, 2002 Aug DISC

>A> @ 200MG

A075753 003 Apr 09, 2002 Aug DISC

LIPOFEN

@ + CIPHER PHARMS INC

100MG

N021612 002 Jan 11, 2006 Jan CRLD

TABLET; ORAL

FENOFIBRATE

AB MACLEODS PHARMS

54MG

A210379 001 Jan 21, 2026 Jan NEWA

AB 160MG

A210379 002 Jan 21, 2026 Jan NEWA

TRIGLIDE

@ JAGOTEC

50MG

N021350 001 May 07, 2005 Jan CAHN

@ +

160MG

N021350 002 May 07, 2005 Jan CAHN

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

@ + ROSEMOUNT

35MG

N022418 001 Aug 14, 2009 Mar CAHN

@ +

105MG

N022418 002 Aug 14, 2009 Mar CAHN

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AB MISEMER

EQ 300MG BASE

A215548 002 May 16, 2023 Jul CMFD

AB RISING

EQ 300MG BASE

A214475 003 Jul 26, 2024 Jul CTEC

FERRIC CARBOXYMALTOSE

SOLUTION; INTRAVENOUS

FERRIC CARBOXYMALTOSE

AP MYLAN

100MG IRON/2ML (50MG IRON/ML)

A217769 001 Jun 25, 2026 Jun NFTG

AP 1GM IRON/20ML (50MG IRON/ML)

A217076 001 Jun 25, 2026 Jun NFTG

AP MYLAN LABS LTD

750MG IRON/15ML (50MG IRON/ML)

A212572 001 Jun 25, 2026 Jun NFTG

INJECTAFER

AP +! AM REGENT

750MG IRON/15ML (50MG IRON/ML)

N203565 001 Jul 25, 2013 Jun CFTG

AP +!

100MG IRON/2ML (50MG IRON/ML)

N203565 004 Feb 04, 2022 Jun CFTG

>D> +!

500MG IRON/10ML (50MG IRON/ML)

N203565 002 Oct 08, 2020 Aug CHRS

>A> +

500MG IRON/10ML (50MG IRON/ML)

N203565 002 Oct 08, 2020 Aug CHRS

>D> AP +!

1GM IRON/20ML (50MG IRON/ML)

N203565 003 Apr 28, 2021 Aug CHRS

>A> AP +

1GM IRON/20ML (50MG IRON/ML)

N203565 003 Apr 28, 2021 Aug CHRS

AP +!

1GM IRON/20ML (50MG IRON/ML)

N203565 003 Apr 28, 2021 Jun CFTG

FERRIC CITRATE

TABLET; ORAL

AURYXIA

AB	+!	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Feb CFTG
		FERRIC CITRATE					
AB		TEVA PHARMS USA	EQ 210MG IRON	A212563	001	Mar 11, 2026	Feb NFTG

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERABRIGHT

>D>	+!	AZURITY	EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025	Aug CHRS
>A>	+		EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025	Aug CHRS
	+!		EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025	Jul CAHN
	+!		EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025	Apr CAHN
	+!		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N219868	002	Oct 16, 2025	Jul CAHN
	+!		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N219868	002	Oct 16, 2025	Apr CAHN
		FERAHEME					
AB	+!	AZURITY	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Jul CAHN
AB	+!		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Apr CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

@	DR REDDYS LABS LTD	30MG	A076502	001	Apr 11, 2006	Mar DISC
@		60MG	A076502	002	Apr 11, 2006	Mar DISC
@		180MG	A076502	003	Apr 11, 2006	Mar DISC
@	RISING	60MG	A077081	003	Apr 11, 2008	Mar DISC
@		180MG	A077081	001	Apr 16, 2007	Mar DISC
@	TEVA	30MG	A076447	001	Sep 01, 2005	Mar DISC
@		60MG	A076447	002	Sep 01, 2005	Mar DISC
@		180MG	A076447	003	Sep 01, 2005	Mar DISC

FIDAXOMICIN

TABLET; ORAL

FIDAXOMICIN

AB		APOTEX	200MG	A219559	001	Feb 02, 2026	Jan NEWA
AB		SANDOZ	200MG	A220465	001	Aug 13, 2026	Jul NEWA
AB		TORRENT	200MG	A220374	001	Jan 27, 2026	Jan NEWA

FINAFLOXACIN

SUSPENSION/DROPS; OTIC

XTORO

	+!	FONSECA BIOSCIENCES	0.3%	N206307	001	Dec 17, 2014	Apr CMFD
--	----	---------------------	------	---------	-----	--------------	----------

FINERENONE

TABLET; ORAL

KERENDIA

	+	BAYER HLTHCARE	20MG	N215341	002	Jul 09, 2021	May CHRS
	+!		40MG	N215341	003	Jul 11, 2025	May CHRS

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

AB		ALEMBIC	EQ 0.5MG BASE	A207974	001	Apr 24, 2026	Apr NEWA
----	--	---------	---------------	---------	-----	--------------	----------

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

>A>	AB	MICRO LABS	50MG	A218093	001	Apr 22, 2026	Aug CAHN
>A>	AB		100MG	A218093	002	Apr 22, 2026	Aug CAHN
>A>	AB		150MG	A218093	003	Apr 22, 2026	Aug CAHN
>D>	AB	OMSAV PHARMA	50MG	A218093	001	Apr 22, 2026	Aug CAHN
	AB		50MG	A218093	001	Apr 22, 2026	Apr NEWA
>D>	AB		100MG	A218093	002	Apr 22, 2026	Aug CAHN
	AB		100MG	A218093	002	Apr 22, 2026	Apr NEWA

TABLET;ORAL							
FLECAINIDE ACETATE							
>D>	AB	150MG	A218093	003	Apr 22, 2026	Aug	CAHN
	AB	150MG	A218093	003	Apr 22, 2026	Apr	NEWA
<u>FLORBETABEN F-18</u>							
SOLUTION;INTRAVENOUS							
NEURACEQ							
	+! LANTHEUS	1.4-135mCi/ML	N204677	001	Mar 19, 2014	Mar	CAHN
>A>	<u>FLOROQUINITAU F-18</u>						
>A>	SOLUTION;INTRAVENOUS						
>A>	TAUKLARIFY						
>A>	+! CERVEAU LANTHEUS	1-40mCi/ML	N220496	001	Aug 13, 2026	Aug	NEWA
<u>FLUCONAZOLE</u>							
TABLET;ORAL							
FLUCONAZOLE							
AB	UNIQUE	50MG	A076957	001	Sep 28, 2005	Mar	CAHN
AB		100MG	A076957	002	Sep 28, 2005	Mar	CAHN
AB		150MG	A076957	004	Feb 27, 2017	Mar	CAHN
AB		200MG	A076957	003	Sep 28, 2005	Mar	CAHN
<u>FLUDARABINE PHOSPHATE</u>							
INJECTABLE;INJECTION							
FLUDARABINE PHOSPHATE							
@ +	CAPLIN ONE LABS	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jan	CAHN
!	HISUN PHARM HANGZHOU	50MG/2ML (25MG/ML)	A220196	001	Jul 23, 2026	Jul	NEWA
<u>FLUDEOXYGLUCOSE F-18</u>							
INJECTABLE;INTRAVENOUS							
FLUDEOXYGLUCOSE F18							
@	NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr	DISC
@	PHARMALOGIC	20-300mCi/ML	A204264	001	Dec 18, 2014	Jun	DISC
<u>FLUDROCORTISONE ACETATE</u>							
TABLET;ORAL							
FLUDROCORTISONE ACETATE							
AB	HIBROW HLTHCARE	0.1MG	A220308	001	Feb 10, 2026	Jan	NEWA
<u>FLUMAZENIL</u>							
INJECTABLE;INJECTION							
FLUMAZENIL							
@	HIKMA	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Mar	DISC
@		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Mar	DISC
<u>FLUOCINOLONE ACETONIDE</u>							
CREAM;TOPICAL							
FLUOCINOLONE ACETONIDE							
AT	COSETTE PHARMS NC	0.01%	A089526	001	Jul 26, 1988	May	CAHN
	@	0.025%	A089525	001	Jul 26, 1988	Jun	CAHN
	@	0.025%	A089525	001	Jul 26, 1988	May	CAHN
AT		0.025%	A210747	001	Nov 05, 2018	May	CAHN
SYNALAR							
AT	+! EUROFARMA	0.01%	N012787	004		Feb	CAHN
AT	+!	0.025%	N012787	002		Feb	CAHN
AT	+!	0.025%	N012787	005		Feb	CAHN
SYNALAR-HP							
	@ EUROFARMA	0.2%	N016161	002		Feb	CAHN
IMPLANT;INTRAVITREAL							
RETISERT							
@ +	BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005	Jun	DISC
OINTMENT;TOPICAL							
FLUOCINOLONE ACETONIDE							
AT	COSETTE PHARMS NC	0.025%	A089524	001	Jul 26, 1988	May	CAHN
SYNALAR							
AT	+! EUROFARMA	0.025%	N013960	001		Feb	CAHN
SOLUTION;TOPICAL							
FLUOCINOLONE ACETONIDE							
@	COSETTE PHARMS NC	0.01%	A207441	001	Sep 28, 2016	Jun	CAHN

SOLUTION; TOPICAL							
SYNALAR							
AT	+	EUROFARMA	0.01%	N015296	001		Feb CAHN
<u>FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE</u>							
CREAM; TOPICAL							
NEO-SYNALAR							
	!	EUROFARMA	0.025%; EQ 3.5MG BASE/GM	A060700	001		Feb CAHN
<u>FLUOCINONIDE</u>							
CREAM; TOPICAL							
FLUOCINONIDE							
AB1		COSETTE PHARMS NC	0.05%	A073085	001	Feb 14, 1992	May CAHN
	@	ENCUBE	0.1%	A211758	001	Apr 03, 2019	May CAHN
FLUOCINONIDE EMULSIFIED BASE							
AB2		COSETTE PHARMS NC	0.05%	A074204	001	Jun 13, 1995	May CAHN
GEL; TOPICAL							
FLUOCINONIDE							
	@	COSETTE PHARMS NC	0.05%	A072537	001	Feb 07, 1989	Jun CAHN
SOLUTION; TOPICAL							
FLUOCINONIDE							
	@	COSETTE PHARMS NC	0.05%	A071535	001	Dec 02, 1988	Jun CAHN
AT		SCIEGEN PHARMS	0.05%	A207554	001	Mar 18, 2019	May CMFD
<u>FLUORESCEIN SODIUM</u>							
INJECTABLE; INTRAVENOUS							
FLUORESCEIN SODIUM							
AP		BPI LABS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A220046	001	Apr 30, 2026	Apr NEWA
	@	NEXUS	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	May DISC
			EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Apr CHRS
AP		ZYDUS LIFESCIENCES	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A218651	001	Jun 01, 2026	May NEWA
	!		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A218651	002	Jun 01, 2026	May NEWA
<u>FLUOROMETHOLONE</u>							
SUSPENSION/DROPS; OPHTHALMIC							
FLUOROMETHOLONE							
AB		DIFGEN PHARMS	0.1%	A218819	001	Feb 12, 2026	Jan NEWA
AB		SANDOZ	0.1%	A218819	001	Feb 12, 2026	May CAHN
<u>FLUOROURACIL</u>							
INJECTABLE; INJECTION							
FLUOROURACIL							
	@	INGENUS PHARMS LLC	500MG/10ML (50MG/ML)	A209219	001	Dec 12, 2019	May CAHN
	@		1GM/20ML (50MG/ML)	A209219	002	Dec 12, 2019	May CAHN
	@		2.5GM/50ML (50MG/ML)	A209271	002	Dec 11, 2019	May CAHN
	@		5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019	May CAHN
SOLUTION; INTRAVENOUS							
FAVLYXA							
	+	AVYXA HOLDINGS	250MG/10ML (25MG/ML)	N220201	001	Feb 20, 2026	Feb NEWA
	+		2.5GM/100ML (25MG/ML)	N220201	002	Jul 06, 2026	Jul NEWA
<u>FLUOXETINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
FLUOXETINE HYDROCHLORIDE							
AB	!	AUROBINDO PHARMA	EQ 40MG BASE	A078619	003	Jan 31, 2008	May CHRS
>D> AB1		MICRO LABS	EQ 10MG BASE	A216232	001	Mar 29, 2022	Aug DISC
>A>	@		EQ 10MG BASE	A216232	001	Mar 29, 2022	Aug DISC
>D> AB1			EQ 20MG BASE	A216232	002	Mar 29, 2022	Aug DISC
>A>	@		EQ 20MG BASE	A216232	002	Mar 29, 2022	Aug DISC
>D> AB			EQ 40MG BASE	A216232	003	Mar 29, 2022	Aug DISC
>A>	@		EQ 40MG BASE	A216232	003	Mar 29, 2022	Aug DISC
AB1		SENORES PHARMS	EQ 10MG BASE	A075049	001	Aug 02, 2001	Feb CAHN
AB1			EQ 20MG BASE	A075049	002	Jan 29, 2002	Feb CAHN
AB			EQ 40MG BASE	A075049	003	Jan 29, 2002	Feb CAHN
	@	STRIDES PHARMA INTL	EQ 10MG BASE	A076922	001	Dec 16, 2004	Jan DISC
	@		EQ 20MG BASE	A076922	002	Dec 16, 2004	Jan DISC
	@		EQ 40MG BASE	A076922	003	Dec 16, 2004	Jan DISC

CAPSULE;ORAL

PROZAC

@ +	ELI LILLY AND CO	EQ 10MG BASE	N018936	006	Dec 23, 1992	May DISC
@ +		EQ 20MG BASE	N018936	001	Dec 29, 1987	May DISC
@ +		EQ 40MG BASE	N018936	003	Jun 15, 1999	May DISC

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA	!	AUROBINDO PHARMA	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Apr CHRS
	@	PHARM ASSOC	EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002	Apr DISC

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

@	LUPIN	EQ 60MG BASE	A211632	001	Feb 08, 2019	Mar DISC
---	-------	--------------	---------	-----	--------------	----------

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

	@	BRECKENRIDGE	1MG	A216891	001	Nov 15, 2022	Feb DISC
	@		2.5MG	A216891	002	Nov 15, 2022	Feb DISC
	@		5MG	A216891	003	Nov 15, 2022	Feb DISC
	@		10MG	A216891	004	Nov 15, 2022	Feb DISC
AB		ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Jan CAHN
AB			2.5MG	A215141	002	Oct 20, 2021	Jan CAHN
AB			5MG	A215141	003	Oct 20, 2021	Jan CAHN
AB			10MG	A215141	004	Oct 20, 2021	Jan CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

@	HIKMA INTL PHARMS	15MG	A071108	002	Dec 08, 1986	Feb CMS1
---	-------------------	------	---------	-----	--------------	----------

FLURBIPROFEN

TABLET;ORAL

FLURBIPROFEN

>A>	!	GENUS	100MG	A074431	001	May 31, 1995	Aug CAHN
>D>	!	NEW HEIGHTSRX	100MG	A074431	001	May 31, 1995	Aug CAHN

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER;INHALATION

BREO ELLIPTA

+!	GLAXO GRP LTD	0.05MG/INH;EQ 0.025MG BASE/INH	N204275	003	May 12, 2023	Jan CHRS
----	---------------	--------------------------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

AEROSOL, METERED;INHALATION

FLOVENT HFA

AB	+!	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004	Feb CFTG
----	----	---------------	-------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

AB		GLENMARK SPECLT	0.044MG/INH	A219602	001	Mar 03, 2026	Feb NFTG
----	--	-----------------	-------------	---------	-----	--------------	----------

CREAM;TOPICAL

CUTIVATE

>A>	@ +	FOUGERA	0.05%	N019958	001	Dec 18, 1990	Aug CAHN
>D>	@ +	FOUGERA PHARMS	0.05%	N019958	001	Dec 18, 1990	Aug CAHN

FLUTICASONE PROPIONATE

AB		COSETTE PHARMS NC	0.05%	A077055	001	Jun 30, 2006	May CAHN
----	--	-------------------	-------	---------	-----	--------------	----------

LOTION;TOPICAL

CUTIVATE

>A>	@ +	FOUGERA	0.05%	N021152	001	Mar 31, 2005	Aug CAHN
>D>	@ +	FOUGERA PHARMS	0.05%	N021152	001	Mar 31, 2005	Aug CAHN

OINTMENT;TOPICAL

CUTIVATE

@ +	FOUGERA	0.005%	N019957	001	Dec 14, 1990	Jul CAHN
-----	---------	--------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

AB		COSETTE PHARMS NC	0.005%	A077168	001	Mar 03, 2006	May CAHN
----	--	-------------------	--------	---------	-----	--------------	----------

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

>A>	AB	GLENMARK PHARMS LTD	0.05MG/SPRAY	A219232	001	Aug 18, 2026	Aug NEWA
>A>	AB	GLENMARK SPECLT	0.05MG/SPRAY	A219232	001	Aug 18, 2026	Aug CAHN

XHANCE

+!	PARATEK PHARMS	0.093MG/SPRAY	N209022	001	Sep 18, 2017	May CPOT
----	----------------	---------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

AIRDUO RESPICLICK

+	!	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017	Jan CHRS
---	---	------------	------------------------------------	---------	-----	--------------	----------

+	!		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017	Jan CHRS
---	---	--	------------------------------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

AB		CIPLA	0.1MG/INH;EQ 0.05MG BASE/INH	A213087	001	Jul 27, 2026	Jul NEWA
AB			0.25MG/INH;EQ 0.05MG BASE/INH	A213087	002	Jul 27, 2026	Jul NEWA
AB			0.5MG/INH;EQ 0.05MG BASE/INH	A213087	003	Jul 27, 2026	Jul NEWA
AB		RESPIRENT PHARMS	0.1MG/INH;EQ 0.05MG BASE/INH	A214464	001	Jan 12, 2026	Jun CMFD
	@		0.1MG/INH;EQ 0.05MG BASE/INH	A214464	001	Jan 12, 2026	Mar DISC
AB			0.1MG/INH;EQ 0.05MG BASE/INH	A214464	001	Jan 12, 2026	Jan NEWA
AB			0.25MG/INH;EQ 0.05MG BASE/INH	A214464	002	Jan 12, 2026	Jun CMFD
	@		0.25MG/INH;EQ 0.05MG BASE/INH	A214464	002	Jan 12, 2026	Mar DISC
AB			0.25MG/INH;EQ 0.05MG BASE/INH	A214464	002	Jan 12, 2026	Jan NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB		APPCO	100MG	A220328	001	Apr 30, 2026	Apr NEWA
AB			150MG	A220328	002	Apr 30, 2026	Apr NEWA
AB		MICRO LABS	100MG	A220768	001	Jun 23, 2026	Jun NEWA
AB			150MG	A220768	002	Jun 23, 2026	Jun NEWA
AB		ZYDUS PHARMS	100MG	A220447	001	Jul 21, 2026	Jul NEWA
AB			150MG	A220447	002	Jul 21, 2026	Jul NEWA

TABLET; ORAL

LUVOX

>D>	AB	+	ANI PHARMS	100MG	N021519	003	Dec 20, 2007	Aug CHRS
>A>	AB	+	!	100MG	N021519	003	Dec 20, 2007	Aug CHRS

FOLIC ACID

SOLUTION; ORAL

QUIOFIC

+	!	CMP DEV LLC	0.2MG/ML	N216395	001	Jan 26, 2026	Jan NEWA
+	!	SOLUBIOMIX	0.2MG/ML	N216395	001	Jan 26, 2026	Mar CAHN

TABLET; ORAL

FOLIC ACID

AA		+	WATSON LABS	1MG	A080680	001	Feb CHRS
----	--	---	-------------	-----	---------	-----	----------

FONDAPARINUX SODIUM

SOLUTION; SUBCUTANEOUS

ARIXTRA

AP		+	!	MYLAN IRELAND LTD	2.5MG/0.5ML (2.5MG/0.5ML)	N021345	001	Dec 07, 2001	Mar CPOT
AP		+	!		2.5MG/0.5ML	N021345	001	Dec 07, 2001	Jan CDFR
AP		+	!		5MG/0.4ML (5MG/0.4ML)	N021345	002	May 28, 2004	Mar CPOT
AP		+	!		5MG/0.4ML	N021345	002	May 28, 2004	Jan CDFR
AP		+	!		7.5MG/0.6ML (7.5MG/0.6ML)	N021345	003	May 28, 2004	Mar CPOT
AP		+	!		7.5MG/0.6ML	N021345	003	May 28, 2004	Jan CDFR
AP		+	!		10MG/0.8ML (10MG/0.8ML)	N021345	004	May 28, 2004	Mar CPOT
AP		+	!		10MG/0.8ML	N021345	004	May 28, 2004	Jan CDFR

FONDAPARINUX SODIUM

	@		BRIGHTGENE	2.5MG/0.5ML (2.5MG/0.5ML)	A218312	001	Dec 18, 2024	Mar CPOT
	@			2.5MG/0.5ML	A218312	001	Dec 18, 2024	Jan CDFR
AP			DR REDDYS LABS LTD	2.5MG/0.5ML (2.5MG/0.5ML)	A091316	001	Jul 11, 2011	Mar CPOT
AP				2.5MG/0.5ML	A091316	001	Jul 11, 2011	Jan CDFR
AP				5MG/0.4ML (5MG/0.4ML)	A091316	002	Jul 11, 2011	Mar CPOT
AP				5MG/0.4ML	A091316	002	Jul 11, 2011	Jan CDFR
AP				7.5MG/0.6ML (7.5MG/0.6ML)	A091316	003	Jul 11, 2011	Mar CPOT
AP				7.5MG/0.6ML	A091316	003	Jul 11, 2011	Jan CDFR
AP				10MG/0.8ML (10MG/0.8ML)	A091316	004	Jul 11, 2011	Mar CPOT
AP				10MG/0.8ML	A091316	004	Jul 11, 2011	Jan CDFR
AP			EUGIA PHARMA	2.5MG/0.5ML (2.5MG/0.5ML)	A206918	001	Dec 26, 2017	Mar CPOT
AP				2.5MG/0.5ML	A206918	001	Dec 26, 2017	Jan CDFR
AP				5MG/0.4ML (5MG/0.4ML)	A206918	002	Dec 26, 2017	Mar CPOT
AP				5MG/0.4ML	A206918	002	Dec 26, 2017	Jan CDFR
AP				7.5MG/0.6ML (7.5MG/0.6ML)	A206918	003	Dec 26, 2017	Mar CPOT
AP				7.5MG/0.6ML	A206918	003	Dec 26, 2017	Jan CDFR
AP				10MG/0.8ML (10MG/0.8ML)	A206918	004	Dec 26, 2017	Mar CPOT
AP				10MG/0.8ML	A206918	004	Dec 26, 2017	Jan CDFR
	@		HANGZHOU ZHONGMEI	2.5MG/0.5ML (2.5MG/0.5ML)	A216493	001	Aug 19, 2024	Mar CPOT

SOLUTION;SUBCUTANEOUS									
FONDAPARINUX SODIUM									
	@		2.5MG/0.5ML	A216493	001	Aug 19, 2024	Jan	CDFR	
	@		5MG/0.4ML (5MG/0.4ML)	A216493	002	Aug 19, 2024	Mar	CPOT	
	@		5MG/0.4ML	A216493	002	Aug 19, 2024	Jan	CDFR	
	@		7.5MG/0.6ML (7.5MG/0.6ML)	A216493	003	Aug 19, 2024	Mar	CPOT	
	@		7.5MG/0.6ML	A216493	003	Aug 19, 2024	Jan	CDFR	
	@		10MG/0.8ML (10MG/0.8ML)	A216493	004	Aug 19, 2024	Mar	CPOT	
	@		10MG/0.8ML	A216493	004	Aug 19, 2024	Jan	CDFR	
	@	HENGRUI PHARMA	2.5MG/0.5ML (2.5MG/0.5ML)	A206812	001	May 15, 2018	Jun	DISC	
AP			2.5MG/0.5ML (2.5MG/0.5ML)	A206812	001	May 15, 2018	Mar	CPOT	
AP			2.5MG/0.5ML	A206812	001	May 15, 2018	Jan	CDFR	
	@		5MG/0.4ML (5MG/0.4ML)	A206812	002	May 15, 2018	Jun	DISC	
AP			5MG/0.4ML (5MG/0.4ML)	A206812	002	May 15, 2018	Mar	CPOT	
AP			5MG/0.4ML	A206812	002	May 15, 2018	Jan	CDFR	
	@		7.5MG/0.6ML (7.5MG/0.6ML)	A206812	003	May 15, 2018	Jun	DISC	
AP			7.5MG/0.6ML (7.5MG/0.6ML)	A206812	003	May 15, 2018	Mar	CPOT	
AP			7.5MG/0.6ML	A206812	003	May 15, 2018	Jan	CDFR	
	@		10MG/0.8ML (10MG/0.8ML)	A206812	004	May 15, 2018	Jun	DISC	
AP			10MG/0.8ML (10MG/0.8ML)	A206812	004	May 15, 2018	Mar	CPOT	
AP			10MG/0.8ML	A206812	004	May 15, 2018	Jan	CDFR	
AP		SCINOPHARM TAIWAN	2.5MG/0.5ML (2.5MG/0.5ML)	A208615	001	Nov 14, 2018	Mar	CPOT	
AP			2.5MG/0.5ML	A208615	001	Nov 14, 2018	Jan	CDFR	
AP			5MG/0.4ML (5MG/0.4ML)	A208615	002	Nov 14, 2018	Mar	CPOT	
AP			5MG/0.4ML	A208615	002	Nov 14, 2018	Jan	CDFR	
AP			7.5MG/0.6ML (7.5MG/0.6ML)	A208615	003	Nov 14, 2018	Mar	CPOT	
AP			7.5MG/0.6ML	A208615	003	Nov 14, 2018	Jan	CDFR	
AP			10MG/0.8ML (10MG/0.8ML)	A208615	004	Nov 14, 2018	Mar	CPOT	
AP			10MG/0.8ML	A208615	004	Nov 14, 2018	Jan	CDFR	
<u>FOSAPREPITANT DIMEGLUMINE</u>									
POWDER;INTRAVENOUS									
FOSAPREPITANT DIMEGLUMINE									
	@	BAXTER HLTHCARE CORP	EQ 150MG BASE/VIAL	A211860	001	Sep 05, 2019	May	DISC	
	@	CAPLIN	EQ 150MG BASE/VIAL	A203939	001	Dec 08, 2020	Jan	CAHN	
	@	CHARTWELL RX	EQ 150MG BASE/VIAL	A212957	002	Aug 20, 2020	Jul	CAHN	
	NAVITRUX								
	+	AVYXA HOLDINGS	EQ 150MG BASE/VIAL	N220436	001	Jun 24, 2026	Jun	NEWA	
<u>FOSCARNET SODIUM</u>									
SOLUTION;INTRAVENOUS									
FOSCARNET SODIUM									
AP		CAPLIN	6GM/250ML (24MG/ML)	A220068	001	May 13, 2026	May	NEWA	
<u>FOSFOMYCIN TROMETHAMINE</u>									
FOR SOLUTION;ORAL									
FOSFOMYCIN TROMETHAMINE									
AA		AUCTA	EQ 3GM BASE/PACKET	A217772	001	Apr 09, 2026	Mar	NEWA	
AA		NOVITIUM PHARMA	EQ 3GM BASE/PACKET	A210426	001	Aug 12, 2026	Jul	NEWA	
<u>FOSTAMATINIB DISODIUM</u>									
TABLET;ORAL									
FOSTAMATINIB DISODIUM									
AB		ANNORA PHARMA	EQ 100MG BASE	A217329	001	Jun 17, 2026	Jun	NFTG	
AB			EQ 150MG BASE	A217329	002	Jun 17, 2026	Jun	NFTG	
TAVALLISSE									
AB	+	RIGEL PHARMS	EQ 100MG BASE	N209299	001	Apr 17, 2018	Jun	CFTG	
AB	+	!	EQ 150MG BASE	N209299	002	Apr 17, 2018	Jun	CFTG	
<u>FROVATRIPTAN SUCCINATE</u>									
TABLET;ORAL									
FROVA									
	@ +	ENDO OPERATIONS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Feb	DISC	
FROVATRIPTAN SUCCINATE									
AB	!	RENATA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	Feb	CHRS	
<u>FULVESTRANT</u>									
SOLUTION;INTRAMUSCULAR									
CLIGAVYX									
	!	AVYXA HOLDINGS	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Jun	CMFD	
	@		250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Apr	CTNA	

SOLUTION;INTRAMUSCULAR							
FULVESTRANT							
	@ EUGIA PHARMA	250MG/5ML (50MG/ML)	A215169	001	Jun 30, 2023	Mar	DISC
<u>FUROSEMIDE</u>							
INJECTABLE;INJECTION							
FUROSEMIDE							
	@ AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016	Jul	DISC
AP	MICRO LABS	10MG/ML	A218188	001	Jan 08, 2026	Jan	NEWA
SOLUTION;SUBCUTANEOUS							
FUROSCIX							
	+! SCPHARMACEUTICALS	80MG/10ML (8MG/ML)	N209988	001	Oct 07, 2022	Jul	CAHN
FUROSCIX READYFLOW (AUTOINJECTOR)							
	+! SCPHARMACEUTICALS	80MG/ML (80MG/ML)	N209988	002	Jul 23, 2026	Jul	NEWA
<u>FUTIBATINIB</u>							
TABLET;ORAL							
LYTGOBI							
	@ + TAIHO ONCOLOGY	16MG	N214801	002	Jul 28, 2025	May	DISC
<u>GABAPENTIN</u>							
CAPSULE;ORAL							
GABAPENTIN							
	@ ALLIED	100MG	A090158	001	Feb 14, 2011	Jun	CAHN
	@	300MG	A090158	002	Feb 14, 2011	Jun	CAHN
	@	400MG	A090158	003	Feb 14, 2011	Jun	CAHN
AB	PRINSTON INC	100MG	A219814	001	Mar 06, 2026	Feb	NEWA
AB		300MG	A219814	002	Mar 06, 2026	Feb	NEWA
AB		400MG	A219814	003	Mar 06, 2026	Feb	NEWA
	@ SENORES PHARMS	100MG	A090158	001	Feb 14, 2011	Jul	CAHN
AB		200MG	A219319	004	May 14, 2026	May	NEWA
	@	300MG	A090158	002	Feb 14, 2011	Jul	CAHN
	@	400MG	A090158	003	Feb 14, 2011	Jul	CAHN
RELGAABI							
AB	SCIEGEN PHARMS	100MG	A204989	001	Feb 18, 2016	Mar	CTNA
AB		200MG	A204989	004	Mar 06, 2026	May	CFTG
		200MG	A204989	004	Mar 06, 2026	Mar	CTNA
		200MG	A204989	004	Mar 06, 2026	Feb	NEWA
AB		300MG	A204989	002	Feb 18, 2016	Mar	CTNA
AB		400MG	A204989	003	Feb 18, 2016	Mar	CTNA
TABLET;ORAL							
GABAPENTIN							
AB2	ACTAVIS ELIZABETH	300MG	A203611	001	Jun 23, 2026	Jun	NEWA
AB2		600MG	A203611	002	Jun 23, 2026	Jun	NEWA
AB2	EPIC PHARMA LLC	300MG	A216252	001	Feb 26, 2024	May	CAHN
AB2		600MG	A216252	002	Feb 26, 2024	May	CAHN
<u>GADOBUTROL</u>							
SOLUTION;INTRAVENOUS							
GADOBUTROL							
	@ HENG Rui PHARMA	1.20944GM/2ML (604.72MG/ML)	A216081	003	Nov 17, 2022	Jun	DISC
	@	4.5354GM/7.5ML (604.72MG/ML)	A216081	004	Nov 17, 2022	Jun	DISC
	@	6.0472GM/10ML (604.72MG/ML)	A216081	005	Nov 17, 2022	Jun	DISC
	@	9.0708GM/15ML (604.72MG/ML)	A216081	006	Nov 17, 2022	Jun	DISC
AP	VIWIT PHARM	4.5354GM/7.5ML (604.72MG/ML)	A219287	001	Jun 11, 2026	Jun	NEWA
AP		6.0472GM/10ML (604.72MG/ML)	A219287	002	Jun 11, 2026	Jun	NEWA
AP		9.0708GM/15ML (604.72MG/ML)	A219287	003	Jun 11, 2026	Jun	NEWA
AP	ZENARA	1.20944GM/2ML (604.72MG/ML)	A219146	001	Jun 08, 2026	May	NEWA
AP		4.5354GM/7.5ML (604.72MG/ML)	A219146	002	Jun 08, 2026	May	NEWA
AP		6.0472GM/10ML (604.72MG/ML)	A219146	003	Jun 08, 2026	May	NEWA
AP		9.0708GM/15ML (604.72MG/ML)	A219146	004	Jun 08, 2026	May	NEWA
AP		18.1416GM/30ML (604.72MG/ML)	A219146	005	Jun 08, 2026	May	NEWA
AP		39.3068GM/65ML (604.72MG/ML)	A219146	006	Jun 08, 2026	May	NEWA
PIXXOSCAN							
AP	GE HLTHCARE	1.20944GM/2ML (604.72MG/ML)	A215957	001	Jun 29, 2026	Jun	NEWA
AP		4.5354GM/7.5ML (604.72MG/ML)	A215957	002	Jun 29, 2026	Jun	NEWA
AP		6.0472GM/10ML (604.72MG/ML)	A215957	003	Jun 29, 2026	Jun	NEWA
AP		9.0708GM/15ML (604.72MG/ML)	A215957	004	Jun 29, 2026	Jun	NEWA

GADOQUATRANE

SOLUTION; INTRAVENOUS

AMBELVIST

+	!	BAYER HEALTHCARE	0.5158GM/2ML (257.9MG/ML)	N219627	001	Jun 12, 2026	Jun NEWA
+	!		1.93425GM/7.5ML (257.9MG/ML)	N219627	002	Jun 12, 2026	Jun NEWA
+	!		2.579GM/10ML (257.9MG/ML)	N219627	003	Jun 12, 2026	Jun NEWA
+	!		3.8685GM/15ML (257.9MG/ML)	N219627	004	Jun 12, 2026	Jun NEWA
+	!		7.737GM/30ML (257.9MG/ML)	N219627	005	Jun 12, 2026	Jun NEWA
+	!		16.7635GM/65ML (257.9MG/ML)	N219627	006	Jun 12, 2026	Jun NEWA

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

GADOTERATE MEGLUMINE

AP		VIWIT PHARM	3.769GM/10ML (376.9MG/ML)	A219286	001	Aug 10, 2026	Jul NEWA
AP			5.6535GM/15ML (376.9MG/ML)	A219286	002	Aug 10, 2026	Jul NEWA
AP			7.538GM/20ML (376.9MG/ML)	A219286	003	Aug 10, 2026	Jul NEWA

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB		SENORES PHARMS	EQ 4MG BASE	A077593	001	Sep 11, 2008	Jan CAHN
AB			EQ 8MG BASE	A077593	002	Sep 11, 2008	Jan CAHN
AB			EQ 12MG BASE	A077593	003	Sep 11, 2008	Jan CAHN

GALLIUM DOTATATE GA-68

POWDER; INTRAVENOUS

NETSPOT

+	!	NOVARTIS	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016	Jun CAHN
---	---	----------	---------------	---------	-----	--------------	----------

GALLIUM GA-68 GOZETOTIDE

SOLUTION; INTRAVENOUS

GALLIUM GA 68 GOZETOTIDE

AP		RADIOMEDIX	0.5-5mCi/ML	A216410	001	Jun 08, 2026	May NEWA		
AP		+	!	UNIV OF CA SAN FRAN	0.5-5mCi/mL	N212643	001	Dec 01, 2020	May CFTG
AP		GALLIUM GA-68 GOZETOTIDE							
AP		IONETIX	0.5-5mCi/mL	A219189	001	May 14, 2026	May NFTG		

GANAXOLONE

SUSPENSION; ORAL

ZTALMY

+	!	IMMEDICA PHARMA	50MG/ML	N215904	001	Jun 01, 2022	Mar CAHN
---	---	-----------------	---------	---------	-----	--------------	----------

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

AP		HAINAN POLY	EQ 500MG BASE/VIAL	A204204	001	Nov 08, 2018	Jul CAHN
----	--	-------------	--------------------	---------	-----	--------------	----------

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE

@		TRIS PHARMA INC	250MCG/0.5ML	A219454	001	Jun 27, 2025	Mar DISC
---	--	-----------------	--------------	---------	-----	--------------	----------

GEDATOLISIB

POWDER; INTRAVENOUS

REVTORPYK

+	!	CELCUITY	180MG/VIAL	N219908	001	Jul 14, 2026	Jul NEWA
---	---	----------	------------	---------	-----	--------------	----------

GEFITINIB

TABLET; ORAL

GEFITINIB

@		APOTEX	250MG	A209532	001	Sep 23, 2022	Jan DISC
@		CIPLA	250MG	A211826	001	May 16, 2025	Apr DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

>A>	AP	ADAPTIS	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Aug CAHN
>A>	AP		200MG/5.26ML (38MG/ML)	A210991	001	Oct 04, 2019	Aug CAHN
>A>	AP		EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Aug CAHN
>A>	AP		1GM/26.3ML (38MG/ML)	A210991	002	Oct 04, 2019	Aug CAHN
>A>	AP		2GM/52.6ML (38MG/ML)	A210991	003	Oct 04, 2019	Aug CAHN

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

@	INGENUS PHARMS LLC	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	May CAHN
@		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	May CAHN
@		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	May CAHN
@	NOVAST LABS	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Feb DISC
@		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Feb DISC
@		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Feb DISC
>D> AP	SHILPA	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Aug CAHN
>D> AP		200MG/5.26ML (38MG/ML)	A210991	001	Oct 04, 2019	Aug CAHN
>D> AP		EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Aug CAHN
>D> AP		1GM/26.3ML (38MG/ML)	A210991	002	Oct 04, 2019	Aug CAHN
>D> AP		2GM/52.6ML (38MG/ML)	A210991	003	Oct 04, 2019	Aug CAHN

SOLUTION; INTRAVENOUS

GEMCITABINE HYDROCHLORIDE

@ +	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017	May DISC
@ +		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017	May DISC
@ +		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017	May DISC
@ +		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017	May DISC

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

AT	COSETTE PHARMS NC	EQ 0.1% BASE	A064056	001	Apr 29, 1994	May CAHN
----	-------------------	--------------	---------	-----	--------------	----------

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT	COSETTE PHARMS NC	EQ 0.1% BASE	A064054	001	Apr 29, 1994	May CAHN
----	-------------------	--------------	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

AT	BAUSCH AND LOMB INC	EQ 0.3% BASE	A064048	001	May 11, 1994	May CAHN
@	PADAGIS US	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Mar DISC

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS

GLATIRAMER ACETATE

AP	HYBIO	20MG/ML	A213382	001	Feb 11, 2026	Jan NEWA
AP		40MG/ML	A214022	001	Feb 11, 2026	Jan NEWA
AP	SYNTHON BV	20MG/ML	A203857	001	Sep 25, 2024	Jun CAHN
AP		40MG/ML	A206873	001	Sep 25, 2024	Jun CAHN

GLECAPREVIR; PIBRENTASVIR

PELLETS; ORAL

MAVYRET

+!	ABBVIE	50MG/PACKET; 20MG/PACKET	N215110	001	Jun 10, 2021	Mar CPOT
----	--------	--------------------------	---------	-----	--------------	----------

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB	AIPING PHARM INC	5MG	A074305	001	Apr 07, 1995	Jul CMFD
AB		10MG	A074305	002	Apr 07, 1995	Jul CMFD
AB	GRAVITI PHARMS	5MG	A219159	001	Mar 04, 2026	Feb NEWA
AB		10MG	A219159	002	Mar 04, 2026	Feb NEWA
!	RUBICON RESEARCH	15MG	A214874	004	Feb 04, 2026	Jan NFTG

GLUCAGON

SOLUTION; INTRAVENOUS

GVOKE VIALDX

@ +	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	006	Mar 14, 2025	May DISC
-----	-------	-----------------------	---------	-----	--------------	----------

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB	IMPAX	1.25MG; 250MG	A076345	001	Feb 18, 2004	Mar CAHN
AB		2.5MG; 500MG	A076345	002	Feb 18, 2004	Mar CAHN
AB		5MG; 500MG	A076345	003	Feb 18, 2004	Mar CAHN

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

GLYCEROL PHENYLBUTYRATE

AA	AUROBINDO PHARMA	1.1GM/ML	A220313	001	Apr 15, 2026	Apr NEWA
>D> AA	ESJAY PHARMA	1.1GM/ML	A220579	001	Jul 28, 2026	Aug CAHN
AA		1.1GM/ML	A220579	001	Jul 28, 2026	Jul NEWA

LIQUID; ORAL

GLYCEROL PHENYLBUTYRATE

AA	LUPIN	1.1GM/ML	A207694	001	Apr 30, 2026	Apr NEWA
AA	MSN	1.1GM/ML	A219540	001	Apr 15, 2026	Apr NEWA
AA	NAVINTA LLC	1.1GM/ML	A220568	001	Apr 23, 2026	Apr NEWA
>A> AA	PAI HOLDINGS	1.1GM/ML	A220579	001	Jul 28, 2026	Aug CAHN
AA	TEVA PHARMS INC	1.1GM/ML	A218738	001	Apr 15, 2026	Apr NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

>A> AP	NIVAGEN	0.2MG/ML	A212591	001	Oct 13, 2021	Aug CAHN
>D> AP	NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021	Aug CAHN
AP		0.2MG/ML	A212591	001	Oct 13, 2021	Apr CAHN

SOLUTION; ORAL

GLYCOPYRROLATE

AA	QUAGEN	1MG/5ML	A216910	001	May 18, 2026	May NEWA
----	--------	---------	---------	-----	--------------	----------

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

PREVDUO

@ +	AZURITY	0.6MG/3ML (0.2MG/ML); 3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Jun DISC
-----	---------	--	---------	-----	--------------	----------

GLYCOPYRRONIUM TOSYLATE

CLOTH; TOPICAL

GLYCOPYRRONIUM TOSYLATE

AB	@	PADAGIS US	EQ 2.4% BASE	A214448	001	Apr 03, 2026	Apr DISC
			EQ 2.4% BASE	A214448	001	Apr 03, 2026	Mar NFTG
		QBREXZA					
	+	JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018	Apr CTEC
AB	+		EQ 2.4% BASE	N210361	001	Jun 28, 2018	Mar CFTG

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	!	BAUSCH AND LOMB INC	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A064047	001	Jan 31, 1996	May CAHN
		NEOSPORIN					
	@	MONARCH PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060582	001		Jan DISC

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

	+	APOTEX	3.1MG/24HR	N022198	001	Sep 12, 2008	Jul CAHN
--	---	--------	------------	---------	-----	--------------	----------

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRISEOFULVIN

AB		COSETTE PHARMS NC	125MG/5ML	A065438	001	Oct 08, 2010	May CAHN
----	--	-------------------	-----------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB		ASCENT PHARMS INC	EQ 1MG BASE	A220675	001	Mar 24, 2026	Mar NEWA
AB			EQ 2MG BASE	A220675	002	Mar 24, 2026	Mar NEWA
AB		RUBICON RESEARCH	EQ 1MG BASE	A216762	001	Oct 17, 2023	Mar CTEC
AB			EQ 2MG BASE	A216762	002	Oct 17, 2023	Mar CTEC

HALOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

HALOBETASOL PROPIONATE

	!	PADAGIS ISRAEL	0.05%	A215266	001	Aug 11, 2023	Feb CTEC
AB	!		0.05%	A215266	001	Aug 11, 2023	Feb CHRS
		LEXETTE					
	@ +	MAYNE PHARMA	0.05%	N210566	001	May 24, 2018	Feb DISC

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	!	COSETTE PHARMS NC	0.05%	A078162	001	Apr 24, 2007	May CAHN
----	---	-------------------	-------	---------	-----	--------------	----------

LOTION; TOPICAL

ULTRAVATE

>D>	+	LACER PHARMA	0.05%	N208183	001	Nov 06, 2015	Aug DISC
>A>	@	+	0.05%	N208183	001	Nov 06, 2015	Aug DISC
>A>	+	!	0.05%	N208183	001	Nov 06, 2015	Aug CMFD

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB		COSETTE PHARMS NC	0.05%	A077109	001	Jun 14, 2005	May CAHN
	@		0.05%	A077721	001	Sep 07, 2006	Jun CAHN
AB		ENCUBE	0.05%	A209978	001	Mar 20, 2018	Jun CMFD

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

AB		AIPING PHARM INC	0.5MG	A071130	004	Apr 08, 2026	Mar NEWA
AB			1MG	A071130	005	Apr 08, 2026	Mar NEWA
AB			2MG	A071130	006	Apr 08, 2026	Mar NEWA
AB		ALEMBIC	1MG	A214470	001	Jun 04, 2026	May NEWA
AB			2MG	A214470	002	Jun 04, 2026	May NEWA
AB			5MG	A214470	003	Jun 04, 2026	May NEWA
AB			10MG	A214470	004	Jun 04, 2026	May NEWA
AB			20MG	A214470	005	Jun 04, 2026	May NEWA
AB		MYLAN	2MG	A070278	001	Jun 10, 1986	Jul CHRS
>D>	AB		10MG	A070278	002	Jul 16, 2009	Aug DISC
>A>	@		10MG	A070278	002	Jul 16, 2009	Aug DISC
	@		20MG	A070278	003	Jul 16, 2009	Apr DISC
AB	!	ZYDUS PHARMS USA	2MG	A077580	006	Jan 17, 2023	Jul CHRS

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM PRESERVATIVE FREE

+	!	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Feb CMFD
---	---	--------	----------------	---------	-----	--------------	----------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

@	APOZEAL PHARMS	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Jul CAHN
@	PADAGIS US	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017	Mar DISC
@	PHARMOBEDIANT	1.5MG/5ML; 5MG/5ML	A088008	001	Mar 03, 1983	Jun DISC

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@	HERITAGE	10MG	A086242	001	Feb 04, 2010	Mar DISC
@		25MG	A086242	003		Mar DISC
@		50MG	A086242	002		Mar DISC
@		100MG	A086242	004	Feb 04, 2010	Mar DISC
@	STRIDES PHARMA INTL	10MG	A087836	001	Oct 05, 1982	Jan DISC
@		25MG	A086961	002		Jan DISC
@		50MG	A086962	001		Jan DISC
@		100MG	A088391	001	Sep 27, 1983	Jan DISC

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

@	STRIDES PHARMA INTL	25MG; 25MG	A088957	001	Oct 21, 1985	Jan DISC
@		50MG; 50MG	A088946	001	Oct 21, 1985	Jan DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB		INGENUS PHARMS LLC	37.5MG; 20MG	A215586	001	Apr 06, 2022	Feb CAHN
----	--	--------------------	--------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

@	CHARTWELL RX	12.5MG; 150MG	A201524	001	Feb 27, 2013	Apr CAHN
@		12.5MG; 300MG	A201524	002	Feb 27, 2013	Apr CAHN
@	HIKMA	12.5MG; 150MG	A090351	001	Oct 15, 2012	Jun DISC
@		12.5MG; 300MG	A090351	002	Oct 15, 2012	Jun DISC
@		25MG; 300MG	A090351	003	Jun 08, 2017	Jun DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	HETERO LABS LTD V	12.5MG; 50MG	A219869	001	May 27, 2026	May NEWA
AB		12.5MG; 100MG	A219869	002	May 27, 2026	May NEWA
AB		25MG; 100MG	A219869	003	May 27, 2026	May NEWA

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

@	STRIDES PHARMA INTL	15MG; 250MG	A070614	002	Feb 02, 1987	Jan CMS1
@		25MG; 250MG	A070614	003	Feb 02, 1987	Jan CMS1
@		30MG; 500MG	A070614	004	Feb 02, 1987	Jan CMS1

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC	25MG; 100MG	A202870	002	Nov 06, 2013	Feb CHRS
AB	! MYLAN	50MG; 100MG	A076792	003	Aug 20, 2004	Feb CHRS

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	MICRO LABS	12.5MG; 20MG	A206371	001	Apr 13, 2026	Apr NEWA
AB		12.5MG; 40MG	A206371	002	Apr 13, 2026	Apr NEWA
AB		25MG; 40MG	A206371	003	Apr 13, 2026	Apr NEWA
AB	SCIEGEN PHARMS	12.5MG; 20MG	A208465	001	Mar 31, 2026	Mar NEWA
AB		12.5MG; 40MG	A208465	002	Mar 31, 2026	Mar NEWA
AB		25MG; 40MG	A208465	003	Mar 31, 2026	Mar NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

>A> AB	RUBICON RESEARCH	25MG; 25MG	A220884	001	Sep 10, 2026	Aug NEWA
--------	------------------	------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

@	LUPIN	12.5MG; 40MG	A091351	001	Aug 07, 2014	Jun DISC
@		12.5MG; 80MG	A091351	002	Aug 07, 2014	Jun DISC
@		25MG; 80MG	A091351	003	Aug 07, 2014	Jun DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

@	LUPIN LTD	12.5MG; 80MG	A078946	003	Mar 21, 2013	May DISC
@		12.5MG; 160MG	A078946	004	Mar 21, 2013	May DISC
@		12.5MG; 320MG	A078946	001	Mar 21, 2013	May DISC
@		25MG; 160MG	A078946	005	Mar 21, 2013	May DISC
@		25MG; 320MG	A078946	002	Mar 21, 2013	May DISC
AB	SCIEGEN PHARMS	12.5MG; 80MG	A204687	001	Apr 23, 2026	Apr NEWA
AB		12.5MG; 160MG	A204687	002	Apr 23, 2026	Apr NEWA
AB		12.5MG; 320MG	A204687	003	Apr 23, 2026	Apr NEWA
AB		25MG; 160MG	A204687	004	Apr 23, 2026	Apr NEWA
AB		25MG; 320MG	A204687	005	Apr 23, 2026	Apr NEWA

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

HYSINGLA ER

AB	+! KNOA PHARMA	20MG	N206627	001	Nov 20, 2014	May CAHN
AB	+	30MG	N206627	002	Nov 20, 2014	May CAHN
AB	+	40MG	N206627	003	Nov 20, 2014	May CAHN
AB	+	60MG	N206627	004	Nov 20, 2014	May CAHN
AB	+	80MG	N206627	005	Nov 20, 2014	May CAHN
AB	+	100MG	N206627	006	Nov 20, 2014	May CAHN
@	+	120MG	N206627	007	Nov 20, 2014	May CAHN

HYDROCODONE BITARTRATE; IBUPROFENTABLET; ORAL
REPREXAIN

AMNEAL PHARMS NY 10MG;200MG

A076642 004 Oct 19, 2007 May CMFD

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ APOZEAL PHARMS 5MG/5ML; 60MG/5ML

A206661 001 Jan 23, 2019 Jul CAHN

HYDROCORTISONE

CREAM; TOPICAL

>D> ANUSOL HC

>D> AT SALIX PHARMS 2.5%

A088250 001 Jun 06, 1984 Aug DISC

>A> @ 2.5%

A088250 001 Jun 06, 1984 Aug DISC

HYDROCORTISONE

@ ACTAVIS MID ATLANTIC 2.5%

A089682 001 Mar 10, 1988 Jun DISC

AT ENCUBE 2.5%

A203810 001 Jul 23, 2018 Jul CMFD

GRANULE; ORAL

ALKINDI SPRINKLE

>D> + ETON 0.5MG

N213876 001 Sep 29, 2020 Aug CHRS

>A> +! 0.5MG

N213876 001 Sep 29, 2020 Aug CHRS

LOTION; TOPICAL

ALA-SCALP

+ LEGACY 2%

A083231 001 Jun CAHN

HYDROCORTISONE

AT RISING 2.5%

A218298 001 Jul 16, 2026 Jul NEWA

STIE-CORT

AT ! PADAGIS US 2.5%

A089074 001 Nov 26, 1985 Jul CTEC

TABLET; ORAL

HYDROCORTISONE

AB APPCO 5MG

A220329 001 Feb 25, 2026 Feb NEWA

AB 10MG

A220329 002 Feb 25, 2026 Feb NEWA

AB 20MG

A220329 003 Feb 25, 2026 Feb NEWA

HYDROCORTISONE ACETATE

CREAM; TOPICAL

MICORT-HC

@ LEGACY 2%

A040398 001 Mar 29, 2002 Jun CAHN

2.5%

A040396 001 Feb 27, 2001 Jun CAHN

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

CREAM; TOPICAL

PRAMOSONE

LEGACY 0.5%;1%

A083778 001 Jun CAHN

1%;1%

A085368 001 Jun CAHN

LOTION; TOPICAL

PRAMOSONE

LEGACY 1%;1%

A085980 001 Jun CAHN

2.5%;1%

A085979 001 Jun CAHN

HYDROCORTISONE BUTYRATE

OINTMENT; TOPICAL

HYDROCORTISONE BUTYRATE

! TARO 0.1%

A076842 001 Dec 27, 2004 Feb CTEC

AB ! 0.1%

A076842 001 Dec 27, 2004 Feb CHRS

LOCOID

@ + PRECISION DERMAT 0.1%

N018652 001 Oct 29, 1982 Feb DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

AP APOTEX EQ 100MG BASE/VIAL

A219856 001 Feb 05, 2026 Jan NEWA

AP ZYDUS PHARMS EQ 100MG BASE/VIAL

A217191 001 May 07, 2026 Apr NEWA

HYDROCORTISONE VALERATE

CREAM;TOPICAL							
HYDROCORTISONE VALERATE							
AB	@	COSETTE PHARMS NC	0.2%	A074489	001	Aug 12, 1998	Jun CAHN
			0.2%	A213724	001	Feb 11, 2021	May CAHN
	@	PADAGIS ISRAEL	0.2%	A075666	001	May 24, 2000	Mar DISC
OINTMENT;TOPICAL							
HYDROCORTISONE VALERATE							
AB		COSETTE PHARMS NC	0.2%	A211764	001	Mar 04, 2020	May CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC							
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE							
AT	!	BAUSCH AND LOMB INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064053	001	Dec 29, 1995	May CAHN
>A>	AT	ORBICULAR PHARM TECH	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A220938	001	Aug 27, 2026	Aug NEWA
SUSPENSION/DROPS;OTIC							
CASPORYN HC							
>D>	AT	+!	CASPER PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613	001	Aug CHRS
>A>	AT	+		1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613	001	Aug CHRS
OTICAIR							
>D>	AT		BAUSCH AND LOMB INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064065	001	Aug 28, 1996
>A>	AT	!		1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064065	001	Aug 28, 1996
	AT			1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064065	001	Aug 28, 1996
							May CAHN

HYDROCORTISONE; UREA

CREAM;TOPICAL							
ALPHADERM							
	@ +	BIOGLAN	1%;10%	A086008	001		May CRLD

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION							
DILAUDID-HP							
AP	+!	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Apr CMFD
HYDROMORPHONE HYDROCHLORIDE							
>D>		HOSPIRA INC	0.25MG/0.5ML	N200403	005	Mar 03, 2023	Aug CRLD
>A>	+		0.25MG/0.5ML	N200403	005	Mar 03, 2023	Aug CRLD
>D>			0.5MG/0.5ML	N200403	004	Jun 13, 2022	Aug CRLD
>A>	+		0.5MG/0.5ML	N200403	004	Jun 13, 2022	Aug CRLD
>D>	AP		1MG/ML	N200403	001	Dec 01, 2011	Aug CRLD
>A>	AP	+	1MG/ML	N200403	001	Dec 01, 2011	Aug CRLD
>D>	AP		2MG/ML	N200403	002	Dec 01, 2011	Aug CRLD
>A>	AP	+	2MG/ML	N200403	002	Dec 01, 2011	Aug CRLD
>D>	AP		4MG/ML	N200403	003	Dec 01, 2011	Aug CRLD
>A>	AP	+	4MG/ML	N200403	003	Dec 01, 2011	Aug CRLD

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL							
HYDROXYCHLOROQUINE SULFATE							
AB		SENORES PHARMS	200MG	A212902	001	May 14, 2020	Jan CAHN

HYDROXYUREA

CAPSULE;ORAL							
DROXIA							
	+	WAYLIS THERAP	200MG	N016295	002	Feb 25, 1998	Jul CMFD
	+		300MG	N016295	003	Feb 25, 1998	Jul CMFD
	+		400MG	N016295	004	Feb 25, 1998	Jul CMFD

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL							
HYDROXYZINE HYDROCHLORIDE							
>D>	AA	SAPTALIS PHARMS	10MG/5ML	A220271	001	Jun 11, 2026	Aug CAHN
	AA		10MG/5ML	A220271	001	Jun 11, 2026	May NEWA
>A>	AA	SCIEGEN PHARMS	10MG/5ML	A220271	001	Jun 11, 2026	Aug CAHN

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

@	AMNEAL PHARM	10MG	A040808	001	Sep 24, 2008	Apr	DISC
@		25MG	A040808	002	Sep 24, 2008	Apr	DISC
@		50MG	A040808	003	Sep 24, 2008	Apr	DISC

HYDROXYZINE PAMOATE

CAPSULE;ORAL

VISTARIL

>D>							
>D>	AB	+ PFIZER	EQ 25MG HYDROCHLORIDE	N011459	002		Aug DISC
>A>		@ +	EQ 25MG HYDROCHLORIDE	N011459	002		Aug DISC
>D>	AB	+	EQ 50MG HYDROCHLORIDE	N011459	004		Aug DISC
>A>		@ +	EQ 50MG HYDROCHLORIDE	N011459	004		Aug DISC

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

@	CHEMI SPA	EQ 3MG BASE/3ML	A202235	001	Sep 02, 2014	May	DISC
@	PHARMOBEDIENT	EQ 3MG BASE/3ML	A202671	001	Sep 02, 2014	Jun	DISC

>A> IBERDOMIDE HYDROCHLORIDE

CAPSULE;ORAL

ZENBEXUS

>A>		+ BRISTOL MYERS SQUIBB	EQ 0.75MG BASE	N221075	001	Aug 13, 2026	Aug NEWA
>A>		+!	EQ 1MG BASE	N221075	002	Aug 13, 2026	Aug NEWA

IBRUTINIB

CAPSULE;ORAL

IBRUTINIB

>A>	AB	HETERO LABS LTD V	140MG	A211182	001	Sep 08, 2026	Aug NEWA
		IMBRUVICA					
>D>		+! PHARMACYCLICS LLC	140MG	N205552	001	Nov 13, 2013	Aug CTEC
>A>	AB	+!	140MG	N205552	001	Nov 13, 2013	Aug CTEC

IBUPROFEN

SOLUTION;INTRAVENOUS

CALDOLOR

@	APOTEX	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009	Jul	CAHN
+!		800MG/8ML (100MG/ML)	N022348	002	Jun 11, 2009	Jul	CAHN
+!		800MG/200ML (4MG/ML)	N022348	003	Jan 25, 2019	Jul	CAHN

TABLET;ORAL

IBUPROFEN

@	ALLIED	400MG	A070045	001	Sep 24, 1985	Jul	CAHN
@		600MG	A070057	001	Sep 24, 1985	Jul	CAHN
@		800MG	A071999	001	Dec 03, 1987	Jul	CAHN
@	SENORES PHARMS	400MG	A070045	001	Sep 24, 1985	Jul	CAHN
@		600MG	A070057	001	Sep 24, 1985	Jul	CAHN
@		800MG	A071999	001	Dec 03, 1987	Jul	CAHN

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

AB	AUROBINDO PHARMA LTD	1GM	A218949	001	Jun 24, 2026	Jun	NEWA
AB	ONESOURCE	500MG	A217844	001	Sep 22, 2023	Jul	CAHN
AB		1GM	A217844	002	Sep 22, 2023	Jul	CAHN
AB	TORRENT	1GM	A218994	001	Dec 20, 2024	Apr	CAHN

ICOTROKINRA HYDROCHLORIDE

TABLET;ORAL

ICOTYDE

+!	JANSSEN BIOTECH	EQ 200MG BASE	N220149	001	Mar 17, 2026	Mar	NEWA
----	-----------------	---------------	---------	-----	--------------	-----	------

IDELALISIB

TABLET;ORAL

IDELALISIB

AB	NATCO	100MG	A216921	001	Feb 17, 2026	Feb	NFTG
AB		150MG	A216921	002	Feb 17, 2026	Feb	NFTG
	ZYDELIG						
AB	+ GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014	Feb	CFTG
AB	+!	150MG	N205858	002	Jul 23, 2014	Feb	CFTG

ILOPROST

SOLUTION; INHALATION

ILOPROST

>D>	!	BELOTECA	10MCG/ML (10MCG/ML)	A214997	001	Jul 10, 2026	Aug CAHN
	!		10MCG/ML (10MCG/ML)	A214997	001	Jul 10, 2026	Jul NFTG
>D>	!		20MCG/ML (20MCG/ML)	A214997	002	Jul 10, 2026	Aug CAHN
	!		20MCG/ML (20MCG/ML)	A214997	002	Jul 10, 2026	Jul NFTG
>A>	!	REGCON HOLDINGS	10MCG/ML (10MCG/ML)	A214997	001	Jul 10, 2026	Aug CAHN
>A>	!		20MCG/ML (20MCG/ML)	A214997	002	Jul 10, 2026	Aug CAHN

IMATINIB MESYLATE

TABLET; ORAL

GLEEVEC

AB	+	NOVARTIS	EQ 100MG BASE	N021588	001	Apr 18, 2003	Mar CHRS
AB	+		EQ 400MG BASE	N021588	002	Apr 18, 2003	Mar CHRS
		IMATINIB MESYLATE					
	@	SUN PHARM	EQ 100MG BASE	A078340	001	Dec 03, 2015	Feb DISC
	@		EQ 400MG BASE	A078340	002	Dec 03, 2015	Feb DISC

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

@	COSETTE PHARMS NC	5%	A200481	001	Apr 18, 2011	Jun CAHN
---	-------------------	----	---------	-----	--------------	----------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

INDIUM IN-111 PENTETREOTIDE KIT

@	SUN PHARM INDS INC	3mCi/ML	A212785	001	Jul 01, 2024	Apr DISC
	OCTREOSCAN					
+	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Apr CTEC

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

	!	RENEW PHARMS	10MG/VIAL	N011525	003		May CMFD
		INDOCYANINE GREEN					
AP		ZYDUS LIFESCIENCES	25MG/VIAL	A219139	001	Aug 03, 2026	Jul NEWA
		SOLUTION; INTRAVENOUS, INTERSTITIAL					
		ZYOGREEN					
	+	PROVEPHARM SAS	25MG/10ML (2.5MG/ML)	N218579	001	Jul 10, 2026	Jul NEWA

INDOMETHACIN

SUPPOSITORY; RECTAL

INDOCIN

@	+	COSETTE	50MG	N017814	001	Aug 13, 1984	Jun CAHN
---	---	---------	------	---------	-----	--------------	----------

SUSPENSION; ORAL

INDOCIN

AB	+	COSETTE	25MG/5ML	N018332	001	Oct 10, 1985	Jun CAHN
----	---	---------	----------	---------	-----	--------------	----------

IOHEXOL

SOLUTION; INJECTION, ORAL

IOHEXOL

AP		AMNEAL	75.5%	A217737	002	Jun 25, 2026	Jun NFTG
		OMNIPAQUE 350					
AP	+	GE HEALTHCARE	75.5%	N018956	004	Dec 26, 1985	Jun CFTG

IOMEPROL

SOLUTION; INTRA-ARTERIAL

IOMERVU

+	!	BRACCO	35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024	Feb CMFD
+	!		40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024	Feb CMFD
+	!		70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Feb CMFD
+	!		80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Feb CMFD

SOLUTION; INTRAVENOUS

IOMERVU

+	!	BRACCO	35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Feb CMFD
---	---	--------	-------------------------------------	---------	-----	--------------	----------

SOLUTION; INTRAVENOUS

IOMERVU

+	!	40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Feb CMFD
+	!	70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Feb CMFD
+	!	80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Feb CMFD

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

AB	+	!	BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004	Feb CFTG
AB			IPRATROPIUM BROMIDE					
AB			ARMSTRONG PHARMS	0.021MG/INH	A217953	001	Feb 23, 2026	Feb NFTG

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

>A>	AP		ADAPTIS	40MG/2ML (20MG/ML)	A208718	001	Dec 28, 2018	Aug CAHN
>A>	AP			100MG/5ML (20MG/ML)	A208718	002	Dec 28, 2018	Aug CAHN
>A>	AP			300MG/15ML (20MG/ML)	A208718	003	Aug 16, 2019	Aug CAHN
	AP		INGENUS PHARMS LLC	40MG/2ML (20MG/ML)	A206935	001	May 26, 2017	May CAHN
	AP			100MG/5ML (20MG/ML)	A206935	002	May 26, 2017	May CAHN
>D>	AP		SHILPA	40MG/2ML (20MG/ML)	A208718	001	Dec 28, 2018	Aug CAHN
>D>	AP			100MG/5ML (20MG/ML)	A208718	002	Dec 28, 2018	Aug CAHN
>D>	AP			300MG/15ML (20MG/ML)	A208718	003	Aug 16, 2019	Aug CAHN

ISONIAZID

TABLET; ORAL

ISONIAZID

>D>	@		GENUS	100MG	A080936	001		Aug CAHN
>D>	@			300MG	A080937	002		Aug CAHN
	@		HIKMA INTL PHARMS	300MG	A080212	002		Jul CMS1
>A>	@		ZETA PHARMS	100MG	A080936	001		Aug CAHN
>A>	@			300MG	A080937	002		Aug CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

AP			ASPIRO	0.2MG/ML	A220299	001	May 18, 2026	May NEWA
AP			J MOLNER	0.2MG/ML	A211237	001	May 19, 2021	Jun CAHN

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

AB			RUBICON RESEARCH	5MG	A215723	001	Jul 08, 2022	May CAHN
AB				10MG	A215723	002	Jul 08, 2022	May CAHN
AB				20MG	A215723	003	Jul 08, 2022	May CAHN
AB				30MG	A215723	004	Jul 08, 2022	May CAHN
AB				40MG	A215723	005	Jul 08, 2022	May CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

AB			ANI PHARMS	10MG	A075147	002	Mar 27, 2026	Apr NEWA
AB				20MG	A075147	001	Nov 27, 1998	Mar CMFD

ISOSULFAN BLUE

SOLUTION; SUBCUTANEOUS

ISOSULFAN BLUE

AP			EUGIA PHARMA	50MG/5ML (10MG/ML)	A206831	001	Feb 02, 2016	May CMFD
	!		MYLAN INSTITUTIONAL	10MG/ML (10MG/ML)	A090874	002	Jan 28, 2026	Jan NFTG
	!			30MG/3ML (10MG/ML)	A090874	003	Jan 28, 2026	Jan NFTG
AP			SABA ILAY SANAYI	50MG/5ML (10MG/ML)	A210714	001	Jan 16, 2019	Jun CMFD
AP			SOMERSET THERAPS LLC	50MG/5ML (10MG/ML)	A210558	001	Jul 12, 2019	May CMFD

ISOTRETINOIN

CAPSULE;ORAL

ISOTRETINOIN

	@	AMNEAL PHARMS NY	10MG	A216097	001	Oct 07, 2025	Mar	DISC
	@		20MG	A216097	002	Oct 07, 2025	Mar	DISC
	@		25MG	A216097	003	Oct 07, 2025	Mar	DISC
	@		30MG	A216097	004	Oct 07, 2025	Mar	DISC
	@		35MG	A216097	005	Oct 07, 2025	Mar	DISC
	@		40MG	A216097	006	Oct 07, 2025	Mar	DISC
>A> AB1		AUROBINDO PHARMA LTD	20MG	A220336	001	Sep 10, 2026	Aug	NEWA
>A> AB1			30MG	A220336	002	Sep 10, 2026	Aug	NEWA
>A> AB1			40MG	A220336	003	Sep 10, 2026	Aug	NEWA

IVABRADINE

SOLUTION;ORAL

CORLANOR

@ +	AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019	Mar	DISC
-----	-----------	------------------	---------	-----	--------------	-----	------

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

CORLANOR

	@ +	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Jan	DISC
	@ +		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Jan	DISC
AB	!	INGENUS PHARMS LLC	EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Jan	CHRS

IVERMECTIN

TABLET;ORAL

IVERMECTIN

AB		AJANTA PHARMA LTD	3MG	A218509	001	Apr 07, 2026	Mar	NEWA
AB		E5 PHARMA	3MG	A216808	001	Mar 09, 2026	Feb	NEWA
AB		ZYDUS LIFESCIENCES	3MG	A216863	001	Feb 26, 2026	Feb	NEWA

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

KETAMINE HYDROCHLORIDE

@	CAPLIN	EQ 10MG BASE/ML	A217858	001	Aug 07, 2025	Apr	DISC
---	--------	-----------------	---------	-----	--------------	-----	------

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

KETAMINE HYDROCHLORIDE

!	BAXTER HLTHCARE CORP	EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	A219684	002	Aug 11, 2026	Jul	NFTG
@		EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A219684	001	Sep 17, 2025	May	DISC

KETOCONAZOLE

CREAM;TOPICAL

KETOCONAZOLE

@	PADAGIS US	2%	A215185	001	Nov 17, 2021	Jan	DISC
---	------------	----	---------	-----	--------------	-----	------

SHAMPOO;TOPICAL

KETOCONAZOLE

AB		COSETTE PHARMS NC	2%	A076942	001	Apr 11, 2005	May	CAHN
----	--	-------------------	----	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ACULAR LS

+	ABBVIE	0.4%	N021528	001	May 30, 2003	Apr	CTEC
---	--------	------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINE

@	APOTEX	0.4%	A077308	001	Nov 05, 2009	Apr	DISC
---	--------	------	---------	-----	--------------	-----	------

SPRAY, METERED;NASAL

SPRIX

+	!	COSETTE	15.75MG/SPRAY	N022382	001	May 14, 2010	Jun	CAHN
---	---	---------	---------------	---------	-----	--------------	-----	------

L-GLUTAMINE

FOR SOLUTION;ORAL

L-GLUTAMINE

AA		ANNORA PHARMA	5GM/PACKET	A219722	001	May 26, 2026	May	NEWA
AA		RENOVA PHARMS	5GM/PACKET	A219750	001	May 14, 2026	May	CAHN
AA		STIRA	5GM/PACKET	A219750	001	May 14, 2026	May	NEWA

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB		APPCO	400MG	A209603	004	Oct 18, 2024	Mar CTEC
AB		HERITAGE PHARMA	400MG	A074787	004	Mar 26, 2026	Mar NEWA
AB		INNOGENIX	100MG	A075215	001	Jul 29, 1999	Jul CAHN
AB			200MG	A075215	002	Jul 29, 1999	Jul CAHN
AB			300MG	A075215	003	Jul 29, 1999	Jul CAHN
	@	PH HEALTH	100MG	A200908	001	Jul 10, 2012	Jul DISC
	@		200MG	A200908	002	Jul 10, 2012	Jul DISC
	@		300MG	A200908	003	Jul 10, 2012	Jul DISC
AB	!	ZYDUS PHARMS	200MG	A207743	002	Sep 19, 2017	Jul CHRS

LACOSAMIDE

SOLUTION; INTRAVENOUS

LACOSAMIDE

AP		ANTHEA PHARMA	200MG/20ML (10MG/ML)	A220268	001	Jan 21, 2026	Jan NEWA
AP		GLENMARK PHARMS	200MG/20ML (10MG/ML)	A220268	001	Jan 21, 2026	Mar CAHN

SOLUTION; ORAL

LACOSAMIDE

	@	APOTEX	10MG/ML	A206355	001	Sep 26, 2022	Feb DISC
AA		INDOCO	10MG/ML	A220386	001	Jan 29, 2026	Jan NEWA
AA		PROD DEVELOPMENT	10MG/ML	A217596	001	Jun 15, 2026	Jun NEWA
AA		REGCON HOLDINGS	10MG/ML	A220386	001	Jan 29, 2026	Jan CAHN
	@	STERANCO HLTHCARE	10MG/ML	A220366	001	May 21, 2026	Jul DISC
AA			10MG/ML	A220366	001	May 21, 2026	May NEWA

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

AA	!	APOTEX	10GM/PACKET	A074712	001	Dec 10, 1997	Jul CAHN
AA	!		20GM/PACKET	A074712	002	Dec 10, 1997	Jul CAHN

SOLUTION; ORAL, RECTAL

LACTULOSE

AA		APOZEAL PHARMS	10GM/15ML	A203762	001	Mar 27, 2015	Jul CAHN
----	--	----------------	-----------	---------	-----	--------------	----------

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

	@	LUPIN	150MG	A205217	001	Dec 18, 2014	Jan DISC
	@		300MG	A205217	002	Dec 18, 2014	Jan DISC

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

	@	PHARMOBEDIENT	150MG; 300MG	A079128	001	May 13, 2015	Jul DISC
--	---	---------------	--------------	---------	-----	--------------	----------

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

AB	+	GLAXOSMITHKLINE LLC	25MG	N020241	005	Dec 27, 1994	Jun CHRS
AB	!	ALEMBIC PHARMS LTD	25MG	A090607	001	Jan 13, 2011	Jun CHRS
	@	LUPIN LTD	25MG	A078691	001	Jun 01, 2010	Apr DISC
	@		100MG	A078691	002	Jun 01, 2010	Apr DISC
	@		150MG	A078691	003	Jun 01, 2010	Apr DISC
	@		200MG	A078691	004	Jun 01, 2010	Apr DISC

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

	@	PH HEALTH	25MG	A201791	001	Jan 18, 2013	Apr DISC
	@		50MG	A201791	002	Jan 18, 2013	Apr DISC
	@		100MG	A201791	003	Jan 18, 2013	Apr DISC
	@		200MG	A201791	004	Jan 18, 2013	Apr DISC
	@		250MG	A201791	005	Jan 18, 2013	Apr DISC
	@		300MG	A201791	006	Jan 18, 2013	Apr DISC

TABLET, ORALLY DISINTEGRATING; ORAL

LAMOTRIGINE

AB		ALEMBIC	25MG	A217278	001	Feb 25, 2026	Feb NEWA
AB			50MG	A217278	002	Feb 25, 2026	Feb NEWA
AB			100MG	A217278	003	Feb 25, 2026	Feb NEWA
AB			200MG	A217278	004	Feb 25, 2026	Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

AB	J MOLNER	25MG	A214124	001	Feb 03, 2022	Jun CAHN
AB		50MG	A214124	002	Feb 03, 2022	Jun CAHN
AB		100MG	A214124	003	Feb 03, 2022	Jun CAHN
AB		200MG	A214124	004	Feb 03, 2022	Jun CAHN
AB	TORRENT	25MG	A217100	001	Jan 08, 2026	Jan NEWA
AB		50MG	A217100	002	Jan 08, 2026	Jan NEWA
AB		100MG	A217100	003	Jan 08, 2026	Jan NEWA
AB		200MG	A217100	004	Jan 08, 2026	Jan NEWA

LASMIDITAN SUCCINATE

TABLET;ORAL

REYVOW

@ +	ELI LILLY AND CO	EQ 50MG BASE	N211280	001	Jan 31, 2020	Jun DISC
@ +		EQ 100MG BASE	N211280	002	Jan 31, 2020	Jun DISC

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

@	CARNEGIE	0.005%	A202077	001	Feb 11, 2013	Feb CAHN
AT	J MOLNER	0.005%	A200925	001	Mar 22, 2011	Jul CAHN
@	MANKIND PHARMA	0.005%	A220360	001	Dec 17, 2025	Jun DISC

LEDIPASVIR; SOFOSBUVIR

PELLETS;ORAL

HARVONI

+	GILEAD SCIENCES INC	33.75MG/PACKET;150MG/PACKET	N212477	001	Aug 28, 2019	Jul CPOT
+	!	45MG/PACKET;200MG/PACKET	N212477	002	Aug 28, 2019	Jul CPOT

LEFLUNOMIDE

TABLET;ORAL

ARAVA

@ +	SANOFI AVENTIS US	100MG	N020905	003	Sep 10, 1998	Jun DISC
-----	-------------------	-------	---------	-----	--------------	----------

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

AB	ALVOGEN	2.5MG	A210480	005	Mar 06, 2023	Jan CAHN
AB		5MG	A210480	001	Aug 31, 2022	Jan CAHN
AB		10MG	A210480	002	Aug 31, 2022	Jan CAHN
AB		15MG	A210480	003	Aug 31, 2022	Jan CAHN
AB		20MG	A210480	006	Mar 06, 2023	Jan CAHN
AB		25MG	A210480	004	Aug 31, 2022	Jan CAHN
AB	CIPLA	5MG	A213165	001	Feb 02, 2026	Jan NEWA
AB		10MG	A213165	002	Feb 02, 2026	Jan NEWA
AB		15MG	A213165	003	Feb 02, 2026	Jan NEWA
AB		20MG	A213165	004	Feb 02, 2026	Jan NEWA
AB		25MG	A213165	005	Feb 02, 2026	Jan NEWA
AB	@ TORRENT	2.5MG	A213405	005	Feb 10, 2026	Mar DISC
AB		2.5MG	A213405	005	Feb 10, 2026	Jan NEWA
AB	@	5MG	A213405	006	Feb 10, 2026	Mar DISC
AB		5MG	A213405	006	Feb 10, 2026	Jan NEWA
AB	@	15MG	A213405	004	Nov 04, 2025	Mar DISC

LETROZOLE

TABLET;ORAL

LETROZOLE

>D>	@	CARNEGIE	2.5MG	A091191	001	Jun 03, 2011	Aug CMFD
>A>	AB		2.5MG	A091191	001	Jun 03, 2011	Aug CMFD

LEUCOVORIN CALCIUM

FOR SOLUTION;ORAL

LEUCOVORIN CALCIUM

@ +	HOSPIRA	EQ 60MG BASE/VIAL	N008107	003	Jan 30, 1987	Jul CRLD
-----	---------	-------------------	---------	-----	--------------	----------

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

LEUCOVORIN CALCIUM

@	INGENUS PHARMS LLC	EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A210917	001	Nov 23, 2018	Feb CAHN
---	--------------------	--------------------------------------	---------	-----	--------------	----------

VYKOURA

+	!	AVYXA HOLDINGS	EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	N220406	001	Feb 03, 2026	Feb NEWA
---	---	----------------	------------------------------------	---------	-----	--------------	----------

+	!		EQ 350MG BASE/35ML (EQ 10MG	N220406	002	Feb 03, 2026	Feb NEWA
---	---	--	-----------------------------	---------	-----	--------------	----------

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
VYKOURA

		BASE/ML)					
+	!	EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	N220406	003	Feb 03, 2026	Feb	NEWA

TABLET;ORAL
LEUCOVORIN CALCIUM

AB	HIKMA	EQ 25MG BASE	A072736	001	Feb 22, 1993	May	CHRS
AB	INGENUS PHARMS LLC	EQ 5MG BASE	A211132	001	Jul 30, 2020	Apr	CAHN
AB		EQ 10MG BASE	A211132	002	Jul 30, 2020	Apr	CAHN
AB		EQ 15MG BASE	A211132	003	Jul 30, 2020	Apr	CAHN
AB	!	EQ 25MG BASE	A211132	004	Jul 30, 2020	May	CHRS
AB		EQ 25MG BASE	A211132	004	Jul 30, 2020	Apr	CAHN

LEUPROLIDE ACETATE

SOLUTION;SUBCUTANEOUS
LEUPROLIDE ACETATE

AP	SOMERSET THERAPS LLC	14MG/2.8ML (1MG/0.2ML)	A213829	001	Aug 13, 2021	Feb	CAHN		
>A>	VOBRIG								
>A>	+	!	SUN PHARM	28MG/2.8ML (10MG/ML)	N213225	001	Aug 26, 2026	Aug	NEWA

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS
CAMCEVI ETM

+	!	ACCORD	EQ 21MG BASE	N219745	001	Aug 25, 2025	Jan	CAHN
---	---	--------	--------------	---------	-----	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN	NEPHRON	EQ 0.021% BASE	A215217	001	May 26, 2026	May	NEWA
AN		EQ 0.042% BASE	A215217	002	May 26, 2026	May	NEWA

LEVETIRACETAM

INJECTABLE;INTRAVENOUS
LEVETIRACETAM

AP	BAXTER HLTHCARE CORP	500MG/5ML (100MG/ML)	A208458	001	Aug 06, 2026	Jul	NEWA	
	@	KNACK	500MG/5ML (100MG/ML)	A215465	001	Dec 02, 2025	May	DISC
		LEVETIRACETAM IN SODIUM CHLORIDE						
AP	MYLAN LABS LTD	500MG/100ML (5MG/ML)	A218364	001	May 08, 2026	May	NEWA	
AP		1GM/100ML (10MG/ML)	A218364	002	May 08, 2026	May	NEWA	
AP		1.5GM/100ML (15MG/ML)	A218364	003	May 08, 2026	May	NEWA	

SOLUTION;ORAL
LEVETIRACETAM

>A>	AA	ADAPTIS	100MG/ML	A218080	001	Nov 21, 2025	Aug	CAHN
>D>	AA	ANDA REPOSITORY	100MG/ML	A218080	001	Nov 21, 2025	Aug	CAHN
	AA		100MG/ML	A218080	001	Nov 21, 2025	Mar	CAHN
>A>	AA	GUARDIAN DRUG	100MG/ML	A218080	001	Nov 21, 2025	Aug	CAHN
	@	STRIDES PHARMA	100MG/ML	A078582	001	Jan 15, 2009	Jun	DISC

TABLET;ORAL
LEVETIRACETAM

AB	NOVAX	250MG	A078869	001	Mar 13, 2009	Jul	CAHN
AB		500MG	A078869	002	Mar 13, 2009	Jul	CAHN
AB		750MG	A078869	003	Mar 13, 2009	Jul	CAHN
AB		1GM	A078869	004	Mar 13, 2009	Jul	CAHN
AB	SENORES PHARMS	250MG	A076920	001	Jan 15, 2009	Jan	CAHN
AB		500MG	A076920	002	Jan 15, 2009	Jan	CAHN
AB		750MG	A076920	003	Jan 15, 2009	Jan	CAHN
AB		1GM	A078904	001	Jan 15, 2009	Jan	CAHN

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE

AT	BAUSCH AND LOMB INC	0.5%	A074326	001	Mar 04, 1994	May	CAHN
----	---------------------	------	---------	-----	--------------	-----	------

LEVOCARNITINE

INJECTABLE;INJECTION
LEVOCARNITINE

AP	BAXTER HLTHCARE CORP	200MG/ML	A217896	001	Jul 02, 2026	Jun	NEWA
----	----------------------	----------	---------	-----	--------------	-----	------

LEVOFLOXACINSOLUTION/DROPS;OPHTHALMIC
LEVOFLOXACIN

>D>	MICRO LABS LTD INDIA	1.5%	A205600	001	Feb 27, 2019	Aug DISC
>A>	@	1.5%	A205600	001	Feb 27, 2019	Aug DISC

TABLET;ORAL

LEVOFLOXACIN

@	LUPIN	250MG	A078424	001	Jun 20, 2011	May DISC
@		500MG	A078424	002	Jun 20, 2011	May DISC
@		750MG	A078424	003	Jun 20, 2011	May DISC

LEVOLEUCOVORIN CALCIUM

SOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

@	AMNEAL	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	Mar DISC
@	INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	May CAHN
@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	May CAHN

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

@	PIRAMAL CRITICAL	100MCG/VIAL	A206163	001	Jun 29, 2016	Jul DISC
@		500MCG/VIAL	A206163	002	Jun 29, 2016	Jul DISC

SOLUTION;ORAL

>D>	ERMEZA					
>D>	+! MYLAN	150MCG/5ML	N215809	001	Apr 29, 2022	Aug DISC
>A>	@ +	150MCG/5ML	N215809	001	Apr 29, 2022	Aug DISC

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

EUTHYROX

@	EMD SERONO INC	0.025MG	N021292	001	May 31, 2002	Apr DISC
@		0.05MG	N021292	002	May 31, 2002	Apr DISC
@		0.075MG	N021292	003	May 31, 2002	Apr DISC
@		0.088MG	N021292	004	May 31, 2002	Apr DISC
@		0.1MG	N021292	005	May 31, 2002	Apr DISC
@		0.112MG	N021292	006	May 31, 2002	Apr DISC
@		0.125MG	N021292	007	May 31, 2002	Apr DISC
@		0.137MG	N021292	008	May 31, 2002	Apr DISC
@		0.15MG	N021292	009	May 31, 2002	Apr DISC
@		0.175MG	N021292	010	May 31, 2002	Apr DISC
@		0.2MG	N021292	011	May 31, 2002	Apr DISC

LEVOTHYROXINE SODIUM

AB2	ALEMBIC	0.025MG	A216370	001	May 20, 2026	May NEWA
AB2		0.05MG	A216370	002	May 20, 2026	May NEWA
AB2		0.075MG	A216370	003	May 20, 2026	May NEWA
AB2		0.088MG	A216370	004	May 20, 2026	May NEWA
AB2		0.1MG	A216370	005	May 20, 2026	May NEWA
AB2		0.112MG	A216370	006	May 20, 2026	May NEWA
AB2		0.125MG	A216370	007	May 20, 2026	May NEWA
AB2		0.137MG	A216370	008	May 20, 2026	May NEWA
AB2		0.15MG	A216370	009	May 20, 2026	May NEWA
AB2		0.175MG	A216370	010	May 20, 2026	May NEWA
AB2		0.2MG	A216370	011	May 20, 2026	May NEWA
AB2		0.3MG	A216370	012	May 20, 2026	May NEWA

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	ALEMBIC	5%	A211469	001	Nov 23, 2018	May CTEC
	@ COSETTE PHARMS NC	5%	A211019	001	Dec 12, 2018	Jun CAHN
AT	ENCUBE	5%	A205318	001	Feb 01, 2016	Jun CMFD

PATCH;TOPICAL

LIDOCAINE

AB	USPHARMA	5%	A207059	001	Feb 09, 2026	Mar CMFD
	@	5%	A207059	001	Feb 09, 2026	Feb DISC
AB		5%	A207059	001	Feb 09, 2026	Jan NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP	ANTHEA PHARMA	2%	A219535	002	Feb 06, 2026	Jan NEWA
AP	VIWIT PHARM	1%	A220071	001	Mar 19, 2026	Mar NEWA
AP		2%	A220071	002	Mar 19, 2026	Mar NEWA

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

@ CHARTWELL RX

2%

A090665 001 Sep 27, 2010 May CAHN

JELLY;TOPICAL

LIDOCAINE HYDROCHLORIDE

@ COSETTE PHARMS NC

2%

A081318 001 Apr 29, 1993 Jun CAHN

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE

AT	QUAGEN	2%	A218676	001	Mar 20, 2026	Mar NEWA
----	--------	----	---------	-----	--------------	----------

SYSTEM;INTRADERMAL

ZINGO

@ POWDER PHARMS

0.5MG

N022114 001 Aug 16, 2007 Jul DISC

LINAGLIPTIN

TABLET;ORAL

LINAGLIPTIN

AB	TEVA PHARMS USA	5MG	A208433	001	May 27, 2026	May NEWA
----	-----------------	-----	---------	-----	--------------	----------

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOMYCIN HYDROCHLORIDE

@ HAINAN POLY

EQ 300MG BASE/ML

A216662 001 Dec 21, 2022 Jul CAHN

LINERIXIBAT

TABLET;ORAL

LYNAVOY

+! GLAXOSMITHKLINE

40MG

N220295 001 Mar 17, 2026 Mar NEWA

+! INTERCEPT

40MG

N220295 001 Mar 17, 2026 May CAHN

LINEZOLID

SOLUTION;INTRAVENOUS

LINEZOLID

>D> AP	PHARMOBEDIENT	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	Aug CAHN
>D> AP		600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	Aug CAHN
>A> AP	SEROVIA	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	Aug CAHN
>A> AP		600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	Aug CAHN

TABLET;ORAL

LINEZOLID

>D>	@ MACLEODS PHARMS	600MG	A210378	001	Oct 10, 2024	Aug CMFD
>A> AB		600MG	A210378	001	Oct 10, 2024	Aug CMFD

LIRAGLUTIDE

SOLUTION;SUBCUTANEOUS

LIRAGLUTIDE

AP1	BIOCON PHARMA	18MG/3ML (6MG/ML)	A215245	001	Mar 11, 2026	Feb NEWA
AP2		18MG/3ML (6MG/ML)	A217063	001	Feb 24, 2026	Feb NEWA
AP1	FRESENIUS KABI USA	18MG/3ML (6MG/ML)	A212552	001	Mar 30, 2026	Mar NEWA
AP1	MYLAN INSTITUTIONAL	18MG/3ML (6MG/ML)	A213155	001	Jun 15, 2026	Jun NEWA
AP2	ORBICULAR	18MG/3ML (6MG/ML)	A217234	001	Feb 24, 2026	Feb NEWA
AP1		18MG/3ML (6MG/ML)	A217590	001	Jan 14, 2026	Jan NEWA
AP1	SANDOZ	18MG/3ML (6MG/ML)	A212972	001	Jul 01, 2026	Jun NEWA

LISINOPRIL

SOLUTION;ORAL

LISINOPRIL

>A> AA	ANNORA PHARMA	1MG/ML	A218419	001	Aug 20, 2026	Aug NFTG
	QBRELIS					
>D>	+! AZURITY	1MG/ML	N208401	001	Jul 29, 2016	Aug CFTG
>A> AA	+!	1MG/ML	N208401	001	Jul 29, 2016	Aug CFTG

LITHIUM CARBONATE

TABLET;ORAL

LITHIUM CARBONATE

+! HIKMA

300MG

N018558 001 Jan 29, 1982 Jul CTEC

@ SUN PHARM INDS INC

300MG

A091027 001 Jun 24, 2010 Jul DISC

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA PAI HOLDINGS PHARM EQ 300MG CARBONATE/5ML

A070755 001 May 21, 1986 Mar CMFD

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

+ CHIESI

EQ 2MG BASE

N203858 007 Feb 25, 2026 Feb NEWA

+!

EQ 30MG BASE

N203858 004 Apr 23, 2015 Mar CHRS

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

>D> AB MICRO LABS 25MG

A091541 001 Sep 24, 2012 Aug DISC

>A> @ 25MG

A091541 001 Sep 24, 2012 Aug DISC

>D> AB 50MG

A091541 002 Sep 24, 2012 Aug DISC

>A> @ 50MG

A091541 002 Sep 24, 2012 Aug DISC

>D> AB 100MG

A091541 003 Sep 24, 2012 Aug DISC

>A> @ 100MG

A091541 003 Sep 24, 2012 Aug DISC

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEPREDNOL ETABONATE

@ SUN PHARM

0.5%

A215384 001 Aug 09, 2023 Jul DISC

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

@ AZURITY

10MG

N021316 001 Jun 26, 2002 Jul CAHN

@ 10MG

N021316 001 Jun 26, 2002 Mar CAHN

@ + 20MG

N021316 002 Jun 26, 2002 Jul CAHN

@ + 20MG

N021316 002 Jun 26, 2002 Mar CAHN

@ + 40MG

N021316 003 Jun 26, 2002 Jul CAHN

@ + 40MG

N021316 003 Jun 26, 2002 Mar CAHN

@ + 60MG

N021316 004 Jun 26, 2002 Jul CAHN

@ + 60MG

N021316 004 Jun 26, 2002 Mar CAHN

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

AB AMNEAL 8MCG

A209450 001 Nov 30, 2021 Jan CMFD

AB 24MCG

A209450 002 Nov 30, 2021 Jan CMFD

MACIMORELIN ACETATE

FOR SOLUTION;ORAL

MACRILEN

@ + AETERNA ZENTARIS

EQ 60MG BASE/POUCH

N205598 001 Dec 20, 2017 Jan CAHN

MACITENTAN

TABLET;ORAL

MACITENTAN

AB AMNEAL 10MG

A211000 001 Jun 08, 2026 May NEWA

AB APOTEX 10MG

A211195 001 Jan 09, 2024 Mar CMFD

>A> AB LEPH PHARM 10MG

A211026 001 Dec 03, 2025 Aug CAHN

AB MYLAN 10MG

A211161 001 Dec 03, 2025 May CMFD

>D> AB SEASONS BIOTECH 10MG

A211026 001 Dec 03, 2025 Aug CAHN

AB 10MG

A211026 001 Dec 03, 2025 Apr CMFD

AB TEVA PHARMS USA INC 10MG

A211187 001 Jun 08, 2026 May NEWA

AB TORRENT 10MG

A211107 001 Aug 05, 2024 Apr CMFD

AB ZYDUS LIFESCIENCES 10MG

A211224 001 Apr 06, 2021 Apr CMFD

MAFENIDE ACETATEFOR SOLUTION; TOPICAL
MAFENIDE ACETATE

@	INGENUS PHARMS LLC	5%	A206716	001	Jul 31, 2017	Feb CAHN
---	--------------------	----	---------	-----	--------------	----------

MAGNESIUM SULFATEINJECTABLE; INJECTION
MAGNESIUM SULFATE

!	BAXTER HLTHCARE CORP	3GM/100ML (30MG/ML)	A211966	004	Jan 08, 2026	Jan NFTG
	MAGNESIUM SULFATE IN PLASTIC CONTAINER					

>D>	@	MYLAN LABS LTD	2GM/50ML (40MG/ML)	A209911	001	Sep 14, 2018	Aug CAHN
	@		2GM/50ML (40MG/ML)	A209911	001	Sep 14, 2018	Mar DISC
>D>	@		4GM/100ML (40MG/ML)	A209911	002	Sep 14, 2018	Aug CAHN
>A>	@	PHARMOBEDIENT	2GM/50ML (40MG/ML)	A209911	001	Sep 14, 2018	Aug CAHN
>A>	@		4GM/100ML (40MG/ML)	A209911	002	Sep 14, 2018	Aug CAHN

SOLUTION; INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

AP		SQUARE PHARMS PLC	1GM/2ML (500MG/ML)	A217461	001	Jul 09, 2026	Jul NEWA
AP			5GM/10ML (500MG/ML)	A217461	002	Jul 09, 2026	Jul NEWA
AP			10GM/20ML (500MG/ML)	A217461	003	Jul 09, 2026	Jul NEWA
AP			25GM/50ML (500MG/ML)	A217461	004	Jul 09, 2026	Jul NEWA

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE

TABLET; ORAL

SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE

AB		LUPIN	0.225GM; 0.188GM; 1.479GM	A216095	001	May 28, 2026	May NFTG
		SUTAB					
AB	+	! AZURITY	0.225GM; 0.188GM; 1.479GM	N213135	001	Nov 10, 2020	May CFTG

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

>A> AA		MACLEODS PHARMS LTD	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BO T	A219429	001	Aug 31, 2026	Aug NEWA
--------	--	---------------------	---------------------------------------	---------	-----	--------------	----------

MARALIXIBAT CHLORIDE

TABLET; ORAL

LIVMARLI

>D>	+	MIRUM	EQ 10MG BASE	N219485	001	Apr 10, 2025	Aug CHRS
>A>	+	!	EQ 10MG BASE	N219485	001	Apr 10, 2025	Aug CHRS
>D>	+		EQ 15MG BASE	N219485	002	Apr 10, 2025	Aug CHRS
>A>	+	!	EQ 15MG BASE	N219485	002	Apr 10, 2025	Aug CHRS
>D>	+		EQ 20MG BASE	N219485	003	Apr 10, 2025	Aug CHRS
>A>	+	!	EQ 20MG BASE	N219485	003	Apr 10, 2025	Aug CHRS

MARAVIROC

TABLET; ORAL

MARAVIROC

@	RHODES PHARMS	150MG	A216143	001	Nov 04, 2025	Apr DISC
@		300MG	A216143	002	Nov 04, 2025	Apr DISC

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA		HERITAGE	50MG	A205136	003	Feb 22, 2019	Jun CMFD
>A> AA		QUAGEN	25MG	A084092	003	May 22, 1989	Aug CAHN
>D> AA		SCIEGEN PHARMS	25MG	A084092	003	May 22, 1989	Aug CAHN
AA		SENORES PHARMS	12.5MG	A087128	002		Feb CAHN
AA			25MG	A087128	001		Feb CAHN

MELOXICAM

TABLET; ORAL

MELOXICAM

@	ZENNOVA	7.5MG	A077933	001	Jul 19, 2006	Jul CAHN
@		15MG	A077933	002	Jul 19, 2006	Jul CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

@	INGENUS PHARMS LLC	EQ 50MG BASE/VIAL	A210947	001	Feb 18, 2020	May CAHN
---	--------------------	-------------------	---------	-----	--------------	----------

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

>A>	AB	H2-PHARMA	7MG	A213985	001	Oct 11, 2022	Aug CAHN
>A>	AB		14MG	A213985	002	Oct 11, 2022	Aug CAHN
>A>	AB		21MG	A213985	004	Feb 06, 2024	Aug CAHN
>A>	AB		28MG	A213985	003	Oct 11, 2022	Aug CAHN
>D>	AB	VITRUVIAS	7MG	A213985	001	Oct 11, 2022	Aug CAHN
>D>	AB		14MG	A213985	002	Oct 11, 2022	Aug CAHN
>D>	AB		21MG	A213985	004	Feb 06, 2024	Aug CAHN
>D>	AB		28MG	A213985	003	Oct 11, 2022	Aug CAHN

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

	@	APOZEAL PHARMS	2MG/ML	A205446	001	Dec 07, 2015	Jul CAHN
AA		MEDLEY PHARMS	2MG/ML	A210319	001	Aug 31, 2020	Mar CAHN

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

AB	!	DR REDDYS LABS LTD	10MG	A090048	002	Apr 14, 2010	Mar CHRS
AB		RENATA	5MG	A209527	001	May 07, 2018	Feb CAHN
AB			10MG	A209527	002	May 07, 2018	Feb CAHN
	@	STRIDES PHARMA	5MG	A202350	001	May 23, 2017	Jun DISC
	@		10MG	A202350	002	May 23, 2017	Jun DISC
		NAMENDA					
	@ +	ABBVIE	5MG	N021487	001	Oct 16, 2003	Mar DISC
	@ +		10MG	N021487	002	Oct 16, 2003	Mar DISC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

!	FRESENIUS KABI USA	1%	A089407	001	Dec 01, 1986	Jan CHRS
!		2%	A089410	001	Dec 01, 1986	Jan CHRS
	POLOCAINE-MPF					
!	FRESENIUS KABI USA	1%	A089406	001	Dec 01, 1986	Jan CHRS
!		1.5%	A089408	001	Dec 01, 1986	Jan CHRS
!		2%	A089409	001	Dec 01, 1986	Jan CHRS

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

@	MYLAN	50MG	A040594	001	Jul 01, 2005	Jun DISC
---	-------	------	---------	-----	--------------	----------

MEROPENEM

POWDER; INTRAVENOUS

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

+	!	B BRAUN MEDICAL	500MG/VIAL	N202106	001	Apr 30, 2015	Jun CHRS
+			500MG/VIAL	N202106	001	Apr 30, 2015	Jun CRLD
+	!		1GM/VIAL	N202106	002	Apr 30, 2015	Jun CHRS
+			1GM/VIAL	N202106	002	Apr 30, 2015	Jun CRLD

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

MESALAMINE

AB		DIFGEN PHARMS	250MG	A219997	001	Mar 10, 2026	Feb NFTG
AB			500MG	A219997	002	Mar 10, 2026	Feb NEWA
AB		SANDOZ	250MG	A219997	001	Mar 10, 2026	Jul CAHN
AB			500MG	A219997	002	Mar 10, 2026	Jul CAHN
		PENTASA					
AB	+	TAKEDA PHARMS USA	250MG	N020049	001	May 10, 1993	Feb CFTG
		ENEMA; RECTAL					
		MESALAMINE					
AB		KLM LABS PVT	4GM/60ML	A220016	001	Mar 31, 2026	Mar NEWA
>D>		SFROWASA					
>D>	AB	+	MYLAN SPECIALITY LP	4GM/60ML	N019618	002	Jun 20, 2008
>A>		@ +	4GM/60ML	N019618	002	Jun 20, 2008	Aug DISC

SUPPOSITORY;RECTAL							
MESALAMINE							
AB	J MOLNER	1GM	A208362	001	Jun 21, 2019	Jun	CAHN
<u>MESNA</u>							
INJECTABLE;INTRAVENOUS							
MESNA							
AP	EUGIA PHARMA	100MG/ML	A220518	001	Jan 27, 2026	Jan	NEWA
TABLET;ORAL							
MESNA							
AB	INGENUS PHARMS LLC	400MG	A218871	001	Jan 13, 2025	Feb	CAHN
<u>METAPROTERENOL SULFATE</u>							
SYRUP;ORAL							
METAPROTERENOL SULFATE							
@	COSETTE PHARMS NC	10MG/5ML	A072761	001	Feb 27, 1992	Jun	CAHN
<u>METAXALONE</u>							
TABLET;ORAL							
METAXALONE							
@	INGENUS PHARMS LLC	800MG	A213836	001	Oct 21, 2020	Feb	CAHN
<u>METFORMIN HYDROCHLORIDE</u>							
TABLET;ORAL							
METFORMIN HYDROCHLORIDE							
AB	CHARTWELL	625MG	A075972	005	Jan 24, 2002	Jan	CTEC
AB		750MG	A075972	004	Jan 24, 2002	Jan	CTEC
AB	SCIEGEN PHARMS	625MG	A203769	004	Feb 09, 2026	Jan	NEWA
AB		750MG	A203769	005	Feb 09, 2026	Jan	NEWA
TABLET, EXTENDED RELEASE;ORAL							
METFORMIN HYDROCHLORIDE							
@	ALLIED	500MG	A215629	001	Jun 20, 2023	Apr	CAHN
@		1GM	A215629	002	Jun 20, 2023	Apr	CAHN
@	AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Mar	DISC
@		750MG	A078596	002	Jan 03, 2008	Mar	DISC
@	APOTEX	500MG	A213356	001	Dec 13, 2021	Feb	DISC
@		1GM	A213356	002	Dec 13, 2021	Feb	DISC
AB1	PLATINUM	500MG	A202306	001	Feb 23, 2017	Apr	CAHN
AB		750MG	A202306	002	Feb 23, 2017	Apr	CAHN
@	RK PHARMA	500MG	A215629	001	Jun 20, 2023	Jan	DISC
@		1GM	A215629	002	Jun 20, 2023	Jan	DISC
@	SENORES PHARMS	500MG	A215629	001	Jun 20, 2023	Apr	CAHN
@		1GM	A215629	002	Jun 20, 2023	Apr	CAHN
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE</u>							
TABLET;ORAL							
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE							
AB	APOTEX	500MG;EQ 50MG BASE	A202426	001	Apr 30, 2026	Apr	NEWA
AB		1GM;EQ 50MG BASE	A202426	002	Apr 30, 2026	Apr	NEWA
TABLET, EXTENDED RELEASE;ORAL							
JANUMET XR							
AB	+ MSD SUB MERCK	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	May	CTEC
AB	+	1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	May	CTEC
AB	+	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	May	CTEC
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE							
AB	PH HEALTH	500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	May	CMFD
AB		1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	May	CMFD
AB		1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	May	CMFD
<u>METHADONE HYDROCHLORIDE</u>							
SOLUTION;ORAL							
METHADONE HYDROCHLORIDE							
AA	VISTAPHARM LLC	5MG/5ML	A090707	001	Jun 30, 2010	Feb	CMFD
<u>METHAZOLAMIDE</u>							
TABLET;ORAL							
METHAZOLAMIDE							
AB	AJANTA PHARMA LTD	25MG	A217408	001	Feb 09, 2026	Jan	NEWA
AB		50MG	A217408	002	Feb 09, 2026	Jan	NEWA
@	POM PHARMA	25MG	A040102	001	Aug 28, 1996	Apr	CAHN
@		50MG	A040102	002	Aug 28, 1996	Apr	CAHN

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB		INGENUS PHARMS LLC	1GM	A210068	001	Nov 27, 2020	Feb CAHN
----	--	--------------------	-----	---------	-----	--------------	----------

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP		HAINAN POLY	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Jul CAHN
----	--	-------------	---------------------	---------	-----	--------------	----------

SUSPENSION; ORAL

ATMEKSI

+! ROSEMONT PHARMS

TABLET; ORAL

METHOCARBAMOL

>D>	AA		DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Aug CAHN
	AA			500MG	A203550	001	Feb 08, 2017	Mar CAHN
>D>	AA			750MG	A203550	002	Feb 08, 2017	Aug CAHN
	AA			750MG	A203550	002	Feb 08, 2017	Mar CAHN
	@		HIKMA INTL PHARMS	500MG	A085123	002		Jun CMS1
>A>	AA		HLTHCARE	500MG	A203550	001	Feb 08, 2017	Aug CAHN
	AA			500MG	A203550	001	Feb 08, 2017	Feb CAHN
>A>	AA			750MG	A203550	002	Feb 08, 2017	Aug CAHN
	AA			750MG	A203550	002	Feb 08, 2017	Feb CAHN

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

@ + COSETTE

@ +

@ +

@ +

@ +

@ +

@ +

@ +

OTREXUP PFS

@ + COSETTE

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

@ +

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM

AP		ALEMBIC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A220225	001	Apr 15, 2026	Apr NEWA
----	--	---------	------------------------------------	---------	-----	--------------	----------

AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A220225	002	Apr 15, 2026	Apr NEWA
----	--	--	------------------------------------	---------	-----	--------------	----------

AP		HETERO LABS LTD VI	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A219865	001	Apr 30, 2026	Apr NEWA
----	--	--------------------	------------------------------------	---------	-----	--------------	----------

AP	!	HIKMA	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Apr CTEC
----	---	-------	-------------------------------------	---------	-----	--------------	----------

METHOTREXATE SODIUM PRESERVATIVE FREE

@ CAPLIN ONE LABS

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

INJECTABLE; INJECTION
METHOTREXATE SODIUM PRESERVATIVE FREE
BASE/ML)

TABLET; ORAL
METHOTREXATE SODIUM
@ DAITO

EQ 2.5MG BASE

A213362 001 Aug 07, 2023 Mar DISC

METHOXSALLEN

CAPSULE; ORAL
METHOXSALLEN

AB ONESOURCE

10MG

A202687 001 Jun 05, 2014 Jul CAHN

METHSCOPOLAMINE BROMIDE

TABLET; ORAL
PAMINE

@ FOUGERA

2.5MG

N008848 001

Jul CAHN

PAMINE FORTE

@ FOUGERA

5MG

N008848 002 Mar 25, 2003 Jul CAHN

METHYLDOPA

TABLET; ORAL
METHYLDOPA

@ QUAGEN

125MG

A070535 001 Jan 02, 1987 Apr CAHN

@

250MG

A070536 001 Jan 02, 1987 Apr CAHN

@

500MG

A070537 001 Jan 02, 1987 Apr CAHN

METHYLENE BLUE

SOLUTION; INTRAVENOUS
METHYLENE BLUE

! ZYDUS LIFESCIENCES

5MG/ML (5MG/ML)

A215636 003 Feb 02, 2026 Jan NFTG

!

100MG/10ML (10MG/ML)

A215636 004 Mar 31, 2026 Mar NFTG

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL
COTEMPLA XR-ODT

AB + NEOS THERAPS INC

8.6MG

N205489 001 Jun 19, 2017 May CTEC

AB +

17.3MG

N205489 002 Jun 19, 2017 May CTEC

AB +!

25.9MG

N205489 003 Jun 19, 2017 May CTEC

METHYLPHENIDATE

AB ACTAVIS ELIZABETH

8.6MG

A210924 001 Jun 19, 2020 May CMFD

AB

17.3MG

A210924 002 Jun 19, 2020 May CMFD

AB

25.9MG

A210924 003 Jun 19, 2020 May CMFD

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ADHANSIA XR

@ + KNOA PHARMA

25MG

N212038 001 Feb 27, 2019 May CAHN

@ +

35MG

N212038 002 Feb 27, 2019 May CAHN

@ +

45MG

N212038 003 Feb 27, 2019 May CAHN

@ +

55MG

N212038 004 Feb 27, 2019 May CAHN

@ +

70MG

N212038 005 Feb 27, 2019 May CAHN

@ +

85MG

N212038 006 Feb 27, 2019 May CAHN

METADATE CD

>D> AB2 + LANNETT

10MG

N021259 003 May 27, 2003 Aug CAHN

>A> AB2 +

10MG

N021259 003 May 27, 2003 Aug CAHN

AB2 +

10MG

N021259 003 May 27, 2003 Jun CAHN

>D> AB2 +

20MG

N021259 001 Apr 03, 2001 Aug CAHN

>A> AB2 +

20MG

N021259 001 Apr 03, 2001 Aug CAHN

AB2 +

20MG

N021259 001 Apr 03, 2001 Jun CAHN

>D> AB2 +

30MG

N021259 002 Jun 19, 2003 Aug CAHN

>A> AB2 +

30MG

N021259 002 Jun 19, 2003 Aug CAHN

AB2 +

30MG

N021259 002 Jun 19, 2003 Jun CAHN

>D> AB2 +

40MG

N021259 004 Feb 19, 2006 Aug CAHN

>A> AB2 +

40MG

N021259 004 Feb 19, 2006 Aug CAHN

AB2 +

40MG

N021259 004 Feb 19, 2006 Jun CAHN

>D> AB2 +

50MG

N021259 005 Feb 19, 2006 Aug CAHN

>A> AB2 +

50MG

N021259 005 Feb 19, 2006 Aug CAHN

AB2 +

50MG

N021259 005 Feb 19, 2006 Jun CAHN

>D> AB2 +!

60MG

N021259 006 Feb 19, 2006 Aug CAHN

>A> AB2 +!

60MG

N021259 006 Feb 19, 2006 Aug CAHN

AB2 +!

60MG

N021259 006 Feb 19, 2006 Jun CAHN

CAPSULE, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB1	DR REDDYS LABS SA	60MG	A078458	004	Jun 23, 2016	Feb CHRS
AB1	! GRANULES	60MG	A211796	005	May 23, 2019	Feb CHRS

TABLET, CHEWABLE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

@	QUAGEN	2.5MG	A204954	001	Jan 26, 2017	Apr CAHN
@		5MG	A204954	002	Jan 26, 2017	Apr CAHN
@		10MG	A204954	003	Jan 26, 2017	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

@	SPECGX LLC	27MG	A202608	001	Dec 28, 2012	Jun DISC
@		36MG	A202608	002	Dec 28, 2012	Jun DISC
@		54MG	A202608	003	Dec 28, 2012	Jun DISC
@	SUN PHARM INDS INC	18MG	A205135	001	Aug 19, 2020	Jul DISC
@		27MG	A205135	002	Aug 19, 2020	Jul DISC
@		36MG	A205135	003	Aug 19, 2020	Jul DISC
@		54MG	A205135	004	Aug 19, 2020	Jul DISC

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

@	INGENUS PHARMS LLC	4MG	A210985	001	Jan 09, 2019	Feb CAHN
---	--------------------	-----	---------	-----	--------------	----------

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	CAPLIN	40MG/ML	A220556	001	Jan 26, 2026	Jan NEWA
AB		80MG/ML	A220556	002	Jan 26, 2026	Jan NEWA
>A> AB	EMERGE BIOSCIENCE	40MG/ML	A040557	001	Feb 23, 2005	Aug CAHN
>A> AB		80MG/ML	A040557	002	Feb 23, 2005	Aug CAHN
>D> AB	HONG KONG	40MG/ML	A040557	001	Feb 23, 2005	Aug CAHN
>D> AB		80MG/ML	A040557	002	Feb 23, 2005	Aug CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Jun CMFD
----	--------------------	----------------	---------	-----	--------------	----------

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	! PAI HOLDINGS	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	May CAHN
----	----------------	-----------------	---------	-----	--------------	----------

SPRAY, METERED;NASAL

GIMOTI

+!	QOL MEDCL	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020	Feb CAHN
----	-----------	--------------------	---------	-----	--------------	----------

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@	STRIDES PHARMA INTL	EQ 10MG BASE	A070581	001	Oct 17, 1985	Jan DISC
---	---------------------	--------------	---------	-----	--------------	----------

METOLAZONE

TABLET;ORAL

METOLAZONE

>A> AB	ACERTIS PHARMS	2.5MG	A218606	001	Apr 17, 2024	Aug CAHN
>A> AB		5MG	A218606	002	Apr 17, 2024	Aug CAHN
>A> AB		10MG	A218606	003	Apr 17, 2024	Aug CAHN
>D> AB	IXORA LIFESCIENCE	2.5MG	A218606	001	Apr 17, 2024	Aug CAHN
>D> AB		5MG	A218606	002	Apr 17, 2024	Aug CAHN
>D> AB		10MG	A218606	003	Apr 17, 2024	Aug CAHN
>D> AB	MICRO LABS	2.5MG	A217563	001	Nov 06, 2024	Aug DISC
>A>	@	2.5MG	A217563	001	Nov 06, 2024	Aug DISC
>D> AB		5MG	A217563	002	Nov 06, 2024	Aug DISC
>A>	@	5MG	A217563	002	Nov 06, 2024	Aug DISC
>D> AB		10MG	A217563	003	Nov 06, 2024	Aug DISC
>A>	@	10MG	A217563	003	Nov 06, 2024	Aug DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

@	MYLAN PHARMS INC	EQ 25MG TARTRATE	A202033	001	Dec 15, 2011	Jun DISC
@		EQ 50MG TARTRATE	A202033	002	Dec 15, 2011	Jun DISC
@		EQ 100MG TARTRATE	A202033	003	Dec 15, 2011	May DISC
@		EQ 200MG TARTRATE	A202033	004	Dec 15, 2011	Mar DISC
AB	ZHEJIANG JUTAI PHARM	EQ 25MG TARTRATE	A214110	004	May 15, 2026	May NEWA

METRONIDAZOLE

CREAM; TOPICAL							
METRONIDAZOLE							
AB	COSETTE PHARMS NC	0.75%	A077549	001	Dec 19, 2007	May	CAHN
GEL; TOPICAL							
METRONIDAZOLE							
AB	! COSETTE PHARMS NC	0.75%	A078178	001	Jan 19, 2011	May	CAHN
AB		1%	A216692	001	Jan 23, 2023	May	CAHN
AB	ZYDUS LIFESCIENCES	0.75%	A220095	001	Feb 13, 2026	Feb	NEWA
GEL; VAGINAL							
METRONIDAZOLE							
AB	COSETTE PHARMS NC	0.75%	A216323	001	Jul 12, 2023	May	CAHN
NUVESSA							
	+! ALEMBIC THERAP	1.3%	N205223	001	Mar 24, 2014	May	CAHN
INJECTABLE; INJECTION							
METRO I.V. IN PLASTIC CONTAINER							
	@ + B BRAUN	500MG/100ML	N018900	001	Sep 29, 1983	Jan	DISC
METRONIDAZOLE IN PLASTIC CONTAINER							
AP	! INFORLIFE	500MG/100ML	A206191	001	Feb 25, 2019	Jan	CHRS

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL							
MEXILETINE HYDROCHLORIDE							
AB	INGENUS PHARMS LLC	150MG	A214352	001	Jan 25, 2021	Feb	CAHN
AB		200MG	A214352	002	Jan 25, 2021	Feb	CAHN
AB		250MG	A214352	003	Jan 25, 2021	Feb	CAHN
AB	MACLEODS PHARMS	150MG	A219987	001	Mar 23, 2026	Mar	NEWA
AB		200MG	A219987	002	Mar 23, 2026	Mar	NEWA
AB		250MG	A219987	003	Mar 23, 2026	Mar	NEWA

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS							
MICAFUNGIN SODIUM							
AP	ASPIRO	EQ 50MG BASE/VIAL	A220296	001	Mar 17, 2026	Mar	NEWA
AP		EQ 100MG BASE/VIAL	A220296	002	Mar 17, 2026	Mar	NEWA
AP	HISUN PHARM HANGZHOU	EQ 50MG BASE/VIAL	A219712	001	Jan 21, 2026	Jan	NEWA
AP		EQ 100MG BASE/VIAL	A219712	002	Jan 21, 2026	Jan	NEWA
AP	YICHANG HUMANWELL	EQ 50MG BASE/VIAL	A219518	001	Feb 24, 2026	Feb	NEWA
AP		EQ 100MG BASE/VIAL	A219518	002	Feb 24, 2026	Feb	NEWA
POWDER; INTRAVENOUS							
>D>	MICAFUNGIN						
>D>	+! PH HEALTH	EQ 50MG BASE/VIAL	N212156	001	Jun 16, 2021	Aug	DISC
>A>	@ +	EQ 50MG BASE/VIAL	N212156	001	Jun 16, 2021	Aug	DISC
>D>	+!	EQ 100MG BASE/VIAL	N212156	002	Jun 16, 2021	Aug	DISC
>A>	@ +	EQ 100MG BASE/VIAL	N212156	002	Jun 16, 2021	Aug	DISC

MIDODRINE HYDROCHLORIDE

TABLET; ORAL							
MIDODRINE HYDROCHLORIDE							
	@ IMPAX PHARMS	2.5MG	A076449	001	May 27, 2004	Apr	DISC
	@	5MG	A076449	002	May 27, 2004	Apr	DISC
	@	10MG	A076449	003	Dec 16, 2005	Apr	DISC
AB	UNIQUE	2.5MG	A207613	001	Nov 02, 2018	Mar	CAHN
AB		5MG	A207613	002	Nov 02, 2018	Mar	CAHN
AB		10MG	A207613	003	Nov 02, 2018	Mar	CAHN

MIGLITOL

TABLET; ORAL							
MIGLITOL							
	! ORIENT PHARMA	25MG	A203965	001	Feb 24, 2015	Mar	CAHN
		50MG	A203965	002	Feb 24, 2015	Mar	CAHN
		100MG	A203965	003	Feb 24, 2015	Mar	CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL							
MILNACIPRAN HYDROCHLORIDE							
AB	AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Jan	CMFD
AB		25MG	A205081	002	Apr 22, 2016	Jan	CMFD
AB		50MG	A205081	003	Apr 22, 2016	Jan	CMFD
AB		100MG	A205081	004	Apr 22, 2016	Jan	CMFD
AB	BRECKENRIDGE	12.5MG	A205071	001	Jan 27, 2016	Jan	CMFD

TABLET;ORAL							
MILNACIPRAN HYDROCHLORIDE							
AB		25MG	A205071	002	Jan 27, 2016	Jan	CMFD
AB		50MG	A205071	003	Jan 27, 2016	Jan	CMFD
AB		100MG	A205071	004	Jan 27, 2016	Jan	CMFD
AB	HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Feb	CMFD
AB		25MG	A205147	002	Oct 03, 2024	Feb	CMFD
AB		50MG	A205147	003	Oct 03, 2024	Feb	CMFD
AB		100MG	A205147	004	Oct 03, 2024	Feb	CMFD
SAVELLA							
AB	+ ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Jan	CTEC
AB	+	25MG	N022256	002	Jan 14, 2009	Jan	CTEC
AB	+	50MG	N022256	003	Jan 14, 2009	Jan	CTEC
AB	+	100MG	N022256	004	Jan 14, 2009	Jan	CTEC
<u>MILRINONE LACTATE</u>							
INJECTABLE;INJECTION							
MILRINONE LACTATE							
@	HIKMA	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Mar	DISC
<u>MILSAPERIDONE</u>							
TABLET;ORAL							
BYSANTI							
	+! VANDA PHARMS INC	1MG	N220358	001	Feb 20, 2026	Feb	NEWA
	+	2MG	N220358	002	Feb 20, 2026	Feb	NEWA
	+	4MG	N220358	003	Feb 20, 2026	Feb	NEWA
	+	6MG	N220358	004	Feb 20, 2026	Feb	NEWA
	+	8MG	N220358	005	Feb 20, 2026	Feb	NEWA
	+	10MG	N220358	006	Feb 20, 2026	Feb	NEWA
	+	12MG	N220358	007	Feb 20, 2026	Feb	NEWA
<u>MINOCYCLINE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	LUPIN	EQ 45MG BASE	A091424	001	Nov 30, 2011	Apr	CAHN
AB		EQ 55MG BASE	A091424	002	Nov 30, 2011	Apr	CAHN
AB		EQ 90MG BASE	A091424	003	Nov 30, 2011	Apr	CAHN
AB		EQ 135MG BASE	A091424	004	Nov 30, 2011	Apr	CAHN
<u>MIRABEGRON</u>							
FOR SUSPENSION, EXTENDED RELEASE;ORAL							
MIRABEGRON							
AB	ALKEM LABS LTD	8MG/ML	A219323	001	Jan 20, 2026	Jan	NFTG
MYRBETRIQ GRANULES							
AB	+! APGDI	8MG/ML	N213801	001	Mar 25, 2021	Jan	CFTG
TABLET, EXTENDED RELEASE;ORAL							
MIRABEGRON							
AB	DEVA HOLDING AS	25MG	A219941	001	May 01, 2026	Apr	NEWA
AB		50MG	A219941	002	May 01, 2026	Apr	NEWA
<u>MIRDAMETINIB</u>							
TABLET, FOR SUSPENSION;ORAL							
GOMEKLI							
	+ SPRINGWORKS	3MG	N219379	002	Jul 28, 2026	Jul	NEWA
	+	4MG	N219379	003	Jul 28, 2026	Jul	NEWA
<u>MIRTAZAPINE</u>							
TABLET;ORAL							
MIRTAZAPINE							
@	ALLIED	15MG	A076176	001	Jun 19, 2003	Jun	CAHN
@		30MG	A076176	002	Jun 19, 2003	Jun	CAHN
@		45MG	A076176	003	Jun 19, 2003	Jun	CAHN
AB	MICRO LABS	7.5MG	A220104	001	May 19, 2026	May	NEWA
AB		15MG	A220104	002	May 19, 2026	May	NEWA
AB		30MG	A220104	003	May 19, 2026	May	NEWA
AB		45MG	A220104	004	May 19, 2026	May	NEWA
AB	NOVITIUM PHARMA	7.5MG	A219919	001	Feb 02, 2026	Jan	NEWA
AB		15MG	A219919	002	Feb 02, 2026	Jan	NEWA
AB		30MG	A219919	003	Feb 02, 2026	Jan	NEWA
AB		45MG	A219919	004	Feb 02, 2026	Jan	NEWA
@	SENORES PHARMS	15MG	A076176	001	Jun 19, 2003	Jul	CAHN
@		30MG	A076176	002	Jun 19, 2003	Jul	CAHN

		TABLET;ORAL							
		MIRTAZAPINE							
		@		45MG		A076176 003		Jun 19, 2003 Jul CAHN	
>D>	AB	!	SUN PHARM INDS INC	7.5MG		A076541	004	Apr 22, 2004	Aug CHRS
>A>	AB			7.5MG		A076541	004	Apr 22, 2004	Aug CHRS
<u>MISOPROSTOL</u>									
		TABLET;ORAL							
		MISOPROSTOL							
>D>	AB		MICRO LABS	0.1MG		A216872	001	Oct 17, 2022	Aug DISC
>A>		@		0.1MG		A216872	001	Oct 17, 2022	Aug DISC
>D>	AB			0.2MG		A216872	002	Oct 17, 2022	Aug DISC
>A>		@		0.2MG		A216872	002	Oct 17, 2022	Aug DISC
<u>MITAPIVAT SULFATE</u>									
		TABLET;ORAL							
		AQVESME							
		+! AGIOS PHARMS INC		EQ 100MG BASE		N216196	004	Dec 23, 2025	Jan NEWA
<u>MODAFINIL</u>									
		TABLET;ORAL							
		MODAFINIL							
>A>	AB		LUPIN	100MG		A208343	001	Sep 03, 2026	Aug NEWA
>A>	AB			200MG		A208343	002	Sep 03, 2026	Aug NEWA
<u>MOMETASONE FUROATE</u>									
		CREAM;TOPICAL							
		MOMETASONE FUROATE							
AB		!	COSETTE PHARMS NC	0.1%		A077447	001	May 22, 2006	May CAHN
		IMPLANT;IMPLANTATION							
		SINUVA							
		+! INTERSECT ENT INC		1.35MG		N209310	001	Dec 08, 2017	Mar CHRS
		LOTION;TOPICAL							
		MOMETASONE FUROATE							
		@ COSETTE PHARMS NC		0.1%		A077678	001	Nov 21, 2007	Jun CAHN
		OINTMENT;TOPICAL							
		MOMETASONE FUROATE							
AB			COSETTE PHARMS NC	0.1%		A077401	001	Jun 20, 2006	May CAHN
AB			ENCUBE	0.1%		A076481	001	Nov 14, 2003	Apr CMFD
		SPRAY, METERED;NASAL							
		MOMETASONE FUROATE							
>D>		@	NASPRESS	0.05MG/SPRAY		A211706	001	May 15, 2025	Aug CMFD
>A>	AB			0.05MG/SPRAY		A211706	001	May 15, 2025	Aug CMFD
<u>MONTELUKAST SODIUM</u>									
		GRANULE;ORAL							
		MONTELUKAST SODIUM							
AB		!	AJANTA PHARMA LTD	EQ 4MG BASE/PACKET		A203438	001	Jul 31, 2015	May CHRS
		SINGULAIR							
		@ + ORGANON		EQ 4MG BASE/PACKET		N021409	001	Jul 26, 2002	May DISC
		TABLET, CHEWABLE;ORAL							
		MONTELUKAST SODIUM							
		@ AMNEAL PHARMS		EQ 4MG BASE		A205107	001	Sep 04, 2020	Mar DISC
		@		EQ 5MG BASE		A205107	002	Sep 04, 2020	Mar DISC
AB			SENORES PHARMS	EQ 4MG BASE		A201581	001	Aug 06, 2012	Jan CAHN
AB				EQ 5MG BASE		A201581	002	Aug 06, 2012	Jan CAHN
		SINGULAIR							
		@ + ORGANON		EQ 4MG BASE		N020830	002	Mar 03, 2000	Jun DISC
<u>MORPHINE SULFATE</u>									
		SOLUTION;ORAL							
		MORPHINE SULFATE							
		@ PADAGIS US		100MG/5ML		A201574	001	Aug 06, 2012	Mar DISC
AA			QUAGEN	10MG/5ML		A213892	001	Jul 07, 2026	Jun NEWA
AA				20MG/5ML		A213892	002	Jul 07, 2026	Jun NEWA
AA				100MG/5ML		A213892	003	Jul 07, 2026	Jun NEWA
		@ TRIS PHARMA INC		10MG/5ML		A203518	001	May 12, 2015	Mar DISC
		TABLET, EXTENDED RELEASE;ORAL							
		MORPHINE SULFATE							
>D>	AB		ACTAVIS ELIZABETH	15MG		A203849	001	Apr 06, 2015	Aug DISC
>A>		@		15MG		A203849	001	Apr 06, 2015	Aug DISC

TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

>D>	AB		30MG	A203849	002	Apr 06, 2015	Aug DISC
>A>		@	30MG	A203849	002	Apr 06, 2015	Aug DISC
>D>	AB		60MG	A203849	003	Apr 06, 2015	Aug DISC
>A>		@	60MG	A203849	003	Apr 06, 2015	Aug DISC
>D>	AB		100MG	A203849	004	Apr 06, 2015	Aug DISC
>A>		@	100MG	A203849	004	Apr 06, 2015	Aug DISC
>D>	AB		200MG	A203849	005	Apr 06, 2015	Aug DISC
>A>		@	200MG	A203849	005	Apr 06, 2015	Aug DISC
		@	STRIDES PHARMA INTL 15MG	A075295	001	Oct 28, 1998	Jan DISC
		@	30MG	A075295	002	Oct 28, 1998	Jan DISC
		@	60MG	A075295	003	Oct 28, 1998	Jan DISC
		@	100MG	A075295	004	Sep 15, 2000	Jan DISC
		@	200MG	A075295	005	Sep 15, 2000	Jan DISC
			MS CONTIN				
AB	+	KNOA PHARMA	15MG	N019516	003	Sep 12, 1989	May CAHN
AB	+		30MG	N019516	001	May 29, 1987	May CAHN
AB	+		60MG	N019516	002	Apr 08, 1988	May CAHN
AB	+	!	100MG	N019516	004	Jan 16, 1990	May CAHN
AB	+		200MG	N019516	005	Nov 08, 1993	May CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

@	FDC LTD	EQ 0.5% BASE	A219475	001	Aug 04, 2025	Feb DISC
---	---------	--------------	---------	-----	--------------	----------

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB		MACLEODS PHARMS	EQ 400MG BASE	A209143	001	Mar 02, 2026	Feb NEWA
	@	TORRENT	EQ 400MG BASE	A200160	001	Apr 03, 2014	Apr DISC

MUPIROCIN

OINTMENT;TOPICAL
CENTANY

@	PADAGIS US	2%	N050788	001	Dec 04, 2002	Mar DISC
---	------------	----	---------	-----	--------------	----------

MUPIROCIN CALCIUM

CREAM;TOPICAL
MUPIROCIN

AB		ALEMBIC	EQ 2% BASE	A213053	001	Nov 16, 2021	Jul CTEC
----	--	---------	------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

@	HIKMA	250MG	A065410	001	Jul 29, 2008	Jun DISC
@	MYLAN	250MG	A065520	001	May 04, 2009	May DISC

FOR SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB		CONCORD BIOTECH LTD	200MG/ML	A218566	001	Jun 01, 2026	May NEWA
AB		QUAGEN	200MG/ML	A214525	001	Jul 29, 2021	Jul CAHN

TABLET;ORAL

MYCOPHENOLATE MOFETIL

@	HIKMA	500MG	A065413	001	Jul 29, 2008	Jun DISC
@	MYLAN	500MG	A065521	001	May 04, 2009	Jun DISC

MYCOPHENOLATE SODIUM

TABLET, DELAYED RELEASE;ORAL
MYCOPHENOLATE SODIUM

@	RK PHARMA	EQ 180MG BASE	A091248	002	Jan 08, 2014	Jan DISC
@		EQ 360MG BASE	A091248	001	Jan 08, 2014	Jan DISC
@	TWI PHARMS	EQ 180MG BASE	A214289	001	Nov 03, 2021	Mar DISC
@		EQ 360MG BASE	A214289	002	Nov 03, 2021	Mar DISC

NABUMETONE

TABLET;ORAL
NABUMETONE

!	LGM PHARMA	1GM	A203166	003	Aug 30, 2019	Jan CHRS
@	SENORES PHARMS	500MG	A090427	001	Dec 30, 2011	Jun CAHN
@		750MG	A090427	002	Dec 30, 2011	Jun CAHN

NADOLOLTABLET; ORAL
NADOLOL

>A>	AB	APPCO	20MG	A212856	001	Sep 13, 2019	Aug CAHN
>A>	AB		40MG	A212856	002	Sep 13, 2019	Aug CAHN
>A>	AB		80MG	A212856	003	Sep 13, 2019	Aug CAHN
		@ INGENUS PHARMS LLC	20MG	A210786	001	Jun 01, 2018	May CAHN
		@	40MG	A210786	002	Jun 01, 2018	May CAHN
		@	80MG	A210786	003	Jun 01, 2018	May CAHN
>D>	AB	RK PHARMA	20MG	A212856	001	Sep 13, 2019	Aug CAHN
>D>	AB		40MG	A212856	002	Sep 13, 2019	Aug CAHN
>D>	AB		80MG	A212856	003	Sep 13, 2019	Aug CAHN

NAFCILLIN SODIUMINJECTABLE; INJECTION
NALLPEN IN PLASTIC CONTAINER

@ +	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989	Jul DISC
-----	-----------------	-----------------	---------	-----	--------------	----------

NAFTIFINE HYDROCHLORIDECREAM; TOPICAL
NAFTIFINE HYDROCHLORIDE

		@ AMNEAL	2%	A206960	001	Apr 10, 2017	Feb DISC
		NAFTIN					
		@ + LEGACY	1%	N019599	001	Feb 29, 1988	Jun CAHN
AB		+!	2%	N019599	002	Jan 13, 2012	Jun CAHN
		GEL; TOPICAL					
		NAFTIFINE HYDROCHLORIDE					
		@ AMNEAL	1%	A206165	001	Mar 20, 2019	Mar DISC
		NAFTIN					
		@ + LEGACY	1%	N019356	001	Jun 18, 1990	Jun CAHN
AB		+!	2%	N204286	001	Jun 27, 2013	Jun CAHN
		@ + LEGACY PHARMA	1%	N019356	001	Jun 18, 1990	Jun DISC
		+!	1%	N019356	001	Jun 18, 1990	Mar CTEC

NALMEFENE HYDROCHLORIDESOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
NALMEFENE HYDROCHLORIDE

AP	!	KNOA PHARMA	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	May CAHN
		SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS					
		ZURNAI (AUTOINJECTOR)					
		+! KNOA PHARMA	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	May CAHN

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION
NALOXONE HYDROCHLORIDE

>A>	AP	STERINOVA INC	0.4MG/ML	A219942	001	Aug 18, 2026	Aug NEWA
>A>	AP		1MG/ML	A219942	002	Aug 18, 2026	Aug NEWA
		SPRAY; NASAL					
		REZENOPY					
		+! SCIENTURE	10MG/SPRAY	N215487	001	Apr 19, 2024	Jan CMFD

NAPROXENSUSPENSION; ORAL
NAPROXEN

@	AUROBINDO PHARMA	25MG/ML	A216504	001	Oct 03, 2025	Mar DISC
---	------------------	---------	---------	-----	--------------	----------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATETABLET; ORAL
TREXIMET

		@ + AZURITY	60MG; EQ 10MG BASE	N021926	002	May 14, 2015	Jul CAHN
AB		+!	500MG; EQ 85MG BASE	N021926	001	Apr 15, 2008	Jul CAHN

NARATRIPTAN HYDROCHLORIDETABLET; ORAL
NARATRIPTAN

@	PADAGIS US	EQ 1MG BASE	A091326	001	Jul 08, 2010	Mar DISC
@		EQ 2.5MG BASE	A091326	002	Jul 08, 2010	Mar DISC

NAVEPEGITIDEPOWDER; SUBCUTANEOUS
YUWIEL

+	!	ASCENDIS	1.3MG/VIAL	N219164	001	Feb 27, 2026	Feb NEWA
+	!		2.8MG/VIAL	N219164	002	Feb 27, 2026	Feb NEWA
+	!		5.5MG/VIAL	N219164	003	Feb 27, 2026	Feb NEWA

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

@	TORRENT	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Mar DISC
@		EQ 5MG BASE	A203966	002	Mar 02, 2018	Mar DISC
@		EQ 10MG BASE	A203966	003	Mar 02, 2018	Mar DISC
@		EQ 20MG BASE	A203966	004	Mar 02, 2018	Mar DISC

NELARABINE

INJECTABLE; INTRAVENOUS

NELARABINE

>A>	AP	PHARMOBEDIANT	250MG/50ML (5MG/ML)	A216510	001	Sep 05, 2024	Aug CAHN
>D>	AP	XGEN PHARMS	250MG/50ML (5MG/ML)	A216510	001	Sep 05, 2024	Aug CAHN

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

AA		SOLARIS PHARMA CORP	500MG	A065220	001	Jul 28, 2006	Apr CAHN
----	--	---------------------	-------	---------	-----	--------------	----------

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

@		WATSON LABS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A062664	001	Apr 08, 1986	Jan DISC
!		XGEN PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A065106	001	Jan 31, 2006	Jan CTEC
AT	!		EQ 40MG BASE/ML; 200,000 UNITS/ML	A065106	001	Jan 31, 2006	Jan CHRS
	!		EQ 40MG BASE/ML; 200,000 UNITS/ML	A065108	001	Jan 31, 2006	Jan CTEC
AT	!		EQ 40MG BASE/ML; 200,000 UNITS/ML	A065108	001	Jan 31, 2006	Jan CHRS
		NEOSPORIN G.U. IRRIGANT					
@		MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A060707	001		Jan DISC

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

@ + EXELA PHARMA

NEOSTIGMINE METHYLSULFATE

@		HIKMA	3MG/3ML (1MG/ML)	A216206	001	Jul 13, 2022	Mar DISC
AP		J MOLNER	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018	Jul CAHN
AP			10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018	Jul CAHN
>A>	AP	NIVAGEN	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Aug CAHN
>A>	AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Aug CAHN
>D>	AP	NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Aug CAHN
AP			5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Mar CAHN
>D>	AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Aug CAHN
AP			10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Mar CAHN

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB		QUAGEN	500MG	A203899	001	Jun 16, 2017	Jul CAHN
AB			1GM	A203899	002	Jun 16, 2017	Jul CAHN

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

@		CHARTWELL RX	20MG	A218638	001	Jun 25, 2025	Jul CAHN
@			30MG	A218638	002	Jun 25, 2025	Jul CAHN
@		NAVINTA LLC	20MG	A218638	001	Jun 25, 2025	Mar DISC
@			30MG	A218638	002	Jun 25, 2025	Mar DISC
AB		SENORES PHARMS	20MG	A215377	001	Jul 17, 2023	Jan CAHN

CAPSULE;ORAL							
NICARDIPINE HYDROCHLORIDE							
AB		30MG	A215377	002	Jul 17, 2023	Jan	CAHN
INJECTABLE;INJECTION							
CARDENE							
AP	+ CHIESI	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	Jan	CMFD
NICARDIPINE HYDROCHLORIDE							
AP	SOMERSET THERAPS LLC	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Jan	CAHN
INJECTABLE;INTRAVENOUS							
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE							
AP	FRESENIUS KABI USA	20MG/200ML (0.1MG/ML)	A219334	001	Aug 04, 2026	Jul	NEWA
AP		40MG/200ML (0.2MG/ML)	A219334	002	Aug 04, 2026	Jul	NEWA
<u>NIFEDIPINE</u>							
CAPSULE;ORAL							
NIFEDIPINE							
AB	! HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar	CHRS
PROCARDIA							
	@ + PFIZER	10MG	N018482	001		Mar	DISC
TABLET, EXTENDED RELEASE;ORAL							
NIFEDIPINE							
AB2	! NOVAST LABS	90MG	A210614	003	Mar 12, 2019	Apr	CHRS
	@ PHARMADAX	30MG	A216019	001	Nov 18, 2022	Mar	CAHN
	@	60MG	A216019	002	Nov 18, 2022	Mar	CAHN
PROCARDIA XL							
	@ + PFIZER	90MG	N019684	003	Sep 06, 1989	Apr	DISC
<u>NILOTINIB</u>							
TABLET, ORALLY DISINTEGRATING;ORAL							
CAVHANZA							
>A>	+ CYCLE	60MG	N217379	001	May 29, 2026	Aug	CAHN
>A>	+	80MG	N217379	002	May 29, 2026	Aug	CAHN
>D>	+ FLEX PHARMA	60MG	N217379	001	May 29, 2026	Aug	CAHN
	+	60MG	N217379	001	May 29, 2026	May	NEWA
>D>	+	80MG	N217379	002	May 29, 2026	Aug	CAHN
	+	80MG	N217379	002	May 29, 2026	May	NEWA
>D>	<u>NILOTINIB D-TARTRATE</u>						
>D>	CAPSULE;ORAL						
>D>	NILOTINIB D-TARTRATE						
>D>	+ CIPLA	EQ 50MG BASE	N218922	001	Feb 19, 2025	Aug	DISC
>A>	@ +	EQ 50MG BASE	N218922	001	Feb 19, 2025	Aug	DISC
>D>	+	EQ 150MG BASE	N218922	002	Feb 19, 2025	Aug	DISC
>A>	@ +	EQ 150MG BASE	N218922	002	Feb 19, 2025	Aug	DISC
>D>	+	EQ 200MG BASE	N218922	003	Feb 19, 2025	Aug	DISC
>A>	@ +	EQ 200MG BASE	N218922	003	Feb 19, 2025	Aug	DISC
<u>NILOTINIB HYDROCHLORIDE</u>							
CAPSULE;ORAL							
NILOTINIB HYDROCHLORIDE							
AB	TEVA PHARMS INC	EQ 50MG BASE	A219134	001	Jun 26, 2026	Jun	NEWA
AB		EQ 150MG BASE	A219134	002	Jun 26, 2026	Jun	NEWA
AB		EQ 200MG BASE	A219134	003	Jun 26, 2026	Jun	NEWA
<u>NILUTAMIDE</u>							
TABLET;ORAL							
NILANDRON							
	@ + ADVANZ PHARMA	150MG	N020169	002	Apr 30, 1999	Apr	DISC
NILUTAMIDE							
	! ANI PHARMS	150MG	A207631	001	Jul 15, 2016	Apr	CTEC
AB	!	150MG	A207631	001	Jul 15, 2016	Apr	CHRS
<u>NINTEDANIB ESYLATE</u>							
CAPSULE;ORAL							
NINTEDANIB ESYLATE							
AB	APOTEX	EQ 100MG BASE	A219227	001	Apr 02, 2026	Mar	NFTG
AB		EQ 150MG BASE	A219227	002	Apr 02, 2026	Mar	NFTG
>A> AB	BIOCON PHARMA	EQ 100MG BASE	A220118	001	Aug 19, 2026	Aug	NEWA
>A> AB		EQ 150MG BASE	A220118	002	Aug 19, 2026	Aug	NEWA
AB	CIPLA	EQ 100MG BASE	A212609	001	Apr 02, 2026	Mar	NFTG
AB		EQ 150MG BASE	A212609	002	Apr 02, 2026	Mar	NFTG
AB	DEXCEL	EQ 100MG BASE	A219819	001	Apr 02, 2026	Mar	NFTG

CAPSULE;ORAL

NINTEDANIB ESYLATE

AB		EQ 150MG BASE	A219819	002	Apr 02, 2026	Mar NFTG
AB	DR REDDYS	EQ 100MG BASE	A219283	001	Apr 02, 2026	Mar NFTG
AB		EQ 150MG BASE	A219283	002	Apr 02, 2026	Mar NFTG
AB	GLENMARK PHARMS LTD	EQ 100MG BASE	A212555	001	Jul 09, 2026	Jul NEWA
AB		EQ 150MG BASE	A212555	002	Jul 09, 2026	Jul NEWA
AB	HUMANWELL PURACAP	EQ 100MG BASE	A218472	001	Jul 09, 2026	Jun NEWA
AB		EQ 150MG BASE	A218472	002	Jul 09, 2026	Jun NEWA
AB	MACLEODS PHARMS	EQ 100MG BASE	A219926	001	Aug 03, 2026	Jul NEWA
AB		EQ 150MG BASE	A219926	002	Aug 03, 2026	Jul NEWA
AB	SANDOZ	EQ 100MG BASE	A216915	001	Apr 02, 2026	Mar NFTG
AB		EQ 150MG BASE	A216915	002	Apr 02, 2026	Mar NFTG
	OFEV					
AB	+ BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar CFTG
AB	+!	EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar CFTG

NIROGACESTAT HYDROBROMIDE

TABLET;ORAL

OGSIVEO

@ +	SPRINGWORKS	EQ 50MG BASE	N217677	001	Nov 27, 2023	Mar DISC
-----	-------------	--------------	---------	-----	--------------	----------

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

AB	AMTA	8.5MG	A216606	001	Apr 10, 2023	Apr CMFD
	!	17MG	A216606	002	Dec 12, 2025	Jun CTEC
AB	!	17MG	A216606	002	Dec 12, 2025	Jun CHRS
	@ MYLAN	8.5MG	A091001	001	Jan 26, 2011	Apr DISC
	@	17MG	A091001	002	Jan 26, 2011	Apr DISC
	@	20MG	A079051	001	Jul 25, 2008	Apr DISC
	@	25.5MG	A091001	003	Jan 26, 2011	Apr DISC
	@	30MG	A079051	002	Jul 25, 2008	Apr DISC
	@	34MG	A091001	004	Jan 26, 2011	Feb DISC
	@	40MG	A079051	003	Jul 25, 2008	Apr DISC
	SULAR					
AB	+! AZURITY	8.5MG	N020356	008	Jan 02, 2008	Jun CAHN
	+!	8.5MG	N020356	008	Jan 02, 2008	Apr CTEC
AB	+!	8.5MG	N020356	008	Jan 02, 2008	Apr CTEC
AB	+!	8.5MG	N020356	008	Jan 02, 2008	Feb CAHN
	@ +	10MG	N020356	001	Feb 02, 1995	Jun CAHN
	@ +	10MG	N020356	001	Feb 02, 1995	Feb CAHN
	@ +	17MG	N020356	007	Jan 02, 2008	Jun CAHN
	@ +	17MG	N020356	007	Jan 02, 2008	Jun DISC
AB	+!	17MG	N020356	007	Jan 02, 2008	Feb CAHN
AB	+!	17MG	N020356	007	Jan 02, 2008	Feb CAHN
AB	+!	17MG	N020356	007	Jan 02, 2008	Feb CAHN
AB	+!	17MG	N020356	007	Jan 02, 2008	Feb CAHN
	@ +	20MG	N020356	002	Feb 02, 1995	Jun CAHN
	@ +	20MG	N020356	002	Feb 02, 1995	Feb CAHN
	@ +	25.5MG	N020356	006	Jan 02, 2008	Jun CAHN
	@ +	25.5MG	N020356	006	Jan 02, 2008	Feb CAHN
	@ +	30MG	N020356	003	Feb 02, 1995	Jun CAHN
	@ +	30MG	N020356	003	Feb 02, 1995	Feb CAHN
	@ +	34MG	N020356	005	Jan 02, 2008	Jun CAHN
	@ +	34MG	N020356	005	Jan 02, 2008	Jun DISC
	+!	34MG	N020356	005	Jan 02, 2008	Feb CAHN
	@ +	40MG	N020356	004	Feb 02, 1995	Jun CAHN
	@ +	40MG	N020356	004	Feb 02, 1995	Feb CAHN
	+! COVIS	34MG	N020356	005	Jan 02, 2008	Feb CTEC

NITRIC OXIDE

GAS;INHALATION

NOXIVENT

@	VERO BIOTECH INC	100PPM	A207141	001	Oct 02, 2018	Mar CAHN
AA		800PPM	A207141	002	Oct 02, 2018	Mar CAHN

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

@	AMNEAL PHARMS	25MG/5ML	A201679	001	May 11, 2011	Apr DISC
---	---------------	----------	---------	-----	--------------	----------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

>D> MACRODANTIN

>D> AB	+	ALMATICA	25MG	N016620	003		Aug	DISC
>A>	@ +		25MG	N016620	003		Aug	DISC
>D> AB	+		50MG	N016620	001		Aug	DISC
>A>	@ +		50MG	N016620	001		Aug	DISC
>D> AB	+	!	100MG	N016620	002		Aug	DISC
>A>	@ +		100MG	N016620	002		Aug	DISC

NITROFURANTOIN

>D> AB		MANKIND PHARMA	100MG	A217272	003	Mar 21, 2023	Aug	CHRS
>A> AB	!		100MG	A217272	003	Mar 21, 2023	Aug	CHRS
	@	POM PHARMA	25MG	A074336	001	Jan 25, 1995	Apr	CAHN
	@		50MG	A074336	002	Jan 25, 1995	Apr	CAHN
	@		100MG	A074336	003	Jan 25, 1995	Apr	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		CREEKWOOD PHARMS	75MG;25MG	A220269	001	Apr 07, 2026	Mar	NEWA
>A> AB		MICRO LABS	75MG;25MG	A217073	001	Nov 03, 2023	Aug	CAHN
>D> AB		OMSAV PHARMA	75MG;25MG	A217073	001	Nov 03, 2023	Aug	CAHN

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITRO-DUR

+	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Jan	CHRS
+		0.2MG/HR	N020145	002	Apr 04, 1995	Jan	CHRS
+		0.3MG/HR	N020145	003	Apr 04, 1995	Jan	CHRS
+		0.6MG/HR	N020145	005	Apr 04, 1995	Jan	CHRS
+		0.8MG/HR	N020145	006	Apr 04, 1995	Jan	CHRS

NITROGLYCERIN

AB2		MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998	Jan	CHRS
AB2			0.2MG/HR	A074559	003	Aug 30, 1996	Jan	CHRS
AB2			0.6MG/HR	A074559	001	Aug 30, 1996	Jan	CHRS

OINTMENT;INTRA-ANAL

NITROGLYCERIN

AB	!	COSETTE	0.4%	A216103	001	Feb 16, 2024	Mar	CHRS
AB	!	COSETTE PHARMS NC	0.4%	A216103	001	Feb 16, 2024	May	CAHN
AB		PADAGIS ISRAEL	0.4%	A214565	001	Jul 06, 2026	Jun	NEWA

RECTIV

@ +	ABBVIE	0.4%	N021359	001	Jun 21, 2011	Mar	DISC
-----	--------	------	---------	-----	--------------	-----	------

SPRAY, METERED;SUBLINGUAL

NITROGLYCERIN

>A> AB		SOCORRO N1	0.4MG/SPRAY	A204681	001	Aug 21, 2026	Aug	NEWA
--------	--	------------	-------------	---------	-----	--------------	-----	------

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

@	AMNEAL	EQ 1MG BASE/ML	A210839	001	Dec 17, 2018	Jul	DISC
AP	NEPHRON	EQ 1MG BASE/ML	A216272	001	Jun 11, 2026	May	NEWA

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+	!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	004	Feb 06, 2026	Feb	NEWA
+	!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	005	Feb 06, 2026	Feb	NEWA
+	!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214313	006	Feb 06, 2026	Feb	NEWA

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

AP	+	!	BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214313	003	Nov 21, 2023	Mar	CFTG
AP			SAGENT	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	A220483	001	Mar 26, 2026	Mar	NFTG

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

AB		INGENUS PHARMS LLC	5MG	A206490	001	Nov 05, 2018	Feb	CAHN
----	--	--------------------	-----	---------	-----	--------------	-----	------

NUSINERSEN SODIUMSOLUTION; INTRATHECAL
SPINRAZA

+	!	BIOGEN	EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)	N209531	001	Dec 23, 2016	May CAHN
+	!		EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML)	N209531	002	Mar 27, 2026	May CAHN
+	!		EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	N209531	003	Mar 27, 2026	May CAHN
+	!	BIOGEN IDEC	EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML)	N209531	002	Mar 27, 2026	Apr NEWA
+	!		EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	N209531	003	Mar 27, 2026	Apr NEWA

NYSTATINCREAM; TOPICAL
NYSTATIN

AT		COSETTE PHARMS NC	100,000 UNITS/GM	A061966	001		May CAHN
----	--	-------------------	------------------	---------	-----	--	----------

SUSPENSION; ORAL
NILSTAT

AA	+	CHARTWELL MOLECULES	100,000 UNITS/ML	N050299	001		Mar CMFD
----	---	---------------------	------------------	---------	-----	--	----------

NYSTATIN

	@	COSETTE PHARMS NC	100,000 UNITS/ML	A062776	001	Dec 17, 1987	Jun CAHN
AA		SCIEGEN PHARMS	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jan CAHN
	@	STERANCO HLTHCARE	100,000 UNITS/ML	A220367	001	Feb 05, 2026	Jul DISC
AA			100,000 UNITS/ML	A220367	001	Feb 05, 2026	Jan NEWA

NYSTATIN; TRIAMCINOLONE ACETONIDECREAM; TOPICAL
MYKACET

@		COSETTE PHARMS NC	100,000 UNITS/GM; 0.1%	A062367	001	May 28, 1985	Jun CAHN
---	--	-------------------	------------------------	---------	-----	--------------	----------

OINTMENT; TOPICAL
MYKACET

@		COSETTE PHARMS NC	100,000 UNITS/GM; 0.1%	A062733	001	Mar 06, 1987	Jun CAHN
---	--	-------------------	------------------------	---------	-----	--------------	----------

OFLOXACINSOLUTION/DROPS; OPHTHALMIC
OFLOXACIN

AT		MICRO LABS	0.3%	A218557	001	Apr 08, 2026	Mar NEWA
----	--	------------	------	---------	-----	--------------	----------

SOLUTION/DROPS; OTIC
OFLOXACIN

AT	!	BAUSCH AND LOMB INC	0.3%	A076128	001	Mar 17, 2008	May CAHN
----	---	---------------------	------	---------	-----	--------------	----------

OLANZAPINEPOWDER; INTRAMUSCULAR
OLANZAPINE

AP		AM REGENT	10MG/VIAL	A201741	001	Mar 20, 2012	Jan CDFR
AP		ANTHEA PHARMA	10MG/VIAL	A220323	001	Mar 05, 2026	Feb NEWA
AP		ASPIRO	10MG/VIAL	A217466	001	Mar 22, 2023	Jan CDFR
AP		EUGIA PHARMA	10MG/VIAL	A210968	001	Oct 22, 2020	Jan CDFR
AP		OMNIVIVUM PHARMS	10MG/VIAL	A219048	001	Jan 23, 2026	Jan NEWA
AP		QILU	10MG/VIAL	A218116	001	May 16, 2025	Jan CDFR
AP		SANDOZ INC	10MG/VIAL	A201588	001	Oct 24, 2011	Jan CDFR
AP		UBI	10MG/VIAL	A211072	001	Jun 11, 2025	Jan CDFR

ZYPREXA

AP	+	!	CHEPLAPHARM	10MG/VIAL	N021253	001	Mar 29, 2004	Jan CDFR
----	---	---	-------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

OLANZAPINE

AB		SUNSHINE	2.5MG	A206238	001	Nov 19, 2018	Feb CMFD
AB			5MG	A206238	002	Nov 19, 2018	Feb CMFD
AB			7.5MG	A206238	003	Nov 19, 2018	Feb CMFD
AB			10MG	A206238	004	Nov 19, 2018	Feb CMFD
AB			15MG	A206238	005	Nov 19, 2018	Feb CMFD
AB			20MG	A206238	006	Nov 19, 2018	Feb CMFD
AB		TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012	Jan CMFD
AB			5MG	A091434	002	Apr 23, 2012	Jan CMFD
AB			7.5MG	A091434	003	Apr 23, 2012	Jan CMFD
AB			10MG	A091434	004	Apr 23, 2012	Jan CMFD
AB			15MG	A091434	005	Apr 23, 2012	Jan CMFD
AB			20MG	A091434	006	Apr 23, 2012	Jan CMFD

OLEZARSEN SODIUMSOLUTION;SUBCUTANEOUS
TRYNGOLZA (AUTOINJECTOR)

+! IONIS PHARMS INC

EQ 50MG BASE/0.8ML (EQ 50MG
BASE/0.8ML)

N218614 002 Jun 24, 2026 Jul NEWA

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

>D> AB	MICRO LABS	5MG	A206372	001	Sep 17, 2019	Aug DISC
>A>	@	5MG	A206372	001	Sep 17, 2019	Aug DISC
>D> AB		20MG	A206372	002	Sep 17, 2019	Aug DISC
>A>	@	20MG	A206372	002	Sep 17, 2019	Aug DISC
>D> AB		40MG	A206372	003	Sep 17, 2019	Aug DISC
>A>	@	40MG	A206372	003	Sep 17, 2019	Aug DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

@	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Apr DISC
@	APOTEX	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A090973	001	Sep 30, 2014	Apr DISC
>D> AB	GLW	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Aug CAHN
@	ONESOURCE	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014	Jul CAHN
AB		1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A203893	001	Sep 19, 2017	Jul CAHN
>A> AB	RENOVA PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Aug CAHN
>D> AB	SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Aug DISC
>A>	@	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Aug DISC

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

@	ALLIED	10MG	A205070	001	Jun 29, 2018	Jun CAHN	
@		20MG	A205070	002	Jun 29, 2018	Jun CAHN	
@		40MG	A205070	003	Jun 29, 2018	Jun CAHN	
AB	!	GLENMARK PHARMS LTD	20MG	A091672	002	Oct 31, 2014	Apr CHRS
AB	!		40MG	A091672	003	Oct 31, 2014	Apr CHRS
AB		SANDOZ	20MG	A075757	002	Jan 28, 2003	Apr CHRS
AB			40MG	A076515	001	Jan 21, 2009	Apr CHRS
@	SENORES PHARMS	10MG	A205070	001	Jun 29, 2018	Jul CAHN	
@		20MG	A205070	002	Jun 29, 2018	Jul CAHN	
@		40MG	A205070	003	Jun 29, 2018	Jul CAHN	

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

+ AZURITY

EQ 2.5MG BASE/PACKET

N022056 001 Mar 20, 2008 Jul CAHN

+

EQ 2.5MG BASE/PACKET

N022056 001 Mar 20, 2008 Feb CAHN

+!

EQ 10MG BASE/PACKET

N022056 002 Mar 20, 2008 Jul CAHN

+!

EQ 10MG BASE/PACKET

N022056 002 Mar 20, 2008 Feb CAHN

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

>A> AB	ADAPTIS	20MG;1.1GM	A212587	001	Apr 30, 2020	Aug CAHN
>A> AB		40MG;1.1GM	A212587	002	Apr 30, 2020	Aug CAHN
>D> AB	ANDA REPOSITORY	20MG;1.1GM	A212587	001	Apr 30, 2020	Aug CAHN
>D> AB		40MG;1.1GM	A212587	002	Apr 30, 2020	Aug CAHN
>A> AB	GUARDIAN DRUG	20MG;1.1GM	A212587	001	Apr 30, 2020	Aug CAHN

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

>A>	AB	40MG;1.1GM	A212587	002	Apr 30, 2020	Aug CAHN
-----	----	------------	---------	-----	--------------	----------

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

>D>	!	CHARTWELL MOLECULES	16MG	A077406	001	Dec 26, 2006	Aug CHRS
>A>			16MG	A077406	001	Dec 26, 2006	Aug CHRS

ONDANSETRON HYDROCHLORIDE

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

AA	PHARM ASSOC	EQ 4MG BASE/5ML	A078127	001	Jun 25, 2007	Feb CMFD
----	-------------	-----------------	---------	-----	--------------	----------

ORFORGLIPRON CALCIUM

TABLET;ORAL

FOUNDAYO

+	ELI LILLY AND CO	EQ 0.8MG BASE	N220934	001	Apr 01, 2026	Apr NEWA
+		EQ 2.5MG BASE	N220934	002	Apr 01, 2026	Apr NEWA
+		EQ 5.5MG BASE	N220934	003	Apr 01, 2026	Apr NEWA
+		EQ 9MG BASE	N220934	004	Apr 01, 2026	Apr NEWA
+		EQ 14.5MG BASE	N220934	005	Apr 01, 2026	Apr NEWA
+	!	EQ 17.2MG BASE	N220934	006	Apr 01, 2026	Apr NEWA

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

@	CEDIPROF INC	EQ 30MG BASE	A217451	001	Dec 03, 2024	Apr DISC
@		EQ 45MG BASE	A217451	002	Dec 03, 2024	Apr DISC
@		EQ 75MG BASE	A217451	003	Dec 03, 2024	Apr DISC
@	UPSHER SMITH LABS	EQ 30MG BASE	A213437	001	Jan 22, 2026	Apr DISC
AB		EQ 30MG BASE	A213437	001	Jan 22, 2026	Jan NEWA
@		EQ 45MG BASE	A213437	002	Jan 22, 2026	Apr DISC
AB		EQ 45MG BASE	A213437	002	Jan 22, 2026	Jan NEWA
@		EQ 75MG BASE	A213437	003	Jan 22, 2026	Apr DISC
AB		EQ 75MG BASE	A213437	003	Jan 22, 2026	Jan NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	ALEMBIC	EQ 6MG BASE/ML	A218307	001	Jun 25, 2026	Jun NEWA
@	AMNEAL PHARMS NY	EQ 6MG BASE/ML	A210186	001	Feb 27, 2018	May DISC

OSILODROSTAT PHOSPHATE

TABLET;ORAL

ISTURISA

+	!	RECORDATI RARE	EQ 5MG BASE	N212801	002	Mar 06, 2020	Jun CHRS
---	---	----------------	-------------	---------	-----	--------------	----------

OXACILLIN SODIUM

INJECTABLE;INJECTION

BACTOCILL IN PLASTIC CONTAINER

@ +	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640	001	Oct 26, 1989	Jul DISC
-----	-----------------	-----------------	---------	-----	--------------	----------

OXALIPLATIN

INJECTABLE;INTRAVENOUS

OXALIPLATIN

@	ACTAVIS	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Apr DISC
@		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Apr DISC
@	HENGRUI PHARMA	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Apr DISC
@		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Apr DISC
@	INGENUS PHARMS LLC	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	May CAHN
@		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	May CAHN
@	NOVAST LABS	100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Apr DISC
AP	SHANDONG	50MG/10ML (5MG/ML)	A219765	001	Jan 15, 2026	Jan NEWA
AP		100MG/20ML (5MG/ML)	A219765	002	Jan 15, 2026	Jan NEWA
@ +	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Apr DISC
@ +		100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Apr DISC

OXAPROZIN

TABLET; ORAL							
DAYPRO							
	@ + PFIZER	600MG	N018841	004	Oct 29, 1992	Jun	DISC
OXAPROZIN							
AB	! DR REDDYS LABS LTD	600MG	A075855	001	Jan 31, 2001	Jun	CHRS

OXCARBAZEPINE

SUSPENSION; ORAL							
OXCARBAZEPINE							
AB	MSN	300MG/5ML	A209020	001	May 29, 2026	May	NEWA
	@ STERANCO HLTHCARE	300MG/5ML	A220281	001	Mar 09, 2026	Jul	DISC
AB		300MG/5ML	A220281	001	Mar 09, 2026	Feb	NEWA
TABLET; ORAL							
OXCARBAZEPINE							
AB	EPIC PHARMA LLC	150MG	A219556	001	Mar 02, 2026	Feb	NEWA
AB		300MG	A219556	002	Mar 02, 2026	Feb	NEWA
AB		600MG	A219556	003	Mar 02, 2026	Feb	NEWA
AB	UMEDICA LABS PVT	150MG	A218341	001	Apr 29, 2026	Apr	NEWA
AB		300MG	A218341	002	Apr 29, 2026	Apr	NEWA
AB		600MG	A218341	003	Apr 29, 2026	Apr	NEWA

OXICONAZOLE NITRATE

CREAM; TOPICAL							
OXISTAT							
>A> AB	+! FOUGERA	EQ 1% BASE	N019828	001	Dec 30, 1988	Aug	CAHN
>D> AB	+! FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Aug	CAHN
LOTION; TOPICAL							
OXISTAT							
	@ + ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr	DISC

OXYBUTYNIN CHLORIDE

TABLET; ORAL							
OXYBUTYNIN CHLORIDE							
AB	AVET LIFESCIENCES	5MG	A211682	001	May 10, 2019	May	CMFD
AB	HERITAGE PHARMA AVET	5MG	A211682	001	May 10, 2019	Jun	CAHN
AB	! NOVITIUM PHARMA	5MG	A209823	001	Oct 23, 2017	Jan	CHRS
AB	! RISING	2.5MG	A209025	002	Feb 07, 2023	Feb	CTEC
AB	STRIDES PHARMA INTL	2.5MG	A075079	002	Mar 10, 2026	Feb	NEWA
AB		5MG	A075079	001	Oct 31, 1997	Jan	CHRS
AB	TP ANDA HOLDINGS	2.5MG	A210125	002	Jul 21, 2026	Jul	NEWA
TABLET, EXTENDED RELEASE; ORAL							
OXYBUTYNIN CHLORIDE							
AB	ACCORD HLTHCARE	15MG	A207138	003	Feb 29, 2016	Jan	CHRS
AB	! ZYDUS PHARMS	15MG	A202332	003	Jun 26, 2017	Jan	CHRS

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL							
OXYCONTIN							
	+ KNOA PHARMA	10MG	N022272	001	Apr 05, 2010	May	CAHN
	+	15MG	N022272	002	Apr 05, 2010	May	CAHN
	+	20MG	N022272	003	Apr 05, 2010	May	CAHN
	+	30MG	N022272	004	Apr 05, 2010	May	CAHN
	+!	40MG	N022272	005	Apr 05, 2010	May	CAHN
	+	60MG	N022272	006	Apr 05, 2010	May	CAHN
	+	80MG	N022272	007	Apr 05, 2010	May	CAHN

OXYMETAZOLINE HYDROCHLORIDE

CREAM; TOPICAL							
OXYMETAZOLINE HYDROCHLORIDE							
AB	SUN PHARMA CANADA	1%	A213584	001	Oct 04, 2021	May	CMFD
RHOFAD							
AB	+! MAYNE PHARMA	1%	N208552	001	Jan 18, 2017	May	CTEC

OZENOXACIN

CREAM; TOPICAL							
XEPI							
	@ + LNHC	1%	N208945	001	Dec 11, 2017	Jan	CAHN

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

@	NATCO PHARMA USA	6MG/ML	A091540	001	Sep 29, 2011	Mar	CAHN
---	------------------	--------	---------	-----	--------------	-----	------

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

PALIPERIDONE

AB		AJANTA PHARMA LTD	3MG	A218514	002	Jun 26, 2024	Mar	CMFD
AB			6MG	A218514	003	Jun 26, 2024	Mar	CMFD
AB			9MG	A218514	004	Jun 26, 2024	Mar	CMFD
	@	APOTEX	3MG	A203279	001	Jan 26, 2026	Apr	DISC
AB			3MG	A203279	001	Jan 26, 2026	Jan	NEWA
	@		6MG	A203279	002	Jan 26, 2026	Apr	DISC
AB			6MG	A203279	002	Jan 26, 2026	Jan	NEWA
	@		9MG	A203279	003	Jan 26, 2026	Apr	DISC
AB			9MG	A203279	003	Jan 26, 2026	Jan	NEWA
AB		I3 PHARMS	1.5MG	A205402	001	May 07, 2026	May	NEWA
AB			3MG	A205402	002	May 07, 2026	May	NEWA
AB			6MG	A205402	003	May 07, 2026	May	NEWA
AB			9MG	A205402	004	May 07, 2026	May	NEWA
	@	RK PHARMA	1.5MG	A203802	001	Sep 24, 2015	Jan	DISC
	@		3MG	A203802	002	Sep 24, 2015	Jan	DISC
	@		6MG	A203802	003	Sep 24, 2015	Jan	DISC
	@		9MG	A203802	004	Sep 24, 2015	Jan	DISC

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA HAFYERA

+	!	JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N207946	005	Aug 30, 2021	Jan	CHRS
+	!		1.560GM/5ML (312MG/ML)	N207946	006	Aug 30, 2021	Jan	CHRS

INVEGA SUSTENNA

+	!	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Mar	CHRS
+	!		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Mar	CHRS
+	!		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar	CHRS
+	!		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Mar	CHRS

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

@	BAXTER HLTHCARE CORP	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206916	001	Nov 12, 2021	Jun	DISC
@	INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	May	CAHN

PALOPEGTERIPARATIDE

SOLUTION; SUBCUTANEOUS

YORVIPATH

+	!	ASCENDIS PHARMA BONE	EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	N216490	002	Aug 09, 2024	May	CHRS
+	!		EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	N216490	003	Aug 09, 2024	May	CHRS

PALOVAROTENE

CAPSULE; ORAL

SOHONOS

>D>	+	IPSEN	2.5MG	N215559	003	Aug 16, 2023	Aug	DISC
>A>	@	+	2.5MG	N215559	003	Aug 16, 2023	Aug	DISC

PANTOPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

PANTOPRAZOLE SODIUM

	@	PHARMOBEDIENT	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Jan	CAHN
AP		SHUANGCHENG	EQ 40MG BASE/VIAL	A219973	001	Apr 22, 2026	Apr	NEWA

PARICALCITOL

CAPSULE; ORAL

ZEMPLAR

@	+	ABBVIE	2MCG	N021606	002	May 26, 2005	Apr	DISC
---	---	--------	------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS

PARICALCITOL

@	CAPLIN	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr	DISC
@		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr	DISC
@		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr	DISC
@	EUGIA PHARMA	0.002MG/ML (0.002MG/ML)	A205982	001	Oct 09, 2018	Jan	DISC
@		0.005MG/ML (0.005MG/ML)	A205982	002	Oct 09, 2018	Jan	DISC
@		0.01MG/2ML (0.005MG/ML)	A205982	003	Oct 09, 2018	Jan	DISC

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

AB	ANNORA PHARMA	EQ 10MG BASE/5ML	A219954	001	Mar 05, 2026	Feb	NEWA
AB	! NOVITIUM PHARMA	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Feb	CTEC

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB	ALEMBIC	EQ 12.5MG BASE	A217280	003	Mar 26, 2026	Mar	NEWA
@	LUPIN	EQ 12.5MG BASE	A204134	001	Jan 20, 2017	Jun	DISC
@		EQ 25MG BASE	A204134	002	Jan 20, 2017	Jun	DISC
@		EQ 37.5MG BASE	A204134	003	Jan 20, 2017	Jun	DISC

PAROXETINE MESYLATE

CAPSULE; ORAL

BRISDELLE

AB	+! LEGACY	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun	CAHN
----	-----------	---------------	---------	-----	--------------	-----	------

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

PEMETREXED DISODIUM

@	APOTEX	EQ 1GM BASE/VIAL	A209085	001	May 25, 2022	Jul	DISC
---	--------	------------------	---------	-----	--------------	-----	------

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN-VK

>A>	CHARTWELL RX	EQ 125MG BASE/5ML	A060456	001		Aug	CAHN
>A>	!	EQ 250MG BASE/5ML	A060456	002		Aug	CAHN
>D>	TEVA	EQ 125MG BASE/5ML	A060456	001		Aug	CAHN
>D>	!	EQ 250MG BASE/5ML	A060456	002		Aug	CAHN

TABLET; ORAL

PENICILLIN-VK

>A> AB	CHARTWELL RX	EQ 250MG BASE	A060711	002		Aug	CAHN
>A> AB		EQ 500MG BASE	A060711	003		Aug	CAHN
>D> AB	TEVA	EQ 250MG BASE	A060711	002		Aug	CAHN
>D> AB		EQ 500MG BASE	A060711	003		Aug	CAHN

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

PENTAMIDINE ISETHIONATE

AN	PAI HOLDINGS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr	CAHN
----	--------------	------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

PENTAMIDINE ISETHIONATE

AP	PAI HOLDINGS	300MG/VIAL	A206666	001	Sep 28, 2017	Apr	CAHN
@	PHARMOBEDIENT	300MG/VIAL	A206982	001	Mar 17, 2022	Apr	DISC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

TRENTAL

>D>	@ + VALIDUS PHARMS	400MG	N018631	001	Aug 30, 1984	Aug	CMFD
>A> AB	+	400MG	N018631	001	Aug 30, 1984	Aug	CMFD

PERAMPANEL

SUSPENSION; ORAL

PERAMPANEL

AB	TARO	0.5MG/ML	A219052	001	Jun 15, 2026	Jun	NEWA
----	------	----------	---------	-----	--------------	-----	------

PERMETHRIN

CREAM; TOPICAL

PERMETHRIN

>D> AB	ACTAVIS LABS	5%	A074806	001	Jan 23, 1998	Aug	DISC
>A>	@	5%	A074806	001	Jan 23, 1998	Aug	DISC
AB	DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023	Jun	CMFD

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

@	INGENUS PHARMS LLC	37.5MG	A091451	001	Sep 21, 2012	Feb CAHN
---	--------------------	--------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1	BAXTER HLTHCARE CORP	10MG/ML (10MG/ML)	A217032	001	Apr 03, 2026	Mar NEWA
AP1		50MG/5ML (10MG/ML)	A217032	002	Apr 03, 2026	Mar NEWA
AP1		100MG/10ML (10MG/ML)	A217032	003	Apr 03, 2026	Mar NEWA
AP1	HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Jan CMFD
AP1		50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Jan CMFD
AP1		100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Jan CMFD

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	! PAI HOLDINGS	5MG/5ML; 6.25MG/5ML	A040654	001	Dec 07, 2006	May CAHN
----	----------------	---------------------	---------	-----	--------------	----------

PHENYTOIN SODIUM

CAPSULE; ORAL

EXTENDED PHENYTOIN SODIUM

@	MANKIND PHARMA	100MG EXTENDED	A219773	001	Jan 02, 2026	Jul DISC
---	----------------	----------------	---------	-----	--------------	----------

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

AB1	ALEMBIC	1MG/0.5ML	A216444	001	Sep 08, 2025	Mar CTEC
AB1	AMNEAL	1MG/0.5ML	A216601	001	Nov 04, 2025	Mar CTEC
AB1		10MG/ML	A217734	001	Jun 01, 2026	May NEWA
AB2	BAXTER HLTHCARE CORP	1MG/0.5ML	A216852	001	Feb 26, 2026	Mar CTEC
AB		1MG/0.5ML	A216852	001	Feb 26, 2026	Feb NEWA
AB2	! CIPLA	1MG/0.5ML	A214596	001	Apr 22, 2022	Mar CTEC
AB1		1MG/0.5ML	A214966	001	Jan 03, 2025	Mar CTEC
AB1	DR REDDYS	1MG/0.5ML	A215820	001	May 15, 2026	May NEWA
AB1	+! INTL MEDICATION	1MG/0.5ML	A083722	001		Mar CTEC
AB1	ORBICULAR	1MG/0.5ML	A216298	001	Mar 13, 2026	Mar CTEC
AB		1MG/0.5ML	A216298	001	Mar 13, 2026	Mar NEWA
AB1	SUNNY	10MG/ML	A215090	001	Jan 09, 2026	Jan NEWA

TABLET; ORAL

PHYTONADIONE

AB	NOVAX	5MG	A220454	001	Feb 26, 2026	Jul CAHN
AB	SINOTHERAPEUTICS INC	5MG	A220454	001	Feb 26, 2026	Feb NEWA

PIFLUFOLASTAT F-18

SOLUTION; INTRAVENOUS

PYLARIFY TRUVU

+!	APHELION	1mCi/mL-120mCi/mL	N220089	001	Mar 06, 2026	Mar NEWA
----	----------	-------------------	---------	-----	--------------	----------

PILOCARPINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PILOCARPINE HYDROCHLORIDE

	!	AMNEAL	1.25%	A217733	001	Apr 28, 2025	Apr CTEC
AB	!		1.25%	A217733	001	Apr 28, 2025	Apr CHRS
>D>	@	FDC LTD	1%	A217052	001	Oct 02, 2025	Aug CMFD
>A> AT			1%	A217052	001	Oct 02, 2025	Aug CMFD
	@		1%	A217052	001	Oct 02, 2025	May DISC
>D>	@		2%	A217052	002	Oct 02, 2025	Aug CMFD
>A> AT			2%	A217052	002	Oct 02, 2025	Aug CMFD
	@		2%	A217052	002	Oct 02, 2025	May DISC
>D>	@		4%	A217052	003	Oct 02, 2025	Aug CMFD
>A> AT			4%	A217052	003	Oct 02, 2025	Aug CMFD
	@		4%	A217052	003	Oct 02, 2025	May DISC
		VUITY					
	@ +	ABBVIE	1.25%	N214028	001	Oct 28, 2021	Apr DISC

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB	AUROBINDO PHARMA USA	5MG	A212377	001	Aug 13, 2019	Jan CAHN	
AB		7.5MG	A212377	002	Aug 13, 2019	Jan CAHN	
	@	PADAGIS US	5MG	A076746	001	Nov 16, 2004	Mar DISC

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB	QUAGEN	5MG	A212377	001	Aug 13, 2019	Jul CAHN
AB		7.5MG	A212377	002	Aug 13, 2019	Jul CAHN

PIMOZIDE

TABLET;ORAL

PIMOZIDE

AB	NOVITIUM PHARMA	1MG	A219897	001	Apr 13, 2026	Apr NEWA
AB		2MG	A219897	002	Apr 13, 2026	Apr NEWA
AB	PH HEALTH	1MG	A204521	001	Sep 28, 2015	Apr CTEC
AB	!	2MG	A204521	002	Sep 28, 2015	Apr CTEC

PINDOLOL

TABLET;ORAL

PINDOLOL

@	COSETTE PHARMS NC	5MG	A073661	001	Oct 31, 1993	Jun CAHN
@		5MG	A073687	001	Feb 26, 1993	Jun CAHN
@		5MG	A074123	001	Apr 17, 1997	Jun CAHN
@		10MG	A073661	002	Oct 31, 1993	Jun CAHN
@		10MG	A073687	002	Feb 26, 1993	Jun CAHN
@		10MG	A074123	002	Apr 17, 1997	Jun CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

@	SANDOZ	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065363	001	Oct 21, 2010	Apr DISC
@		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065363	002	Oct 21, 2010	Apr DISC
@		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065363	003	Oct 21, 2010	Apr DISC

PIRFENIDONE

CAPSULE;ORAL

ESBRIET

AB	+! LEGACY	267MG	N022535	001	Oct 15, 2014	Jun CAHN
AB	AUROBINDO PHARMA	267MG	A212597	001	Apr 20, 2026	Apr NEWA
AB	ESBRIET					
AB	+ LEGACY	267MG	N208780	001	Jan 11, 2017	Jun CAHN
	@ +	534MG	N208780	002	Jan 11, 2017	Jun CAHN
AB	+!	801MG	N208780	003	Jan 11, 2017	Jun CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

@	UNICHEM	10MG	A208340	001	Apr 13, 2017	May DISC
@		20MG	A208340	002	Apr 13, 2017	May DISC

PITOLISANT HYDROCHLORIDE

TABLET;ORAL

PITOLISANT HYDROCHLORIDE

>A>	AB	LUPIN	EQ 4.45MG BASE	A218846	001	Aug 14, 2026	Aug NEWA
>A>	AB		EQ 17.8MG BASE	A218846	002	Aug 14, 2026	Aug NEWA
>A>	AB	MSN	EQ 4.45MG BASE	A218873	001	Aug 14, 2026	Aug NEWA
>A>	AB		EQ 17.8MG BASE	A218873	002	Aug 14, 2026	Aug NEWA
	AB	NOVITIUM PHARMA	EQ 4.45MG BASE	A218495	001	Jul 21, 2026	Jul NFTG
	AB		EQ 17.8MG BASE	A218495	002	Jul 21, 2026	Jul NFTG
	AB	WAKIX					
	AB	+ HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Jul CFTG
	AB	+!	EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Jul CFTG

PIVMECILLINAM HYDROCHLORIDE

TABLET;ORAL

PIVYA

+!	ALEMBIC THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Jan CAHN
----	----------------	---------------	---------	-----	--------------	----------

PLAZOMICIN SULFATESOLUTION; INTRAVENOUS
ZEMDRI

@ +	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018	May DISC
-----	-----------	--------------------------------------	---------	-----	--------------	----------

PLERIXAFORSOLUTION; SUBCUTANEOUS
PLERIXAFOR

@	TEVA PHARMS USA INC	24MG/1.2ML (20MG/ML)	A205197	001	Jul 24, 2023	Mar DISC
---	---------------------	----------------------	---------	-----	--------------	----------

PODOFILOXGEL; TOPICAL
CONDYLOX

@ +	ALLERGAN	0.5%	N020529	001	Mar 13, 1997	Jan DISC
-----	----------	------	---------	-----	--------------	----------

PODOFILOX

!	PADAGIS US	0.5%	A211871	001	Nov 22, 2023	Jan CHRS
		0.5%	A211871	001	Nov 22, 2023	Jan CTEC

SOLUTION; TOPICAL
CONDYLOX

AT	@ +	TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Apr DISC
	+	!	0.5%	N019795	001	Dec 13, 1990	Feb CAHN

PODOFILOX

AT	!	PADAGIS US	0.5%	A075600	001	Jan 29, 2002	Apr CTEC
	!		0.5%	A075600	001	Jan 29, 2002	Apr CHRS

POLIDOCANOLSOLUTION; INTRAVENOUS
VARITHENA

@ +	BOSTON SCITFC	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	May CAHN
+	!	180MG/18ML (10MG/ML)	N205098	001	Nov 25, 2013	May CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDEFOR SOLUTION; ORAL
TRILYTE

AA		AUROBINDO PHARMA USA	420GM/BOT; 1.48GM/BOT; 5.72GM/BO T; 11.2GM/BOT	A076491	001	Feb 05, 2004	Apr CMFD
----	--	----------------------	---	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUSFOR SOLUTION; ORAL
COLYTE

@ +	QUAGEN	120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET	N018983	005	Oct 26, 1984	Apr CRLD
-----	--------	---	---------	-----	--------------	----------

@ +		227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N018983	004	Oct 26, 1984	Apr CRLD
-----	--	--	---------	-----	--------------	----------

@ +		227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	010	Jan 31, 1989	Apr CRLD
-----	--	---	---------	-----	--------------	----------

@ +		240GM/BOT; 2.98GM/BOT; 6.72GM/BO T; 5.84GM/BOT; 22.72GM/BOT	N018983	007	Jun 12, 1987	Apr CRLD
-----	--	--	---------	-----	--------------	----------

@ +		360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET	N018983	006	Oct 26, 1984	Apr CRLD
-----	--	--	---------	-----	--------------	----------

@ +	STRIDES PHARMA INTL	120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET	N018983	005	Oct 26, 1984	Apr CAHN
-----	---------------------	---	---------	-----	--------------	----------

@ +		227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N018983	004	Oct 26, 1984	Apr CAHN
-----	--	--	---------	-----	--------------	----------

@ +		227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	010	Jan 31, 1989	Apr CAHN
-----	--	---	---------	-----	--------------	----------

@ +		240GM/BOT; 2.98GM/BOT; 6.72GM/BO T; 5.84GM/BOT; 22.72GM/BOT	N018983	007	Jun 12, 1987	Apr CAHN
-----	--	--	---------	-----	--------------	----------

@ +		360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET	N018983	006	Oct 26, 1984	Apr CAHN
-----	--	--	---------	-----	--------------	----------

COLYTE WITH FLAVOR PACKS

@ +	QUAGEN	240GM/BOT; 2.98GM/BOT; 6.72GM/BO T; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998	Apr CRLD
-----	--------	--	---------	-----	--------------	----------

@ +	STRIDES PHARMA INTL	240GM/BOT; 2.98GM/BOT; 6.72GM/BO T; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998	Apr CAHN
-----	---------------------	--	---------	-----	--------------	----------

FOR SOLUTION;ORAL
COLYTE-FLAVORED

@ +	QUAGEN	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Apr	CRLD
@ +		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Apr	CRLD
@ +	STRIDES PHARMA INTL	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Apr	CAHN
@ +		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Apr	CAHN
	PEG 3350 AND ELECTROLYTES						
!	NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr	CHRS

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	BAUSCH AND LOMB INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A064120	001	Feb 14, 1997	May	CAHN
----	---------------------	--------------------------------	---------	-----	--------------	-----	------

POMALIDOMIDE

CAPSULE;ORAL

POMALIDOMIDE

AB	APOTEX	1MG	A210164	001	Jun 11, 2024	Jan	CMFD
AB		2MG	A210164	002	Jun 11, 2024	Jan	CMFD
AB		3MG	A210164	003	Jun 11, 2024	Jan	CMFD
AB		4MG	A210164	004	Jun 11, 2024	Jan	CMFD
AB	BRECKENRIDGE	1MG	A210111	001	Oct 30, 2020	Jan	CMFD
AB		2MG	A210111	002	Oct 30, 2020	Jan	CMFD
AB		3MG	A210111	003	Oct 30, 2020	Jan	CMFD
AB		4MG	A210111	004	Oct 30, 2020	Jan	CMFD
>A> AB	CIPLA	1MG	A219718	001	Aug 31, 2026	Aug	NEWA
>A> AB		2MG	A219718	002	Aug 31, 2026	Aug	NEWA
>A> AB		3MG	A219718	003	Aug 31, 2026	Aug	NEWA
>A> AB		4MG	A219718	004	Aug 31, 2026	Aug	NEWA
>A> AB	DR REDDYS	1MG	A213234	001	Aug 31, 2026	Aug	NEWA
>A> AB		2MG	A213234	002	Aug 31, 2026	Aug	NEWA
>A> AB		3MG	A213234	003	Aug 31, 2026	Aug	NEWA
>A> AB		4MG	A213234	004	Aug 31, 2026	Aug	NEWA
AB	EUGIA PHARMA	1MG	A210249	001	Oct 30, 2020	Jan	CMFD
AB		2MG	A210249	002	Oct 30, 2020	Jan	CMFD
AB		3MG	A210249	003	Oct 30, 2020	Jan	CMFD
AB		4MG	A210249	004	Oct 30, 2020	Jan	CMFD
AB	HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Jan	CMFD
AB		2MG	A210236	002	Sep 26, 2024	Jan	CMFD
AB		3MG	A210236	003	Sep 26, 2024	Jan	CMFD
AB		4MG	A210236	004	Sep 26, 2024	Jan	CMFD
>A> AB	MSN	2MG	A210245	001	Sep 02, 2026	Aug	NEWA
>A> AB		3MG	A210245	002	Sep 02, 2026	Aug	NEWA
>A> AB		4MG	A210245	003	Sep 02, 2026	Aug	NEWA
>A> AB	SANDOZ	1MG	A220741	001	Aug 31, 2026	Aug	NEWA
>A> AB		2MG	A220741	002	Aug 31, 2026	Aug	NEWA
>A> AB		3MG	A220741	003	Aug 31, 2026	Aug	NEWA
>A> AB		4MG	A220741	004	Aug 31, 2026	Aug	NEWA
>A> AB	SPIL	1MG	A210232	001	Aug 31, 2026	Aug	NEWA
>A> AB		2MG	A210232	002	Aug 31, 2026	Aug	NEWA
>A> AB		3MG	A210232	003	Aug 31, 2026	Aug	NEWA
>A> AB		4MG	A210232	004	Aug 31, 2026	Aug	NEWA
AB	TEVA PHARMS USA	1MG	A209956	001	May 04, 2022	Jan	CMFD
AB		2MG	A209956	002	May 04, 2022	Jan	CMFD
AB		3MG	A209956	003	May 04, 2022	Jan	CMFD
AB		4MG	A209956	004	May 04, 2022	Jan	CMFD
	POMALYST						
AB	+ BRISTOL	1MG	N204026	001	Feb 08, 2013	Jan	CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	Jan	CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	Jan	CTEC
AB	+!	4MG	N204026	004	Feb 08, 2013	Jan	CTEC

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

+	TAKEDA PHARMS USA	EQ 10MG BASE	N203469	004	Dec 18, 2020	Jan	CHRS
+		EQ 45MG BASE	N203469	002	Dec 14, 2012	Jan	CHRS

POSACONAZOLE

SOLUTION; INTRAVENOUS

NOXAFIL

@ + MERCK SHARP DOHME 300MG/16.7ML (18MG/ML)

N205596 001 Mar 13, 2014 Jan DISC

POSACONAZOLE

AP ! GLAND 300MG/16.7ML (18MG/ML)

A217553 001 Dec 26, 2023 Jan CHRS

TABLET, DELAYED RELEASE; ORAL

POSACONAZOLE

AB APOTEX 100MG

A213331 001 Jun 29, 2026 Jun NEWA

>A> AB SOMERSET THERAPS LLC 100MG

A216326 001 Jun 20, 2023 Aug CAHN

>D> AB WELDING 100MG

A216326 001 Jun 20, 2023 Aug CAHN

AB 100MG

A216326 001 Jun 20, 2023 Apr CAHN

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE

@ EXELA PHARMA 2MEQ/ML

A206203 001 Dec 29, 2015 Jan DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

@ PADAGIS US 8MEQ

A200185 001 May 18, 2011 Mar DISC

@ 10MEQ

A200185 002 May 18, 2011 Mar DISC

FOR SOLUTION; ORAL

POKONZA

+ GENUS 15MEQ

N208019 004 Nov 12, 2025 Apr NEWA

POTASSIUM CHLORIDE

>A> AA ADAPTIS 20MEQ

A219009 001 Jul 11, 2025 Aug CAHN

>D> AA ANDA REPOSITORY 20MEQ

A219009 001 Jul 11, 2025 Aug CAHN

@ + GENUS 40MEQ

N208019 003 Aug 25, 2023 Jun DISC

>A> AA GUARDIAN DRUG 20MEQ

A219009 001 Jul 11, 2025 Aug CAHN

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

@ + BAXTER HLTHCARE 2.24GM/100ML

N019904 003 Dec 26, 1989 Mar DISC

SOLUTION; ORAL

POTASSIUM CHLORIDE

>A> AA ADAPTIS 20MEQ/15ML

A214892 001 Dec 30, 2022 Aug CAHN

>A> AA 40MEQ/15ML

A214892 002 Dec 30, 2022 Aug CAHN

>D> AA ANDA REPOSITORY 20MEQ/15ML

A214892 001 Dec 30, 2022 Aug CAHN

>D> AA 40MEQ/15ML

A214892 002 Dec 30, 2022 Aug CAHN

@ APOTEX 20MEQ/15ML

A211067 001 Aug 08, 2018 May DISC

@ 40MEQ/15ML

A211067 002 Aug 08, 2018 May DISC

>A> AA GUARDIAN DRUG 20MEQ/15ML

A214892 001 Dec 30, 2022 Aug CAHN

>A> AA 40MEQ/15ML

A214892 002 Dec 30, 2022 Aug CAHN

@ STRIDES PHARMA 20MEQ/15ML

A211665 002 Jan 16, 2024 Jun DISC

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

>A> AB2 TWI PHARMS 8MEQ

A218979 001 Oct 28, 2024 Aug CTNA

>A> AB2 10MEQ

A218979 002 Oct 28, 2024 Aug CTNA

>D> POTASSIUM CHLORIDE

>D> AB2 TWI PHARMS 8MEQ

A218979 001 Oct 28, 2024 Aug CTNA

>D> AB2 10MEQ

A218979 002 Oct 28, 2024 Aug CTNA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION; INTRAVENOUS

POTASSIUM PHOSPHATES

AP CAPLIN 1.18GM/5ML
(236MG/ML); 1.12GM/5ML

A220373 001 Mar 12, 2026 Mar NEWA

AP 3.54GM/15ML
(236MG/ML); 3.36GM/15ML

A220373 002 Mar 12, 2026 Mar NEWA

AP 11.8GM/50ML
(236MG/ML); 11.2GM/50ML

A220373 003 Mar 12, 2026 Mar NEWA

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PROTOPAM CHLORIDE

@ BAXTER HLTHCARE CORP 300MG/ML

N018799 001 Dec 13, 1982 Jun CTNA

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

PRASUGREL

@	SENORES PHARMS	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan CAHN
@		EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan CAHN

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

AB	SENORES PHARMS	10MG	A077491	002	Oct 23, 2006	Feb CAHN
AB		20MG	A077491	003	Oct 23, 2006	Feb CAHN
		30MG	A077491	005	Aug 06, 2026	Jul NEWA
AB		40MG	A077491	004	Oct 23, 2006	Feb CAHN
		60MG	A077491	006	Aug 06, 2026	Jul NFTG
AB		80MG	A077491	001	Feb 11, 2008	Feb CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

AA	+! PAI HOLDINGS	EQ 5MG BASE/5ML	N019157	001	May 28, 1986	Apr CAHN
----	-----------------	-----------------	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

!	BAUSCH AND LOMB INC	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994	May CAHN
---	---------------------	-------------------	---------	-----	--------------	----------

PREDNISONE

TABLET, DELAYED RELEASE; ORAL

PREDNISONE

	DR REDDYS	1MG	A219477	001	Oct 01, 2025	Jun CHRS
!		5MG	A218035	001	Jun 26, 2026	Jun NEWA

PREGABALIN

CAPSULE; ORAL

PREGABALIN

AB	FOURRTS LABS	25MG	A218529	001	Feb 24, 2026	Feb NEWA
AB		50MG	A218529	002	Feb 24, 2026	Feb NEWA
AB		75MG	A218529	003	Feb 24, 2026	Feb NEWA
AB		100MG	A218529	004	Feb 24, 2026	Feb NEWA
AB		150MG	A218529	005	Feb 24, 2026	Feb NEWA
AB		200MG	A218529	006	Feb 24, 2026	Feb NEWA
AB		225MG	A218529	007	Feb 24, 2026	Feb NEWA
AB		300MG	A218529	008	Feb 24, 2026	Feb NEWA
AB	RENATA	50MG	A210585	001	Dec 26, 2019	Feb CAHN
AB		75MG	A210585	002	Dec 26, 2019	Feb CAHN
AB		100MG	A210585	003	Dec 26, 2019	Feb CAHN
AB		150MG	A210585	004	Dec 26, 2019	Feb CAHN
AB		200MG	A210585	005	Dec 26, 2019	Feb CAHN
AB		300MG	A210585	006	Dec 26, 2019	Feb CAHN
	@ STRIDES PHARMA	25MG	A215755	001	Apr 26, 2023	Jun DISC
	@	50MG	A215755	002	Apr 26, 2023	Jun DISC
	@	75MG	A215755	003	Apr 26, 2023	Jun DISC
	@	100MG	A215755	004	Apr 26, 2023	Jun DISC
	@	150MG	A215755	005	Apr 26, 2023	Jun DISC
	@	200MG	A215755	006	Apr 26, 2023	Jun DISC
	@	225MG	A215755	007	Apr 26, 2023	Jun DISC
	@	300MG	A215755	008	Apr 26, 2023	Jun DISC
AB	UNICHEM	25MG	A219593	001	Apr 30, 2026	Apr NEWA
AB		50MG	A219593	002	Apr 30, 2026	Apr NEWA
AB		75MG	A219593	003	Apr 30, 2026	Apr NEWA
AB		100MG	A219593	004	Apr 30, 2026	Apr NEWA
AB		150MG	A219593	005	Apr 30, 2026	Apr NEWA
AB		200MG	A219593	006	Apr 30, 2026	Apr NEWA
AB		225MG	A219593	007	Apr 30, 2026	Apr NEWA
AB		300MG	A219593	008	Apr 30, 2026	Apr NEWA

SOLUTION; ORAL

PREGABALIN

>A>	AA	ANDA REPOSITORY	20MG/ML	A212604	001	Feb 18, 2022	Aug CAHN
>D>	AA	PATRIN	20MG/ML	A212604	001	Feb 18, 2022	Aug CAHN
	AA		20MG/ML	A212604	001	Feb 18, 2022	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

PREGABALIN

AB	AIPING PHARM INC	165MG	A217857	002	Jun 24, 2026	Jun NEWA
----	------------------	-------	---------	-----	--------------	----------

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE PHOSPHATE

AB	INGENUS PHARMS LLC	EQ 15MG BASE	A206043	001	Jun 23, 2016	Feb CAHN
----	--------------------	--------------	---------	-----	--------------	----------

PRIMIDONE

TABLET; ORAL

PRIMIDONE

AB	CARNEGIE	50MG	A218366	001	Jan 23, 2024	Feb CAHN
AB		250MG	A218366	002	Jan 23, 2024	Feb CAHN

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

AP	!	GLAND	100MG/ML	A218135	001	Jul 22, 2024	Jan CHRS
AP	!		500MG/ML	A218135	002	Jul 22, 2024	Jan CHRS
AP		HOSPIRA	100MG/ML	A089069	001	Feb 12, 1986	Jan CHRS
	@		500MG/ML	A089070	001	Feb 12, 1986	Jan DISC

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

PROCHLORPERAZINE

AB	!	COSETTE PHARMS NC	25MG	A040058	001	Nov 24, 1993	May CAHN
----	---	-------------------	------	---------	-----	--------------	----------

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

	@	AMNEAL	EQ 5MG BASE/ML	A214192	001	Nov 28, 2022	Feb DISC
--	---	--------	----------------	---------	-----	--------------	----------

PROGESTERONE

GEL; VAGINAL

CRINONE

@ + ABBVIE

INJECTABLE; INJECTION

PROGESTERONE

	@ +	ABBVIE	4%	N020701	001	Jul 31, 1997	Apr DISC
AO		ACCORD HLTHCARE	50MG/ML	A217707	001	Nov 21, 2023	Jul CMFD
		INSERT; VAGINAL					
		PROGESTERONE					
AB		GLENMARK PHARMS	100MG	A216363	001	Apr 08, 2026	Apr CAHN
AB		GLENMARK PHARMS LTD	100MG	A216363	001	Apr 08, 2026	Mar NEWA

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PHENERGAN

@ + PHARMOBEDIENT

@ +

PROMETHAZINE HYDROCHLORIDE

	@ +	PHARMOBEDIENT	12.5MG	N010926	002		May CAHN
	@ +		25MG	N010926	001		May CAHN
AB		COSETTE PHARMS NC	12.5MG	A040428	002	Mar 31, 2003	May CAHN
AB	!		25MG	A040428	001	Feb 05, 2002	May CAHN
		PROMETHEGAN					
	!	COSETTE PHARMS NC	50MG	A087165	001	Aug 14, 1987	May CAHN
		SYRUP; ORAL					
		PROMETHAZINE HYDROCHLORIDE					
AA		COSETTE PHARMS NC	6.25MG/5ML	A091675	001	Jun 28, 2012	May CAHN

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

@ WATSON LABS

@

	@	WATSON LABS	150MG	A075203	001	Oct 24, 2000	Jul DISC
	@		225MG	A075203	002	Oct 24, 2000	Jul DISC

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PROPARACAINE HYDROCHLORIDE

AT	!	BAUSCH AND LOMB INC	0.5%	A040074	001	Sep 29, 1995	May CAHN
----	---	---------------------	------	---------	-----	--------------	----------

PROPOFOLINJECTABLE;INJECTION
PROPOFOL

AB	ANTHEA PHARMA	10MG/ML	A220857	001	Jul 14, 2026	Jul NEWA
AB	EMERGE BIOSCIENCE	10MG/ML	A217945	001	Dec 02, 2025	May CAHN

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
PROPRANOLOL HYDROCHLORIDE

	@	CHARTWELL RX	60MG	A078022	001	Feb 15, 2007	May CAHN
	@		80MG	A078022	002	Feb 15, 2007	May CAHN
	@		120MG	A078022	003	Feb 15, 2007	May CAHN
	@		160MG	A078022	004	Feb 15, 2007	May CAHN
>A>	AB	CREEKWOOD PHARMS	60MG	A219460	001	Aug 14, 2026	Aug NEWA
>A>	AB		80MG	A219460	002	Aug 14, 2026	Aug NEWA
>A>	AB		120MG	A219460	003	Aug 14, 2026	Aug NEWA
>A>	AB		160MG	A219460	004	Aug 14, 2026	Aug NEWA
	AB	IPCA LABS LTD	60MG	A203103	001	May 01, 2026	Apr NEWA
	AB		80MG	A203103	002	May 01, 2026	Apr NEWA
	AB		120MG	A203103	003	May 01, 2026	Apr NEWA
	AB		160MG	A203103	004	May 01, 2026	Apr NEWA
	AB	MICRO LABS	60MG	A217238	001	Jun 24, 2026	Jun NEWA
	AB		80MG	A217238	002	Jun 24, 2026	Jun NEWA
	AB		120MG	A217238	003	Jun 24, 2026	Jun NEWA
	AB		160MG	A217238	004	Jun 24, 2026	Jun NEWA

INJECTABLE;INJECTION
PROPRANOLOL HYDROCHLORIDE

>D>	@	ALLIED	1MG/ML	A076400	001	Feb 26, 2003	Aug CAHN
	@		1MG/ML	A076400	001	Feb 26, 2003	Apr CAHN
>A>	@	SCIEGEN PHARMS	1MG/ML	A076400	001	Feb 26, 2003	Aug CAHN

SOLUTION;ORAL

HEMANGEOL

	+	!	ETON	4.28MG/ML	N205410	001	Mar 14, 2014	Mar CAHN
			PROPRANOLOL HYDROCHLORIDE					
AA	!		HIKMA	20MG/5ML	A070690	002	May 15, 1987	May CTEC
	!			20MG/5ML	A070690	002	May 15, 1987	Feb CMS1
AA			PAI HOLDINGS	20MG/5ML	A219165	001	Jun 10, 2026	May NEWA

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB		MANKIND PHARMA	10MG	A216663	001	Jan 27, 2026	Jan NEWA
AB			20MG	A216663	002	Jan 27, 2026	Jan NEWA
AB			40MG	A216663	003	Jan 27, 2026	Jan NEWA
AB			60MG	A216663	004	Jan 27, 2026	Jan NEWA
AB			80MG	A216663	005	Jan 27, 2026	Jan NEWA

PRUCALOPRIDE SUCCINATE

TABLET;ORAL

PRUCALOPRIDE SUCCINATE

AB		AJANTA PHARMA LTD	EQ 1MG BASE	A219220	001	Jan 16, 2026	Jan NEWA
AB			EQ 2MG BASE	A219220	002	Jan 16, 2026	Jan NEWA
AB		ALEMBIC	EQ 1MG BASE	A219234	001	Jul 27, 2026	Jul NEWA
AB			EQ 2MG BASE	A219234	002	Jul 27, 2026	Jul NEWA
>A>	AB	BIONPHARMA	EQ 1MG BASE	A219216	001	Jun 24, 2025	Aug CAHN
>A>	AB		EQ 2MG BASE	A219216	002	Jun 24, 2025	Aug CAHN
>D>	AB	H2-PHARMA	EQ 1MG BASE	A219216	001	Jun 24, 2025	Aug CAHN
>D>	AB		EQ 2MG BASE	A219216	002	Jun 24, 2025	Aug CAHN
	AB	MICRO LABS	EQ 1MG BASE	A219180	001	Jun 29, 2026	Jun NEWA
	AB		EQ 2MG BASE	A219180	002	Jun 29, 2026	Jun NEWA
>D>	AB	TEVA PHARMS INC	EQ 1MG BASE	A219071	001	Feb 05, 2026	Aug DISC
>A>	@		EQ 1MG BASE	A219071	001	Feb 05, 2026	Aug DISC
	AB		EQ 1MG BASE	A219071	001	Feb 05, 2026	Jan NEWA
>D>	AB		EQ 2MG BASE	A219071	002	Feb 05, 2026	Aug DISC
>A>	@		EQ 2MG BASE	A219071	002	Feb 05, 2026	Aug DISC
	AB		EQ 2MG BASE	A219071	002	Feb 05, 2026	Jan NEWA

PYRIDOSTIGMINE BROMIDETABLET, EXTENDED RELEASE;ORAL
MESTINON

>D>	AB	+	!	BAUSCH	180MG	N011665	001	Aug CHRS
>A>	AB	+			180MG	N011665	001	Aug CHRS

TABLET, EXTENDED RELEASE;ORAL
PYRIDOSTIGMINE BROMIDE

>D>	AB	ALVOGEN	180MG	A204737	001	Jun 26, 2015	Aug CHRS
>A>	AB	!	180MG	A204737	001	Jun 26, 2015	Aug CHRS
		@ IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015	Jan DISC

QUETIAPINE FUMARATE

TABLET;ORAL
QUETIAPINE FUMARATE

@	SUN PHARM	EQ 25MG BASE	A201190	001	Mar 27, 2012	Apr DISC
@		EQ 400MG BASE	A201190	006	Mar 27, 2012	Apr DISC

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

AB	PLATINUM	EQ 50MG BASE	A202939	001	May 09, 2017	Apr CAHN
AB		EQ 150MG BASE	A202939	002	May 09, 2017	Apr CAHN
AB		EQ 200MG BASE	A202939	003	May 09, 2017	Apr CAHN
AB		EQ 300MG BASE	A202939	004	May 09, 2017	Apr CAHN
AB		EQ 400MG BASE	A202939	005	May 09, 2017	Apr CAHN

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
QUINIDINE SULFATE

@	COSETTE PHARMS NC	300MG	A040045	001	Jun 30, 1994	Jun CAHN
---	-------------------	-------	---------	-----	--------------	----------

QUININE SULFATE

CAPSULE;ORAL
QUININE SULFATE

AB	! INGENUS PHARMS LLC	324MG	A204372	001	Jul 22, 2015	May CAHN
----	----------------------	-------	---------	-----	--------------	----------

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL
RABEPRAZOLE SODIUM

AB	AUROBINDO PHARMA USA	20MG	A205761	001	Feb 17, 2017	Jan CAHN
AB	QUAGEN	20MG	A205761	001	Feb 17, 2017	Jul CAHN

RALTEGRAVIR POTASSIUM

TABLET;ORAL
ISENTRESS

>D>		+! MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007	Aug CTEC
>A>	AB	+!	EQ 400MG BASE	N022145	001	Oct 12, 2007	Aug CTEC
>D>		@ HETERO LABS LTD III	EQ 400MG BASE	A203540	001	Dec 19, 2024	Aug CMFD
>A>	AB		EQ 400MG BASE	A203540	001	Dec 19, 2024	Aug CMFD

RAMELTEON

TABLET;ORAL
RAMELTEON

AB	AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Feb CTEC
AB	HIBROW HLTHCARE	8MG	A215485	001	Jun 04, 2026	May NEWA
AB	XIROMED	8MG	A216209	001	Nov 25, 2022	Mar CTEC

RAMIPRIL

CAPSULE;ORAL
RAMIPRIL

AB	SENORES PHARMS	1.25MG	A078191	001	Jun 18, 2008	Jan CAHN
AB		2.5MG	A078191	002	Jun 18, 2008	Jan CAHN
AB		5MG	A078191	003	Jun 18, 2008	Jan CAHN
AB		10MG	A078191	004	Jun 18, 2008	Jan CAHN

SOLUTION;ORAL
VOSTALLY

@ +	ROSEMONT PHARMS	1MG/ML	N219757	001	Jul 23, 2025	Apr DISC
+!		1MG/ML	N219757	001	Jul 23, 2025	Feb CAHN

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL
RANITIDINE HYDROCHLORIDE

@	RISING	EQ 150MG BASE	A075564	001	Oct 27, 2000	Mar CAHN
@		EQ 300MG BASE	A075564	002	Oct 27, 2000	Mar CAHN

RANOLAZINEGRANULE, EXTENDED RELEASE;ORAL
ASPRUZYO SPRINKLE@ + SPIL 500MG
@ + 1GMN216018 001 Feb 28, 2022 Apr CDFR
N216018 002 Feb 28, 2022 Apr CDFRTABLET, EXTENDED RELEASE;ORAL
RANOLAZINE@ ACTAVIS ELIZABETH 500MG
@ 1GMA208862 001 May 28, 2019 Jun DISC
A208862 002 May 28, 2019 Jun DISC

>D> AB MICRO LABS 500MG

A211745 001 Feb 27, 2020 Aug DISC

>A> @ 500MG

A211745 001 Feb 27, 2020 Aug DISC

>D> AB 1GM

A211745 002 Feb 27, 2020 Aug DISC

>A> @ 1GM

A211745 002 Feb 27, 2020 Aug DISC

AB PIRAMAL 500MG

A213085 001 Jul 25, 2023 Feb CMFD

AB 1GM

A213085 002 Jul 25, 2023 Feb CMFD

AB UMEDICA 500MG

A214551 001 Aug 05, 2026 Jul NEWA

AB 1GM

A214551 002 Aug 05, 2026 Jul NEWA

REGADENOSONSOLUTION;INTRAVENOUS
REGADENOSON@ GE HEALTHCARE 0.4MG/5ML (0.08MG/ML)
@ MYLAN 0.4MG/5ML (0.08MG/ML)A215955 001 Aug 05, 2024 Feb DISC
A213856 001 Apr 04, 2023 Jul DISCRELACORILANTCAPSULE;ORAL
LIFYORLI (COPACKAGED)

+! CORCEPT THERAP 100MG;25MG

N220641 001 Mar 25, 2026 Mar NEWA

REMIFENTANIL HYDROCHLORIDEINJECTABLE;INJECTION
REMIFENTANIL HYDROCHLORIDE

>A> AP NIVAGEN EQ 1MG BASE/VIAL

A215635 001 Jun 28, 2024 Aug CAHN

>A> AP EQ 2MG BASE/VIAL

A215635 002 Jun 28, 2024 Aug CAHN

>A> AP EQ 5MG BASE/VIAL

A215635 003 Jun 28, 2024 Aug CAHN

>D> AP NIVAGEN PHARMS INC EQ 1MG BASE/VIAL

A215635 001 Jun 28, 2024 Aug CAHN

>D> AP EQ 2MG BASE/VIAL

A215635 002 Jun 28, 2024 Aug CAHN

>D> AP EQ 5MG BASE/VIAL

A215635 003 Jun 28, 2024 Aug CAHN

REPAGLINIDETABLET;ORAL
REPAGLINIDE@ PADAGIS US 0.5MG
@ 1MG
@ 2MGA201189 001 Jul 17, 2013 Mar DISC
A201189 002 Jan 22, 2014 Mar DISC
A201189 003 Jan 22, 2014 Mar DISCRIBAVIRINFOR SOLUTION;INHALATION
RIBAVIRIN@ CHARTWELL RX 6GM/VIAL
@ NAVINTA LLC 6GM/VIALA207366 001 Oct 06, 2016 Jul CAHN
A207366 001 Oct 06, 2016 Mar DISCRIFABUTINCAPSULE;ORAL
RIFABUTIN

AB I3 PHARMS 150MG

A212430 001 Mar 19, 2026 Mar NEWA

>A> AB ZYDUS LIFESCIENCES 150MG

A219519 001 Aug 21, 2026 Aug NEWA

RIFAMPINCAPSULE;ORAL
RIFAMPIN

AB NOVITIUM PHARMA 150MG

A219918 001 Jun 29, 2026 Jun NEWA

AB 300MG

A219918 002 Jun 29, 2026 Jun NEWA

RIFAPENTINETABLET;ORAL
PRIFTIN

AB +! SANOFI AVENTIS US 150MG

N021024 001 Jun 22, 1998 Jun CFTG

AB RIFAPENTINE 150MG

A217042 001 Jun 23, 2026 Jun NFTG

RIFAXIMIN

TABLET;ORAL

RIFAXIMIN

AB	ACTAVIS LABS FL INC	550MG	A208959	001	Mar 19, 2026	Mar NFTG
	XIFAXAN					
AB	+! SALIX PHARMS	550MG	N021361	002	Mar 24, 2010	Mar CFTG

RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

EDURANT

AB	+! JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011	Jan CFTG
	RILPIVIRINE HYDROCHLORIDE					
AB	LAURUS	EQ 25MG BASE	A219788	001	Jul 10, 2026	Jul NEWA
AB	SOMERSET THERAPS LLC	EQ 25MG BASE	A218798	001	Jan 29, 2026	Jan NFTG

RILUZOLE

TABLET;ORAL

RILUTEK

@ +	AZURITY	50MG	N020599	001	Dec 12, 1995	Jul CAHN
@ +		50MG	N020599	001	Dec 12, 1995	Mar CAHN

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RYKINDO

@ +	SHANDONG LUYE	37.5MG	N212849	003	Jan 13, 2023	Jun DISC
@ +		50MG	N212849	004	Jan 13, 2023	Jun DISC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

PERSERIS KIT

@ +	INDIVIOR	90MG	N210655	001	Jul 27, 2018	Jun DISC
@ +		120MG	N210655	002	Jul 27, 2018	Jun DISC

POWDER;INTRAMUSCULAR

RISPERDAL CONSTA

AB	+! JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan CHRS
AB	+	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan CDFR
AB	+!	25MG/VIAL	N021346	001	Oct 29, 2003	Jan CDFR
AB	+!	37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan CHRS
AB	+	37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan CDFR
AB	+!	50MG/VIAL	N021346	003	Oct 29, 2003	Jan CHRS
AB	+	50MG/VIAL	N021346	003	Oct 29, 2003	Jan CDFR

RISPERIDONE

AB	AMNEAL	12.5MG/VIAL	A218586	001	Sep 02, 2025	Jan CDFR
AB		25MG/VIAL	A218586	002	Sep 02, 2025	Jan CDFR
AB		37.5MG/VIAL	A218586	003	Sep 02, 2025	Jan CDFR
AB		50MG/VIAL	A218586	004	Sep 02, 2025	Jan CDFR
AB	NANOMI	25MG/VIAL	A211220	001	Sep 02, 2025	Jan CDFR
AB		37.5MG/VIAL	A211220	002	Sep 02, 2025	Jan CDFR
AB		50MG/VIAL	A211220	003	Sep 02, 2025	Jan CDFR
AB	TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan CDFR
AB		25MG/VIAL	A214068	002	Dec 05, 2023	Jan CDFR
AB		37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan CDFR
AB		50MG/VIAL	A214068	004	Dec 05, 2023	Jan CDFR

TABLET;ORAL

RISPERIDONE

>D>	AB	AMNEAL	0.25MG	A078071	001	Jun 17, 2009	Aug DISC
>A>	@		0.25MG	A078071	001	Jun 17, 2009	Aug DISC
>D>	AB		0.5MG	A078071	002	Jun 17, 2009	Aug DISC
>A>	@		0.5MG	A078071	002	Jun 17, 2009	Aug DISC
>D>	AB		1MG	A078071	003	Jun 17, 2009	Aug DISC
>A>	@		1MG	A078071	003	Jun 17, 2009	Aug DISC
>D>	AB		2MG	A078071	004	Jun 17, 2009	Aug DISC
>A>	@		2MG	A078071	004	Jun 17, 2009	Aug DISC
>D>	AB		3MG	A078071	005	Jun 17, 2009	Aug DISC
>A>	@		3MG	A078071	005	Jun 17, 2009	Aug DISC
>D>	AB		4MG	A078071	006	Jun 17, 2009	Aug DISC
>A>	@		4MG	A078071	006	Jun 17, 2009	Aug DISC
	@	NATCO PHARMA USA	0.25MG	A076288	001	Sep 15, 2008	Mar CAHN
	@		0.5MG	A076288	002	Sep 15, 2008	Mar CAHN
	@		1MG	A076288	003	Sep 15, 2008	Mar CAHN
	@		2MG	A076288	004	Sep 15, 2008	Mar CAHN
	@		3MG	A076288	005	Sep 15, 2008	Mar CAHN
	@		4MG	A076288	006	Sep 15, 2008	Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

@	NATCO PHARMA USA	0.25MG	A091537	006	Feb 12, 2013	Mar CAHN
@		0.5MG	A091537	001	Mar 30, 2011	Mar CAHN
@		1MG	A091537	002	Mar 30, 2011	Mar CAHN
@		2MG	A091537	003	Mar 30, 2011	Mar CAHN
@		3MG	A091537	004	Mar 30, 2011	Mar CAHN
@		4MG	A091537	005	Mar 30, 2011	Mar CAHN

RITONAVIR

TABLET;ORAL
NORVIR

AB	+	ABBVIE	100MG	N022417	001	Feb 10, 2010	Jan CHRS
		RITONAVIR					
	@	AMNEAL	100MG	A208890	001	Sep 17, 2018	Mar DISC
AB	!	AUROBINDO PHARMA LTD	100MG	A206614	001	Sep 17, 2018	Jan CHRS

RIVAROXABAN

FOR SUSPENSION;ORAL
RIVAROXABAN

AB		APOTEX	1MG/ML	A218427	001	Mar 02, 2026	Feb NEWA
		TABLET;ORAL					
		RIVAROXABAN					
	@	APOTEX	10MG	A208579	001	Nov 14, 2025	Apr DISC
	@		15MG	A208579	002	Nov 14, 2025	Apr DISC
	@		20MG	A208579	003	Nov 14, 2025	Apr DISC
BX		BIOCON PHARMA	2.5MG	A218107	001	May 14, 2025	Feb CTEC
BX			10MG	A218107	002	May 14, 2025	Feb CTEC
BX			15MG	A218107	003	May 14, 2025	Feb CTEC
BX			20MG	A218107	004	May 14, 2025	Feb CTEC
>A>	AB	EPIC PHARMA LLC	2.5MG	A216255	001	Aug 19, 2026	Aug NEWA
>A>	AB		10MG	A216255	002	Aug 19, 2026	Aug NEWA
>A>	AB		15MG	A216255	003	Aug 19, 2026	Aug NEWA
>A>	AB		20MG	A216255	004	Aug 19, 2026	Aug NEWA
	AB	INVAGEN PHARMS	2.5MG	A218768	001	Feb 20, 2026	Feb NEWA
	AB	MANKIND PHARMA	2.5MG	A220874	001	Jul 01, 2026	Jun NEWA
	AB		10MG	A220874	002	Jul 01, 2026	Jun NEWA
	AB		15MG	A220874	003	Jul 01, 2026	Jun NEWA
	AB		20MG	A220874	004	Jul 01, 2026	Jun NEWA
	AB	MICRO LABS	2.5MG	A208334	001	Jun 30, 2026	Jun NEWA
	AB		10MG	A208334	002	Jun 30, 2026	Jun NEWA
	AB		15MG	A208334	003	Jun 30, 2026	Jun NEWA
	AB		20MG	A208334	004	Jun 30, 2026	Jun NEWA

RIZATRIPTAN BENZOATE

FILM;ORAL
RIZAFILM

@	+	GENSCO	EQ 5MG BASE	N205394	002	Feb 26, 2026	Jul DISC
	+	!	EQ 5MG BASE	N205394	002	Feb 26, 2026	Feb NEWA

TABLET;ORAL

RIZATRIPTAN BENZOATE

@		PHARMOBEDIENT	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb DISC
@			EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

AP		ASPIRO	50MG/5ML (10MG/ML)	A220124	001	Mar 04, 2026	Feb NEWA
AP			100MG/10ML (10MG/ML)	A220124	002	Mar 04, 2026	Feb NEWA
	@	KNACK	50MG/5ML (10MG/ML)	A213476	001	Jan 06, 2026	May DISC
	@		100MG/10ML (10MG/ML)	A213476	002	Jan 06, 2026	May DISC

ROFLUMILAST

TABLET;ORAL
ROFLUMILAST

	@	PHARMOBEDIENT	500MCG	A208257	001	Jul 13, 2018	Feb DISC
AB		SENORES PHARMS	250MCG	A208236	002	Oct 19, 2023	Feb CMFD
AB			500MCG	A208236	001	Oct 03, 2018	Feb CMFD

ROMIDEPSINSOLUTION; INTRAVENOUS
ROMIDEPSIN

! AMNEAL 27.5MG/5.5ML (5MG/ML) A219099 001 Jun 02, 2026 May NFTG

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

@	COSETTE PHARMS NC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Jun CAHN
@		EQ 0.5MG BASE	A077460	002	May 05, 2008	Jun CAHN
@		EQ 1MG BASE	A077460	003	May 05, 2008	Jun CAHN
@		EQ 2MG BASE	A077460	004	May 05, 2008	Jun CAHN
@		EQ 3MG BASE	A077460	005	May 05, 2008	Jun CAHN
@		EQ 4MG BASE	A077460	006	May 05, 2008	Jun CAHN
@		EQ 5MG BASE	A077460	007	May 19, 2008	Jun CAHN

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

@	ANVI	EQ 5MG BASE	A079161	001	Jul 19, 2016	Mar CAHN
@		EQ 10MG BASE	A079161	002	Jul 19, 2016	Mar CAHN
@		EQ 20MG BASE	A079161	003	Jul 19, 2016	Mar CAHN
@		EQ 40MG BASE	A079161	004	Jul 19, 2016	Mar CAHN
@	STRIDES PHARMA INTL	EQ 5MG BASE	A079161	001	Jul 19, 2016	Jun CAHN
@		EQ 10MG BASE	A079161	002	Jul 19, 2016	Jun CAHN
@		EQ 20MG BASE	A079161	003	Jul 19, 2016	Jun CAHN
@		EQ 40MG BASE	A079161	004	Jul 19, 2016	Jun CAHN
AB	SUNSHINE	EQ 5MG BASE	A210667	001	Apr 01, 2020	Jun CMFD
AB		EQ 10MG BASE	A210667	002	Apr 01, 2020	Jun CMFD
AB		EQ 20MG BASE	A210667	003	Apr 01, 2020	Jun CMFD
AB		EQ 40MG BASE	A210667	004	Apr 01, 2020	Jun CMFD

RUFINAMIDE

TABLET; ORAL

RUFINAMIDE

AB	ALLIED	200MG	A205095	001	May 16, 2016	Jun CAHN
AB		400MG	A205095	002	May 16, 2016	Jun CAHN
AB	SCIEGEN PHARMS	200MG	A205095	001	May 16, 2016	Jul CAHN
AB		400MG	A205095	002	May 16, 2016	Jul CAHN

>A> RUSFERTIDE ACETATE

>A> POWDER; SUBCUTANEOUS

>A> MIMRYLO

>A>	+!	TAKEDA PHARMS AM	EQ 9.5MG BASE/VIAL	N220605	001	Aug 28, 2026	Aug NEWA
>A>	+!		EQ 19MG BASE/VIAL	N220605	002	Aug 28, 2026	Aug NEWA
>A>	+!		EQ 28MG BASE/VIAL	N220605	003	Aug 28, 2026	Aug NEWA
>A>	+!		EQ 41MG BASE/VIAL	N220605	004	Aug 28, 2026	Aug NEWA
>A>	+!		EQ 54MG BASE/VIAL	N220605	005	Aug 28, 2026	Aug NEWA

RUXOLITINIB PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL

JAKAFI XR

+	INCYTE CORP	EQ 11MG BASE	N217180	001	May 01, 2026	May NEWA
+		EQ 22MG BASE	N217180	002	May 01, 2026	May NEWA
+		EQ 33MG BASE	N217180	003	May 01, 2026	May NEWA
+		EQ 44MG BASE	N217180	004	May 01, 2026	May NEWA
+		EQ 55MG BASE	N217180	005	May 01, 2026	May NEWA

SACUBITRIL; VALSARTAN

TABLET; ORAL

SACUBITRIL AND VALSARTAN

>A>	AB	AUROBINDO PHARMA LTD	24MG;26MG	A213631	001	Sep 02, 2026	Aug NEWA
>A>	AB		49MG;51MG	A213631	002	Sep 02, 2026	Aug NEWA
>A>	AB		97MG;103MG	A213631	003	Sep 02, 2026	Aug NEWA
	AB	SOMERSET THERAPS LLC	24MG;26MG	A219983	001	Jan 20, 2026	Jan NEWA
	AB		49MG;51MG	A219983	002	Jan 20, 2026	Jan NEWA
	AB		97MG;103MG	A219983	003	Jan 20, 2026	Jan NEWA
	AB	UMEDICA	24MG;26MG	A219946	001	Aug 04, 2026	Jul NEWA
	AB		49MG;51MG	A219946	002	Aug 04, 2026	Jul NEWA
	AB		97MG;103MG	A219946	003	Aug 04, 2026	Jul NEWA

SAPROPTERIN DIHYDROCHLORIDE

FOR SOLUTION;ORAL

KUVAN

AB	+	BIOMARIN PHARM	100MG/PACKET	N205065	001	Dec 19, 2013	Jun CDFR
AB	+		500MG/PACKET	N205065	002	Oct 27, 2015	Jun CDFR

SAPROPTERIN DIHYDROCHLORIDE

AB		ANNORA PHARMA	100MG/PACKET	A215420	001	Aug 18, 2022	Jun CDFR
AB			500MG/PACKET	A215420	002	Aug 18, 2022	Jun CDFR
AB		DR REDDYS	100MG/PACKET	A209452	001	Mar 30, 2021	Jun CDFR
AB			500MG/PACKET	A215798	001	May 13, 2022	Jun CDFR
AB		MICRO LABS	100MG/PACKET	A219511	001	Jan 08, 2026	Jun CDFR
AB			500MG/PACKET	A219511	002	Jan 08, 2026	Jun CDFR
AB		PH HEALTH	100MG/PACKET	A207207	001	Aug 20, 2019	Jun CDFR
AB			500MG/PACKET	A210027	001	Aug 20, 2019	Jun CDFR
AB		TP ANDA HOLDINGS	100MG/PACKET	A216432	001	Sep 03, 2025	Jun CDFR
AB			500MG/PACKET	A216432	002	Sep 03, 2025	Jun CDFR

ZELVYSIA

AB		AUCTA	100MG/PACKET	A218645	001	Apr 29, 2025	Jun CDFR
AB			500MG/PACKET	A218645	002	Apr 29, 2025	Jun CDFR

POWDER;ORAL

KUVAN

AB	+	BIOMARIN PHARM	500MG/PACKET	N205065	002	Oct 27, 2015	Jan CHRS
AB		MICRO LABS	100MG/PACKET	A219511	001	Jan 08, 2026	Jan NEWA
AB			500MG/PACKET	A219511	002	Jan 08, 2026	Jan NEWA

TABLET;ORAL

SAPROPTERIN DIHYDROCHLORIDE

AB		HIKMA	100MG	A218797	001	Jun 11, 2025	Jun CAHN
----	--	-------	-------	---------	-----	--------------	----------

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@	COSETTE PHARMS NC	5MG	A074744	001	Jan 27, 1997	Jun CAHN
@		5MG	A074756	001	Nov 25, 1998	Jun CAHN

SELENIOS ACID

SOLUTION;INTRAVENOUS

SELENIOS ACID

@	CIPLA	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A218661	001	Jul 21, 2025	Jan DISC	
@		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218661	002	Jul 21, 2025	Jan DISC	
>A>	AP	EMERGE BIOSCIENCE	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219472	001	Feb 03, 2026	Aug CAHN
>D>	AP	KINDOS	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219472	001	Feb 03, 2026	Aug CAHN
	AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219472	001	Feb 03, 2026	Jan NEWA
	AP	STIRA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218536	001	Dec 31, 2025	Apr CAHN
	AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218536	002	Dec 31, 2025	Apr CAHN
	AP	ZYDUS PHARMS	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A219322	001	Jun 30, 2026	Jun NEWA
	AP		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A219322	002	Jun 30, 2026	Jun NEWA
	AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219322	003	Jun 30, 2026	Jun NEWA

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL

SELENIUM SULFIDE

@	COSETTE PHARMS NC	2.5%	A086209	001		Jun CAHN
---	-------------------	------	---------	-----	--	----------

SELEXIPAG

TABLET;ORAL

SELEXIPAG

AB		RK PHARMA	0.2MG	A214055	001	Apr 16, 2026	Apr NEWA
AB			0.4MG	A214055	002	Apr 16, 2026	Apr NEWA
AB			0.6MG	A214055	003	Apr 16, 2026	Apr NEWA
AB			0.8MG	A214055	004	Apr 16, 2026	Apr NEWA
AB			1MG	A214055	005	Apr 16, 2026	Apr NEWA
AB			1.2MG	A214055	006	Apr 16, 2026	Apr NEWA

TABLET;ORAL							
SELEXIPAG							
AB		1.4MG	A214055	007	Apr 16, 2026	Apr	NEWA
AB		1.6MG	A214055	008	Apr 16, 2026	Apr	NEWA
UPTRAVI							
	+ ACTELION	0.1MG	N207947	010	May 23, 2026	Jun	NEWA
	+	0.15MG	N207947	011	May 23, 2026	Jun	NEWA
AB	+	1MG	N207947	005	Dec 21, 2015	Apr	CTEC
AB	+	1.2MG	N207947	006	Dec 21, 2015	Apr	CTEC
<u>SELUMETINIB SULFATE</u>							
GRANULE;ORAL							
KOSELUGO							
	+! ASTRAZENECA	EQ 5MG BASE	N219943	001	Sep 10, 2025	May	CHRS
	+	EQ 7.5MG BASE	N219943	002	Sep 10, 2025	May	CHRS
<u>SEMAGLUTIDE</u>							
SOLUTION;SUBCUTANEOUS							
OZEMPIC							
	+! NOVO	0.25MG/0.5ML (0.25MG/0.5ML)	N209637	005	May 05, 2026	May	NEWA
	+!	0.5MG/0.5ML (0.5MG/0.5ML)	N209637	006	May 05, 2026	May	NEWA
	+!	1MG/0.5ML (1MG/0.5ML)	N209637	007	May 05, 2026	May	NEWA
WEGOVY							
	+! NOVO	0.25MG/0.5ML (0.25MG/0.5ML)	N215256	007	May 05, 2026	May	NEWA
	+!	0.5MG/0.5ML (0.5MG/0.5ML)	N215256	008	May 05, 2026	May	NEWA
	+!	1MG/0.5ML (1MG/0.5ML)	N215256	009	May 05, 2026	May	NEWA
	+!	1.7MG/0.75ML (1.7MG/0.75ML)	N215256	010	May 05, 2026	May	NEWA
	+!	2.4MG/0.75ML (2.4MG/0.75ML)	N215256	011	May 05, 2026	May	NEWA
WEGOVY FLEXTOUCH							
	+! NOVO	9.6MG/3ML (3.2MG/ML)	N215256	012	Jun 18, 2026	Jun	NEWA
WEGOVY HD							
	+! NOVO	7.2MG/0.75ML (7.2MG/0.75ML)	N215256	006	Mar 19, 2026	Mar	NEWA
TABLET;ORAL							
OZEMPIC							
	+! NOVO	1.5MG	N213051	004	Dec 09, 2024	Mar	CTNA
	+!	4MG	N213051	005	Dec 09, 2024	Mar	CTNA
	+!	9MG	N213051	006	Dec 09, 2024	Mar	CTNA
WEGOVY							
	+! NOVO	1.5MG	N218316	001	Dec 22, 2025	Mar	CHRS
	+!	4MG	N218316	002	Dec 22, 2025	Mar	CHRS
	+!	9MG	N218316	003	Dec 22, 2025	Mar	CHRS
<u>SERTRALINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
SERTRALINE HYDROCHLORIDE							
AB	AMNEAL	EQ 150MG BASE	A219655	001	Jan 28, 2026	Mar	CAHN
AB		EQ 200MG BASE	A219655	002	Jan 28, 2026	Mar	CAHN
AB	APPCO	EQ 150MG BASE	A218712	001	Jan 20, 2026	Jan	NEWA
AB		EQ 200MG BASE	A218712	002	Jan 20, 2026	Jan	NEWA
AB	NOVITIUM PHARMA	EQ 150MG BASE	A219714	001	Jan 20, 2026	Jan	NEWA
AB		EQ 200MG BASE	A219714	002	Jan 20, 2026	Jan	NEWA
AB	SKG PHARMA	EQ 150MG BASE	A219655	001	Jan 28, 2026	Jan	NEWA
AB		EQ 200MG BASE	A219655	002	Jan 28, 2026	Jan	NEWA
AB	UMEDICA	EQ 150MG BASE	A218342	001	Jan 20, 2026	Jan	NEWA
AB		EQ 200MG BASE	A218342	002	Jan 20, 2026	Jan	NEWA
AB	ZYDUS LIFESCIENCES	EQ 150MG BASE	A220275	001	Jan 29, 2026	Jan	NEWA
AB		EQ 200MG BASE	A220275	002	Jan 29, 2026	Jan	NEWA
TABLET;ORAL							
SERTRALINE HYDROCHLORIDE							
	@ APPCO	EQ 25MG BASE	A077713	001	Feb 06, 2007	Jan	CAHN
	@	EQ 50MG BASE	A077713	002	Feb 06, 2007	Jan	CAHN
	@	EQ 100MG BASE	A077713	003	Feb 06, 2007	Jan	CAHN
	! ASCENT PHARMS INC	EQ 75MG BASE	A214790	004	Aug 10, 2026	Jul	NFTG
<u>SEVELAMER CARBONATE</u>							
FOR SUSPENSION;ORAL							
RENVELA							
	@ + GENZYME	800MG/PACKET	N022318	001	Aug 12, 2009	Jun	DISC
	@ +	2.4GM/PACKET	N022318	002	Feb 18, 2009	Jun	DISC
SEVELAMER CARBONATE							
AB	! STRIDES PHARMA INTL	2.4GM/PACKET	A211917	002	Sep 08, 2023	Jun	CHRS

TABLET; ORAL

REVELA

@ + SANOFI

800MG

N022127 001 Oct 19, 2007 Jun DISC

SEVELAMER CARBONATE

AB ! AUROBINDO PHARMA

800MG

A207179 001 Jul 17, 2017 Jun CHRS

>D> AB MICRO LABS

800MG

A215537 001 Feb 07, 2022 Aug DISC

>A> @

800MG

A215537 001 Feb 07, 2022 Aug DISC

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

@ + VIATRIS

EQ 10MG BASE/ML

N203109 001 Aug 30, 2012 Mar DISC

SILDENAFIL CITRATE

AB ! AUROBINDO PHARMA LTD

EQ 10MG BASE/ML

A214773 001 Dec 23, 2022 Mar CHRS

TABLET; ORAL

SILDENAFIL CITRATE

@ TEVA PHARMS

EQ 20MG BASE

A078380 001 Jan 07, 2013 Apr DISC

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

>D> AB MICRO LABS

5MG

A090383 001 Sep 16, 2011 Aug DISC

>A> @

5MG

A090383 001 Sep 16, 2011 Aug DISC

>D> AB

10MG

A090383 002 Sep 16, 2011 Aug DISC

>A> @

10MG

A090383 002 Sep 16, 2011 Aug DISC

>D> AB

20MG

A090383 003 Sep 16, 2011 Aug DISC

>A> @

20MG

A090383 003 Sep 16, 2011 Aug DISC

>D> AB

40MG

A090383 004 Sep 16, 2011 Aug DISC

>A> @

40MG

A090383 004 Sep 16, 2011 Aug DISC

>D> AB

80MG

A090383 005 Sep 16, 2011 Aug DISC

>A> @

80MG

A090383 005 Sep 16, 2011 Aug DISC

SIPONIMOD

TABLET; ORAL

MAYZENT

+ NOVARTIS

EQ 0.25MG BASE

N209884 001 Mar 26, 2019 Mar CTEC

AB

+

EQ 0.25MG BASE

N209884 001 Mar 26, 2019 Feb CTEC

+

EQ 1MG BASE

N209884 003 Aug 24, 2021 Mar CTEC

AB

+

EQ 1MG BASE

N209884 003 Aug 24, 2021 Feb CTEC

+!

EQ 2MG BASE

N209884 002 Mar 26, 2019 Mar CTEC

AB

+!

EQ 2MG BASE

N209884 002 Mar 26, 2019 Feb CTEC

SIPONIMOD

@ AUROBINDO PHARMA LTD

EQ 0.25MG BASE

A218459 001 Mar 06, 2026 Mar DISC

AB

@ EQ 0.25MG BASE

A218459 001 Mar 06, 2026 Feb NEWA

@

EQ 1MG BASE

A218459 002 Mar 06, 2026 Mar DISC

AB

@ EQ 1MG BASE

A218459 002 Mar 06, 2026 Feb NEWA

@

EQ 2MG BASE

A218459 003 Mar 06, 2026 Mar DISC

AB

@ EQ 2MG BASE

A218459 003 Mar 06, 2026 Feb NEWA

SIROLIMUS

POWDER; INTRAVENOUS

FYARRO

+! AADI

100MG/VIAL

N213312 001 Nov 22, 2021 Apr CAHN

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

AB + MSD

EQ 25MG BASE

N021995 001 Oct 16, 2006 May CAHN

AB

+

EQ 50MG BASE

N021995 002 Oct 16, 2006 May CAHN

AB

+!

EQ 100MG BASE

N021995 003 Oct 16, 2006 May CAHN

SITAGLIPTIN PHOSPHATE

AB APOTEX

EQ 25MG BASE

A202425 001 Jan 20, 2026 Jan NEWA

AB

EQ 50MG BASE

A202425 002 Jan 20, 2026 Jan NEWA

AB

EQ 100MG BASE

A202425 003 Jan 20, 2026 Jan NEWA

AB SANDOZ

EQ 25MG BASE

A202387 001 Jan 14, 2026 Jan NEWA

AB

EQ 50MG BASE

A202387 002 Jan 14, 2026 Jan NEWA

AB

EQ 100MG BASE

A202387 003 Jan 14, 2026 Jan NEWA

SODIUM ACETATESOLUTION; INTRAVENOUS
SODIUM ACETATE

AP	AMNEAL	40MEQ/20ML (2MEQ/ML)	A218469	003	Mar 02, 2026	Feb NEWA
>A>	DR REDDYS	100MEQ/50ML (2MEQ/ML)	A220274	001	Apr 17, 2026	Aug CAHN
>A>		200MEQ/100ML (2MEQ/ML)	A220274	002	Apr 17, 2026	Aug CAHN
>D>	EXTROVIS	100MEQ/50ML (2MEQ/ML)	A220274	001	Apr 17, 2026	Aug CAHN
AP		100MEQ/50ML (2MEQ/ML)	A220274	001	Apr 17, 2026	Apr NEWA
>D>		200MEQ/100ML (2MEQ/ML)	A220274	002	Apr 17, 2026	Aug CAHN
AP		200MEQ/100ML (2MEQ/ML)	A220274	002	Apr 17, 2026	Apr NEWA

SODIUM BICARBONATESOLUTION; INTRAVENOUS
SODIUM BICARBONATE

AP	AMNEAL	50MEQ/50ML (1MEQ/ML)	A217523	001	Jan 13, 2026	Jan NEWA
	+	150MEQ/1000ML (0.15MEQ/ML)	N220790	001	Jul 09, 2026	Jul NEWA
AP	ASPIRO	5MEQ/10ML (0.5MEQ/ML)	A220788	001	Apr 15, 2026	Apr NEWA
AP		10MEQ/10ML (1MEQ/ML)	A220788	002	Apr 15, 2026	Apr NEWA
AP		50MEQ/50ML (1MEQ/ML)	A220788	003	Apr 15, 2026	Apr NEWA
>A>	+	BAXTER HLTHCARE CORP 150MEQ/1000ML (0.15MEQ/ML)	N218524	001	Aug 14, 2026	Aug NEWA
AP	MILLA PHARMS	50MEQ/50ML (1MEQ/ML)	A219089	001	Jul 08, 2026	Jun NEWA

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18
@ NUKEMED

10-200mCi/ML

A203912 001 Apr 22, 2015 Apr DISC

SODIUM GLYCEROPHOSPHATESOLUTION; INTRAVENOUS
GLYCOPHOS+! FRESENIUS KABI USA
+!4.32GM/20ML (216MG/ML)
21.6GM/100ML (216MG/ML)N220381 001 Jul 29, 2026 Jul NEWA
N220381 002 Jul 29, 2026 Jul NEWASODIUM NITROPRUSSIDEINJECTABLE; INJECTION
SODIUM NITROPRUSSIDE

AP HAINAN POLY 25MG/ML

A214199 001 Aug 25, 2020 Jul CAHN

SOLUTION; INTRAVENOUS
SODIUM NITROPRUSSIDE

AP	HAINAN POLY	10MG/50ML (0.2MG/ML)	A215846	001	Aug 26, 2022	Jul CAHN
AP		20MG/100ML (0.2MG/ML)	A215846	002	Aug 26, 2022	Jul CAHN
AP		50MG/100ML (0.5MG/ML)	A215846	003	Aug 26, 2022	Jul CAHN

A215846	001	Aug 26, 2022	Jul CAHN
A215846	002	Aug 26, 2022	Jul CAHN
A215846	003	Aug 26, 2022	Jul CAHN

SODIUM OXYBATEFOR SUSPENSION, EXTENDED RELEASE; ORAL
LUMRYZ

>A>	+	ALKERMES INC	4.5GM/PACKET	N214755	001	May 01, 2023	Aug CAHN
>A>	+		6GM/PACKET	N214755	002	May 01, 2023	Aug CAHN
>A>	+		7.5GM/PACKET	N214755	003	May 01, 2023	Aug CAHN
>A>	+		9GM/PACKET	N214755	004	May 01, 2023	Aug CAHN
>D>	+	AVADEL CNS	4.5GM/PACKET	N214755	001	May 01, 2023	Aug CAHN
>D>	+		6GM/PACKET	N214755	002	May 01, 2023	Aug CAHN
>D>	+		7.5GM/PACKET	N214755	003	May 01, 2023	Aug CAHN
>D>	+		9GM/PACKET	N214755	004	May 01, 2023	Aug CAHN

SODIUM PHENYL BUTYRATE

POWDER; ORAL

BUPHENYL

@ + HORIZON THERAP US

3GM/TEASPOONFUL

N020573 001 Apr 30, 1996 Jan DISC

SODIUM PHENYL BUTYRATE

! PH HEALTH

3GM/TEASPOONFUL

A203918 001 Jun 15, 2016 Jun CTEC

AB ! PH HEALTH

3GM/TEASPOONFUL

A203918 001 Jun 15, 2016 Jan CHRS

@ SIGMAPHARM LABS LLC

3GM/TEASPOONFUL

A202819 001 Mar 22, 2013 Jun DISC

TABLET; ORAL

BUPHENYL

@ + HORIZON THERAP US

500MG

N020572 001 May 13, 1996 Jan DISC

SODIUM PHENYL BUTYRATE

AB NAVINTA LLC

500MG

A220418 001 Feb 17, 2026 Feb NEWA

AB ! PH HEALTH

500MG

A204395 001 Apr 15, 2016 Jan CHRS

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATESOLUTION; INTRAVENOUS
SODIUM PHOSPHATES

AP	CAPLIN	1.34GM/5ML; 1.38GM/5ML (268MG/ML; 276MG/ML)	A220683	001	Feb 23, 2026	Feb NEWA
AP		4.02GM/15ML; 4.14GM/15ML (268MG/ML; 276MG/ML)	A220683	002	Feb 23, 2026	Feb NEWA
AP		13.4GM/50ML; 13.8GM/50ML (268MG/ML; 276MG/ML)	A220683	003	Feb 23, 2026	Feb NEWA

SODIUM ZIRCONIUM CYCLOSILICATEFOR SUSPENSION; ORAL
LOKELMA

AB	+ ASTRAZENECA	5GM/PACKET	N207078	001	May 18, 2018	Jul CFTG
AB	+!	10GM/PACKET	N207078	002	May 18, 2018	Jul CFTG
	SODIUM ZIRCONIUM CYCLOSILICATE					
AB	LUPIN	5GM/PACKET	A217549	001	Aug 07, 2026	Jul NFTG
AB		10GM/PACKET	A217549	002	Aug 07, 2026	Jul NFTG

SOFOSBUVIR; VELPATASVIRPELLETS; ORAL
EPCLUSA

	+ GILEAD SCIENCES INC	150MG/PACKET; 37.5MG/PACKET	N214187	001	Jun 10, 2021	Jul CPOT
	+!	200MG/PACKET; 50MG/PACKET	N214187	002	Jun 10, 2021	Jul CPOT

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

AB	SUNSHINE	5MG	A213346	001	Apr 13, 2020	May CMFD
AB		10MG	A213346	002	Apr 13, 2020	May CMFD

SOLRIAMFETOL HYDROCHLORIDE

TABLET; ORAL

SOLRIAMFETOL HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 75MG BASE	A218722	001	Jun 17, 2026	Jun NFTG
AB		EQ 150MG BASE	A218722	002	Jun 17, 2026	Jun NFTG
AB	HIKMA	EQ 75MG BASE	A218016	001	Jun 17, 2026	Jun NFTG
AB		EQ 150MG BASE	A218016	002	Jun 17, 2026	Jun NFTG
	SUNOSI					
AB	+ AXSOME MALTA	EQ 75MG BASE	N211230	001	Jun 17, 2019	Jun CFTG
AB	+!	EQ 150MG BASE	N211230	002	Jun 17, 2019	Jun CFTG

SONROTOCLAX

TABLET; ORAL

BEQALZI

	+ BEONE MEDICINES USA	1MG	N220711	001	May 13, 2026	May NEWA
	+	5MG	N220711	002	May 13, 2026	May NEWA
	+!	20MG	N220711	003	May 13, 2026	Jun CHRS
	+	20MG	N220711	003	May 13, 2026	May NEWA
	+	80MG	N220711	004	May 13, 2026	Jun CHRS
	+!	80MG	N220711	004	May 13, 2026	May NEWA

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

AB	+ LEGACY	80MG	N019865	001	Oct 30, 1992	Jun CAHN
AB	+	120MG	N019865	005	Apr 20, 1994	Jun CAHN
AB	+!	160MG	N019865	002	Oct 30, 1992	Jun CAHN
AB	+	240MG	N019865	003	Oct 30, 1992	Jun CAHN
	@	320MG	N019865	004	Oct 30, 1992	Jun CAHN
	BETAPACE AF					
	@ LEGACY	40MG	N021151	006	Apr 02, 2003	Jul CAHN
	@	60MG	N021151	007	Apr 02, 2003	Jul CAHN
AB	+	80MG	N021151	001	Feb 22, 2000	Jul CAHN
	@	100MG	N021151	005	Mar 14, 2003	Jul CAHN
AB	+	120MG	N021151	002	Feb 22, 2000	Jul CAHN
AB	+!	160MG	N021151	003	Feb 22, 2000	Jul CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

	@	AMNEAL	20MG/ML	A211432	001	Nov 16, 2018	Jul	DISC
AP		J MOLNER	20MG/ML	A210231	001	Jun 04, 2018	Jun	CAHN
>A>	AP	NIVAGEN	20MG/ML	A211625	001	May 19, 2020	Aug	CAHN
>D>	AP	NIVAGEN PHARMS INC	20MG/ML	A211625	001	May 19, 2020	Aug	CAHN
	AP		20MG/ML	A211625	001	May 19, 2020	Apr	CAHN

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

AP	!	FRESENIUS KABI USA	100MG/5ML (20MG/ML)	A217884	001	Feb 11, 2025	Mar	CHRS
	@ +	HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Mar	DISC

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

	@ +	ABBVIE	1GM/10ML	N019183	001	Dec 16, 1993	Jun	DISC
		SUCRALFATE						
AB		CHARTWELL RX	1GM/10ML	A211780	001	Apr 14, 2025	Jun	CAHN
AB		COSETTE PHARMS NC	1GM/10ML	A217126	001	Nov 13, 2024	May	CAHN
AB	!	VISTAPHARM LLC	1GM/10ML	A211884	001	Mar 15, 2022	Jun	CHRS

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

	@	HIKMA	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Mar	DISC
--	---	-------	-------------------	---------	-----	--------------	-----	------

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

AP	+!	MSD SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jul	CHRS
		SUGAMMADEX SODIUM						
AP		DR REDDYS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214236	001	Jul 28, 2026	Jul	NEWA
AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214236	002	Jul 28, 2026	Jul	NEWA
AP		FRESENIUS KABI USA	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A219448	001	Jul 28, 2026	Jul	NEWA
AP		GLAND	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214364	001	Jul 28, 2026	Jul	NEWA
AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214364	002	Jul 28, 2026	Jul	NEWA
AP		HIKMA	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A218727	001	Jul 28, 2026	Jul	NEWA
AP			EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A218728	001	Jul 28, 2026	Jul	NEWA
AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A218728	002	Jul 28, 2026	Jul	NEWA
AP		LUPIN	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214338	001	Jul 28, 2026	Jul	NEWA
AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214338	002	Jul 28, 2026	Jul	NEWA
AP		MANKIND PHARMA	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214230	001	Jul 28, 2026	Jul	NEWA
AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214230	002	Jul 28, 2026	Jul	NEWA
AP		MSN	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214368	001	Jul 28, 2026	Jul	NEWA
AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214368	002	Jul 28, 2026	Jul	NEWA
AP		MYLAN	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A213915	001	Jul 28, 2026	Jul	NEWA
AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A213915	002	Jul 28, 2026	Jul	NEWA
AP		QILU PHARM HAINAN	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A215575	001	Jul 28, 2026	Jul	NEWA
AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A215575	002	Jul 28, 2026	Jul	NEWA
AP		SANDOZ	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214311	001	Jul 28, 2026	Jul	NEWA
AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214311	002	Jul 28, 2026	Jul	NEWA
AP		STERISCIENCE	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A218814	001	Jul 28, 2026	Jul	NEWA
AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A218814	002	Jul 28, 2026	Jul	NEWA

SOLUTION;INTRAVENOUS
SUGAMMADEX SODIUM

		BASE/ML)							
AP	SUN PHARM INDS INC	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214319	001	Jul 28, 2026	Jul	NEWA		
AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214319	002	Jul 28, 2026	Jul	NEWA		
AP	TAMARANG	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A215260	001	Jul 28, 2026	Jul	NEWA		
AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A215260	002	Jul 28, 2026	Jul	NEWA		
AP	TEVA PHARMS USA INC	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214126	001	Jul 28, 2026	Jul	NEWA		
AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214126	002	Jul 28, 2026	Jul	NEWA		
AP	ZENARA	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214306	001	Jul 28, 2026	Jul	NEWA		
AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214306	002	Jul 28, 2026	Jul	NEWA		
AP	ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290	001	Oct 04, 2023	May	CMFD		
AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290	002	Oct 04, 2023	May	CMFD		

SULCONAZOLE NITRATE

SOLUTION;TOPICAL
EXELDERM

@ +	JOURNEY	1%	N018738	001	Aug 30, 1985	Jul	DISC		
-----	---------	----	---------	-----	--------------	-----	------	--	--

SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC
SULFACETAMIDE SODIUM

@	PADAGIS US	10%	A080029	001		Mar	DISC		
---	------------	-----	---------	-----	--	-----	------	--	--

SOLUTION/DROPS;OPHTHALMIC
SULFACETAMIDE SODIUM

AT	! BAUSCH AND LOMB	10%	A040066	001	Dec 28, 1994	May	CAHN		
----	-------------------	-----	---------	-----	--------------	-----	------	--	--

SULFANILAMIDE

CREAM;VAGINAL
SULFANILAMIDE

@	COSETTE PHARMS NC	15%	A088718	001	Sep 19, 1985	Jun	CAHN		
---	-------------------	-----	---------	-----	--------------	-----	------	--	--

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

>D>	@ NORVIUM BIOSCIENCE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014	Aug	CAHN		
	@ ONESOURCE SPECIALTY	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Jun	DISC		
AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb	CMFD		
>A>	@ PHARMOBEDIENT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014	Aug	CAHN		
AB	SUMATRIPTAN SUCCINATE (AUTOINJECTOR) ONESOURCE SPECIALTY	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	002	Jan 30, 2026	Jun	NEWA		

POWDER;NASAL
ONZETRA XSAIL
+! AZURITY

EQ 11MG BASE	N206099	001	Jan 27, 2016	Jul	CAHN		
--------------	---------	-----	--------------	-----	------	--	--

SUNVOZERTINIB

TABLET;ORAL
ZEGFROVY

+ DIZAL	150MG	N219839	001	Jul 02, 2025	Jul	CAHN		
+!	200MG	N219839	002	Jul 02, 2025	Jul	CAHN		

TADALAFIL

TABLET;ORAL
TADALAFIL

AB1	JUBILANT GENERICS	2.5MG	A210329	001	May 15, 2026	May	NEWA		
AB1		5MG	A210329	002	May 15, 2026	May	NEWA		
AB1		10MG	A210329	003	May 15, 2026	May	NEWA		
AB1		20MG	A210329	004	May 15, 2026	May	NEWA		
>A>	AB2	20MG	A210592	001	Aug 17, 2026	Aug	NEWA		
>D>	@ NORVIUM BIOSCIENCE	5MG	A206957	001	Apr 29, 2019	Aug	CAHN		

TABLET;ORAL									
TADALAFIL									
>A>	@	PHARMOBEDIENT	5MG	A206957	001	Apr 29, 2019	Aug CAHN		
	!	TORRENT	40MG	A212062	002	May 20, 2026	May NFTG		
<u>TAFAMIDIS MEGLUMINE</u>									
CAPSULE;ORAL									
VYNDAQEL									
	@ +	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	Jan DISC		
<u>TAMSULOSIN HYDROCHLORIDE</u>									
CAPSULE;ORAL									
TAMSULOSIN HYDROCHLORIDE									
	@	SANDOZ	0.4MG	A078015	001	Apr 27, 2010	Jun DISC		
<u>TAPENTADOL HYDROCHLORIDE</u>									
SOLUTION;ORAL									
TAPENTADOL HYDROCHLORIDE									
		NOVITIUM PHARMA	EQ 20MG BASE/ML	A219119	001	Jan 26, 2026	Jan NFTG		
TABLET;ORAL									
NUCYNTA									
AB	+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	Jan CFTG		
AB	+		EQ 75MG BASE	N022304	002	Nov 20, 2008	Jan CFTG		
AB	+	!	EQ 100MG BASE	N022304	003	Nov 20, 2008	Jan CFTG		
TAPENTADOL HYDROCHLORIDE									
AB		EPIC PHARMA LLC	EQ 50MG BASE	A214378	001	Jan 27, 2026	May CAHN		
AB			EQ 75MG BASE	A214378	002	Jan 27, 2026	May CAHN		
AB			EQ 100MG BASE	A214378	003	Jan 27, 2026	May CAHN		
	@	HIKMA	EQ 50MG BASE	A205057	001	Feb 10, 2026	May DISC		
AB			EQ 50MG BASE	A205057	001	Feb 10, 2026	Jan NEWA		
	@		EQ 75MG BASE	A205057	002	Feb 10, 2026	May DISC		
AB			EQ 75MG BASE	A205057	002	Feb 10, 2026	Jan NEWA		
	@		EQ 100MG BASE	A205057	003	Feb 10, 2026	May DISC		
AB			EQ 100MG BASE	A205057	003	Feb 10, 2026	Jan NEWA		
AB		HUMANWELL	EQ 50MG BASE	A214378	001	Jan 27, 2026	Jan NFTG		
AB			EQ 75MG BASE	A214378	002	Jan 27, 2026	Jan NFTG		
AB			EQ 100MG BASE	A214378	003	Jan 27, 2026	Jan NFTG		
>A>	AB	MSN	EQ 50MG BASE	A220865	001	Sep 03, 2026	Aug NEWA		
>A>	AB		EQ 75MG BASE	A220865	002	Sep 03, 2026	Aug NEWA		
>A>	AB		EQ 100MG BASE	A220865	003	Sep 03, 2026	Aug NEWA		
<u>TAVABOROLE</u>									
SOLUTION;TOPICAL									
TAVABOROLE									
	@	CIPLA	5%	A212224	001	Feb 09, 2021	Jan DISC		
	@	LUPIN	5%	A212168	001	Feb 08, 2021	Feb DISC		
	@	PADAGIS US	5%	A211848	001	Oct 13, 2020	Mar DISC		
<u>TAZAROTENE</u>									
CREAM;TOPICAL									
TAZAROTENE									
AB		COSETTE PHARMS NC	0.05%	A208662	002	Mar 10, 2025	May CAHN		
AB			0.1%	A208662	001	Dec 22, 2017	May CAHN		
AB		SOLARIS PHARMA CORP	0.05%	A214560	001	Nov 24, 2025	Jan CAHN		
GEL;TOPICAL									
TAZAROTENE									
AB		COSETTE PHARMS NC	0.05%	A215433	001	Sep 13, 2022	May CAHN		
AB			0.1%	A214136	001	Sep 13, 2022	May CAHN		
<u>TAZEMETOSTAT HYDROBROMIDE</u>									
TABLET;ORAL									
TAZVERIK									
	@ +	EPIZYME INC	EQ 200MG BASE	N211723	001	Jan 23, 2020	May DISC		
<u>TEBIPENEM PIVOXIL HYDROBROMIDE</u>									
TABLET;ORAL									
UTEBZI									
	+	GLAXOSMITHKLINE	EQ 300MG BASE	N215960	001	Jun 17, 2026	Jun NEWA		

TECHNETIUM TC-99M BICISATE KITINJECTABLE; INJECTION
NEUROLITE

+	!	SHINE	N/A	N020256	001	Nov 23, 1994	Feb CAHN
---	---	-------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M SESTAMIBI KITINJECTABLE; INJECTION
CARDIOLITE

AP	+	!	SHINE	N/A	N019785	001	Dec 21, 1990	Feb CAHN
----	---	---	-------	-----	---------	-----	--------------	----------

MIRALUMA

@		SHINE	N/A	N019785	003	May 23, 1997	Feb CAHN
---	--	-------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION; INTRAVENOUS
TECHNELITE

+	!	SHINE	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014	Feb CAHN
---	---	-------	-------------------	---------	-----	--------------	----------

@			0.0083-2.7 CI/GENERATOR	N017771	001		Feb CAHN
---	--	--	-------------------------	---------	-----	--	----------

TELAVANCIN HYDROCHLORIDEPOWDER; INTRAVENOUS
VIBATIV

@	+	APOTEX	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	Jul CAHN
---	---	--------	--------------------	---------	-----	--------------	----------

+	!		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	Jul CAHN
---	---	--	--------------------	---------	-----	--------------	----------

TELMISARTANTABLET; ORAL
MICARDIS

@	+	BOEHRINGER INGELHEIM	40MG	N020850	001	Nov 10, 1998	Jul DISC
---	---	----------------------	------	---------	-----	--------------	----------

TELMISARTAN

>D>	AB		MICRO LABS	20MG	A207016	001	Oct 03, 2017	Aug DISC
-----	----	--	------------	------	---------	-----	--------------	----------

>A>		@		20MG	A207016	001	Oct 03, 2017	Aug DISC
-----	--	---	--	------	---------	-----	--------------	----------

>D>	AB			40MG	A207016	002	Oct 03, 2017	Aug DISC
-----	----	--	--	------	---------	-----	--------------	----------

>A>		@		40MG	A207016	002	Oct 03, 2017	Aug DISC
-----	--	---	--	------	---------	-----	--------------	----------

>D>	AB			80MG	A207016	003	Oct 03, 2017	Aug DISC
-----	----	--	--	------	---------	-----	--------------	----------

>A>		@		80MG	A207016	003	Oct 03, 2017	Aug DISC
-----	--	---	--	------	---------	-----	--------------	----------

TEMAZEPAMCAPSULE; ORAL
TEMAZEPAM

AB		AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	Jan CMFD
----	--	---------------	-------	---------	-----	--------------	----------

AB			15MG	A203482	002	May 23, 2016	Jan CMFD
----	--	--	------	---------	-----	--------------	----------

AB			22.5MG	A203482	003	May 23, 2016	Jan CMFD
----	--	--	--------	---------	-----	--------------	----------

AB			30MG	A203482	004	May 23, 2016	Jan CMFD
----	--	--	------	---------	-----	--------------	----------

TEMOZOLOMIDECAPSULE; ORAL
TEMOZOLOMIDE

>A>		@	NIVAGEN	5MG	A213328	001	Nov 23, 2021	Aug CAHN
-----	--	---	---------	-----	---------	-----	--------------	----------

>A>		@		20MG	A213328	002	Nov 23, 2021	Aug CAHN
-----	--	---	--	------	---------	-----	--------------	----------

>A>		@		100MG	A213328	003	Nov 23, 2021	Aug CAHN
-----	--	---	--	-------	---------	-----	--------------	----------

>A>		@		140MG	A213328	004	Nov 23, 2021	Aug CAHN
-----	--	---	--	-------	---------	-----	--------------	----------

>A>		@		180MG	A213328	005	Nov 23, 2021	Aug CAHN
-----	--	---	--	-------	---------	-----	--------------	----------

>A>		@		250MG	A213328	006	Nov 23, 2021	Aug CAHN
-----	--	---	--	-------	---------	-----	--------------	----------

>D>		@	NIVAGEN PHARMS INC	5MG	A213328	001	Nov 23, 2021	Aug CAHN
-----	--	---	--------------------	-----	---------	-----	--------------	----------

>D>		@		20MG	A213328	002	Nov 23, 2021	Aug CAHN
-----	--	---	--	------	---------	-----	--------------	----------

>D>		@		100MG	A213328	003	Nov 23, 2021	Aug CAHN
-----	--	---	--	-------	---------	-----	--------------	----------

>D>		@		140MG	A213328	004	Nov 23, 2021	Aug CAHN
-----	--	---	--	-------	---------	-----	--------------	----------

>D>		@		180MG	A213328	005	Nov 23, 2021	Aug CAHN
-----	--	---	--	-------	---------	-----	--------------	----------

>D>		@		250MG	A213328	006	Nov 23, 2021	Aug CAHN
-----	--	---	--	-------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDECAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

AB		SENORES PHARMS	EQ 1MG BASE	A074823	001	Mar 30, 1998	Feb CAHN
----	--	----------------	-------------	---------	-----	--------------	----------

AB			EQ 2MG BASE	A074823	002	Mar 30, 1998	Feb CAHN
----	--	--	-------------	---------	-----	--------------	----------

AB			EQ 5MG BASE	A074823	003	Mar 30, 1998	Feb CAHN
----	--	--	-------------	---------	-----	--------------	----------

AB			EQ 10MG BASE	A074823	004	Mar 30, 1998	Feb CAHN
----	--	--	--------------	---------	-----	--------------	----------

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

AB	CIPLA	EQ 250MG BASE	A077137	001	Jul 02, 2007	May CMFD
@	INVAGEN PHARMS	EQ 250MG BASE	A077533	001	Jul 02, 2007	Jun DISC

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

>A> BX	+!	FOUGERA	0.8%	N021735	001	Oct 01, 2004	Aug CAHN
>D> BX	+!	FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004	Aug CAHN

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

AB	CONCORD BIOTECH LTD	7MG	A218663	001	Apr 07, 2025	Feb CMFD
AB		14MG	A218663	002	Apr 07, 2025	Feb CMFD

TESTOSTERONE

SOLUTION, METERED; TRANSDERMAL

TESTOSTERONE

AT	ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jun CMFD
----	--------	----------------------	---------	-----	--------------	----------

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

>A> AO	BPI LABS	200MG/ML	A219478	001	Sep 03, 2026	Aug NEWA
@	CAPLIN ONE LABS	100MG/ML	A040615	001	Aug 10, 2006	Mar DISC
AO		100MG/ML	A040615	001	Aug 10, 2006	Jan CAHN
@		200MG/ML	A040615	002	Aug 10, 2006	Mar DISC
AO		200MG/ML	A040615	002	Aug 10, 2006	Jan CAHN

TESTOSTERONE UNDECANOATE

CAPSULE; ORAL

KYZATREX

>A>	+	MARIUS	50MG	N213953	004	Aug 25, 2026	Aug NEWA
-----	---	--------	------	---------	-----	--------------	----------

THALIDOMIDE

CAPSULE; ORAL

THALIDOMIDE

AB	NATCO	50MG	A213267	002	Apr 24, 2026	Apr NFTG
AB		100MG	A213267	003	Apr 24, 2026	Apr NFTG
AB		200MG	A213267	004	Apr 24, 2026	Apr NFTG

THALOMID

AB	+	BRISTOL-MYERS	50MG	N020785	001	Jul 16, 1998	Apr CFTG
AB	+		100MG	N020785	002	Jan 17, 2003	Apr CFTG
AB	+!		200MG	N020785	003	Jan 17, 2003	Apr CFTG

THEOPHYLLINE

SOLUTION, ELIXIR; ORAL

ELIXOPHYLLIN

@ + SOLIS PHARMS

THEOPHYLLINE

! PHARM ASSOC

80MG/15ML

80MG/15ML

80MG/15ML

A085186 001 Jan DISC

A206344 001 Dec 16, 2016 Jan CHRS

A206344 001 Dec 16, 2016 Jan CTEC

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP	MANKIND PHARMA	100MG/ML	A220513	001	Jul 31, 2026	Jul NEWA
----	----------------	----------	---------	-----	--------------	----------

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

@ HENGRUI PHARMA

POWDER; INTRAVENOUS

TEPADINA AND SODIUM CHLORIDE

+! ADIENNE SA

400MG

A209150 001 May 04, 2018 Apr DISC

N208264 004 Jan 15, 2026 Jan NEWA

TICAGRELOR

TABLET; ORAL

TICAGRELOR

	@	AMNEAL	60MG	A208531	002	Oct 28, 2025	Mar	DISC
>A>	AB	LAURUS	60MG	A218869	001	Aug 20, 2026	Aug	NEWA
>A>	AB		90MG	A218869	002	Aug 20, 2026	Aug	NEWA
	AB	MANKIND PHARMA	60MG	A217679	001	Feb 06, 2026	Jan	NEWA
	AB		90MG	A217679	002	Feb 06, 2026	Jan	NEWA
	AB	MICRO LABS	60MG	A208539	001	Apr 27, 2026	Apr	NEWA
	AB		90MG	A208539	002	Apr 27, 2026	Apr	NEWA
	AB	ZHEJIANG JINGXIN	60MG	A219006	001	Mar 24, 2026	Mar	NEWA
	AB		90MG	A219006	002	Mar 24, 2026	Mar	NEWA

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

@ +	FRESENIUS KABI USA	50MG/VIAL	N205645	001	Dec 01, 2016	Mar	DISC
-----	--------------------	-----------	---------	-----	--------------	-----	------

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

>A>	AT1	ABBVIE	EQ 0.25% BASE	A074746	001	Mar 25, 1997	Aug	CAHN
>A>	AT1		EQ 0.5% BASE	A074747	001	Mar 25, 1997	Aug	CAHN
	AT3	J MOLNER	EQ 0.25% BASE	A212592	001	Dec 13, 2021	Jun	CAHN
	AT3		EQ 0.5% BASE	A212592	002	Dec 13, 2021	Jun	CAHN
>D>	AT1	PACIFIC PHARMA	EQ 0.25% BASE	A074746	001	Mar 25, 1997	Aug	CAHN
>D>	AT1		EQ 0.5% BASE	A074747	001	Mar 25, 1997	Aug	CAHN

TABLET; ORAL

TIMOLOL MALEATE

@	MYLAN	5MG	A072668	002	Jun 08, 1990	Mar	DISC
@		20MG	A072668	001	Jun 08, 1990	Mar	DISC
	RISING	5MG	A207556	001	May 02, 2019	Mar	CTEC
!		20MG	A207556	003	May 02, 2019	Mar	CHRS
		20MG	A207556	003	May 02, 2019	Mar	CTEC

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

AB	UNIQUE	250MG	A202489	001	Oct 09, 2013	Mar	CAHN
AB		500MG	A202489	002	Oct 09, 2013	Mar	CAHN

TIOPRONIN

TABLET; ORAL

TIOCYSTIN

+	CASPER PHARMA LLC	100MG	N212927	001	Jun 02, 2026	Jun	NEWA
+	!	200MG	N212927	002	Jun 02, 2026	Jun	NEWA

TABLET, DELAYED RELEASE; ORAL

TIOPRONIN

@	AMNEAL	100MG	A216278	002	Aug 29, 2025	Mar	DISC
@		300MG	A216278	001	Aug 15, 2023	Mar	DISC

TIRZEPATIDE

SOLUTION; SUBCUTANEOUS

MOUNJARO

+	!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N215866	013	Jan 07, 2026	Jan	NEWA
+	!		20MG/2.4ML (8.33MG/ML)	N215866	014	Jan 07, 2026	Jan	NEWA
+	!		30MG/2.4ML (12.5MG/ML)	N215866	015	Jan 07, 2026	Jan	NEWA
+	!		40MG/2.4ML (16.7MG/ML)	N215866	016	Jan 07, 2026	Jan	NEWA
+	!		50MG/2.4ML (20.8MG/ML)	N215866	017	Jan 07, 2026	Jan	NEWA
+	!		60MG/2.4ML (25MG/ML)	N215866	018	Jan 07, 2026	Jan	NEWA

MOUNJARO KWIKPEN

+	!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N215866	019	Jan 20, 2026	Jan	NEWA
+	!		20MG/2.4ML (8.33MG/ML)	N215866	020	Jan 20, 2026	Jan	NEWA
+	!		30MG/2.4ML (12.5MG/ML)	N215866	021	Jan 20, 2026	Jan	NEWA
+	!		40MG/2.4ML (16.7MG/ML)	N215866	022	Jan 20, 2026	Jan	NEWA
+	!		50MG/2.4ML (20.8MG/ML)	N215866	023	Jan 20, 2026	Jan	NEWA
+	!		60MG/2.4ML (25MG/ML)	N215866	024	Jan 20, 2026	Jan	NEWA

ZEPBOUND

+	!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N217806	013	Jan 07, 2026	Jan	NEWA
+	!		20MG/2.4ML (8.33MG/ML)	N217806	014	Jan 07, 2026	Jan	NEWA
+	!		30MG/2.4ML (12.5MG/ML)	N217806	015	Jan 07, 2026	Jan	NEWA

SOLUTION;SUBCUTANEOUS

ZEPBOUND

+	40MG/2.4ML (16.7MG/ML)	N217806	016	Jan 07, 2026	Jan NEWA
+	50MG/2.4ML (20.8MG/ML)	N217806	017	Jan 07, 2026	Jan NEWA
+	60MG/2.4ML (25MG/ML)	N217806	018	Jan 07, 2026	Jan NEWA

ZEPBOUND KWIKPEN

+	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N217806	019	Jan 20, 2026	Jan NEWA
+		20MG/2.4ML (8.33MG/ML)	N217806	020	Jan 20, 2026	Jan NEWA
+		30MG/2.4ML (12.5MG/ML)	N217806	021	Jan 20, 2026	Jan NEWA
+		40MG/2.4ML (16.7MG/ML)	N217806	022	Jan 20, 2026	Jan NEWA
+		50MG/2.4ML (20.8MG/ML)	N217806	023	Jan 20, 2026	Jan NEWA
+		60MG/2.4ML (25MG/ML)	N217806	024	Jan 20, 2026	Jan NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB	INGENUS PHARMS LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb CAHN
AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb CAHN
AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb CAHN
AB	SENORES PHARMS	EQ 4MG BASE	A213365	001	May 13, 2024	Jan CAHN
AB		EQ 6MG BASE	A213365	002	May 13, 2024	Jan CAHN

ZANAFLEX

AB	+	LEGACY	EQ 2MG BASE	N021447	001	Aug 29, 2002	Jun CAHN
AB	+		EQ 4MG BASE	N021447	002	Aug 29, 2002	Jun CAHN
AB	+		EQ 6MG BASE	N021447	003	Aug 29, 2002	Jun CAHN
AB	+	LEGACY PHARMA USA	EQ 4MG BASE	N021447	002	Aug 29, 2002	Mar CHRS
AB	+		EQ 6MG BASE	N021447	003	Aug 29, 2002	Mar CHRS

TABLET;ORAL

ZANAFLEX

	@	+	LEGACY	EQ 2MG BASE	N020397	002	Feb 04, 2000	Jun CAHN
AB		+		EQ 4MG BASE	N020397	001	Nov 27, 1996	Jun CAHN

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

@	TEVA PHARMS USA	300MG/4ML	A210915	001	Jun 26, 2019	Jul DISC
---	-----------------	-----------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	BAUSCH AND LOMB INC	0.3%	A064052	001	Nov 29, 1993	May CAHN
----	---------------------	------	---------	-----	--------------	----------

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

>D>	AP	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Aug DISC
>A>	@		EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Aug DISC
	AP	EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023	Apr CMFD
	AP	HAINAN POLY	EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Jul CAHN

TOFACITINIB CITRATE

SOLUTION;ORAL

TOFACITINIB CITRATE

>D>	AA	AUSON	EQ 1MG BASE/ML	A219370	001	Jun 09, 2026	Aug CAHN
	AA		EQ 1MG BASE/ML	A219370	001	Jun 09, 2026	May NEWA
	AA	HIKMA	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	May CMFD
	AA	MSN	EQ 1MG BASE/ML	A217298	001	Jun 03, 2026	May NEWA
>A>	AA	PHARMACO	EQ 1MG BASE/ML	A219370	001	Jun 09, 2026	Aug CAHN
	AA	SAPTALIS PHARMS	EQ 1MG BASE/ML	A218900	001	Jun 09, 2026	May NEWA
	AA	SUN PHARM INDS INC	EQ 1MG BASE/ML	A218407	001	Jun 03, 2026	May NEWA

XELJANZ

AA	+	PFIZER	EQ 1MG BASE/ML	N213082	001	Sep 25, 2020	May CTEC
----	---	--------	----------------	---------	-----	--------------	----------

TABLET;ORAL

TOFACITINIB CITRATE

AB	AJANTA PHARMA LTD	EQ 10MG BASE	A212943	001	Jun 01, 2021	Apr CMFD
AB	APOTEX	EQ 5MG BASE	A218096	001	Jun 03, 2026	May NEWA
AB		EQ 10MG BASE	A218096	002	Jun 03, 2026	May NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A215356	001	Jun 03, 2026	May NEWA
AB		EQ 10MG BASE	A215356	002	Jun 03, 2026	May NEWA
AB	BRECKENRIDGE	EQ 5MG BASE	A209633	001	Jun 03, 2026	May NEWA
AB		EQ 10MG BASE	A209633	002	Jun 03, 2026	May NEWA
AB	CONCORD BIOTECH LTD	EQ 5MG BASE	A218821	001	Jun 09, 2026	May NEWA
AB		EQ 10MG BASE	A218821	002	Jun 09, 2026	May NEWA
AB	MACLEODS PHARMS	EQ 5MG BASE	A219530	001	Jun 03, 2026	May NEWA

TABLET;ORAL

TOFACITINIB CITRATE

AB		EQ 10MG BASE	A219530	002	Jun 03, 2026	May NEWA
AB	MICRO LABS	EQ 5MG BASE	A209738	001	Mar 13, 2023	Apr CMFD
AB		EQ 10MG BASE	A209738	002	Jun 03, 2026	May NEWA
AB	MSN	EQ 5MG BASE	A217299	001	Jun 03, 2026	May NEWA
AB		EQ 10MG BASE	A217299	002	Jun 03, 2026	May NEWA
AB	SOMERSET THERAPS LLC	EQ 5MG BASE	A220137	001	Jun 03, 2026	May NEWA
AB		EQ 10MG BASE	A220137	002	Jun 03, 2026	May NEWA
AB	SPECGX LLC	EQ 5MG BASE	A219395	001	Jun 03, 2026	May NEWA
AB		EQ 10MG BASE	A219395	002	Jun 03, 2026	May NEWA
AB	YAOPHARMA CO LTD	EQ 5MG BASE	A215552	001	Jun 09, 2026	May NEWA
AB		EQ 10MG BASE	A215552	002	Jun 09, 2026	May NEWA
AB	ZYDUS PHARMS	EQ 5MG BASE	A209829	001	Mar 13, 2023	Apr CMFD
AB		EQ 10MG BASE	A209829	002	Jun 05, 2026	May NEWA

XELJANZ

AB	+ PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	Apr CTEC
AB	+	EQ 10MG BASE	N203214	002	May 30, 2018	Apr CTEC

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB CITRATE

AB	AJANTA PHARMA LTD	EQ 11MG BASE	A219542	001	Aug 19, 2025	Apr CMFD
	@	EQ 11MG BASE	A219542	001	Aug 19, 2025	Jan DISC
AB	APOTEX	EQ 11MG BASE	A220458	001	Jun 03, 2026	May NEWA
AB	AUROBINDO PHARMA LTD	EQ 11MG BASE	A218462	001	Jun 03, 2024	Apr CMFD
AB	DEXCEL	EQ 11MG BASE	A218668	001	Dec 16, 2024	Apr CMFD
AB	ORIENT PHARMA	EQ 11MG BASE	A219830	001	Jun 09, 2026	May NEWA
AB	SCIEGEN PHARMS	EQ 11MG BASE	A220972	001	Jun 25, 2026	Jun NEWA
>A> AB	TEVA PHARMS USA	EQ 11MG BASE	A209813	001	Aug 17, 2026	Aug NEWA
>A> AB		EQ 22MG BASE	A209813	002	Aug 17, 2026	Aug NEWA
AB	ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Apr CMFD
AB		EQ 22MG BASE	A214264	002	Aug 19, 2021	Apr CHRS
AB	!	EQ 22MG BASE	A214264	002	Aug 19, 2021	Apr CMFD
	XELJANZ XR					
AB	+! PFIZER	EQ 22MG BASE	N208246	002	Dec 12, 2019	Apr CTEC

>D> TOLCAPONE

>D> TABLET;ORAL

>D> TASMAR

>D>	+! BAUSCH	100MG	N020697	001	Jan 29, 1998	Aug DISC
>A>	@ +	100MG	N020697	001	Jan 29, 1998	Aug DISC
	+!	100MG	N020697	001	Jan 29, 1998	Mar CTEC

TOLCAPONE

	@ INGENUS PHARMS LLC	100MG	A208937	001	Aug 07, 2018	Mar DISC
AB		100MG	A208937	001	Aug 07, 2018	Feb CAHN

TOLMETIN SODIUM

TABLET;ORAL

TOLMETIN SODIUM

	@ COSETTE PHARMS NC	EQ 600MG BASE	A074399	001	Mar 28, 1996	Jun CAHN
	@	EQ 600MG BASE	A074729	001	Feb 27, 1997	Jun CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

>D>	DETROL LA					
>D> AB	+ UPJOHN	2MG	N021228	001	Dec 22, 2000	Aug DISC
>A>	@ +	2MG	N021228	001	Dec 22, 2000	Aug DISC
>D> AB	+!	4MG	N021228	002	Dec 22, 2000	Aug DISC
>A>	@ +	4MG	N021228	002	Dec 22, 2000	Aug DISC
	TOLTERODINE TARTRATE					
>D> AB	TORRENT	4MG	A203016	002	Aug 11, 2015	Aug CHRS
>A> AB	!	4MG	A203016	002	Aug 11, 2015	Aug CHRS

TABLET;ORAL

TOLTERODINE TARTRATE

AB	UNIQUE	1MG	A204721	001	Jan 24, 2020	Mar CAHN
AB		2MG	A204721	002	Jan 24, 2020	Mar CAHN

TOLVAPTAN

TABLET;ORAL

JYNARQUE

>D> AB	+! OTSUKA	45MG	N204441	003	Apr 23, 2018	Aug CTEC
>A> AB2	+!	45MG	N204441	003	Apr 23, 2018	Aug CTEC
>D> AB	+	90MG	N204441	005	Apr 23, 2018	Aug CTEC

TABLET;ORAL							
JYNARQUE							
>A>	AB2	+	90MG	N204441	005	Apr 23, 2018	Aug CTEC
		TOLVAPTAN					
	AB2	ALKEM LABS LTD	15MG	A220147	001	Apr 21, 2026	Apr NEWA
	AB2		30MG	A220147	002	Apr 21, 2026	Apr NEWA
>D>	AB		45MG	A220147	003	Apr 21, 2026	Aug CTEC
>A>	AB2		45MG	A220147	003	Apr 21, 2026	Aug CTEC
	AB		45MG	A220147	003	Apr 21, 2026	Apr NEWA
	AB2		60MG	A220147	004	Apr 21, 2026	Apr NEWA
>D>	AB		90MG	A220147	005	Apr 21, 2026	Aug CTEC
>A>	AB2		90MG	A220147	005	Apr 21, 2026	Aug CTEC
	AB		90MG	A220147	005	Apr 21, 2026	Apr NEWA
>D>	AB	APOTEX	45MG	A218381	003	Nov 10, 2025	Aug CTEC
>A>	AB2		45MG	A218381	003	Nov 10, 2025	Aug CTEC
>D>	AB		90MG	A218381	005	Nov 10, 2025	Aug CTEC
>A>	AB2		90MG	A218381	005	Nov 10, 2025	Aug CTEC
>D>	AB	LUPIN	45MG	A216063	003	Apr 23, 2025	Aug CTEC
>A>	AB2		45MG	A216063	003	Apr 23, 2025	Aug CTEC
>D>	AB		90MG	A216063	005	Apr 23, 2025	Aug CTEC
>A>	AB2		90MG	A216063	005	Apr 23, 2025	Aug CTEC
	AB2	TEVA PHARMS INC	15MG	A216933	001	Jul 21, 2026	Jul NEWA
	AB2		30MG	A216933	002	Jul 21, 2026	Jul NEWA
>D>	AB		45MG	A216933	003	Jul 21, 2026	Aug CTEC
>A>	AB2		45MG	A216933	003	Jul 21, 2026	Aug CTEC
	AB		45MG	A216933	003	Jul 21, 2026	Jul NEWA
	AB2		60MG	A216933	004	Jul 21, 2026	Jul NEWA
>D>	AB		90MG	A216933	005	Jul 21, 2026	Aug CTEC
>A>	AB2		90MG	A216933	005	Jul 21, 2026	Aug CTEC
	AB		90MG	A216933	005	Jul 21, 2026	Jul NEWA
<u>TOPIRAMATE</u>							
CAPSULE;ORAL							
TOPIRAMATE							
	AB	SENORES PHARMS	15MG	A218642	001	Oct 10, 2024	Jan CAHN
	AB		25MG	A218642	002	Oct 10, 2024	Jan CAHN
	AB	STRIDES PHARMA	50MG	A078418	003	Feb 02, 2026	Jan NEWA
CAPSULE, EXTENDED RELEASE;ORAL							
TOPIRAMATE							
	AB1	ASCENT PHARMS INC	25MG	A217443	001	Jan 12, 2026	Jan NEWA
	AB1		50MG	A217443	002	Jan 12, 2026	Jan NEWA
	AB1		100MG	A217443	003	Jan 12, 2026	Jan NEWA
	AB1		200MG	A217443	004	Jan 12, 2026	Jan NEWA
	AB1	BIOCON PHARMA	25MG	A220943	001	Jul 22, 2026	Jul NEWA
	AB1		50MG	A220943	002	Jul 22, 2026	Jul NEWA
	AB1		100MG	A220943	003	Jul 22, 2026	Jul NEWA
	AB1		200MG	A220943	004	Jul 22, 2026	Jul NEWA
>A>	AB1	MICRO LABS	25MG	A219183	001	Sep 04, 2026	Aug NEWA
>A>	AB1		50MG	A219183	002	Sep 04, 2026	Aug NEWA
>A>	AB1		100MG	A219183	003	Sep 04, 2026	Aug NEWA
>A>	AB1		200MG	A219183	004	Sep 04, 2026	Aug NEWA
	@	RICONPHARMA LLC	25MG	A220041	001	May 26, 2026	Jun DISC
	AB2		25MG	A220041	001	May 26, 2026	May NEWA
	@		50MG	A220041	002	May 26, 2026	Jun DISC
	AB2		50MG	A220041	002	May 26, 2026	May NEWA
	@		100MG	A220041	003	May 26, 2026	Jun DISC
	AB2		100MG	A220041	003	May 26, 2026	May NEWA
	@		150MG	A220041	004	May 26, 2026	Jun DISC
	AB2		150MG	A220041	004	May 26, 2026	May NEWA
	@		200MG	A220041	005	May 26, 2026	Jun DISC
	AB2		200MG	A220041	005	May 26, 2026	May NEWA
TABLET;ORAL							
TOPIRAMATE							
	@	SENORES PHARMS	25MG	A090353	001	Sep 01, 2010	Jan CAHN
	@		50MG	A090353	002	Sep 01, 2010	Jan CAHN
	@		100MG	A090353	003	Sep 01, 2010	Jan CAHN
	@		200MG	A090353	004	Sep 01, 2010	Jan CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION							
TOPOTECAN HYDROCHLORIDE							
AP	INGENUS PHARMS LLC	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Feb	CAHN
SOLUTION; INTRAVENOUS							
TOPOTECAN HYDROCHLORIDE							
@	NATCO PHARMA USA	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar	CAHN

TORSEMIDE

TABLET; ORAL							
TORSEMIDE							
AB	MICRO LABS	5MG	A217239	001	May 01, 2026	Apr	NEWA
AB		10MG	A217239	002	May 01, 2026	Apr	NEWA
AB		20MG	A217239	003	May 01, 2026	Apr	NEWA
@	STRIDES PHARMA INTL	5MG	A076226	001	May 27, 2003	Jun	DISC
@		5MG	A090613	001	Mar 22, 2011	Jun	DISC
@		10MG	A076226	002	May 27, 2003	Jun	DISC
@		10MG	A090613	002	Mar 22, 2011	Jun	DISC
@		20MG	A076226	003	May 27, 2003	Jun	DISC
@		20MG	A090613	003	Mar 22, 2011	Jun	DISC
@		100MG	A076226	004	May 27, 2003	Jun	DISC
@		100MG	A090613	004	Mar 22, 2011	Jun	DISC

TRABECTEDIN

SOLUTION; INTRAVENOUS							
EVDI							
+	APOTEX	1MG/20ML (0.05MG/ML)	N220837	001	May 01, 2026	May	NEWA

TRAMADOL HYDROCHLORIDE

SOLUTION; ORAL							
QDOLO							
@ +	ROSEMOUNT	5MG/ML	N214044	001	Sep 01, 2020	Mar	CAHN
TRAMADOL HYDROCHLORIDE							
!	NOVITIUM PHARMA	5MG/ML	A219647	001	Jun 26, 2026	Jun	NFTG
TABLET; ORAL							
TRAMADOL HYDROCHLORIDE							
AB	GRAVITI PHARMS	25MG	A075968	003	Jul 28, 2026	Jul	NEWA
AB	RUBICON	25MG	A208708	003	Nov 27, 2023	Mar	CTEC
AB	RUBICON RESEARCH	25MG	A208708	003	Nov 27, 2023	May	CAHN
AB		50MG	A208708	001	Jun 28, 2019	May	CAHN
		75MG	A208708	004	Apr 04, 2024	May	CAHN
AB	!	100MG	A208708	002	Jun 28, 2019	May	CAHN
AB	STRIDES PHARMA	25MG	A202075	002	Mar 23, 2026	Mar	NEWA

TRANDOLAPRIL

TABLET; ORAL							
TRANDOLAPRIL							
@	SENORES PHARMS	1MG	A078493	001	Aug 25, 2008	Jan	CAHN
@		2MG	A078493	002	Aug 25, 2008	Jan	CAHN
@		4MG	A078493	003	Aug 25, 2008	Jan	CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION							
TRANEXAMIC ACID							
>A>	AP	PHARMOBEDIENT	100MG/ML	A201580	001	Jun 14, 2013	Aug CAHN
>D>	AP	XGEN PHARMS	100MG/ML	A201580	001	Jun 14, 2013	Aug CAHN
TABLET; ORAL							
LYSTEDA							
AB	+	J MOLNER	650MG	N022430	001	Nov 13, 2009	Jun CAHN
TRANEXAMIC ACID							
	@	BIONPHARMA	650MG	A219123	001	Aug 19, 2025	May DISC
AB		I 3 PHARMS	650MG	A219702	001	Jan 26, 2026	Jan NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL								
TRAZODONE HYDROCHLORIDE								
>A>	!	OXFORD PHARMS	25MG	A072193	002	Sep 01, 2026	Aug	NFTG
>A>	!		75MG	A072193	003	Sep 01, 2026	Aug	NFTG

TRETINOIN

CREAM;TOPICAL

RETIN-A

AB1	+	!	BAUSCH	0.05%	N017522	001		Jun	CAHN
AB	+	!		0.1%	N017340	001		Jun	CAHN

TRETINOIN

AB1			ALEMBIC	0.05%	A214590	001	Jun 11, 2026	Jun	NEWA
AB1			ENCUBE	0.05%	A217832	001	Mar 25, 2026	Mar	NEWA
AB				0.1%	A217833	001	Feb 10, 2026	Jan	NEWA

GEL;TOPICAL

RETIN-A-MICRO

AB	+	!	BAUSCH	0.06%	N020475	004	Oct 23, 2017	Apr	CFTG
AB			AMNEAL	0.08%	A217497	001	May 14, 2026	May	NEWA
AB			TRETINOIN MICROSPHERE						
AB			ENCUBE	0.06%	A215609	002	Apr 15, 2026	Apr	NFTG

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT			COSETTE PHARMS NC	0.025%	A089797	001	May 31, 1991	May	CAHN
AT				0.1%	A089798	001	May 31, 1991	May	CAHN
>D>	@	+	NORVIUM BIOSCIENCE	0.025%	N011601	003		Aug	CAHN
>D>	@	+		0.1%	N011601	006		Aug	CAHN
>A>	@	+	PHARMOBEDIENT	0.025%	N011601	003		Aug	CAHN
>A>	@	+		0.1%	N011601	006		Aug	CAHN

INJECTABLE;INJECTION

KENALOG-10

AB	+		APOTHECON	10MG/ML	N012041	001		May	CHRS
AB	+	!		10MG/ML	N012041	001		Jan	CHRS

TRIAMCINOLONE ACETONIDE

	@		CAPLIN	10MG/ML	A090166	001	May 27, 2009	Jan	CAHN
AB	!		DR REDDYS	10MG/ML	A218773	001	Mar 12, 2025	May	CHRS

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT			COSETTE PHARMS NC	0.1%	A089129	001	Aug 14, 1986	May	CAHN
	@		ENCUBE	0.1%	A204606	001	Jul 07, 2016	May	CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT			COSETTE PHARMS NC	0.025%	A089795	001	Dec 23, 1988	May	CAHN
AT				0.1%	A089796	001	Dec 23, 1988	May	CAHN
	@			0.5%	A208925	001	Oct 06, 2017	Jun	CAHN
	@		ENCUBE	0.5%	A208590	001	Mar 03, 2017	May	CAHN

PASTE;DENTAL

TRIAMCINOLONE ACETONIDE

AT			COSETTE PHARMS NC	0.1%	A205592	001	Jan 12, 2017	May	CAHN
----	--	--	-------------------	------	---------	-----	--------------	-----	------

TRIAZOLAM

TABLET;ORAL

TRIAZOLAM

	@		BRECKENRIDGE	0.125MG	A216890	001	Nov 08, 2022	Feb	DISC
	@			0.25MG	A216890	002	Nov 08, 2022	Feb	DISC
AB			INGENUS PHARMS LLC	0.125MG	A214219	001	Oct 20, 2020	Feb	CAHN
AB				0.25MG	A214219	002	Oct 20, 2020	Feb	CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

@			PH HEALTH	250MG	A210096	001	Sep 25, 2019	Jun	DISC
!			RISING	500MG	A212238	002	Sep 22, 2023	Jan	CHRS
@			WATSON LABS TEVA	250MG	A207567	001	Feb 07, 2018	May	DISC

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET;ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

@			POM PHARMA	EQ 1MG BASE	A040153	001	Oct 25, 1996	Apr	CAHN
@				EQ 2MG BASE	A040153	002	Oct 25, 1996	Apr	CAHN
@				EQ 5MG BASE	A040153	003	Oct 25, 1996	Apr	CAHN
@				EQ 10MG BASE	A040153	004	Oct 25, 1996	Apr	CAHN

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM;VAGINAL

GYNE-SULF

@ COSETTE PHARMS NC 3.7%;2.86%;3.42%

A088607 001 Jun 09, 1986 Jun CAHN

VAGILIA

@ COSETTE PHARMS NC 3.7%;2.86%;3.42%

A088821 001 Nov 09, 1987 Jun CAHN

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

TROPICAMIDE

AT BAUSCH AND LOMB 1%

A040064 001 Jul 27, 1994 May CAHN

TROSPIMUM CHLORIDE

TABLET;ORAL

TROSPIMUM CHLORIDE

AB ZAMEER PHARMS 20MG

A215781 001 Feb 16, 2022 Jan CAHN

URSODIOL

CAPSULE;ORAL

URSODIOL

>D> AB ALLIED 300MG

A214329 001 Jul 28, 2021 Aug CAHN

AB 300MG

A214329 001 Jul 28, 2021 Jul CAHN

LGM PHARMA 200MG

A205789 001 May 08, 2020 Jun CHRS

400MG

A205789 002 May 08, 2020 Jun CHRS

>A> AB SENORES PHARMS 300MG

A214329 001 Jul 28, 2021 Aug CAHN

STRIDES PHARMA 150MG

A210344 002 Jan 16, 2026 Jan NFTG

VADADUSTAT

TABLET;ORAL

VAFSEO

>D> +! AKEBIA 450MG

N215192 003 Mar 27, 2024 Aug DISC

>A> @ + 450MG

N215192 003 Mar 27, 2024 Aug DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB ! HETERO LABS LTD V EQ 1GM BASE

A203047 002 Apr 08, 2015 Feb CHRS

VALTREX

AB + GLAXOSMITHKLINE EQ 1GM BASE

N020487 002 Jun 23, 1995 Feb CHRS

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB MICRO LABS 50MG/ML

A218838 001 Mar 19, 2026 Mar NEWA

TABLET;ORAL

VALCYTE

>D> AB +! CHEPLAPHARM EQ 450MG BASE

N021304 001 Mar 29, 2001 Aug DISC

>A> @ + EQ 450MG BASE

N021304 001 Mar 29, 2001 Aug DISC

VALGANCICLOVIR HYDROCHLORIDE

>D> AB HETERO LABS LTD V EQ 450MG BASE

A205166 001 Mar 18, 2016 Aug CHRS

>A> AB ! EQ 450MG BASE

A205166 001 Mar 18, 2016 Aug CHRS

VALSARTAN

SOLUTION;ORAL

PREXXARTAN

AB + CARMEL BIOSCIENCES 4MG/ML

N209139 001 Dec 19, 2017 Jul CMFD

VALSARTAN

AB RUBICON RESEARCH 4MG/ML

A216460 001 Jun 05, 2025 May CAHN

TABLET;ORAL

VALSARTAN

AB BOSTAL DRUG 40MG

A205357 001 Aug 11, 2026 Jul NEWA

AB 80MG

A205357 002 Aug 11, 2026 Jul NEWA

AB 160MG

A205357 003 Aug 11, 2026 Jul NEWA

AB 320MG

A205357 004 Aug 11, 2026 Jul NEWA

AB LAURUS 40MG

A218897 001 Apr 21, 2026 Apr NEWA

AB 80MG

A218897 002 Apr 21, 2026 Apr NEWA

AB 160MG

A218897 003 Apr 21, 2026 Apr NEWA

AB 320MG

A218897 004 Apr 21, 2026 Apr NEWA

@ LUPIN 40MG

A201677 001 Jan 05, 2015 May DISC

@ 80MG

A201677 002 Jan 05, 2015 May DISC

@ 160MG

A201677 003 Jan 05, 2015 May DISC

TABLET;ORAL
VALSARTAN

@		320MG	A201677	004	Jan 05, 2015	May DISC
@	RENATA	40MG	A218169	001	Aug 05, 2024	Feb CAHN
@		80MG	A218169	002	Aug 05, 2024	Feb CAHN
@		160MG	A218169	003	Aug 05, 2024	Feb CAHN
@		320MG	A218169	004	Aug 05, 2024	Feb CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

@	LUPIN	EQ 125MG BASE	A090439	001	Jan 28, 2015	May DISC
@		EQ 250MG BASE	A090439	002	Jan 28, 2015	May DISC
AB	PAI HOLDINGS	EQ 125MG BASE	A065478	001	Apr 09, 2012	Mar CMFD
AB		EQ 250MG BASE	A065478	002	Apr 09, 2012	Mar CMFD

FOR SOLUTION;ORAL

FIRVANQ KIT

AA	+! AZURITY	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Apr CTEC
AA	+!	EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Apr CTEC

VANCOMYCIN HYDROCHLORIDE

AA	ALKEM LABS LTD	EQ 25MG BASE/ML	A214913	001	Nov 14, 2022	Apr CTEC
AA		EQ 50MG BASE/ML	A214913	002	Nov 14, 2022	Apr CTEC
AA	AUROBINDO PHARMA	EQ 25MG BASE/ML	A218130	001	Aug 07, 2026	Jul NEWA
AA		EQ 50MG BASE/ML	A218130	002	Aug 07, 2026	Jul NEWA

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	EUROFARMA	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb CAHN
AP	HAINAN POLY	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Jul CAHN
AP		EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Jul CAHN
AP		EQ 5GM BASE/VIAL	A215821	001	Nov 18, 2021	Jul CAHN
AP		EQ 10GM BASE/VIAL	A215821	002	Nov 18, 2021	Jul CAHN

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

!	SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016	Jan CHRS
		EQ 100GM BASE	A091532	001	Jan 06, 2016	Jan CTNA

VARENICLINE TARTRATE

TABLET;ORAL

VARENICLINE TARTRATE

>A>	AB	ADAPTIS	EQ 0.5MG BASE	A216615	001	Apr 08, 2025	Aug CAHN
>A>	AB		EQ 1MG BASE	A216615	002	Apr 08, 2025	Aug CAHN
	@	PHARMOBEDIENT	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	May DISC
>D>	AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	Aug DISC
>A>	@		EQ 1MG BASE	A202019	002	Feb 28, 2024	Aug DISC
	AB	PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Jan CMFD
	AB		EQ 1MG BASE	A217115	002	Jul 23, 2024	Jan CMFD
>D>	AB	SHILPA	EQ 0.5MG BASE	A216615	001	Apr 08, 2025	Aug CAHN
>D>	AB		EQ 1MG BASE	A216615	002	Apr 08, 2025	Aug CAHN
	AB	SOMERSET THERAPS LLC	EQ 0.5MG BASE	A219382	001	Jul 06, 2026	Jun NEWA
	AB		EQ 1MG BASE	A219382	002	Jul 06, 2026	Jun NEWA
	AB	UMEDICA	EQ 0.5MG BASE	A218985	001	Jan 09, 2026	Jan NEWA
	AB		EQ 1MG BASE	A218985	002	Jan 09, 2026	Jan NEWA

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOPRESSIN

@	EAGLE PHARMS	20UNITS/ML (20UNITS/ML)	A211538	001	Dec 15, 2021	Mar DISC
AP	SANDOZ	20UNITS/ML (20UNITS/ML)	A212068	001	May 06, 2026	Apr NEWA
AP		200UNITS/10ML (20UNITS/ML)	A212069	001	May 06, 2026	Apr NFTG
		VASOPRESSIN IN DEXTROSE 5%				
AP	DR REDDYS	40UNITS/100ML (0.4UNITS/ML)	A213988	002	Jun 03, 2026	May NEWA
		VASOSTRICT				
AP	+! PH HEALTH	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Apr CFTG

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDE

AP	!	EUGIA PHARMA	10MG/VIAL	A206670	001	Dec 20, 2018	May CHRS
AP	!		20MG/VIAL	A206670	002	Dec 20, 2018	May CHRS
AP		SUN PHARM	10MG/VIAL	A079001	001	Jun 17, 2009	May CHRS
	@		20MG/VIAL	A079001	002	Jun 17, 2009	May DISC

VENETOCLAX

TABLET; ORAL

VENCLEXTA

AB	+	ABBVIE	10MG	N208573	001	Apr 11, 2016	May CFTG
AB	+		50MG	N208573	002	Apr 11, 2016	May CFTG
AB	+	!	100MG	N208573	003	Apr 11, 2016	May CFTG

VENETOCLAX

AB		DR REDDYS	10MG	A214733	001	May 15, 2026	May NFTG
AB			50MG	A214733	002	May 15, 2026	May NFTG
AB			100MG	A214733	003	May 15, 2026	May NFTG

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB		INVENTIA	EQ 37.5MG BASE	A203332	001	Mar 12, 2020	Jul CAHN
AB			EQ 75MG BASE	A203332	002	Mar 12, 2020	Jul CAHN
			EQ 100MG BASE	A203332	004	Jul 14, 2026	Jul CAHN
AB			EQ 150MG BASE	A203332	003	Mar 12, 2020	Jul CAHN
		INVENTIA HLTHCARE	EQ 100MG BASE	A203332	004	Jul 14, 2026	Jul NFTG
AB		PLATINUM	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Apr CAHN
AB			EQ 75MG BASE	A201272	002	Nov 23, 2018	Apr CAHN
AB			EQ 150MG BASE	A201272	003	Nov 23, 2018	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

@	ADAPTIS	EQ 75MG BASE	A213927	001	Jan 21, 2021	Mar DISC
@	PHARMADAX	EQ 75MG BASE	A214423	001	Jan 04, 2022	Mar CAHN
@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Mar CAHN

VEPDEGESTRANT

TABLET; ORAL

VEPPANU

	+	ARVINAS OPERATIONS	100MG	N219835	001	May 01, 2026	May NEWA
	+	!	200MG	N219835	002	May 01, 2026	May NEWA
	+	RIGEL PHARMS	100MG	N219835	001	May 01, 2026	Jun CAHN
	+	!	200MG	N219835	002	May 01, 2026	Jun CAHN

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

AP		KNACK	2.5MG/ML	A220076	001	Jul 22, 2026	Jul NEWA
----	--	-------	----------	---------	-----	--------------	----------

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

@	AMNEAL	5MG/2ML (2.5MG/ML)	A210994	001	Jul 13, 2018	Mar DISC
@		10MG/4ML (2.5MG/ML)	A210994	002	Jul 13, 2018	Mar DISC
@	HOSPIRA	5MG/2ML (2.5MG/ML)	A075136	001	Oct 20, 1998	Jun DISC
@		10MG/4ML (2.5MG/ML)	A075136	001	Oct 20, 1998	Jun CPOT

VIGABATRIN

FOR SOLUTION; ORAL

VIGABATRIN

>A>	@	ADAPTIS	500MG/PACKET	A214992	001	May 13, 2021	Aug CAHN
>D>	@	DEXCEL	500MG/PACKET	A214992	001	May 13, 2021	Aug CAHN
	@	TEVA PHARMS USA	500MG/PACKET	A209824	001	Apr 23, 2018	Jan DISC

VIGADRONE

AA		BORA	500MG/PACKET	A210196	001	Jun 21, 2018	Jul CAHN
----	--	------	--------------	---------	-----	--------------	----------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

@	INGENUS PHARMS LLC	EQ 10MG BASE/ML	A208997	001	Aug 05, 2019	May CAHN
---	--------------------	-----------------	---------	-----	--------------	----------

VORICONAZOLE

POWDER; INTRAVENOUS

VORICONAZOLE

AP		HAINAN POLY	200MG/VIAL	A211661	001	Nov 30, 2018	Jul CAHN
AP		ZHEJIANG NOVUS	200MG/VIAL	A220078	001	May 05, 2026	Apr NEWA

XENON XE-133

GAS; INHALATION

XENON XE 133

SHINE

10mCi/VIAL

N017284 001

Feb CAHN

20mCi/VIAL

N017284 002

Feb CAHN

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+! ESTEVE

100MCG/1ML (100MCG/ML)

N021060 002 Dec 28, 2004

Apr CAHN

@

200MCG/2ML (100MCG/ML)

N021060 003 Dec 28, 2004

Apr CAHN

+!

500MCG/20ML (25MCG/ML)

N021060 001 Dec 28, 2004

Apr CAHN

+!

500MCG/5ML (100MCG/ML)

N021060 004 Dec 28, 2004

Apr CAHN

ZIDESAMTINIB

TABLET; ORAL

JIDEYTRO

+ NUVALENT

25MG

N220185 001 Jul 22, 2026

Jul NEWA

+!

100MG

N220185 002 Jul 22, 2026

Jul NEWA

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE

AP STIRA

EQ 1MG ZINC/ML

A217625 001 Apr 14, 2025

Apr CAHN

ZINC SULFATE

SOLUTION; INTRAVENOUS

ZINC SULFATE

>A> AP NIVAGEN

EQ 10MG BASE/10ML (EQ 1MG
BASE/ML)

A214597 001 Jul 05, 2024

Aug CAHN

>A> AP

EQ 25MG BASE/5ML (EQ 5MG
BASE/ML)

A214597 002 Jul 05, 2024

Aug CAHN

>A> AP

EQ 30MG BASE/10ML (EQ 3MG
BASE/ML)

A214597 003 Jul 05, 2024

Aug CAHN

>D> AP NIVAGEN PHARMS INC

EQ 10MG BASE/10ML (EQ 1MG
BASE/ML)

A214597 001 Jul 05, 2024

Aug CAHN

>D> AP

EQ 25MG BASE/5ML (EQ 5MG
BASE/ML)

A214597 002 Jul 05, 2024

Aug CAHN

>D> AP

EQ 30MG BASE/10ML (EQ 3MG
BASE/ML)

A214597 003 Jul 05, 2024

Aug CAHN

AP STIRA

EQ 10MG BASE/10ML (EQ 1MG
BASE/ML)

A217624 001 Jun 10, 2025

Apr CAHN

AP

EQ 25MG BASE/5ML (EQ 5MG
BASE/ML)

A217624 002 Jun 10, 2025

Apr CAHN

AP

EQ 30MG BASE/10ML (EQ 3MG
BASE/ML)

A217624 003 Jun 10, 2025

Apr CAHN

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

ZOLEDRONIC ACID

>A> @ ADAPTIS

EQ 4MG BASE/5ML

A208513 001 May 15, 2019

Aug CAHN

AP GLAND

EQ 4MG BASE/100ML

A219984 001 Feb 05, 2026

Jan NEWA

@ HOSPIRA INC

EQ 5MG BASE/100ML

A202837 001 Apr 05, 2013

Jan DISC

@ INGENUS PHARMS LLC

EQ 4MG BASE/5ML

A208968 001 Feb 19, 2020

Jun CAHN

>D> @ SHILPA

EQ 4MG BASE/5ML

A208513 001 May 15, 2019

Aug CAHN

ZOLPIDEM TARTRATE

CAPSULE; ORAL

ZOLPIDEM TARTRATE

AB +! ALMATICA

7.5MG

N215721 001 May 09, 2023

May CFTG

AB UMEDICA LABS PVT

7.5MG

A220717 001 May 12, 2026

May NFTG

TABLET; ORAL

ZOLPIDEM TARTRATE

@ SENORES PHARMS

5MG

A077985 001 Apr 23, 2007

Jan CAHN

@

10MG

A077985 002 Apr 23, 2007

Jan CAHN

@ TEVA

5MG

A076410 001 Apr 23, 2007

May DISC

@

10MG

A076410 002 Apr 23, 2007

May DISC

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB BRECKENRIDGE

6.25MG

A213592 001 Jun 04, 2020

Jan CMFD

AB

12.5MG

A213592 002 Jun 04, 2020

Jan CMFD

ACETAMINOPHENSUPPOSITORY;RECTAL
ACEPHEN

@	COSETTE PHARMS NC	120MG	A 072218	001	Mar 27, 1992	May CAHN
@		325MG	A 072344	001	Mar 27, 1992	May CAHN
@		650MG	A 072237	001	Mar 27, 1992	May CAHN

ACETAMINOPHEN; NAPROXEN SODIUM

TABLET;ORAL

TYLENOL WITH NAPROXEN

+	!	KENVUE BRANDS	325MG;110MG	N 219962	001	Jul 24, 2026	Jul NEWA
---	---	---------------	-------------	----------	-----	--------------	----------

ADAPALENE

GEL;TOPICAL

ADAPALENE

		UNIQUE	0.1%	A 219565	001	Jun 30, 2026	Jun NEWA
--	--	--------	------	----------	-----	--------------	----------

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

DIFFERIN EPIDUO

+	!	GALDERMA LABS LP	0.1%;2.5%	N 220736	001	May 22, 2026	May NEWA
---	---	------------------	-----------	----------	-----	--------------	----------

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

AVAGARD

+	!	SOLVENTUM	61%;1%	N 021074	001	Jun 07, 2001	Apr CAHN
---	---	-----------	--------	----------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

@		AMNEAL	0.2055MG/SPRAY	A 216576	001	Jun 05, 2024	Feb DISC
---	--	--------	----------------	----------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

		ONESOURCE	10MG	A 205291	001	Jul 21, 2017	Jul CAHN
--	--	-----------	------	----------	-----	--------------	----------

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@		AMNEAL PHARMS NY	5MG	A 078780	001	Jan 21, 2010	Mar DISC
---	--	------------------	-----	----------	-----	--------------	----------

@			10MG	A 078780	004	Jan 21, 2010	Mar DISC
---	--	--	------	----------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@		AMNEAL PHARMS NY	5MG	A 078780	003	Jan 21, 2010	Mar DISC
---	--	------------------	-----	----------	-----	--------------	----------

@			10MG	A 078780	002	Jan 21, 2010	Mar DISC
---	--	--	------	----------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

DYNA-HEX 2

+	!	XTTRIUM	2%	N 019422	001	Dec 17, 1985	Feb CTNA
---	---	---------	----	----------	-----	--------------	----------

DYNA-HEX 4

		XTTRIUM	4%	N 019125	001	Dec 24, 1984	Feb CTNA
--	--	---------	----	----------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

SOLUPREP S

+	!	SOLVENTUM	2%;70%	N 208288	001	Aug 08, 2018	Apr CAHN
---	---	-----------	--------	----------	-----	--------------	----------

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

!		ENCUBE	1%	A 074165	001	Jul 16, 1993	May CAHN
---	--	--------	----	----------	-----	--------------	----------

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

MUCINEX DM

+		RECKITT BENCKISER	30MG;600MG	N 021620	002	Apr 29, 2004	Jun CAHN
---	--	-------------------	------------	----------	-----	--------------	----------

+	!		60MG;1.2GM	N 021620	001	Apr 29, 2004	Jun CAHN
---	---	--	------------	----------	-----	--------------	----------

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM

TABLET, EXTENDED RELEASE;ORAL

MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM

+! RECKITT BENCKISER 30MG;600MG;110MG

N217338 001 Dec 22, 2025 Jun CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

+! RECKITT BENCKISER EQ 30MG HYDROBROMIDE/5ML

N018658 001 Oct 08, 1982 Jun CAHN

DEXTROMETHORPHAN POLISTIREX

AUROBINDO PHARMA LTD EQ 30MG HYDROBROMIDE/5ML

A218417 001 Apr 15, 2026 Apr NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

ONESOURCE 25MG;EQ 200MG FREE ACID AND
POTASSIUM SALT

A200888 001 Mar 05, 2012 Jul CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

@ AMNEAL PHARMS CO 25MG;220MG

A209726 001 Oct 23, 2018 Mar DISC

DOCOSANOL

CREAM;TOPICAL

DOCOSANOL

KLM LABS PVT 10%

A220017 001 Jul 31, 2026 Jul NEWA

ESOMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

@ MYLAN EQ 20MG BASE

A212088 001 Jun 25, 2020 Jun DISC

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

@ TEVA 30MG

A076447 004 Apr 13, 2011 Mar DISC

TIME CAP LABS 30MG

A079112 002 Feb 08, 2012 Mar CAHN

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

@ TEVA 30MG

A076447 005 Apr 13, 2011 Mar DISC

TIME CAP LABS 30MG

A079112 001 Feb 08, 2012 Mar CAHN

FEXOFENADINE HYDROCHLORIDE

DR REDDYS 60MG

A220413 001 Jul 30, 2026 Jul NEWA

180MG

A220413 002 Jul 30, 2026 Jul NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

@ RISING 60MG

A077081 006 Jul 21, 2011 Mar DISC

@ 180MG

A077081 008 Jul 21, 2011 Mar DISC

@ TEVA 60MG

A076447 006 Apr 13, 2011 Mar DISC

@ 180MG

A076447 008 Apr 13, 2011 Mar DISC

TIME CAP LABS 60MG

A079112 004 Feb 08, 2012 Mar CAHN

180MG

A079112 006 Feb 08, 2012 Mar CAHN

FEXOFENADINE HYDROCHLORIDE HIVES

@ RISING 60MG

A077081 007 Jul 21, 2011 Mar DISC

@ 180MG

A077081 009 Jul 21, 2011 Mar DISC

@ TEVA 60MG

A076447 007 Apr 13, 2011 Mar DISC

TIME CAP LABS 60MG

A079112 003 Feb 08, 2012 Mar CAHN

180MG

A079112 005 Feb 08, 2012 Mar CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 180MG;240MG

A215232 001 Apr 17, 2025 Feb CMFD

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

GLENMARK PHARMS LTD 0.05MG/SPRAY

A218742 001 Mar 16, 2026 Mar NEWA

GLENMARK SPECLT 0.05MG/SPRAY

A218742 001 Mar 16, 2026 Apr CAHN

RUBICON RESEARCH 0.05MG/SPRAY

A219060 001 Aug 15, 2025 May CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL
MUCINEX

+	RECKITT BENCKISER	600MG	N021282	001	Jul 12, 2002	Jun CAHN
+	!	1.2GM	N021282	002	Dec 18, 2002	Jun CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
MUCINEX D

+	RECKITT BENCKISER	600MG;60MG	N021585	001	Jun 22, 2004	Jun CAHN
+	!	1.2GM;120MG	N021585	002	Jun 22, 2004	Jun CAHN

IBUPROFEN

CAPSULE;ORAL
IBUPROFEN

ONESOURCE	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018	Jul CAHN
-----------	--	---------	-----	--------------	----------

SUSPENSION;ORAL
IBUPROFEN

RUBICON RESEARCH	100MG/5ML	A220239	001	Mar 05, 2026	Feb NEWA		
MOTRIN IB							
+	!	KENVUE BRANDS	200MG/10ML	N020516	002	Jul 22, 2026	Jul NEWA

TABLET;ORAL
IBUPROFEN

@	ALLIED	200MG	A071870	001	May 05, 1988	Jul CAHN
@	AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Apr DISC
@	AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987	Mar DISC
@	PH HEALTH	200MG	A071229	001	Apr 01, 1987	May DISC

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL
IBUPROHM COLD AND SINUS

@	OHM LABS	200MG;30MG	A074567	001	Apr 17, 2001	Jul DISC
---	----------	------------	---------	-----	--------------	----------

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE;TOPICAL
DURAPREP

+	!	SOLVENTUM	EQ 0.7% IODINE;74% (6ML)	N021586	001	Sep 29, 2006	Apr CAHN
+	!		EQ 0.7% IODINE;74% (26ML)	N021586	002	Sep 29, 2006	Apr CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC
KETOTIFEN FUMARATE

@	APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006	Apr DISC
---	------------	----------------	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE
ONESOURCE

2MG	A213070	001	Aug 11, 2021	Jul CAHN
-----	---------	-----	--------------	----------

LORATADINE

CAPSULE;ORAL
LORATADINE

@	ONESOURCE	10MG	A211926	001	Jan 15, 2020	Jul CAHN
---	-----------	------	---------	-----	--------------	----------

TABLET;ORAL
LORATADINE

>A>		ADAPTIS	10MG	A207569	001	Mar 12, 2019	Aug CAHN
	@	ALLIED	10MG	A075790	001	Nov 07, 2008	Jul CAHN
>D>		ANDA REPOSITORY	10MG	A207569	001	Mar 12, 2019	Aug CAHN
>A>		GUARDIAN DRUG	10MG	A207569	001	Mar 12, 2019	Aug CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
LORATADINE

INSTAPILL	5MG	A212795	001	Sep 18, 2020	Feb CAHN
	10MG	A213294	001	Oct 30, 2020	Feb CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

DR REDDYS

5MG;120MG

A220448 001 Aug 06, 2026 Jul NEWA

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS

+! HISAMITSU PHARM CO 3%;10%

N022029 002 Nov 05, 2012 Mar CHRS

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE 7

ENCUBE

2%

A074164 001 Mar 29, 1996 May CAHN

MICONAZOLE NITRATE

@ COSETTE PHARMS NC 2%

A074366 001 Feb 22, 1996 Jun CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

COSETTE PHARMS NC 2%,200MG

A074926 001 Apr 16, 1999 May CAHN

MICONAZOLE 7 COMBINATION PACK

@ COSETTE PHARMS NC 2%,100MG

A076585 001 Mar 26, 2004 Jun CAHN

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

COSETTE PHARMS NC 100MG

A073507 001 Nov 19, 1993 May CAHN

@ 100MG

A074414 001 Apr 30, 1997 Jun CAHN

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

AUROBINDO PHARMA LTD 2%

A074767 001 Feb 28, 1997 Jul CMFD

MINOXIDIL (FOR WOMEN)

AUROBINDO PHARMA LTD 2%

A074767 002 Nov 25, 1997 Jul CMFD

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

REXTOVY

+! AMPHASTAR PHARMS INC 4MG/SPRAY

N208969 001 Mar 07, 2023 Jun CMKT

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

@ ONESOURCE EQ 200MG BASE

A215472 001 Aug 17, 2022 Jul CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

HABITROL

DR REDDYS LABS SA EQ 2MG BASE

A215276 001 Jul 17, 2025 Jul CTNA

EQ 4MG BASE

A215276 002 Jul 17, 2025 Jul CTNA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@ FDC LTD EQ 0.2% BASE

A217051 001 Jul 14, 2025 Feb DISC

PERMETHRIN

LOTION;TOPICAL

PERMETHRIN

@ PERRIGO NEW YORK 1%

A076090 001 Dec 20, 2001 Feb DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

ALLIED 17GM/SCOOPFUL

A090812 001 Oct 07, 2009 Apr CAHN

LNK INTL INC 17GM/SCOOPFUL

A217505 001 Jul 29, 2026 Jul NEWA

17GM/PACKET

A217505 002 Jul 29, 2026 Jul NEWA

POINTVIEW HLDINGS 17GM/SCOOPFUL

A090812 001 Oct 07, 2009 Jun CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ RISING EQ 75MG BASE

A075497 001 Jan 14, 2000 Mar CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

AUROBINDO PHARMA LTD 0.055MG/SPRAY

A220110 001 Aug 11, 2026 Jul NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST 2026

NO AUGUST 2026 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2026 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11207311	Jul 28, 2037	U-2830		I-980	Dec 12, 2028
	11207311	Jul 28, 2037	U-4368			
	11673877	Mar 27, 2038	DS DP U-2830			
	11673877	Mar 27, 2038	DS DP U-4368			
	11986468	Jul 28, 2037	U-2830			
	11986468	Jul 28, 2037	U-4368			
	11986469	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-4368			
	11986470	Jul 28, 2037	U-4368			
	11992486	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-4368			
	12383543	Jul 28, 2037	U-2830			
	12383543	Jul 28, 2037	U-4368			
	8071579	Aug 12, 2027	U-2830			
	8071579	Aug 12, 2027	U-4368			
	8143241	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-4368			
	8859562	Aug 04, 2031	U-2830			
	8859562	Aug 04, 2031	U-4368			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11207311	Jul 28, 2037	U-2830		I-980	Dec 12, 2028
	11207311	Jul 28, 2037	U-4368			
	11673877	Mar 27, 2038	DS DP U-2830			
	11673877	Mar 27, 2038	DS DP U-4368			
	11986468	Jul 28, 2037	U-2830			
	11986468	Jul 28, 2037	U-4368			
	11986469	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-4368			
	11986470	Jul 28, 2037	U-4368			
	11992486	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-4368			
	12383543	Jul 28, 2037	U-2830			
	12383543	Jul 28, 2037	U-4368			
	8071579	Aug 12, 2027	U-2830			
	8071579	Aug 12, 2027	U-4368			
	8143241	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-4368			
	8859562	Aug 04, 2031	U-2830			
	8859562	Aug 04, 2031	U-4368			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	11166951	Aug 11, 2035	U-4426		D-200	Feb 19, 2029
	11166951	Aug 11, 2035	U-4427			
	11166951	Aug 11, 2035	U-4428			
	11166951	Aug 11, 2035	U-4429			
	11166951	Aug 11, 2035	U-4430			
	11166951	Aug 11, 2035	U-4431			
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	11166951	Aug 11, 2035	U-4426		D-200	Feb 19, 2029
	11166951	Aug 11, 2035	U-4427			
	11166951	Aug 11, 2035	U-4428			
	11166951	Aug 11, 2035	U-4429			
	11166951	Aug 11, 2035	U-4430			
	11166951	Aug 11, 2035	U-4431			
<u>ACECLIDINE HYDROCHLORIDE - VIZZ</u>						
N 218585 001	12533347	Oct 08, 2039	U-3741			
	12653779	Jun 18, 2035	U-3741			
<u>ACETAMINOPHEN; NAPROXEN SODIUM - TYLENOL WITH NAPROXEN</u>						
N 219962 001					>A> NP	Jul 24, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001	12539290	Aug 16, 2039	DP			
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	12653789	Aug 21, 2043	DP			
<u>ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CABTREO</u>						
N 216632 001	12616710	Jul 31, 2040	DP			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 001	10836755	Jan 18, 2039	DS DP	U-4371		
	12370179	Jul 15, 2042		U-4371		
<u>AFICAMTEN - MYOORZO</u>						
N 219083 002	10836755	Jan 18, 2039	DS DP	U-4371		
	12370179	Jul 15, 2042		U-4371		
<u>AFICAMTEN - MYOORZO</u>						
N 219083 003	10836755	Jan 18, 2039	DS DP	U-4371		
	12370179	Jul 15, 2042		U-4371		
<u>AFICAMTEN - MYOORZO</u>						
N 219083 004	10836755	Jan 18, 2039	DS DP	U-4371		
	12370179	Jul 15, 2042		U-4371		
<u>ALBUTEROL SULFATE - ALBUTEROL SULFATE</u>						
A 219409 001					CGT	Dec 19, 2026
<u>ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K - MULTIPLE VITAMINS INJECTION ADULT</u>						
A 210672 001					CGT	Dec 01, 2026
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u>						
N 208078 001					ODE-553	Sep 29, 2029
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	12616708	May 15, 2035	U-2414			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 002	10117951	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9750822	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 003	10117951	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9750822	Mar 13, 2029	DP			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	>A> 12721843	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK</u>						
N 219423 003	12673047	Jan 23, 2038	DP			
<u>AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK</u>						
N 215152 001	7977488	Apr 10, 2030	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	11723898	Jan 14, 2041	U-4449			
	12303497	Jan 30, 2040	U-4448			
	12303497	Jan 30, 2040	U-4494			
	8445507	Feb 14, 2032	DS DP U-2237			
	8445507	Feb 14, 2032	DS DP U-2624			
	RE50642	Sep 23, 2033	U-4450			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	11723898	Jan 14, 2041	U-4449			
	12303497	Jan 30, 2040	U-4448			
	12303497	Jan 30, 2040	U-4494			
	8445507	Feb 14, 2032	DS DP U-2237			
	8445507	Feb 14, 2032	DS DP U-2624			
	RE50642	Sep 23, 2033	U-4450			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	12576034	Nov 30, 2033	DP U-1858			
	12576034	Nov 30, 2033	DP U-4290			
	12576034	Nov 30, 2033	DP U-4291			
	12576034*PED	May 30, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 002	12576034	Nov 30, 2033	DP U-1858			
	12576034	Nov 30, 2033	DP U-4290			
	12576034	Nov 30, 2033	DP U-4291			
	12576034*PED	May 30, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 003	12576034	Nov 30, 2033	DP U-1858			
	12576034	Nov 30, 2033	DP U-4290			
	12576034	Nov 30, 2033	DP U-4291			
	12576034*PED	May 30, 2034				
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 001	11707456	Nov 19, 2041	DS DP U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 002	11707456	Nov 19, 2041	DS DP U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 003	11707456	Nov 19, 2041	DS DP U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 004	11707456	Nov 19, 2041	DS DP U-4021			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	>A> 12691056	Apr 01, 2041	U-3245			
	>A> 12691056	Apr 01, 2041	U-814			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	>A> 12691056	Apr 01, 2041	U-3245			
	>A> 12691056	Apr 01, 2041	U-814			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	>A> 12691056	Apr 01, 2041	U-3245			
	>A> 12691056	Apr 01, 2041	U-814			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	>A> 12691056	Apr 01, 2041	U-3245			
	>A> 12691056	Apr 01, 2041	U-814			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	11097006	Sep 19, 2033	DP U-764			
	11969469	Apr 06, 2034	DP			
	12629366	Dec 06, 2032	DP U-764			
	12653822	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	11097006	Sep 19, 2033	DP U-764			
	11969469	Apr 06, 2034	DP			
	12629366	Dec 06, 2032	DP U-764			
	12653822	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	11097006	Sep 19, 2033	DP U-764			
	11969469	Apr 06, 2034	DP			
	12629366	Dec 06, 2032	DP U-764			
	12653822	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	11097006	Sep 19, 2033	DP U-764			
	11969469	Apr 06, 2034	DP			
	12629366	Dec 06, 2032	DP U-764			
	12653822	Mar 19, 2035	U-2402			
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001	12390442	Feb 16, 2044	U-4433			
<u>ARTICAINE HYDROCHLORIDE - CYKLX</u>						
N 218643 001	11096922	Mar 27, 2039	DP U-4423			
	11826347	Mar 27, 2039	DP U-4423			
	12403126	Mar 27, 2039	DP U-4422			
<u>ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K - MULTIPLE VITAMINS INJECTION PEDIATRIC</u>						
A 210671 001					CGT	Dec 21, 2026
<u>ATOGEPAANT - OULIPTA</u>						
N 215206 001	12622897	Sep 27, 2042	U-4536			
	8754096	Sep 28, 2035	DS DP U-3534			
<u>ATOGEPAANT - OULIPTA</u>						
N 215206 002	12622897	Sep 27, 2042	U-4536			
	8754096	Sep 28, 2035	DS DP U-3534			
<u>ATOGEPAANT - OULIPTA</u>						
N 215206 003	8754096	Sep 28, 2035	DS DP U-3534			
<u>ATORVASTATIN CALCIUM - ATORVALIQ</u>						
N 213260 001	12599553	Jun 07, 2037	DP			
<u>ATRASENTAN HYDROCHLORIDE - VANRAFIA</u>						
N 219208 001	12521369	Mar 02, 2041	U-3980			
	12582631	Mar 25, 2043	U-3980			
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	7579456	Feb 14, 2027	DS			
	9617546	Feb 14, 2027	DS U-3673			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	8906938	Jan 06, 2034	DS DP			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001					ODE-548	Jul 24, 2032

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVATROMBOPAG MALEATE - DOPTELET SPRINKLE</u>						
N 219696 001					ODE-548	Jul 24, 2032
<u>AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)</u>						
N 219616 001	12509450	Dec 29, 2042	DP		ODE-525	May 08, 2032
<u>AXITINIB - INLYTA</u>						
N 202324 001	12534530	Feb 03, 2035	U-4411			
	12534530	Feb 03, 2035	U-4412			
	12534530*PED	Aug 03, 2035				
<u>AXITINIB - INLYTA</u>						
N 202324 002	12534530	Feb 03, 2035	U-4411			
	12534530	Feb 03, 2035	U-4412			
	12534530*PED	Aug 03, 2035				
<u>AZILSARTAN KAMEDOXOMIL - AZILSARTAN MEDOXOMIL</u>						
A 214489 001					PC	Dec 12, 2026
<u>AZILSARTAN KAMEDOXOMIL - AZILSARTAN MEDOXOMIL</u>						
A 214489 002					PC	Dec 12, 2026
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 002	8987441	Oct 24, 2032	DS DP		M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 003	8987441	Oct 24, 2032	DS DP		M-187	Dec 19, 2027
<u>BAXDROSTAT - BAXFENDY</u>						
N 219878 001	9353081	Feb 04, 2033	DS DP		NCE	May 15, 2031
<u>BAXDROSTAT - BAXFENDY</u>						
N 219878 002	9353081	Feb 04, 2033	DS DP		NCE	May 15, 2031
<u>BECLOMETHASONE DIPROPIONATE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - TRIMBOW</u>						
N 219622 001	10159645	Dec 23, 2030	DP U-4538		NP	May 14, 2029
	10617638	Dec 23, 2034	DP U-4538			
	10806701	Dec 23, 2030	DP			
	11389401	Dec 23, 2030	DP			
	11590074	Dec 23, 2030	U-4538			
	12357568	Dec 23, 2030	DP U-4538			
<u>BECLOMETHASONE DIPROPIONATE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - TRIMBOW</u>						
N 219622 002	10159645	Dec 23, 2030	DP U-4538		NP	May 14, 2029
	10617638	Dec 23, 2034	DP U-4538			
	10806701	Dec 23, 2030	DP			
	11389401	Dec 23, 2030	DP			
	11590074	Dec 23, 2030	U-4538			
	12357568	Dec 23, 2030	DP U-4538			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					>A> NPP	Jul 28, 2028
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002					>A> NPP	Jul 28, 2028
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	10335388	Apr 14, 2036	U-4565		I-994	Jun 12, 2029
	9908845	Sep 05, 2034	DS DP U-3201			
	9908845	Sep 05, 2034	DS DP U-4176			
	9908845	Sep 05, 2034	DS DP U-4195			
	9908845	Sep 05, 2034	DS DP U-4565			
	RE49948	Sep 05, 2034	DS DP U-3201			
	RE49948	Sep 05, 2034	DS DP U-4176			
	RE49948	Sep 05, 2034	DS DP U-4195			
	RE49948	Sep 05, 2034	DS DP U-4565			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	12551491	Jul 23, 2045	U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	12551491	Jul 23, 2045	U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	12551491	Jul 23, 2045	U-713			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 001	10125102	Apr 07, 2035	DS U-4535			
	10125102*PED	Oct 07, 2035				
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS U-4535			
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035	U-4535			
	10689346*PED	Sep 09, 2035				
	11117867	Nov 01, 2039	DP U-4535			
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035	U-4535			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 001	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039	U-4535			
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035	U-4535			
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039	U-4535			
	12344585*PED	May 01, 2040				
	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 002	10125102	Apr 07, 2035	DS U-4535			
	10125102*PED	Oct 07, 2035				
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS U-4535			
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035	U-4535			
	10689346*PED	Sep 09, 2035				
	11117867	Nov 01, 2039	DP U-4535			
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035	U-4535			
	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039	U-4535			
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035	U-4535			
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039	U-4535			
	12344585*PED	May 01, 2040				
	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 003	10125102	Apr 07, 2035	DS U-4535			
	10125102*PED	Oct 07, 2035				
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS U-4535			
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035	U-4535			
	10689346*PED	Sep 09, 2035				
	11117867	Nov 01, 2039	DP U-4535			
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035	U-4535			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 003	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039	U-4535			
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035	U-4535			
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039	U-4535			
	12344585*PED	May 01, 2040				
	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 004	10125102	Apr 07, 2035	DS U-4535			
	10125102*PED	Oct 07, 2035				
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS U-4535			
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035	U-4535			
	10689346*PED	Sep 09, 2035				
	11117867	Nov 01, 2039	DP U-4535			
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035	U-4535			
	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039	U-4535			
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035	U-4535			
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039	U-4535			
	12344585*PED	May 01, 2040				
	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001 >A>	12661489	Nov 19, 2045	U-4596			
<u>BEXAGLIFLOZIN - BREZAVVY</u>						
N 214373 001	12594243	Oct 05, 2041	DP			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	12594244	Nov 08, 2036	DP U-257		ODE-540	Jul 30, 2032

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	12594244	Nov 08, 2036	DP U-257		ODE-540	Jul 30, 2032
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2027	DS DP			
<u>BIRCH TRITERPENES - FILSUVEZ</u>						
N 215064 001	8828444	Jun 21, 2027	DP			
<u>BOSUTINIB MONOHYDRATE - BOSUTINIB MONOHYDRATE</u>						
A 209543 001					>A> PC	Nov 23, 2026
<u>BOSUTINIB MONOHYDRATE - BOSUTINIB MONOHYDRATE</u>						
A 209543 002					>A> PC	Nov 23, 2026
<u>BOSUTINIB MONOHYDRATE - BOSUTINIB MONOHYDRATE</u>						
A 209624 001					>A> PC	Nov 23, 2026
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	>A> 12514857	Jul 27, 2029	U-2222			
<u>BRIMONIDINE TARTRATE - LUMIFY PRESERVATIVE FREE</u>						
N 218424 001	>A> 12311050	Jul 27, 2029	U-2222			
	>A> 12514857	Jul 27, 2029	U-2222			
<u>BRIMONIDINE TARTRATE; CARBACHOL - YUVEZZI</u>						
N 220142 001	12268662	Nov 10, 2042	DP U-3741		NP	Jan 28, 2029
	12268662	Nov 10, 2042	DP U-4419			
	12268662	Nov 10, 2042	DP U-4420			
	8455494	May 24, 2030	U-3741			
	8455494	May 24, 2030	U-4419			
	8455494	May 24, 2030	U-4420			
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214460 001	9303051	Jul 30, 2034	DS DP U-3165			
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214461 001	9303051	Jul 30, 2034	DS DP U-3165			
<u>BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE</u>						
N 216579 001	10716753	May 28, 2030	DP U-3203		I-988	Apr 27, 2029
	10716753	May 28, 2030	DP U-4513			
	9415009	May 28, 2030	U-3203			
	9415009	May 28, 2030	U-4513			
<u>BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE</u>						
N 216579 002	10716753	May 28, 2030	DP U-4513		NS	Apr 27, 2029
	9415009	May 28, 2030	U-4513			
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122 002	10716753	May 28, 2030	DP U-4503		NS	Apr 27, 2029
	11331442	Oct 05, 2038	DP			
	11833292	Oct 05, 2038	DP			
	8324266	May 28, 2030	U-4503			
	8703806	May 28, 2030	U-4503			
	8808713	May 28, 2030	DP U-4503			
	8815258	Mar 17, 2031	U-4503			
	9415009	May 28, 2030	U-4503			
	9463161	May 28, 2030	DP U-4503			
<u>BUMETANIDE - ENBUMYST</u>						
N 219500 001	12558330	May 14, 2045	DP U-4279			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	12622904	Nov 06, 2035	U-4528			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	12622904	Nov 06, 2035	U-4528			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	10058518	Nov 05, 2034	U-3419		I-913	Apr 30, 2029
	10058518	Nov 05, 2034	U-4522			
	10064857	Nov 05, 2034	U-3419			
	10064857	Nov 05, 2034	U-4517			
	10080727	Nov 05, 2034	U-3419			
	10080727	Nov 05, 2034	U-4520			
	10092560	Nov 05, 2034	U-3419			
	10092560	Nov 05, 2034	U-4517			
	10092561	Nov 05, 2034	U-3419			
	10092561	Nov 05, 2034	U-4517			
	10105361	Nov 05, 2034	U-3419			
	10105361	Nov 05, 2034	U-4522			
	10251879	Nov 05, 2034	U-3419			
	10251879	Nov 05, 2034	U-4517			
	10463634	Nov 05, 2034	U-3419			
	10463634	Nov 05, 2034	U-4517			
	10512643	Nov 05, 2034	U-3419			
	10512643	Nov 05, 2034	U-4517			
	10596167	Nov 05, 2034	U-3419			
	10596167	Nov 05, 2034	U-4517			
	10780066	Nov 05, 2034	U-3419			
	10780066	Nov 05, 2034	U-4517			
	10786496	Nov 05, 2034	U-3419			
	10786496	Nov 05, 2034	U-4517			
	10806710	Nov 05, 2034	U-3419			
	10806710	Nov 05, 2034	U-4517			
	10881624	Nov 05, 2034	U-3419			
	10881624	Nov 05, 2034	U-4517			
	10966941	Nov 05, 2034	U-3419			
	10966941	Nov 05, 2034	U-4517			
	11007189	Nov 05, 2034	U-4516			
	11065248	Nov 05, 2034	U-3419			
	11065248	Nov 05, 2034	U-4517			
	11123344	Nov 05, 2034	U-3419			
	11123344	Nov 05, 2034	U-4517			
	11191739	Nov 05, 2034	DP U-3419			
	11191739	Nov 05, 2034	DP U-4516			
	11197839	Nov 05, 2034	DP U-3419			
	11197839	Nov 05, 2034	DP U-4516			
	11207281	Nov 05, 2034	U-3419			
	11207281	Nov 05, 2034	U-4537			
	11234946	Nov 05, 2034	U-3419			
	11234946	Nov 05, 2034	U-4526			
	11253492	Nov 05, 2034	U-3419			
	11253492	Nov 05, 2034	U-4526			
	11273133	Nov 05, 2034	U-3419			
	11273133	Nov 05, 2034	U-4526			
	11273134	Nov 05, 2034	U-3419			
	11273134	Nov 05, 2034	U-4517			
	11285118	Nov 05, 2034	U-3419			
	11285118	Nov 05, 2034	U-4526			
	11285146	Nov 05, 2034	U-3419			
	11285146	Nov 05, 2034	U-4517			
	11291638	Nov 05, 2034	U-3419			
	11291638	Nov 05, 2034	U-4517			
	11291665	Nov 05, 2034	U-3419			
	11291665	Nov 05, 2034	U-4517			
	11298352	Nov 05, 2034	U-3419			
	11298352	Nov 05, 2034	U-4517			
	11344544	Nov 05, 2034	U-3419			
	11344544	Nov 05, 2034	U-4517			
	11357744	Nov 05, 2034	U-3419			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11357744	Nov 05, 2034	U-4517			
	11382874	Nov 05, 2034	U-3419			
	11382874	Nov 05, 2034	U-4517			
	11419867	Nov 05, 2034	U-3419			
	11419867	Nov 05, 2034	U-4517			
	11426370	Nov 05, 2034	U-3419			
	11426370	Nov 05, 2034	U-4526			
	11426401	Nov 05, 2034	U-3419			
	11426401	Nov 05, 2034	U-4517			
	11433067	Nov 05, 2034	DP U-3419			
	11433067	Nov 05, 2034	DP U-4516			
	11439636	Nov 05, 2034	U-3419			
	11439636	Nov 05, 2034	U-4517			
	11534414	Nov 05, 2034	DP U-3419			
	11534414	Nov 05, 2034	DP U-4516			
	11571417	Nov 05, 2034	U-3419			
	11571417	Nov 05, 2034	U-4526			
	11576909	Nov 05, 2034	U-3419			
	11576909	Nov 05, 2034	U-4526			
	11590124	Nov 05, 2034	U-3419			
	11590124	Nov 05, 2034	U-4526			
	11617747	Nov 05, 2034	U-3563			
	11617747	Nov 05, 2034	U-4526			
	12194005	Jan 23, 2043	U-4523			
	12194036	Apr 20, 2043	U-4521			
	12239642	Jan 20, 2043	U-4515			
	12263161	Jan 20, 2043	U-4515			
	12364674	Jan 23, 2043	U-4516			
	12370154	Feb 15, 2043	U-4518			
	12433884	Jun 05, 2040	U-4514			
	12472155	Feb 23, 2043	U-4519			
	12472156	Jun 05, 2040	U-4516			
	12472174	Jan 20, 2043	U-4515			
	12478622	Jan 20, 2043	U-4515			
	12564587	Jan 20, 2043	U-4515			
	12576078	Jun 05, 2040	U-4516			
	12599576	Feb 15, 2043	U-4518			
	12653795	Nov 28, 2043	U-4516			
	12661408	Jan 20, 2043	U-3419			
	12678506	Jan 20, 2043	DP			
	8569328	Jul 18, 2032	DP U-3419			
	8569328	Jul 18, 2032	DP U-4516			
	9168234	Nov 05, 2034	U-3419			
	9168234	Nov 05, 2034	U-4517			
	9198905	Nov 05, 2034	U-3419			
	9198905	Nov 05, 2034	U-4520			
	9205083	Nov 05, 2034	U-3419			
	9205083	Nov 05, 2034	U-4520			
	9238032	Nov 05, 2034	U-3419			
	9238032	Nov 05, 2034	U-4520			
	9278095	Nov 05, 2034	U-3419			
	9278095	Nov 05, 2034	U-4517			
	9314462	Nov 05, 2034	U-3419			
	9314462	Nov 05, 2034	U-4517			
	9370513	Nov 05, 2034	U-3419			
	9370513	Nov 05, 2034	U-4520			
	9375429	Nov 05, 2034	U-3419			
	9375429	Nov 05, 2034	U-4517			
	9408815	Nov 05, 2034	U-3419			
	9408815	Nov 05, 2034	U-4517			
	9421176	Nov 05, 2034	U-3419			
	9421176	Nov 05, 2034	U-4517			
	9457023	Nov 05, 2034	U-3419			
	9457023	Nov 05, 2034	U-4517			
	9457025	Nov 05, 2034	U-3419			
	9457025	Nov 05, 2034	U-4517			
	9474731	Nov 05, 2034	U-3419			
	9474731	Nov 05, 2034	U-4520			
	9486450	Nov 05, 2034	U-3419			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	9486450	Nov 05, 2034	U-4517			
	9700528	Nov 05, 2034	U-3419			
	9700528	Nov 05, 2034	U-4517			
	9700553	Nov 05, 2034	U-3419			
	9700553	Nov 05, 2034	U-4517			
	9707191	Nov 05, 2034	U-3419			
	9707191	Nov 05, 2034	U-4522			
	9763932	Nov 05, 2034	U-3419			
	9763932	Nov 05, 2034	U-4517			
	9861595	Nov 05, 2034	U-3419			
	9861595	Nov 05, 2034	U-4517			
	9867819	Nov 05, 2034	U-3419			
	9867819	Nov 05, 2034	U-4517			
	9968568	Nov 05, 2034	U-3419			
	9968568	Nov 05, 2034	U-4517			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 002	10058518	Nov 05, 2034	U-4522		I-913	Apr 30, 2029
	10064857	Nov 05, 2034	U-4517			
	10080727	Nov 05, 2034	U-4520			
	10092560	Nov 05, 2034	U-4517			
	10092561	Nov 05, 2034	U-4517			
	10105361	Nov 05, 2034	U-4522			
	10251879	Nov 05, 2034	U-4517			
	10463634	Nov 05, 2034	U-4517			
	10512643	Nov 05, 2034	U-4517			
	10780066	Nov 05, 2034	U-4517			
	10881624	Nov 05, 2034	U-4517			
	11007189	Nov 05, 2034	U-4516			
	11207281	Nov 05, 2034	U-4537			
	11234946	Nov 05, 2034	U-4526			
	11253492	Nov 05, 2034	U-4526			
	11273133	Nov 05, 2034	U-4526			
	11273134	Nov 05, 2034	U-4517			
	11285118	Nov 05, 2034	U-4526			
	11285146	Nov 05, 2034	U-4517			
	11291638	Nov 05, 2034	U-4517			
	11291665	Nov 05, 2034	U-4517			
	11298352	Nov 05, 2034	U-4517			
	11344544	Nov 05, 2034	U-4517			
	11382874	Nov 05, 2034	U-4517			
	11419867	Nov 05, 2034	U-4517			
	11426370	Nov 05, 2034	U-4526			
	11571417	Nov 05, 2034	U-4526			
	11590124	Nov 05, 2034	U-4526			
	11617747	Nov 05, 2034	U-4526			
	12433884	Jun 05, 2040	U-4514			
	12472156	Jun 05, 2040	U-4516			
	12472174	Jan 20, 2043	U-4515			
	12576078	Jun 05, 2040	U-4516			
	12678506	Jan 20, 2043	DP			
	8569328	Jul 18, 2032	DP U-4516			
	9168234	Nov 05, 2034	U-4517			
	9198905	Nov 05, 2034	U-4520			
	9205083	Nov 05, 2034	U-4520			
	9238032	Nov 05, 2034	U-4520			
	9278095	Nov 05, 2034	U-4517			
	9314462	Nov 05, 2034	U-4517			
	9370513	Nov 05, 2034	U-4520			
	9375429	Nov 05, 2034	U-4517			
	9408815	Nov 05, 2034	U-4517			
	9421176	Nov 05, 2034	U-4517			
	9457023	Nov 05, 2034	U-4517			
	9457025	Nov 05, 2034	U-4517			
	9474731	Nov 05, 2034	U-4520			
	9486450	Nov 05, 2034	U-4517			
	9700528	Nov 05, 2034	U-4517			
	9700553	Nov 05, 2034	U-4517			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 002	9707191	Nov 05, 2034	U-4522			
	9763932	Nov 05, 2034	U-4517			
	9861595	Nov 05, 2034	U-4517			
	9867819	Nov 05, 2034	U-4517			
	9968568	Nov 05, 2034	U-4517			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	10583110	Oct 27, 2030	U-2753			
	10583110*PED	Apr 27, 2031				
	10716777	Oct 27, 2030	U-2856			
	10716777*PED	Apr 27, 2031				
	12453712	Oct 27, 2030	U-4334			
	12453712*PED	Apr 27, 2031				
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	12636285	Oct 01, 2040	U-3348			
	12636286	Oct 01, 2040	U-3348			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	12636285	Oct 01, 2040	U-3348			
	12636286	Oct 01, 2040	U-3348			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001					ODE-530	Mar 26, 2032
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002					ODE-530	Mar 26, 2032
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003					ODE-530	Mar 26, 2032
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	12582622	Feb 22, 2041	U-4044			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	12661365	Sep 24, 2042	U-4573			
	12661365	Sep 24, 2042	U-4574			
	12661365	Sep 24, 2042	U-4575			
<u>CAPIVASERTIB - TRUOAP</u>						
N 218197 001	10039766	Apr 16, 2033	U-3762		I-991	Jun 12, 2029
	10039766	Apr 16, 2033	U-4559			
	11236095	Oct 10, 2028	U-4559			
	9492453	Oct 10, 2028	U-4559			
<u>CAPIVASERTIB - TRUOAP</u>						
N 218197 002	10039766	Apr 16, 2033	U-3762		I-991	Jun 12, 2029
	10039766	Apr 16, 2033	U-4559			
	11236095	Oct 10, 2028	U-4559			
	9492453	Oct 10, 2028	U-4559			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	12691074	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	12691074	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	12691074	Oct 07, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	12691074	Oct 07, 2034	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	12636340	Apr 29, 2041	U-4551			
	12636340*PED	Oct 29, 2041				
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	12636340	Apr 29, 2041	U-4551			
	12636340*PED	Oct 29, 2041				
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	12636340	Apr 29, 2041	U-4551			
	12636340*PED	Oct 29, 2041				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030			PED	Jun 18, 2029
	7943621	Dec 16, 2028	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 005	7737142	Sep 17, 2029	DS DP U-2543		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503		PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030				
	7943621	Dec 20, 2028	DS DP			
	7943621*PED	Jun 20, 2029				
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 006	7737142	Sep 17, 2029	DS DP U-2543		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503		PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030				
	7943621	Dec 20, 2028	DS DP			
	7943621*PED	Jun 20, 2029				
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576 001	>A> 12697347	Dec 10, 2042	U-4587		I-990	May 13, 2029
	>A> 8268800	Feb 12, 2034	DS U-2864			
	>A> 8268800	Feb 12, 2034	DS U-2865			
	>A> 8268800	Feb 12, 2034	DS U-2866			
	>A> 8268800	Feb 12, 2034	DS U-2867			
<u>CEFEPIME HYDROCHLORIDE; ZIDEACTAM - ZAYNICH</u>						
N 220787 001	8822450	Aug 24, 2032	DS DP		NCE	May 29, 2031
	8853197	Aug 24, 2032	DS		GAIN	May 29, 2036
	9132133	Aug 24, 2032	U-4558			
	9381200	Aug 24, 2032	DP			
	9657021	Oct 12, 2033	DS			
	9827235	Aug 24, 2032	DP U-4558			
	9834557	Oct 12, 2033	DS			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10028963	Sep 07, 2032	U-2565		NPP	May 12, 2029
	10028963	Sep 07, 2032	U-2566		PED	Nov 12, 2029
	10028963	Sep 07, 2032	U-4542			
	10028963	Sep 07, 2032	U-4543			
	10028963*PED	Mar 07, 2033				
	10125149	Aug 14, 2035	DP			
	10125149*PED	Feb 14, 2036				
	10376496	Sep 09, 2034	U-2610			
	10376496	Sep 09, 2034	U-2611			
	10376496	Sep 09, 2034	U-4548			
	10376496	Sep 09, 2034	U-4549			
	10376496*PED	Mar 09, 2035				
	10420841	Mar 14, 2034	U-1672			
	10420841	Mar 14, 2034	U-2631			
	10420841	Mar 14, 2034	U-3360			
	10420841	Mar 14, 2034	U-3361			
	10420841	Mar 14, 2034	U-4546			
	10420841	Mar 14, 2034	U-4547			
	10420841*PED	Sep 14, 2034				
	10933053	Sep 09, 2034	U-3090			
	10933053	Sep 09, 2034	U-3091			
	10933053	Sep 09, 2034	U-4544			
	10933053	Sep 09, 2034	U-4545			
	10933053*PED	Mar 09, 2035				
	11278622	Mar 14, 2034	U-3335			
	11278622	Mar 14, 2034	U-3336			
	11278622	Mar 14, 2034	U-4542			
	11278622	Mar 14, 2034	U-4543			
	11278622*PED	Sep 14, 2034				
	7129232	May 15, 2028	DS DP U-1676			
	7129232	May 15, 2028	DS DP U-3360			
	7129232	May 15, 2028	DS DP U-3361			
	7129232	May 15, 2028	DS DP U-36			
	7129232	May 15, 2028	DS DP U-4542			
	7129232	May 15, 2028	DS DP U-4543			
	7129232	May 15, 2028	DS DP U-4547			
	7129232	May 15, 2028	DS DP U-4550			
	7129232*PED	Nov 15, 2028				
	8906898	May 28, 2034	DS DP			
	8906898*PED	Nov 28, 2034				
	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
	8968753	Mar 14, 2034	U-3360			
	8968753	Mar 14, 2034	U-3361			
	8968753	Mar 14, 2034	U-4547			
	8968753	Mar 14, 2034	U-4550			
	8968753*PED	Sep 14, 2034				
	9320740	Mar 14, 2034	DP			
	9320740*PED	Sep 14, 2034				
	9724353	Sep 07, 2032	U-2565			
	9724353	Sep 07, 2032	U-2566			
	9724353	Sep 07, 2032	U-4542			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9724353	Sep 07, 2032	U-4543			
	9724353*PED	Mar 07, 2033				
	9872906	Mar 14, 2034	DP			
	9872906*PED	Sep 14, 2034				
<u>CELECOXIB - VYSCOX</u>						
N 211759 001	12678405	Sep 17, 2045	DP			
<u>CHENODIOL - CTEXLI</u>						
N 219488 001					ODE-523	Feb 21, 2032
<u>CHLORTHALIDONE - HEMICLOR</u>						
N 218647 001	12667554	Sep 04, 2045	DP			
<u>CIPEPOFOL - CYPSEDO</u>						
N 220482 001					>A> NCE	Aug 27, 2031
<u>CITALOPRAM HYDROBROMIDE - CITALOPRAM HYDROBROMIDE</u>						
A 219985 001					CGT	Sep 16, 2026
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	12576072	Jun 23, 2034	DP U-3261			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	12533408	Sep 10, 2041	U-4395			
	12539329	Sep 10, 2041	U-4399			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	11179465	Aug 31, 2030	DP U-1858			
<u>CLONIDINE HYDROCHLORIDE - ONYDA XR</u>						
N 217645 001	12576032	Jul 28, 2041	U-2357			
<u>CLONIDINE HYDROCHLORIDE - OLONILIK</u>						
N 221094 001	12551466	Aug 22, 2045	DP U-4581			
<u>CLOTRIMAZOLE - CLOTIC</u>						
N 217628 001					ODE-549 GAIN	Sep 26, 2032 Sep 26, 2037
<u>COBICISTAT - TYBOST</u>						
N 203094 001					NPP	Jun 20, 2028
<u>COBICISTAT - TYBOST</u>						
N 203094 002					NS	Jun 20, 2028
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	12514819	Nov 22, 2036	U-2814			
<u>COPPER - MIUDELLA</u>						
N 218201 001	9180040	Mar 22, 2034	DP			
<u>COPPER HISTIDINATE - ZYCUBO</u>						
N 211241 001					NCE ODE-520	Jan 12, 2031 Jan 12, 2033
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 001	12582634	Jan 12, 2043	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 002	12582634	Jan 12, 2043	DS			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 003	12582634	Jan 12, 2043	DS			
<u>CRINECERFONT - CRENESSITY</u>						
N 218820 001	12582634	Jan 12, 2043	DS			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	12569514	Jan 15, 2039	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Oct 15, 2032	DP U-3149		ODE-350	Mar 30, 2028
	10028912	Oct 15, 2032	DP U-3150		PED	Sep 30, 2028
	10028912*PED	Apr 15, 2033				
	10166184	Oct 15, 2032	DP U-3149			
	10166184*PED	Apr 15, 2033				
	10835492	Oct 15, 2032	U-3150			
	10835492*PED	Apr 15, 2033				
	7850990	Jan 23, 2027	DP U-3147			
	7850990*PED	Jul 23, 2027				
	8022279	Sep 14, 2027	DP U-3147			
	8022279*PED	Mar 14, 2028				
	8092828	Apr 01, 2029	U-3147			
	8092828*PED	Oct 01, 2029				
	9271931	Jan 23, 2027	DP			
	9271931*PED	Jul 23, 2027				
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211156 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211156 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211312 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211312 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211467 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211467 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211470 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211470 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211482 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211482 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211523 001					PC	Oct 03, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211523 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211541 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211541 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211545 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211545 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211560 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211560 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211479 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211479 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211479 003					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211479 004					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211491 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211491 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211491 003					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211563 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211563 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211563 003					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211563 004					PC	Oct 03, 2026
<u>DAPTOMYCIN - DAPTOMYCIN</u> N 217415 001	12629337	Jan 09, 2043	DP			
<u>DAPTOMYCIN - DAPTOMYCIN</u> N 217415 002	12629337	Jan 09, 2043	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 001	9732075	Jun 03, 2033	DS DP U-620			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 002	9732075	Jun 03, 2033	DS DP U-620			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	12329742	Jun 17, 2042	DP			
	12611397	Jul 02, 2040	DP			
<u>DASATINIB - PHYRAGO</u>						
N 216099 001	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 002	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 003	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 004	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 005	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 006	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE</u>						
N 214231 001	10442847	Mar 22, 2035	DS DP		NPP	Jun 18, 2029
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)</u>						
N 214231 002	10442847	Mar 22, 2035	DS DP		NPP	Jun 18, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	12529052	Jun 22, 2032	DP			
	12534722	Jun 22, 2032	DP			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	12514898	Feb 20, 2029	U-1978			
	12533387	Feb 20, 2029	U-4417			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	12514898	Feb 20, 2029	U-1978			
	12533387	Feb 20, 2029	U-4417			
<u>DEHYDRATED ALCOHOL - DEHYDRATED ALCOHOL</u>						
N 214988 001					ODE-521	Oct 23, 2032
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	12558349	Mar 14, 2034	U-3967			
<u>DESMOPRESSIN ACETATE - DESMODA</u>						
N 219873 001	12214010	Apr 03, 2044	DP			
	12343372	Apr 03, 2044	DP U-4432			
<u>DEUCRAVACITINIB - SOTYKTU</u>						
N 214958 001	12521390	Feb 11, 2043	DP U-3434		I-986	Mar 06, 2029
	12521390	Feb 11, 2043	DP U-4451			
	RE47929	Nov 07, 2033	DS DP U-3434			
	RE47929	Nov 07, 2033	DS DP U-4452			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 004	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 005	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 006	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 007	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 008	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 001	10081621	Mar 25, 2031	DP U-4087		ODE-526	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4468		ODE-536	Mar 27, 2033
	10239867	Apr 09, 2027	DS DP U-4090			
	10239867	Apr 09, 2027	DS DP U-4464			
	11564916	Aug 13, 2029	U-4095			
	11564916	Aug 13, 2029	U-4466			
	11578062	Mar 25, 2031	DP U-4096			
	11578062	Mar 25, 2031	DP U-4465			
	11639347	Apr 09, 2027	DS DP U-4090			
	11639347	Apr 09, 2027	DS DP U-4464			
	11866450	Feb 14, 2039	U-4082			
	11866450	Feb 14, 2039	U-4463			
	11873300	Aug 13, 2040	DS DP U-4083			
	11873300	Aug 13, 2040	DS DP U-4462			
	8324242	Aug 05, 2027	U-4090			
	8324242	Aug 05, 2027	U-4464			
	8415387	Nov 12, 2027	U-4082			
	8415387	Nov 12, 2027	U-4463			
	8598181	May 01, 2027	U-4090			
	8598181	May 01, 2027	U-4463			
	9181192	May 17, 2032	DS DP U-4094			
	9181192	May 17, 2032	DS DP U-4472			
	9512079	May 17, 2032	DS DP U-4098			
	9512079	May 17, 2032	DS DP U-4471			
	9670163	Dec 28, 2026	DP U-4080			
	9670163	Dec 28, 2026	DP U-4470			
	9931334	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4469			
	9974781	Apr 09, 2027	DP U-4082			
	9974781	Apr 09, 2027	DP U-4463			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	10081621	Mar 25, 2031	DP U-4087		ODE-526	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4468		ODE-536	Mar 27, 2033
	10206877	Apr 14, 2035	DP U-4092			
	10206877	Apr 14, 2035	DP U-4467			
	10239867	Apr 09, 2027	DS DP U-4090			
	10239867	Apr 09, 2027	DS DP U-4464			
	11564916	Aug 13, 2029	U-4095			
	11564916	Aug 13, 2029	U-4466			
	11578062	Mar 25, 2031	DP U-4096			
	11578062	Mar 25, 2031	DP U-4465			
	11639347	Apr 09, 2027	DS DP U-4090			
	11639347	Apr 09, 2027	DS DP U-4464			
	11866450	Feb 14, 2039	U-4082			
	11866450	Feb 14, 2039	U-4463			
	11873300	Aug 13, 2040	DS DP U-4083			
	11873300	Aug 13, 2040	DS DP U-4462			
	11951212	Apr 14, 2035	DP U-4089			
	11951212	Apr 14, 2035	DP U-4461			
	12186306	Jan 10, 2043	U-4088			
	12186306	Jan 10, 2043	U-4460			
	8324242	Aug 05, 2027	U-4090			
	8324242	Aug 05, 2027	U-4464			
	8415387	Nov 12, 2027	U-4082			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	8415387	Nov 12, 2027	U-4463			
	8598181	May 01, 2027	U-4090			
	8598181	May 01, 2027	U-4463			
	9181192	May 17, 2032	DS DP U-4094			
	9181192	May 17, 2032	DS DP U-4472			
	9512079	May 17, 2032	DS DP U-4098			
	9512079	May 17, 2032	DS DP U-4471			
	9670163	Dec 28, 2026	DP U-4080			
	9670163	Dec 28, 2026	DP U-4470			
	9931334	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4469			
	9974781	Apr 09, 2027	DP U-4082			
	9974781	Apr 09, 2027	DP U-4463			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 001	9079928	May 07, 2035	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 002	9079928	May 07, 2035	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 003	9079928	May 07, 2035	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 001	12678504	Mar 12, 2034	DP U-4583			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	12678504	Mar 12, 2034	DP U-4583			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 003	12678504	Mar 12, 2034	DP U-4583			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 004	12678504	Mar 12, 2034	DP U-4583			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM - MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM</u>						
N 217338 001	11278506	Oct 11, 2036	DP			
	12257218	Oct 11, 2036	DP			
	12370189	Oct 11, 2036	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	12521400	Mar 27, 2029	DP			
	12599611	Jun 10, 2042	U-4455			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	12521400	Mar 27, 2029	DP			
	12599611	Jun 10, 2042	U-4455			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	12521400	Mar 27, 2029	DP			
	12599611	Jun 10, 2042	U-4455			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 001					ODE-532	Mar 26, 2032
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 002					ODE-532	Mar 26, 2032
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 003					ODE-532	Mar 26, 2032

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC EPOLAMINE - LICART</u>						
N 206976 001					NPP	Mar 27, 2029
<u>DIFAMILAST - ADOUEY</u>						
N 219474 001	10588893	Dec 31, 2036	DS DP		NCE	Feb 12, 2031
	RE46792	Mar 01, 2028	DS DP U-4445			
<u>DIFELIKEFALIN ACETATE - KORSUVA</u>						
N 214916 001	7402564	Nov 12, 2032	DS DP U-3204			
<u>DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)</u>						
N 215400 001	11083712	Jun 30, 2039	DP U-2718			
	11083712	Jun 30, 2039	DP U-4508			
	11541043	Mar 20, 2039	DP			
	12329749	May 27, 2039	DP U-2718			
	12329749	May 27, 2039	DP U-4508			
	12414941	Aug 24, 2039	DP			
	12533351	Feb 26, 2039	DP			
<u>DIHYDROERGOTAMINE MESYLATE - ATZUMI</u>						
N 217901 001	12594273	Sep 24, 2033	DP			
<u>DONIDALORSEN SODIUM - DAWNZERA (AUTOINJECTOR)</u>						
N 219407 001					ODE-550	Aug 21, 2032
<u>DORAVIRINE; ISLATRAVIR - IDVNSO</u>						
N 216964 001	7339053	May 31, 2027	DS		NCE	Apr 20, 2031
	8486975	Aug 30, 2032	DS DP U-4527			
<u>DORDAVIPRONE HYDROCHLORIDE - MODEYSO</u>						
N 219876 001	>A> RE46290	Aug 30, 2032	U-4254		ODE-547	Aug 06, 2032
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
N 219131 001	>A> 12721817	Jan 13, 2046	DP			
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
N 219131 002	>A> 12721817	Jan 13, 2046	DP			
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
N 219131 003	>A> 12721817	Jan 13, 2046	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001	8193182	Sep 24, 2032	DS			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002	8193182	Sep 24, 2032	DS			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	12527769	Nov 12, 2041	U-4111			
	12569469	Nov 12, 2041	U-4111			
	12599586	Nov 01, 2039	DP			
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001	12582625	Feb 12, 2036	U-4444			
<u>ELAFIBRANOR - IQIRVO</u>						
N 218860 001	12589086	Mar 30, 2037	U-4473			
	12673035	Mar 05, 2044	DP U-1854			
<u>ELAMIPRETIDE HYDROCHLORIDE - FORZINITY</u>						
N 215244 001	7576061	Jan 20, 2027	DS DP		ODE-551	Sep 19, 2032

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031	DP U-3032		ODE-543	Mar 27, 2033
	10081621	Mar 25, 2031	DP U-3157			
	10081621	Mar 25, 2031	DP U-4075			
	10081621	Mar 25, 2031	DP U-4480			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10239867	Apr 09, 2027	DS DP U-4056			
	10239867	Apr 09, 2027	DS DP U-4475			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10758534	Oct 06, 2035	DS DP U-4475			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-4475			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11179367	Dec 08, 2037	DP U-4487			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11426407	Oct 06, 2035	DS DP U-4475			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4067			
	11517564	Dec 08, 2037	DP U-4475			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11564916	Aug 13, 2029	U-4491			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11578062	Mar 25, 2031	DP U-4490			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	11639347	Apr 09, 2027	DS DP U-4475			
	12350262	Jul 17, 2038	U-4221			
	12350262	Jul 17, 2038	U-4475			
	12458635	Aug 13, 2029	DP U-4330			
	12458635	Aug 13, 2029	DP U-4486			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8324242	Aug 05, 2027	U-4475			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8415387	Nov 12, 2027	U-4475			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8598181	May 01, 2027	U-4475			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9670163	Dec 28, 2026	DP U-4477			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-4479			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
	9974781	Apr 09, 2027	DP U-4475			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10081621	Mar 25, 2031	DP U-3157		ODE-543	Mar 27, 2033
	10081621	Mar 25, 2031	DP U-4075			
	10081621	Mar 25, 2031	DP U-4480			
	10239867	Apr 09, 2027	DS DP U-3158			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10239867	Apr 09, 2027	DS DP U-4056			
	10239867	Apr 09, 2027	DS DP U-4475			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10758534	Oct 06, 2035	DS DP U-4475			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-4475			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11179367	Dec 08, 2037	DP U-4487			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11426407	Oct 06, 2035	DS DP U-4475			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4069			
	11517564	Dec 08, 2037	DP U-4475			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11564916	Aug 13, 2029	U-4491			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11578062	Mar 25, 2031	DP U-4490			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	11639347	Apr 09, 2027	DS DP U-4475			
	12350262	Jul 17, 2038	U-4222			
	12350262	Jul 17, 2038	U-4475			
	12458635	Aug 13, 2029	DP U-4330			
	12458635	Aug 13, 2029	DP U-4486			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8324242	Aug 05, 2027	U-4475			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8415387	Nov 12, 2027	U-4475			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8598181	May 01, 2027	U-4475			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9670163	Dec 28, 2026	DP U-4477			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-4479			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
	9974781	Apr 09, 2027	DP U-4475			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	10081621	Mar 25, 2031	DP U-3600		ODE-543	Mar 27, 2033
	10081621	Mar 25, 2031	DP U-4065			
	10081621	Mar 25, 2031	DP U-4481			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10239867	Apr 09, 2027	DS DP U-4476			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10272046	Feb 27, 2033	DP U-4482			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10758534	Oct 06, 2035	DS DP U-4476			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-4476			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11147770	Feb 27, 2033	DP U-4483			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11179367	Dec 08, 2037	DP U-4484			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11426407	Oct 06, 2035	DS DP U-4476			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11517564	Dec 08, 2037	DP U-4476			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11564916	Aug 13, 2029	U-4485			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11578062	Mar 25, 2031	DP U-4488			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11639347	Apr 09, 2027	DS DP U-4476			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	11752106	Feb 27, 2033	DP U-4489			
	12214083	Feb 27, 2033	DP U-4141			
	12214083	Feb 27, 2033	DP U-4492			
	12458635	Aug 13, 2029	DP U-4333			
	12458635	Aug 13, 2029	DP U-4493			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8324242	Aug 05, 2027	U-4476			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8415387	Nov 12, 2027	U-4476			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8598181	May 01, 2027	U-4476			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9670163	Dec 28, 2026	DP U-4478			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-4478			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
	9974781	Apr 09, 2027	DP U-4476			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	10081621	Mar 25, 2031	DP U-3600		ODE-543	Mar 27, 2033
	10081621	Mar 25, 2031	DP U-4065			
	10081621	Mar 25, 2031	DP U-4481			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10239867	Apr 09, 2027	DS DP U-4476			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10272046	Feb 27, 2033	DP U-4482			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10758534	Oct 06, 2035	DS DP U-4476			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-4476			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11147770	Feb 27, 2033	DP U-4483			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11179367	Dec 08, 2037	DP U-4484			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	11426407	Oct 06, 2035	DS DP U-4476			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11517564	Dec 08, 2037	DP U-4476			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11564916	Aug 13, 2029	U-4485			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11578062	Mar 25, 2031	DP U-4488			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11639347	Apr 09, 2027	DS DP U-4476			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	11752106	Feb 27, 2033	DP U-4489			
	12214083	Feb 27, 2033	DP U-4141			
	12214083	Feb 27, 2033	DP U-4492			
	12350262	Jul 17, 2038	U-4220			
	12350262	Jul 17, 2038	U-4476			
	12458635	Aug 13, 2029	DP U-4333			
	12458635	Aug 13, 2029	DP U-4493			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8324242	Aug 05, 2027	U-4476			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8415387	Nov 12, 2027	U-4476			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8598181	May 01, 2027	U-4476			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9670163	Dec 28, 2026	DP U-4478			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-4478			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
	9974781	Apr 09, 2027	DP U-4476			
<u>ELINZANETANT - LYNKUET</u>						
N 219469 001	12533358	May 14, 2045	U-4402			
	7683056	Sep 15, 2027	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	>A> 12678442	Apr 02, 2029	DP			
	>A> 12678442*PED	Oct 02, 2029				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	>A> 12678442	Apr 02, 2029	DP			
	>A> 12678442*PED	Oct 02, 2029				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	>A> 12678442	Apr 02, 2029	DP			
	>A> 12678442*PED	Oct 02, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	>A> 12678442	Apr 02, 2029	DP			
	>A> 12678442*PED	Oct 02, 2029				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	12629338	Jun 29, 2036	DP		ODE-556	Jun 20, 2032
	12648911	Jun 29, 2036	U-1259			
	12648911	Jun 29, 2036	U-1663			
	12661323	Jun 29, 2036	DP			
	12678408	Jun 29, 2036	DP			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	12661323	Jun 29, 2036	DP		ODE-554 ODE-556	Jan 07, 2029 Jun 20, 2032
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001					>A> I-997	Feb 24, 2029
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		>A> I-997	Feb 24, 2029
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10005761	Aug 27, 2030	U-3738			
	10005761	Aug 27, 2030	U-4051			
	10005761	Aug 27, 2030	U-4440			
	10258622	Nov 21, 2032	U-2802			
	10258622	Nov 21, 2032	U-4051			
	10258622	Nov 21, 2032	U-4439			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8541575	Feb 26, 2030	DS DP U-3738			
	8541575	Feb 26, 2030	DS DP U-4051			
	8541575	Feb 26, 2030	DS DP U-4440			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9314464	Jul 04, 2031	U-3738			
	9314464	Jul 04, 2031	U-4051			
	9314464	Jul 04, 2031	U-4440			
	9474754	Aug 05, 2033	U-2802			
	9474754	Aug 05, 2033	U-4051			
	9474754	Aug 05, 2033	U-4440			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
	9850230	Aug 27, 2030	U-3738			
	9850230	Aug 27, 2030	U-4051			
	9850230	Aug 27, 2030	U-4440			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENLICITIDE DECANOATE - LIPFENDRA</u>						
N 220848 001	11427616	Feb 04, 2040	DS DP U-4585		NCE	Jul 15, 2031
<u>ENSITRELVIR - XOCOVA</u>						
N 220442 001	11814368	May 01, 2042	DS DP U-4553		NCE	May 29, 2031
	12559474	May 01, 2042	DS DP U-4553			
	9150546	Dec 12, 2030	DS DP			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 215425 001	12539283	Jan 17, 2045	DP			
<u>EPLONTERSEN SODIUM - WAINUA</u>						
N 217388 002	10683499	Aug 25, 2034	DS DP U-2378			
	9127276	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	8906887	Aug 27, 2032	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	8906887	Aug 27, 2032	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	12678498	Jun 13, 2036	U-4584			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	12678498	Jun 13, 2036	U-4584			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	12678498	Jun 13, 2036	U-4584			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 001	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 002	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 003	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 004	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	8080580	Dec 19, 2031	DS DP U-2214			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	12551447	Nov 05, 2042	DP			
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - GWYN LO</u>						
N 219990 001					>A> NP	Jul 28, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529	002				D-199	Jan 16, 2029
<u>ETRIPAMIL - CARDAMYST</u>						
N 218571	001	10010522	Jun 19, 2028	U-38		
		10010523	Jun 19, 2028	DS		
		10117848	Apr 13, 2036	DP	U-4370	
		12257224	Jul 15, 2042		U-4370	
		9227918	Jun 19, 2028	DP		
		9463179	Jun 19, 2028		U-4370	
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565	001	7612109	Feb 05, 2027	DS DP		
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565	002	7612109	Feb 05, 2027	DS DP		
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565	003	7612109	Feb 05, 2027	DS DP		
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565	004	7612109	Feb 05, 2027	DS DP		
<u>FINERENONE - KERENDIA</u>						
N 215341	001	8436180	Aug 26, 2033	DS DP		
<u>FINERENONE - KERENDIA</u>						
N 215341	002	8436180	Aug 26, 2033	DS DP		
<u>FINERENONE - KERENDIA</u>						
N 215341	003	8436180	Aug 26, 2033	DS DP		
<u>FLIBANSERIN - ADDYI</u>						
N 022526	001				I-983	Dec 13, 2028
<u>FLORQUINITAU F-18 - TAUKLARIFY</u>						
N 220496	001	>A> 10022461	Jun 09, 2035	U-4597	>A> NCE	Aug 13, 2031
		>A> 9808542	Jun 09, 2035	DS DP U-4597		
<u>FLURPIRIDAZ F-18 - FLYRCADO</u>						
N 215168	001	12527884	May 13, 2042	DP U-4406		
<u>FLUTICASONE PROPIONATE - FLUTICASONE PROPIONATE</u>						
A 219602	001				CGT	Sep 20, 2026
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022	001	12616806	Feb 23, 2036	U-4524		
		12616806	Feb 23, 2036	U-4525		
<u>FOSFOMYCIN DISODIUM - CONTEPO</u>						
N 212271	001	>A> 12702676	Jan 30, 2039	U-4331	NP GAIN	Oct 22, 2028 Oct 22, 2033
<u>FUROSEMIDE - FUROSCIX READYFLOW (AUTOINJECTOR)</u>						
N 209988	002	>A> 11497755	Jan 30, 2040	DP		
		>A> 11559535	Jan 30, 2040	DP		
		>A> 11571434	Jan 30, 2040	DP		
		>A> 11998555	Jan 30, 2040	DP U-4589		
		>A> 12048709	Jan 30, 2040	DP U-4588		
		>A> 12491193	Jan 30, 2040	DP U-4588		
		>A> 12491194	Jan 30, 2040	DP U-4588		
		>A> 12491195	Jan 30, 2040	DP U-4588		
		>A> 12491196	Jan 30, 2040	DP U-4588		
		>A> 12491197	Jan 30, 2040	DP U-4588		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FUROSEMIDE - FUROSCIX READYFLOW (AUTOINJECTOR)</u>						
N 209988 002	>A> 11497755	Jan 30, 2040	DP			
	>A> 11559535	Jan 30, 2040	DP			
	>A> 11571434	Jan 30, 2040	DP			
	>A> 11998555	Jan 30, 2040	DP U-4589			
	>A> 12048709	Jan 30, 2040	DP U-4588			
	>A> 12491193	Jan 30, 2040	DP U-4588			
	>A> 12491194	Jan 30, 2040	DP U-4588			
	>A> 12491195	Jan 30, 2040	DP U-4588			
	>A> 12491196	Jan 30, 2040	DP U-4588			
	>A> 12491197	Jan 30, 2040	DP U-4588			
<u>FUROSEMIDE - LASIX ONYU</u>						
N 217294 001	11246851	Jan 03, 2040	DP U-4576			
	12318363	Jan 03, 2040	DP			
	12403120	Jan 10, 2042	DP U-4576			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 001	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	8114863	May 25, 2032	DS DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 002	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	8114863	May 25, 2032	DS DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	8114863	May 25, 2032	DS DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 004	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	8114863	May 25, 2032	DS DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 005	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	8114863	May 25, 2032	DS DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 006	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	8114863	May 25, 2032	DS DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 007	>A> 12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	8114863	May 25, 2032	DS DP			
<u>GADOOQUATRANE - AMBELVIST</u>						
N 219627 001	10137209	May 30, 2036	DS U-4424		NCE	Jun 12, 2031
	10722601	May 30, 2036	DS U-4424			
	11491245	May 30, 2036	DS			
	11944690	May 19, 2040	DP			
	12303573	Nov 21, 2039	DP			
	12478696	May 30, 2036	DS			
<u>GADOOQUATRANE - AMBELVIST</u>						
N 219627 002	10137209	May 30, 2036	DS U-4424		NCE	Jun 12, 2031
	10722601	May 30, 2036	DS U-4424			
	11491245	May 30, 2036	DS			
	11944690	May 19, 2040	DP			
	12303573	Nov 21, 2039	DP			
	12478696	May 30, 2036	DS			
<u>GADOOQUATRANE - AMBELVIST</u>						
N 219627 003	10137209	May 30, 2036	DS U-4424		NCE	Jun 12, 2031
	10722601	May 30, 2036	DS U-4424			
	11491245	May 30, 2036	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOQUATRANE - AMBELVIST</u>						
N 219627 003	11944690	May 19, 2040	DP			
	12303573	Nov 21, 2039	DP			
	12478696	May 30, 2036	DS			
<u>GADOQUATRANE - AMBELVIST</u>						
N 219627 004	10137209	May 30, 2036	DS	U-4424	NCE	Jun 12, 2031
	10722601	May 30, 2036	DS	U-4424		
	11491245	May 30, 2036	DS			
	11944690	May 19, 2040	DP			
	12303573	Nov 21, 2039	DP			
	12478696	May 30, 2036	DS			
<u>GADOQUATRANE - AMBELVIST</u>						
N 219627 005	10137209	May 30, 2036	DS	U-4424	NCE	Jun 12, 2031
	10722601	May 30, 2036	DS	U-4424		
	11491245	May 30, 2036	DS			
	11944690	May 19, 2040	DP			
	12303573	Nov 21, 2039	DP			
	12478696	May 30, 2036	DS			
<u>GADOQUATRANE - AMBELVIST</u>						
N 219627 006	10137209	May 30, 2036	DS	U-4424	NCE	Jun 12, 2031
	10722601	May 30, 2036	DS	U-4424		
	11491245	May 30, 2036	DS			
	11944690	May 19, 2040	DP			
	12303573	Nov 21, 2039	DP			
	12478696	May 30, 2036	DS			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	8318714	Nov 28, 2031	DP			
<u>GEDATOLISIB - REVTORPYK</u>						
N 219908 001					NCE	Jul 14, 2031
<u>GEMCITABINE HYDROCHLORIDE - INLEXZO</u>						
N 219683 001	12576253	Dec 17, 2030	DP			
	12636300	Nov 07, 2038		U-4552		
<u>GEPOTIDACIN MESYLATE - BLUJEPÄ</u>						
N 218230 001	12528809	Dec 13, 2042	DS DP	U-4361		
	12528809	Dec 13, 2042	DS DP	U-4408		
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	12606519	May 03, 2040	DS DP			
	7329689	Jan 15, 2027	DS DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	8148401	Nov 21, 2032	DS DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	8148401	Nov 21, 2032	DS DP			
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001					NPP	Mar 17, 2028
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
N 217812 001	12653820	Jan 10, 2043	DP	U-4571		
<u>IBERDOMIDE HYDROCHLORIDE - ZENBEXUS</u>						
N 221075 001					>A> NCE	Aug 13, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBERDOMIDE HYDROCHLORIDE - ZENBEXUS</u>						
N 221075 002					>A> NCE	Aug 13, 2031
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	12551448	Mar 03, 2036	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	12551448	Mar 03, 2036	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	12551448	Mar 03, 2036	DP			
<u>ICOTROKINRA HYDROCHLORIDE - ICOTYDE</u>						
N 220149 001	11845808	Jan 14, 2041	DS	U-4447	NCE	Mar 17, 2031
	11939361	Nov 19, 2041	DP	U-4447		
	12552836	Jul 12, 2039	DS DP			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	10563259	Jul 24, 2030		U-4562		
	10563259	Jul 24, 2030		U-4563		
	10570453	Mar 28, 2028		U-4562		
	10570453	Mar 28, 2028		U-4563		
	12606869	Sep 22, 2030		U-4504		
	12606869	Sep 22, 2030		U-4505		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	10563259	Jul 24, 2030		U-4562		
	10563259	Jul 24, 2030		U-4563		
	10570453	Mar 28, 2028		U-4562		
	10570453	Mar 28, 2028		U-4563		
	12606869	Sep 22, 2030		U-4504		
	12606869	Sep 22, 2030		U-4505		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	10563259	Jul 24, 2030		U-4562		
	10563259	Jul 24, 2030		U-4563		
	10570453	Mar 28, 2028		U-4562		
	10570453	Mar 28, 2028		U-4563		
	12606869	Sep 22, 2030		U-4504		
	12606869	Sep 22, 2030		U-4505		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	10563259	Jul 24, 2030		U-4562		
	10563259	Jul 24, 2030		U-4563		
	10570453	Mar 28, 2028		U-4562		
	10570453	Mar 28, 2028		U-4563		
	12606869	Sep 22, 2030		U-4504		
	12606869	Sep 22, 2030		U-4505		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	10563259	Jul 24, 2030		U-4562		
	10563259	Jul 24, 2030		U-4563		
	10570453	Mar 28, 2028		U-4562		
	10570453	Mar 28, 2028		U-4563		
	12606869	Sep 22, 2030		U-4504		
	12606869	Sep 22, 2030		U-4505		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	10563259	Jul 24, 2030		U-4562		
	10563259	Jul 24, 2030		U-4563		
	10570453	Mar 28, 2028		U-4562		
	10570453	Mar 28, 2028		U-4563		
	12606869	Sep 22, 2030		U-4504		
	12606869	Sep 22, 2030		U-4505		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	10563259	Jul 24, 2030	U-4562			
	10563259	Jul 24, 2030	U-4563			
	10570453	Mar 28, 2028	U-4562			
	10570453	Mar 28, 2028	U-4563			
	12606869	Sep 22, 2030	U-4504			
	12606869	Sep 22, 2030	U-4505			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	7494982	Dec 27, 2026	DS DP			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	7494982	Dec 27, 2026	DS DP			
<u>INCLISIRAN SODIUM - LEQVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-4249		I-985	Feb 12, 2029
	10125369	Aug 18, 2034	DS DP U-4413		NPP	Feb 12, 2029
	10125369	Aug 18, 2034	DS DP U-4414		ODE-555	Feb 12, 2033
	10131907	Aug 24, 2028	DS DP U-4249			
	10131907	Aug 24, 2028	DS DP U-4413			
	10131907	Aug 24, 2028	DS DP U-4414			
	10851377	Aug 25, 2036	U-4249			
	10851377	Aug 25, 2036	U-4413			
	10851377	Aug 25, 2036	U-4414			
	8106022	Dec 12, 2029	DS DP U-4249			
	8106022	Dec 12, 2029	DS DP U-4413			
	8106022	Dec 12, 2029	DS DP U-4414			
	8222222	Dec 29, 2027	U-4249			
	8222222	Dec 29, 2027	U-4413			
	8222222	Dec 29, 2027	U-4414			
	8809292	May 10, 2027	DS DP U-4249			
	8809292	May 10, 2027	DS DP U-4413			
	8809292	May 10, 2027	DS DP U-4414			
	8828956	Dec 04, 2028	DS DP U-4249			
	8828956	Dec 04, 2028	DS DP U-4413			
	8828956	Dec 04, 2028	DS DP U-4414			
	9370582	Dec 04, 2028	DS DP U-4249			
	9370582	Dec 04, 2028	DS DP U-4413			
	9370582	Dec 04, 2028	DS DP U-4414			
<u>INDOCYANINE GREEN - INDOCYANINE GREEN</u>						
A 219139 001					CGT	Jan 31, 2027
<u>IOHEXOL - IOHEXOL</u>						
A 217737 001					CGT	Jul 26, 2026
<u>IPRATROPIUM BROMIDE - IPRATROPIUM BROMIDE</u>						
A 217953 001					PC	Oct 13, 2026
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001					ODE-524	Mar 20, 2032
<u>LAMOTRIGINE - SUBVENITE</u>						
N 218879 001	12629377	May 29, 2040	DP U-4539			
	12629377	May 29, 2040	DP U-4540			
	12629377	May 29, 2040	DP U-4541			
	12636289	May 29, 2040	DP			
<u>LANDIOLOL HYDROCHLORIDE - RAPIBLYK</u>						
N 217202 001					NPP	Feb 13, 2029
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 001	12599606	May 14, 2040	U-4512			
	>A> RE50528	Oct 13, 2035	DS DP U-3985			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 002	12599606	May 14, 2040	U-4511			
	>A> RE50528	Oct 13, 2035	DS DP U-3985			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001	12594267	Jul 15, 2039	DP			
<u>LENACAPAVIR SODIUM - YEZTUGO</u>						
N 220018 001	12594267	Jul 15, 2039	DP			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	10799506	Apr 14, 2036	DP		I-951	Sep 17, 2027
	10799506*PED	Oct 14, 2036			>A> M-14	Jul 01, 2029
	12064434	Apr 14, 2036	DP		PED	Mar 17, 2028
	12064434*PED	Oct 14, 2036			>A> PED	Jan 01, 2030
	12419894	Apr 14, 2036	DP			
	12419894*PED	Oct 14, 2036				
	12544380	Aug 07, 2034	U-3264			
	12544380	Aug 07, 2034	U-3998			
	12544380*PED	Feb 07, 2035				
	8324225	Jun 17, 2028	DS DP			
	8324225*PED	Dec 17, 2028				
	8415355	Mar 13, 2031	DS DP			
	8415355*PED	Sep 13, 2031				
	8685980	May 25, 2030	DS DP			
	8685980*PED	Nov 25, 2030				
	8962630	Dec 09, 2029	U-2505			
	8962630	Dec 09, 2029	U-3264			
	8962630	Dec 09, 2029	U-3998			
	8962630*PED	Jun 09, 2030				
	9193732	Nov 09, 2031	DS DP			
	9193732*PED	May 09, 2032				
	9416136	Aug 20, 2029	U-2505			
	9416136	Aug 20, 2029	U-3264			
	9416136	Aug 20, 2029	U-3998			
	9416136*PED	Feb 20, 2030				
	9868739	Nov 09, 2031	U-2505			
	9868739	Nov 09, 2031	U-3264			
	9868739	Nov 09, 2031	U-3998			
	9868739*PED	May 09, 2032				
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406 001	12564592	Dec 23, 2044	DP			
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406 002	12564592	Dec 23, 2044	DP			
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406 003	12564592	Dec 23, 2044	DP			
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488 001	9572857	Aug 02, 2029	DP			
<u>LEUPROLIDE MESYLATE - CAMCEVI ETM</u>						
N 219745 001	10646572	Jan 16, 2027	DP			
	11717555	Jan 01, 2039	DP			
	12133878	Dec 18, 2037	DP			
	9572857	Aug 02, 2029	DP			
	9744207	Jan 16, 2027	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	12564565	Sep 26, 2044	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 011	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 012	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 013	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 014	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 015	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 016	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	12564565	Sep 26, 2044	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 013	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 014	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 015	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 001	12636270	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 002	12636270	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 003	12636270	Dec 01, 2036	DP			
<u>LIDOCAINE - BONDILDO</u>						
N 215029 001	>A> 8722065	Nov 10, 2028	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001	12558328	Jan 14, 2031	U-4421			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	7314938	Jun 25, 2029	DS DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001					NPP PED	Nov 04, 2028 May 04, 2029
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	10702576	Aug 11, 2031	U-1516		NPP	May 21, 2029
	10702576	Aug 11, 2031	U-3644			
	10702576	Aug 11, 2031	U-4566			
	10702576*PED	Feb 11, 2032				
	7304036	Aug 30, 2026	DS DP U-1516			
	7304036	Aug 30, 2026	DS DP U-3644			
	7304036	Aug 30, 2026	DS DP U-4566			
	7304036*PED	Feb 28, 2027				
	8933030	Feb 17, 2031	DP U-1516			
	8933030	Feb 17, 2031	DP U-3644			
	8933030	Feb 17, 2031	DP U-4566			
	8933030*PED	Aug 17, 2031				
	9708371	Aug 16, 2033	DP U-1516			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	9708371	Aug 16, 2033	DP U-3644			
	9708371	Aug 16, 2033	DP U-4566			
	9708371*PED	Feb 16, 2034				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	12678442	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	12678442	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	12678442	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	12678442	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	12678442	Apr 02, 2029	DP			
<u>LINERIXIBAT - LYNABOY</u>						
N 220295 001	9040518	Sep 06, 2031	DS DP		NCE ODE-517	Mar 17, 2031 Mar 17, 2033
<u>LISDEXAMFETAMINE DIMESYLATE - ARYNIA</u>						
N 219847 001	12582620	Apr 16, 2040	DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	12472172	Jul 29, 2041	U-4438		NPP	Feb 25, 2029
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	12472172	Jul 29, 2041	U-4438		NPP	Feb 25, 2029
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	12472172	Jul 29, 2041	U-4438		NPP	Feb 25, 2029
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	12472172	Jul 29, 2041	U-4438		NPP	Feb 25, 2029
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005					NPP	Feb 25, 2029
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 007	12472172	Jul 29, 2041	U-4438		NS	Feb 25, 2029
	7932268	Aug 19, 2027	U-1316			
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 001					CGT	May 19, 2026
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 002					CGT	May 19, 2026
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 003					CGT	May 19, 2026
<u>LOSARTAN POTASSIUM - ARBLI</u>						
N 218772 001	12605365	Oct 07, 2041	DP U-4159			
	12605365	Oct 07, 2041	DP U-4160			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	12589069	Jan 26, 2036	DP U-2764			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE; TOBRAMYCIN - LOTE PREDNOL ETABONATE AND TOBRAMYCIN</u>						
A 217597 001					CGT	Jul 14, 2026
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001					M-319	Apr 24, 2029
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002					M-319	Apr 24, 2029
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003					M-319	Apr 24, 2029
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO</u>						
N 215833 001	10398791	Mar 23, 2036	DS DP		>A> I-996	Jul 31, 2029
	>A> 10406240	Aug 15, 2028	DS DP U-4169			
	>A> 10406240	Aug 15, 2028	DS DP U-4593			
	>A> 10406240	Aug 15, 2028	DS DP U-4594			
	>A> 11318121	Aug 15, 2028	DS DP U-4169			
	>A> 11318121	Aug 15, 2028	DS DP U-4593			
	>A> 11318121	Aug 15, 2028	DS DP U-4594			
	>A> 11951190	Nov 12, 2035	U-4169			
	>A> 11951190	Nov 12, 2035	U-4593			
	>A> 11951190	Nov 12, 2035	U-4594			
	>A> 12208102	Sep 18, 2041	U-4169			
	>A> 12208102	Sep 18, 2041	U-4592			
	>A> 12208102	Sep 18, 2041	U-4593			
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001	8192719	Oct 12, 2027	U-2220		>A> M-14	Jul 23, 2029
	8192719*PED	Apr 12, 2028			>A> PED	Jan 23, 2030
<u>MACITENTAN - MACITENTAN</u>						
A 211026 001					PC	Dec 03, 2026
<u>MACITENTAN - MACITENTAN</u>						
A 211120 001					PC	Dec 03, 2026
<u>MACITENTAN - MACITENTAN</u>						
A 211187 001					PC	Dec 03, 2026
<u>MACITENTAN - MACITENTAN</u>						
A 211224 001					PC	Dec 03, 2026
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE</u>						
N 215344 001	12594298	Jun 14, 2044	DP			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	12599602	Feb 12, 2040	U-3290			
	12599602	Feb 12, 2040	U-3974			
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	12527771	Oct 11, 2043	DS DP			
	12661368	Oct 27, 2031	U-4572			
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	10265399	Apr 11, 2036	U-4509			
	10265400	Apr 11, 2036	U-4509			
	10307484	Apr 11, 2036	U-4509			
	10369225	Apr 11, 2036	U-4356			
	10456471	Apr 11, 2036	U-4509			
	11266657	Apr 11, 2036	U-1719			
	11433078	Apr 11, 2036	U-1719			
	11433079	Apr 11, 2036	U-1719			
	11944683	Apr 11, 2036	U-1719			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	12005118	Jan 25, 2043	U-1719			
	12544383	Mar 10, 2045	U-1719			
	12551488	May 28, 2040	U-1719			
	12551489	May 28, 2040	U-1719			
	12611413	Dec 29, 2041	U-1719			
	12616752	May 18, 2038	U-4510			
>A>	12685736	May 09, 2040	U-1719			
>A>	12691123	Apr 11, 2036	U-1719			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	12533342	Apr 06, 2039	U-3421			
<u>METAXALONE - METAXALONE</u>						
N 022503 001	12485111	May 14, 2043	DP U-4453			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					M-14	Oct 11, 2027
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					M-14	Oct 11, 2027
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					M-14	Oct 11, 2027
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - SITAGLIPTIN AND METFORMIN HYDROCHLORIDE</u>						
A 202388 001					PC	Nov 24, 2026
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - SITAGLIPTIN AND METFORMIN HYDROCHLORIDE</u>						
A 202388 002					PC	Nov 24, 2026
<u>METHOTREXATE - JYLAMVO</u>						
N 212479 001	12605385	Oct 25, 2035	DP			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	12594268	May 23, 2041	U-2371			
	12599594	Jul 19, 2036	U-2371			
	12599595	Apr 28, 2028	U-2371			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 001	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 002	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 002	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 003	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 004	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 005	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 005	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 006	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 007	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	12661407	Oct 01, 2030	U-1631			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - EMROSI</u>						
N 219015 001	12594252	Jan 07, 2039	U-4043			
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219379 001	>A> 11819487	Feb 17, 2041	U-4590			
	>A> 12011424	Feb 17, 2041	U-4595			
	>A> 12295925	Feb 17, 2041	U-4590			
	>A> 12324791	Mar 16, 2043	U-4591			
	12661330	Feb 05, 2044	U-4130			
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219379 002	>A> 11066358	Feb 17, 2041	DS DP		>A> NCE	Feb 11, 2030
	>A> 11084780	Feb 17, 2041	DS		>A> ODE*	Feb 11, 2032
	>A> 11453641	Feb 17, 2041		U-4130		
	>A> 11571402	Feb 17, 2041	DP			
	>A> 11806321	Feb 17, 2041		U-4130		
	>A> 11819487	Feb 17, 2041		U-4590		
	>A> 11883375	Mar 16, 2043		U-4130		
	>A> 12029711	Mar 15, 2044	DP	U-4130		
	>A> 12037306	Feb 17, 2041		U-4130		
	>A> 12220390	Mar 16, 2043		U-4130		
	>A> 12257215	Mar 16, 2043		U-4130		
	>A> 12263146	Feb 17, 2041		U-4130		
	>A> 12295925	Feb 17, 2041		U-4590		
	>A> 12324791	Mar 16, 2043		U-4591		
	>A> 12357597	Feb 17, 2041		U-4130		
	>A> 12390430	Oct 10, 2044		U-4130		
	>A> 12661330	Feb 05, 2044		U-4130		
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219379 003	>A> 11066358	Feb 17, 2041	DS DP		>A> NCE	Feb 11, 2030
	>A> 11084780	Feb 17, 2041	DS		>A> ODE*	Feb 11, 2032
	>A> 11453641	Feb 17, 2041		U-4130		
	>A> 11571402	Feb 17, 2041	DP			
	>A> 11806321	Feb 17, 2041		U-4130		
	>A> 11819487	Feb 17, 2041		U-4590		
	>A> 12029711	Mar 15, 2044	DP	U-4130		
	>A> 12037306	Feb 17, 2041		U-4130		
	>A> 12220390	Mar 16, 2043		U-4130		
	>A> 12263146	Feb 17, 2041		U-4130		
	>A> 12295925	Feb 17, 2041		U-4590		
	>A> 12324791	Mar 16, 2043		U-4591		
	>A> 12357597	Feb 17, 2041		U-4130		
	>A> 12390430	Oct 10, 2044		U-4130		
	>A> 12661330	Feb 05, 2044		U-4130		
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 001	>A> 11819487	Feb 17, 2041	U-4590			
	>A> 12011424	Feb 17, 2041	U-4595			
	>A> 12295925	Feb 17, 2041	U-4590			
	>A> 12324791	Mar 16, 2043	U-4591			
	12661330	Feb 05, 2044	U-4130			
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 002	>A> 11819487	Feb 17, 2041	U-4590			
	>A> 12295925	Feb 17, 2041	U-4590			
	>A> 12324791	Mar 16, 2043	U-4591			
	12661330	Feb 05, 2044	U-4130			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	RE49582	Apr 11, 2035	DS DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	RE49582	Apr 11, 2035	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	RE49582	Apr 11, 2035	DS DP			
<u>MITAPIVAT SULFATE - AOVESME</u>						
N 216196 004	10632114	May 03, 2032	U-4391		NCE	Feb 17, 2027
	11254652	Nov 21, 2038	DS DP		NP	Dec 23, 2028
	11878049	Jul 31, 2041	U-4390		ODE-522	Dec 23, 2032
	9193701	Oct 26, 2032	U-4393			
	9682080	May 03, 2032	U-4392			
	RE49582	Apr 11, 2035	DS DP			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	12576089	Aug 21, 2039	U-4441			
	8486941	Jan 03, 2035	DS DP U-1201			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	12576089	Aug 21, 2039	U-4441			
	8486941	Jan 03, 2035	DS DP U-1201			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	12576089	Aug 21, 2039	U-4441			
	8486941	Jan 03, 2035	DS DP U-1201			
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	12653833	Nov 21, 2044	DP U-4564		NPP	Jul 07, 2029
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					ODE-528	Feb 07, 2032
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001	12514854	Feb 05, 2041	U-4397			
	12622903	Feb 05, 2041	DP			
<u>NAVEPEGITIDE - YUWIVEL</u>						
N 219164 001	10835578	Jan 05, 2037	DS DP U-4425		NCE	Feb 27, 2031
	11154593	Jan 05, 2037	DS DP U-4425		ODE-516	Feb 27, 2033
	11224661	Jan 05, 2037	DS DP			
	11311604	Jan 05, 2037	DS DP U-4425			
	11389510	Jan 05, 2037	DS DP			
	11389511	Jan 05, 2037	DP U-4425			
	11413351	Jan 05, 2037	DS DP			
	12083182	Jan 05, 2037	U-4425			
	12156917	Jan 05, 2037	U-4425			
	12239689	Jan 05, 2037	U-4425			
	12377133	Nov 12, 2042	DP U-4425			
	8906847	Apr 30, 2031	DS DP U-4425			
<u>NAVEPEGITIDE - YUWIVEL</u>						
N 219164 002	10835578	Jan 05, 2037	DS DP U-4425		NCE	Feb 27, 2031
	11154593	Jan 05, 2037	DS DP U-4425		ODE-516	Feb 27, 2033
	11224661	Jan 05, 2037	DS DP			
	11311604	Jan 05, 2037	DS DP U-4425			
	11389510	Jan 05, 2037	DS DP			
	11389511	Jan 05, 2037	DP U-4425			
	11413351	Jan 05, 2037	DS DP			
	12083182	Jan 05, 2037	U-4425			
	12156917	Jan 05, 2037	U-4425			
	12239689	Jan 05, 2037	U-4425			
	12377133	Nov 12, 2042	DP U-4425			
	8906847	Apr 30, 2031	DS DP U-4425			
<u>NAVEPEGITIDE - YUWIVEL</u>						
N 219164 003	10835578	Jan 05, 2037	DS DP U-4425		NCE	Feb 27, 2031
	11154593	Jan 05, 2037	DS DP U-4425		ODE-516	Feb 27, 2033
	11224661	Jan 05, 2037	DS DP			
	11311604	Jan 05, 2037	DS DP U-4425			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NAVEPEGRTIDE - YUWIEL</u>						
N 219164 003	11389510	Jan 05, 2037	DS DP			
	11389511	Jan 05, 2037	DP U-4425			
	11413351	Jan 05, 2037	DS DP			
	12083182	Jan 05, 2037	U-4425			
	12156917	Jan 05, 2037	U-4425			
	12239689	Jan 05, 2037	U-4425			
	12377133	Nov 12, 2042	DP U-4425			
	8906847	Apr 30, 2031	DS DP U-4425			
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 001					ODE-531	Mar 27, 2032
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 002					ODE-531	Mar 27, 2032
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 003					ODE-531	Mar 27, 2032
<u>NERANDOMILAST - JASCAYD</u>						
N 218764 001	11406638	Oct 22, 2038	U-4297		I-979	Dec 19, 2028
	11406638	Oct 22, 2038	U-4373		ODE-546	Oct 07, 2032
	11813266	Oct 22, 2038	U-4292			
	11813266	Oct 22, 2038	U-4372			
<u>NERANDOMILAST - JASCAYD</u>						
N 218764 002	11406638	Oct 22, 2038	U-4297		I-979	Dec 19, 2028
	11406638	Oct 22, 2038	U-4373		ODE-546	Oct 07, 2032
	11813266	Oct 22, 2038	U-4292			
	11813266	Oct 22, 2038	U-4372			
<u>NILOTINIB - CAVHANZA</u>						
N 217379 001	11389450	Jan 29, 2041	U-4556			
	11389450	Jan 29, 2041	U-4557			
	11559485	Apr 30, 2041	DP			
	12016861	Jan 29, 2041	U-4554			
	12016861	Jan 29, 2041	U-4555			
	12029740	Jan 29, 2041	DP			
<u>NILOTINIB - CAVHANZA</u>						
N 217379 002	11389450	Jan 29, 2041	U-4556			
	11389450	Jan 29, 2041	U-4557			
	11559485	Apr 30, 2041	DP			
	12016861	Jan 29, 2041	U-4554			
	12016861	Jan 29, 2041	U-4555			
	12029740	Jan 29, 2041	DP			
<u>NILOTINIB TARTRATE - DANZITEN</u>						
N 219293 001	12629369	Feb 18, 2040	DP			
<u>NILOTINIB TARTRATE - DANZITEN</u>						
N 219293 002	12629369	Feb 18, 2040	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	12599587	Jul 08, 2042	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	12599587	Jul 08, 2042	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	12599587	Jul 08, 2042	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITISINONE - HARLIKU</u>						
N 209449	004				ODE-529	Jun 10, 2032
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700	004	10888534	Apr 26, 2039	DP		
		RE49422	Feb 26, 2035	DP		
		RE49443	Feb 26, 2035	DP		
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531	002	7838657	Jul 11, 2027	DS DP	NS	Mar 27, 2029
		8361977	Dec 23, 2030	DS DP		
		8980853	Nov 24, 2030	U-1941		
		9717750	Jun 17, 2030	U-1942		
		9717750	Jun 17, 2030	U-1943		
		9717750	Jun 17, 2030	U-2093		
		9717750	Jun 17, 2030	U-2094		
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531	003	7838657	Jul 11, 2027	DS DP	NS	Mar 27, 2029
		8361977	Dec 23, 2030	DS DP		
		8980853	Nov 24, 2030	U-1941		
		9717750	Jun 17, 2030	U-1942		
		9717750	Jun 17, 2030	U-1943		
		9717750	Jun 17, 2030	U-2093		
		9717750	Jun 17, 2030	U-2094		
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589	001				CGT	Aug 02, 2026
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589	002				CGT	Jul 27, 2026
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589	003				CGT	Jul 27, 2026
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498	001	12508234	Jun 20, 2039	U-3186		
		12508234	Jun 20, 2039	U-3648		
		12545705	Nov 08, 2031	U-3186		
		12545705	Nov 08, 2031	U-3648		
		9694018	Mar 18, 2034	U-3186		
		9694018	Mar 18, 2034	U-3648		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498	002	12508234	Jun 20, 2039	U-3186		
		12508234	Jun 20, 2039	U-3648		
		12545705	Nov 08, 2031	U-3186		
		12545705	Nov 08, 2031	U-3648		
		9694018	Mar 18, 2034	U-3186		
		9694018	Mar 18, 2034	U-3648		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498	003	12508234	Jun 20, 2039	U-3186		
		12508234	Jun 20, 2039	U-3648		
		12545705	Nov 08, 2031	U-3186		
		12545705	Nov 08, 2031	U-3648		
		9694018	Mar 18, 2034	U-3186		
		9694018	Mar 18, 2034	U-3648		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498	004	12508234	Jun 20, 2039	U-3186		
		12508234	Jun 20, 2039	U-3648		
		12545705	Nov 08, 2031	U-3186		
		12545705	Nov 08, 2031	U-3648		
		9694018	Mar 18, 2034	U-3186		
		9694018	Mar 18, 2034	U-3648		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
	9694018	Mar 18, 2034	U-3186			
	9694018	Mar 18, 2034	U-3648			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)</u>						
N 218614 001	12509684	May 01, 2034	U-4050		I-992	Jun 24, 2029
	12509684	May 01, 2034	U-4580			
	9157082	Apr 27, 2032	U-4050			
	9157082	Apr 27, 2032	U-4580			
<u>OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)</u>						
N 218614 002	12509684	May 01, 2034	U-4580		NS	Jun 24, 2029
	9127276	May 01, 2034	DS			
	9157082	Apr 27, 2032	U-4580			
	9163239	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001					M-320	May 13, 2029
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001					M-320	May 13, 2029
<u>OMEPRazole - OMEPRazole</u>						
N 022032 001	12599565	Jan 31, 2030	DP			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	8168793	Oct 10, 2027	DS DP U-3869			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	8168793	Oct 10, 2027	DS DP U-3869			
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 001	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 002	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 003	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 004	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 005	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 006	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	12514899	Aug 29, 2029	U-4398			
<u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u>						
N 214155 001	12514899	Aug 29, 2029	U-4398			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	10709691	Oct 12, 2035	U-4529		ODE-535	Apr 15, 2032
	8314097	May 20, 2033	DS DP			
	8609862	Jan 13, 2031	U-4529			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 002	10709691	Oct 12, 2035	U-4529		ODE-535	Apr 15, 2032
	8314097	May 20, 2033	DS DP			
	8609862	Jan 13, 2031	U-4529			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 003					ODE-535	Apr 15, 2032
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	7771707	Oct 09, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	12605363	Dec 16, 2039	DP			
	12648930	Dec 16, 2039	U-2849			
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001	9061057	Nov 29, 2035	DS DP U-3291			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001					I-995	Jun 24, 2029
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002					I-995	Jun 24, 2029
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003					I-995	Jun 24, 2029
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001					I-995	Jun 24, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002					I-995	Jun 24, 2029
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003					I-995	Jun 24, 2029
<u>PALTUSOTINE HYDROCHLORIDE - PALSONIFY</u>						
N 219070 001					ODE-537	Sep 25, 2032
<u>PALTUSOTINE HYDROCHLORIDE - PALSONIFY</u>						
N 219070 002					ODE-537	Sep 25, 2032
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001					ODE-533 ODE-539	Jul 28, 2032 Jul 28, 2032
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	12528836	Oct 07, 2036	U-4394			
<u>PEMETREXED DIPOTASSIUM - AXTLE</u>						
N 210661 001	>A> 12721811	Jun 25, 2045	DP			
<u>PEMETREXED DIPOTASSIUM - AXTLE</u>						
N 210661 002	>A> 12721811	Jun 25, 2045	DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	12552792	Oct 03, 2040	DS DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	12552792	Oct 03, 2040	DS DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	12552792	Oct 03, 2040	DS DP			
<u>PERAMPANEL - PERAMPANEL</u>						
A 218152 001					PC	Jun 14, 2026
<u>PERFLUOROHEXYLOCTANE - MIEBO</u>						
N 216675 001	>A> 10682315	Sep 29, 2036	U-4586			
	>A> 12005033	Sep 12, 2033	U-4586			
	>A> 12128010	Sep 29, 2036	DP			
	>A> RE50060	Jun 21, 2037	U-4586			
<u>PHENOBARBITAL SODIUM - SEZABY</u>						
N 215910 001	12636254	Apr 07, 2042	DP U-3779			
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	12201615	Oct 25, 2039	U-3804			
	12576066	Oct 25, 2039	U-3804			
	12576067	Oct 25, 2039	U-3804			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE</u>						
N 216830 001	12564561	Aug 08, 2044	DP			
<u>PIFLUFOLASTAT F-18 - PYLARIFY TRUVU</u>						
N 220089 001	10947197	Jun 09, 2037	DS DP U-3317		NCE	May 26, 2026
	11851407	Jun 09, 2037	DS DP U-3317			
	12070513	Jul 31, 2029	DS DP U-3317			
	8487129	Nov 07, 2027	DS DP			
	8778305	Sep 21, 2030	DS DP U-3317			
	9861713	Jul 31, 2029	DS DP U-3317			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	7601740	Apr 29, 2030	DS DP		M-14	Apr 27, 2029
	7601740*PED	Oct 29, 2030			PED	Oct 27, 2029
	7732615	Jun 03, 2028	DS DP			
	7732615*PED	Dec 03, 2028				
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10517860	Mar 23, 2037		U-1974	M-14	Apr 27, 2029
	10517860*PED	Sep 23, 2037			PED	Oct 27, 2029
	10953000	Mar 23, 2037		U-1974		
	10953000*PED	Sep 23, 2037				
	7601740	Apr 29, 2030	DS DP			
	7601740*PED	Oct 29, 2030				
	7732615	Jun 03, 2028	DS DP			
	7732615*PED	Dec 03, 2028				
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	10449185	Aug 27, 2038	DP		M-14	Apr 27, 2029
	10449185*PED	Feb 27, 2039			PED	Oct 27, 2029
	10646480	Aug 27, 2038	DP			
	10646480*PED	Feb 27, 2039				
	10849891	Aug 27, 2038	DP U-1974			
	10849891*PED	Feb 27, 2039				
	11452721	Aug 27, 2038	DP			
	11452721*PED	Feb 27, 2039				
	7601740	Apr 29, 2030	DS DP			
	7601740*PED	Oct 29, 2030				
	7732615	Jun 03, 2028	DS DP			
	7732615*PED	Dec 03, 2028				
<u>PIMOZIDE - PIMOZIDE</u>						
A 219897 001					CGT	Oct 18, 2026
<u>PIMOZIDE - PIMOZIDE</u>						
A 219897 002					CGT	Oct 18, 2026
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001					I-981	Dec 02, 2028
					ODE-518	Dec 03, 2032
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002					I-981	Dec 02, 2028
					ODE-518	Dec 03, 2032
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					ODE-519	Feb 13, 2033
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					ODE-519	Feb 13, 2033
<u>PLOZASIRAN SODIUM - REDEMPLO</u>						
N 219947 001					ODE-541	Nov 18, 2032
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 001					PC	Aug 29, 2026
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 002					PC	Aug 29, 2026
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 003					PC	Aug 29, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111	004				PC	Aug 29, 2026
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053	001				NPP	Jan 27, 2029
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596	001	9023790	Jul 04, 2031	DP U-1698	NPP	Jan 27, 2029
		9023790	Jul 04, 2031	DP U-3160		
		9023790	Jul 04, 2031	DP U-3171		
		9023790	Jul 04, 2031	DP U-4415		
		9023790	Jul 04, 2031	DP U-4416		
		9358297	Jun 24, 2031	DP U-3160		
		9358297	Jun 24, 2031	DP U-3171		
		9358297	Jun 24, 2031	DP U-4415		
		9358297	Jun 24, 2031	DP U-4416		
<u>POSACONAZOLE - NOXAFIL POWDERMIX KIT</u>						
N 214770	001				I-984	Jan 27, 2029
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
N 206814	001	12539314	Mar 07, 2039	DP		
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
N 206814	002	12539314	Mar 07, 2039	DP		
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE</u>						
N 218343	001	11925661	Oct 12, 2041	DP U-4185		
<u>PRALSETINIB - GAVRETO</u>						
N 213721	001	12448366	Jul 07, 2042	DS		
		12539303	Apr 03, 2039	U-2828		
		12655128	Nov 01, 2036	DS DP		
	>A>	12692251	Apr 19, 2043	DP		
<u>PRETOMANID - PRETOMANID</u>						
N 212862	001				>A> ODE-253	Aug 14, 2026
					>A> GAIN	Aug 14, 2031
<u>PROBENECID; SULOPENEM ETZADROXIL - ORLYNVAH</u>						
N 213972	001	12544337	Dec 23, 2039	DP U-4026		
<u>PROPRANOLOL HYDROCHLORIDE - PROPRANOLOL HYDROCHLORIDE</u>						
A 219165	001				>A> CGT	Feb 15, 2027
<u>RELACORILANT - LIFYORLI (COPACKAGED)</u>						
N 220641	001	10456392	May 24, 2033	U-4457	NCE	Mar 25, 2031
		11285145	May 26, 2041	U-4457		
		11285145	May 26, 2041	U-4458		
		11285145	May 26, 2041	U-4459		
		11464764	Apr 14, 2040	DP		
		11576907	May 24, 2033	DS DP U-4457		
		11576907	May 24, 2033	DS DP U-4458		
		11576907	May 24, 2033	DS DP U-4459		
		11925626	Dec 18, 2039	DP		
		12152028	Dec 22, 2041	DP U-4457		
		12152028	Dec 22, 2041	DP U-4458		
		12152028	Dec 22, 2041	DP U-4459		
		12514849	Dec 18, 2039	DP		
		12589094	May 26, 2041	U-4457		
		12589094	May 26, 2041	U-4458		
		12589094	May 26, 2041	U-4459		
		8859774	May 24, 2033	DS DP		
		9273047	May 24, 2033	U-4457		
		9273047	May 24, 2033	U-4458		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RELACORILANT - LIFYORLI (COPACKAGED)</u>						
N 220641 001	9273047	May 24, 2033	U-4459			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	12629370	Sep 29, 2037	U-3020			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10065958	Nov 18, 2032	DS		>A> NPP	Feb 28, 2027
	10065958*PED	May 18, 2033			>A> PED	Aug 28, 2027
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Nov 18, 2032	DS		>A> NPP	Feb 28, 2027
	10065958*PED	May 18, 2033			>A> PED	Aug 28, 2027
<u>REMIBRUTINIB - RHAPSIDO</u>						
N 218436 001	12419889	Jan 19, 2043	U-4281			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	12661359	Jan 28, 2042	U-4568			
	12667575	Feb 04, 2045	U-4567			
	7452882	Sep 12, 2027	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	12661359	Jan 28, 2042	U-4568			
	12667575	Feb 04, 2045	U-4567			
	7452882	Sep 12, 2027	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	12661359	Jan 28, 2042	U-4568			
	7452882	Sep 12, 2027	DS DP			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 001	12564590	Dec 18, 2042	DP U-4045			
	12564590	Dec 18, 2042	DP U-4327			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 002	12564590	Dec 18, 2042	DP U-4045			
	12564590	Dec 18, 2042	DP U-4327			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 003	12564590	Dec 18, 2042	DP U-4045			
	12564590	Dec 18, 2042	DP U-4327			
<u>REZAFUNGIN ACETATE - REZZAYO</u>						
N 217417 001	8722619	May 09, 2036	DS DP U-3566			
<u>RIBOCICLIB SUCCINATE - KISQALI</u>						
N 209092 001	10799506	Apr 14, 2036	DP		I-950	Sep 17, 2027
	10799506*PED	Oct 14, 2036			>A> M-14	Jul 01, 2029
	12064434	Apr 14, 2036	DP		PED	Mar 17, 2028
	12064434*PED	Oct 14, 2036			>A> PED	Jan 01, 2030
	12419894	Apr 14, 2036	DP			
	12419894*PED	Oct 14, 2036				
	12544379	Aug 07, 2034	U-3975			
	12544379*PED	Feb 07, 2035				
	12544380	Aug 07, 2034	U-4404			
	12544380	Aug 07, 2034	U-4405			
	12544380*PED	Feb 07, 2035				
	8324225	Jun 17, 2028	DS DP			
	8324225*PED	Dec 17, 2028				
	8415355	Mar 13, 2031	DS DP			
	8415355*PED	Sep 13, 2031				
	8685980	May 25, 2030	DS DP			
	8685980*PED	Nov 25, 2030				
	8962630	Dec 09, 2029	U-1981			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	8962630	Dec 09, 2029	U-2355			
	8962630	Dec 09, 2029	U-2356			
	8962630	Dec 09, 2029	U-3265			
	8962630	Dec 09, 2029	U-3266			
	8962630	Dec 09, 2029	U-3975			
	8962630	Dec 09, 2029	U-3999			
	8962630*PED	Jun 09, 2030				
	9193732	Nov 09, 2031	DS DP			
	9193732*PED	May 09, 2032				
	9416136	Aug 20, 2029	U-1981			
	9416136	Aug 20, 2029	U-2355			
	9416136	Aug 20, 2029	U-2356			
	9416136	Aug 20, 2029	U-3265			
	9416136	Aug 20, 2029	U-3266			
	9416136	Aug 20, 2029	U-3975			
	9416136	Aug 20, 2029	U-3999			
	9416136*PED	Feb 20, 2030				
	9868739	Nov 09, 2031	U-1981			
	9868739	Nov 09, 2031	U-2355			
	9868739	Nov 09, 2031	U-2356			
	9868739	Nov 09, 2031	U-3265			
	9868739	Nov 09, 2031	U-3266			
	9868739	Nov 09, 2031	U-3975			
	9868739	Nov 09, 2031	U-3999			
	9868739*PED	May 09, 2032				
<u>RILZABRUTINIB - WAYRILZ</u>						
N 219685 001					ODE-552	Aug 29, 2032
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	>A> 12708617	Dec 30, 2040	U-3219			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	>A> 11129818	Aug 25, 2037	U-3408		NPP	Jun 29, 2029
	>A> 11129818	Aug 25, 2037	U-3712			
	>A> 11129818	Aug 25, 2037	U-4578			
	>A> 11819496	Jun 07, 2037	U-3748			
	>A> 11819496	Jun 07, 2037	U-4578			
	>A> 11992480	Jun 07, 2037	U-4578			
	>A> 12005051	Jun 07, 2037	U-4578			
	>A> 12310956	Jun 07, 2037	U-4578			
	>A> 9907788	Jun 07, 2037	U-3408			
	>A> 9907788	Jun 07, 2037	U-3712			
	>A> 9907788	Jun 07, 2037	U-4578			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROMIDEPSIN - ROMIDEPSIN</u>						
A 219099	001				CGT	Dec 07, 2026
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	001				I-982	Dec 17, 2028
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	002				I-982	Dec 17, 2028
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	003				I-982	Dec 17, 2028
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309	001	12544381	May 20, 2031	DP		
		12564593	May 20, 2031	DP		
		12589096	Sep 04, 2040	U-3505		
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180	001	10016429	Jun 12, 2028	U-3226	ODE*	Sep 22, 2028
		10016429	Jun 12, 2028	U-3230	PED	Mar 22, 2029
		10016429*PED	Dec 12, 2028			
		10874616	Nov 14, 2033	DP		
		10874616*PED	May 14, 2034			
		11213528	Jun 12, 2028	DP		
		11213528*PED	Dec 12, 2028			
		11337927	Jan 17, 2034	U-3226		
		11337927	Jan 17, 2034	U-3227		
		11337927	Jan 17, 2034	U-3228		
		11337927	Jan 17, 2034	U-3230		
		11337927*PED	Jul 17, 2034			
		11576864	Nov 14, 2033	U-3226		
		11576864	Nov 14, 2033	U-3227		
		11576864	Nov 14, 2033	U-3228		
		11576864	Nov 14, 2033	U-3230		
		11576864*PED	May 14, 2034			
		11576865	Nov 14, 2033	DP U-3226		
		11576865	Nov 14, 2033	DP U-3227		
		11576865	Nov 14, 2033	DP U-3228		
		11576865	Nov 14, 2033	DP U-3230		
		11576865*PED	May 14, 2034			
		11744832	Dec 12, 2026	U-3226		
		11744832	Dec 12, 2026	U-3230		
		11896717	Nov 14, 2033	DP U-3226		
		11896717	Nov 14, 2033	DP U-3227		
		11896717	Nov 14, 2033	DP U-3228		
		11896717	Nov 14, 2033	DP U-3230		
		11896717*PED	May 14, 2034			
		7598257	Dec 24, 2027	DS DP U-3227		
		7598257	Dec 24, 2027	DS DP U-3228		
		7598257*PED	Jun 24, 2028			
		8415362	Dec 24, 2027	DS DP		
		8415362*PED	Jun 24, 2028			
		8530485	Dec 12, 2026	DP		
		8722693	Jun 12, 2028	DS DP		
		8722693*PED	Dec 12, 2028			
		8822481	Jun 12, 2028	U-3226		
		8822481	Jun 12, 2028	U-3227		
		8822481	Jun 12, 2028	U-3228		
		8822481	Jun 12, 2028	U-3230		
		8822481*PED	Dec 12, 2028			
		8829013	Jun 12, 2028	U-3227		
		8829013	Jun 12, 2028	U-3228		
		8829013*PED	Dec 12, 2028			
		9079912	Dec 12, 2026	U-3226		
		9079912	Dec 12, 2026	U-3227		
		9079912	Dec 12, 2026	U-3228		
		9079912	Dec 12, 2026	U-3230		
		9206187	Dec 12, 2026	U-3227		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 001	9206187	Dec 12, 2026	U-3228			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 002	10016429	Jun 12, 2028	U-3226		ODE*	Sep 22, 2028
	10016429	Jun 12, 2028	U-3230		PED	Mar 22, 2029
	10016429*PED	Dec 12, 2028				
	10874616	Nov 14, 2033	DP			
	10874616*PED	May 14, 2034				
	11213528	Jun 12, 2028	DP			
	11213528*PED	Dec 12, 2028				
	11337927	Jan 17, 2034	U-3226			
	11337927	Jan 17, 2034	U-3227			
	11337927	Jan 17, 2034	U-3228			
	11337927	Jan 17, 2034	U-3230			
	11337927*PED	Jul 17, 2034				
	11576864	Nov 14, 2033	U-3226			
	11576864	Nov 14, 2033	U-3227			
	11576864	Nov 14, 2033	U-3228			
	11576864	Nov 14, 2033	U-3230			
	11576864*PED	May 14, 2034				
	11576865	Nov 14, 2033	DP U-3226			
	11576865	Nov 14, 2033	DP U-3227			
	11576865	Nov 14, 2033	DP U-3228			
	11576865	Nov 14, 2033	DP U-3230			
	11576865*PED	May 14, 2034				
	11744832	Dec 12, 2026	U-3226			
	11744832	Dec 12, 2026	U-3230			
	11896717	Nov 14, 2033	DP U-3226			
	11896717	Nov 14, 2033	DP U-3227			
	11896717	Nov 14, 2033	DP U-3228			
	11896717	Nov 14, 2033	DP U-3230			
	11896717*PED	May 14, 2034				
	7598257	Dec 24, 2027	DS DP U-3227			
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8530485	Dec 12, 2026	DP			
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9206187	Dec 12, 2026	U-3227			
	9206187	Dec 12, 2026	U-3228			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 003	10016429	Jun 12, 2028	U-3226		ODE*	Sep 22, 2028
	10016429	Jun 12, 2028	U-3230		PED	Mar 22, 2029
	10016429*PED	Dec 12, 2028				
	10874616	Nov 14, 2033	DP			
	10874616*PED	May 14, 2034				
	11213528	Jun 12, 2028	DP			
	11213528*PED	Dec 12, 2028				
	11337927	Jan 17, 2034	U-3226			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 003	11337927	Jan 17, 2034	U-3227			
	11337927	Jan 17, 2034	U-3228			
	11337927	Jan 17, 2034	U-3230			
	11337927*PED	Jul 17, 2034				
	11576864	Nov 14, 2033	U-3226			
	11576864	Nov 14, 2033	U-3227			
	11576864	Nov 14, 2033	U-3228			
	11576864	Nov 14, 2033	U-3230			
	11576864*PED	May 14, 2034				
	11576865	Nov 14, 2033	DP U-3226			
	11576865	Nov 14, 2033	DP U-3227			
	11576865	Nov 14, 2033	DP U-3228			
	11576865	Nov 14, 2033	DP U-3230			
	11576865*PED	May 14, 2034				
	11744832	Dec 12, 2026	U-3226			
	11744832	Dec 12, 2026	U-3230			
	11896717	Nov 14, 2033	DP U-3226			
	11896717	Nov 14, 2033	DP U-3227			
	11896717	Nov 14, 2033	DP U-3228			
	11896717	Nov 14, 2033	DP U-3230			
	11896717*PED	May 14, 2034				
	7598257	Dec 24, 2027	DS DP U-3227			
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8530485	Dec 12, 2026	DP			
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9206187	Dec 12, 2026	U-3227			
	9206187	Dec 12, 2026	U-3228			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 004	10016429	Jun 12, 2028	U-3226		ODE*	Sep 22, 2028
	10016429	Jun 12, 2028	U-3230		PED	Mar 22, 2029
	10016429*PED	Dec 12, 2028				
	10874616	Nov 14, 2033	DP			
	10874616*PED	May 14, 2034				
	11213528	Jun 12, 2028	DP			
	11213528*PED	Dec 12, 2028				
	11337927	Jan 17, 2034	U-3226			
	11337927	Jan 17, 2034	U-3227			
	11337927	Jan 17, 2034	U-3228			
	11337927	Jan 17, 2034	U-3230			
	11337927*PED	Jul 17, 2034				
	11576864	Nov 14, 2033	U-3226			
	11576864	Nov 14, 2033	U-3227			
	11576864	Nov 14, 2033	U-3228			
	11576864	Nov 14, 2033	U-3230			
	11576864*PED	May 14, 2034				
	11576865	Nov 14, 2033	DP U-3226			
	11576865	Nov 14, 2033	DP U-3227			
	11576865	Nov 14, 2033	DP U-3228			
	11576865	Nov 14, 2033	DP U-3230			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 004	11576865*PED	May 14, 2034				
	11744832	Dec 12, 2026	U-3226			
	11744832	Dec 12, 2026	U-3230			
	11896717	Nov 14, 2033	DP U-3226			
	11896717	Nov 14, 2033	DP U-3227			
	11896717	Nov 14, 2033	DP U-3228			
	11896717	Nov 14, 2033	DP U-3230			
	11896717*PED	May 14, 2034				
	7598257	Dec 24, 2027	DS DP U-3227			
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8530485	Dec 12, 2026	DP			
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9206187	Dec 12, 2026	U-3227			
	9206187	Dec 12, 2026	U-3228			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 005	10016429	Jun 12, 2028	U-3226		ODE*	Sep 22, 2028
	10016429	Jun 12, 2028	U-3230		PED	Mar 22, 2029
	10016429*PED	Dec 12, 2028				
	10874616	Nov 14, 2033	DP			
	10874616*PED	May 14, 2034				
	11213528	Jun 12, 2028	DP			
	11213528*PED	Dec 12, 2028				
	11337927	Jan 17, 2034	U-3226			
	11337927	Jan 17, 2034	U-3227			
	11337927	Jan 17, 2034	U-3228			
	11337927	Jan 17, 2034	U-3230			
	11337927*PED	Jul 17, 2034				
	11576864	Nov 14, 2033	U-3226			
	11576864	Nov 14, 2033	U-3227			
	11576864	Nov 14, 2033	U-3228			
	11576864	Nov 14, 2033	U-3230			
	11576864*PED	May 14, 2034				
	11576865	Nov 14, 2033	DP U-3226			
	11576865	Nov 14, 2033	DP U-3227			
	11576865	Nov 14, 2033	DP U-3228			
	11576865	Nov 14, 2033	DP U-3230			
	11576865*PED	May 14, 2034				
	11744832	Dec 12, 2026	U-3226			
	11744832	Dec 12, 2026	U-3230			
	11896717	Nov 14, 2033	DP U-3226			
	11896717	Nov 14, 2033	DP U-3227			
	11896717	Nov 14, 2033	DP U-3228			
	11896717	Nov 14, 2033	DP U-3230			
	11896717*PED	May 14, 2034				
	7598257	Dec 24, 2027	DS DP U-3227			
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 005	8530485	Dec 12, 2026	DP			
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9206187	Dec 12, 2026	U-3227			
	9206187	Dec 12, 2026	U-3228			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-14	Oct 11, 2027
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-14	Oct 11, 2027
<u>SEBETRALSTAT - EKTERLY</u>						
N 219301 001					ODE-534	Jul 03, 2032
<u>SELADELPAR LYSINE - LIVDELZI</u>						
N 217899 001	>A> 7301050	Aug 02, 2027	DS DP			
	>A> 7709682	Sep 13, 2027	DS			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
N 207947 005	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
N 207947 007	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
N 207947 007	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 010	10821108	Dec 01, 2036	DP U-2992		NS	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 011	10821108	Dec 01, 2036	DP U-2992		NS	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 214275 001	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-3018			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-3018			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-3018			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 004	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-3018			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 005	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-3018			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-3018			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001					ODE-545	Nov 19, 2032
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002					ODE-545	Nov 19, 2032
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 219943 001					ODE*	Nov 19, 2032

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 219943	002				ODE*	Nov 19, 2032
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	001	9457154	Sep 29, 2027	DP	Y	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	002	12295988	Oct 10, 2038	U-1852		
		12569543	Apr 28, 2037	U-4446		
		9457154	Sep 29, 2027	DP	Y	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	003	12569543	Apr 28, 2037	U-4446		
		9457154	Sep 29, 2027	DP	Y	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	004	12295988	Oct 10, 2038	U-1852		
		12569543	Apr 28, 2037	U-4446		
		9457154	Sep 29, 2027	DP	Y	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	005	10888605	Aug 24, 2038	DP U-1852		
		11318191	Feb 17, 2041	DP U-1852		
		11318191	Feb 17, 2041	DP U-4561		
		11752198	Aug 24, 2038	DP U-1852		
		12214017	Aug 24, 2038	DP U-1852		
		12569543	Apr 28, 2037	U-4446		
		8129343	Dec 05, 2031	DS DP U-3355		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	006	10888605	Aug 24, 2038	DP U-1852		
		11318191	Feb 17, 2041	DP U-1852		
		11318191	Feb 17, 2041	DP U-4561		
		11752198	Aug 24, 2038	DP U-1852		
		12214017	Aug 24, 2038	DP U-1852		
		12569543	Apr 28, 2037	U-4446		
		8129343	Dec 05, 2031	DS DP U-3355		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	007	10335462	Jun 21, 2033	U-1852		
		10888605	Aug 24, 2038	DP U-1852		
		11318191	Feb 17, 2041	DP U-1852		
		11318191	Feb 17, 2041	DP U-4561		
		11752198	Aug 24, 2038	DP U-1852		
		12214017	Aug 24, 2038	DP U-1852		
		12295988	Oct 10, 2038	U-1852		
		12569543	Apr 28, 2037	U-4446		
		8129343	Dec 05, 2031	DS DP U-3355		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	001	11033499	Jun 19, 2033	DP U-2628		
		12514822	May 02, 2034	U-2628		
		12594326	Mar 15, 2033	DP		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	002	11033499	Jun 19, 2033	DP U-2628		
		12514822	May 02, 2034	U-2628		
		12594326	Mar 15, 2033	DP		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	003	11033499	Jun 19, 2033	DP U-2628		
		12514822	May 02, 2034	U-2628		
		12594326	Mar 15, 2033	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 213051 004	11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 213051 005	11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 213051 006	11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12551536	Oct 10, 2038	U-4418			
<u>SEMAGLUTIDE - WEGOVY HD</u>						
N 215256 006	10888605	Aug 24, 2038	DP U-4418		NS	Mar 19, 2029
	11318191	Feb 17, 2041	DP U-4418			
	11752198	Aug 24, 2038	DP U-4418			
	12029779	Oct 10, 2038	U-4418			
	12214017	Aug 24, 2038	DP U-4418			
	12551536	Oct 10, 2038	U-4418			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-4418			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 007	10888605	Aug 24, 2038	DP U-3162			
	11318191	Feb 17, 2041	DP U-3162			
	11318191	Feb 17, 2041	DP U-4443			
	11318191	Feb 17, 2041	DP U-4560			
	11478533	May 13, 2040	U-3861			
	11752198	Aug 24, 2038	DP U-3162			
	12029779	Oct 10, 2038	U-3162			
	12214017	Aug 24, 2038	DP U-3162			
	12551536	Oct 10, 2038	U-4418			
	12569543	Apr 28, 2037	U-4443			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 008	10888605	Aug 24, 2038	DP U-3162			
	11318191	Feb 17, 2041	DP U-3162			
	11318191	Feb 17, 2041	DP U-4443			
	11318191	Feb 17, 2041	DP U-4560			
	11478533	May 13, 2040	U-3861			
	11752198	Aug 24, 2038	DP U-3162			
	12029779	Oct 10, 2038	U-3162			
	12214017	Aug 24, 2038	DP U-3162			
	12551536	Oct 10, 2038	U-4418			
	12569543	Apr 28, 2037	U-4443			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 009	10888605	Aug 24, 2038	DP U-3162			
	11318191	Feb 17, 2041	DP U-3162			
	11318191	Feb 17, 2041	DP U-4443			
	11318191	Feb 17, 2041	DP U-4560			
	11478533	May 13, 2040	U-3861			
	11752198	Aug 24, 2038	DP U-3162			
	12029779	Oct 10, 2038	U-3162			
	12214017	Aug 24, 2038	DP U-3162			
	12551536	Oct 10, 2038	U-4418			
	12569543	Apr 28, 2037	U-4443			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-3161			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 009	10888605	Aug 24, 2038	DP U-3162			
	11318191	Feb 17, 2041	DP U-3162			
	11318191	Feb 17, 2041	DP U-4443			
	11318191	Feb 17, 2041	DP U-4560			
	11478533	May 13, 2040	U-3861			
	11752198	Aug 24, 2038	DP U-3162			
	12029779	Oct 10, 2038	U-3162			
	12214017	Aug 24, 2038	DP U-3162			
	12551536	Oct 10, 2038	U-4418			
	12569543	Apr 28, 2037	U-4443			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 010	10888605	Aug 24, 2038	DP U-3162			
	11318191	Feb 17, 2041	DP U-3162			
	11318191	Feb 17, 2041	DP U-4443			
	11318191	Feb 17, 2041	DP U-4560			
	11478533	May 13, 2040	U-3861			
	11752198	Aug 24, 2038	DP U-3162			
	12029779	Oct 10, 2038	U-3162			
	12214017	Aug 24, 2038	DP U-3162			
	12551536	Oct 10, 2038	U-4418			
	12569543	Apr 28, 2037	U-4443			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 011	10888605	Aug 24, 2038	DP U-3162			
	11318191	Feb 17, 2041	DP U-3162			
	11318191	Feb 17, 2041	DP U-4443			
	11318191	Feb 17, 2041	DP U-4560			
	11478533	May 13, 2040	U-3861			
	11752198	Aug 24, 2038	DP U-3162			
	12029779	Oct 10, 2038	U-3162			
	12214017	Aug 24, 2038	DP U-3162			
	12551536	Oct 10, 2038	U-4418			
	12569543	Apr 28, 2037	U-4443			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY FLEXTOUCH</u>						
N 215256 012	11478533	May 13, 2040	U-3861		I-935	Mar 08, 2027
	12029779	Oct 10, 2038	U-3162		I-973	Aug 15, 2028
	12551536	Oct 10, 2038	U-4418			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 001	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
	11382957	Dec 16, 2031	DP			
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 002	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
	11382957	Dec 16, 2031	DP			
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 002	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
	11382957	Dec 16, 2031	DP			
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 003	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
	11382957	Dec 16, 2031	DP			
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9278123	Dec 16, 2031	DP U-4389			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 004	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
	11382957	Dec 16, 2031	DP			
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9278123	Dec 16, 2031	DP U-4389			
<u>SEPIAPTERIN - SEPHIENCE</u>						
N 219666 001					ODE-542	Jul 28, 2032
<u>SEPIAPTERIN - SEPHIENCE</u>						
N 219666 002					ODE-542	Jul 28, 2032
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001					I-987	Mar 19, 2029
<u>SEVABERTINIB - HYRNUO</u>						
N 219972 001	10428063	Oct 10, 2035	DS DP			
	12679836	Nov 14, 2043	DS DP U-4582			
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 001	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 002	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 003	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 004	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	12533340	Apr 23, 2036	U-4407			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	12533340	Apr 23, 2036	U-4407			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	12533340	Apr 23, 2036	U-4407			
<u>SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE</u>						
A 202387 001					PC	Nov 24, 2026
<u>SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE</u>						
A 202387 002					PC	Nov 24, 2026
<u>SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE</u>						
A 202387 003					PC	Nov 24, 2026
<u>SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE</u>						
A 202425 001					PC	Nov 24, 2026
<u>SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE</u>						
A 202425 002					PC	Nov 24, 2026
<u>SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE</u>						
A 202425 003					PC	Nov 24, 2026
<u>SOFFIRONIUM BROMIDE - SOFDRA</u>						
N 217347 001 >A>	12703682	May 22, 2040	DS DP			
<u>SONROTOCLAX - BEQALZI</u>						
N 220711 001	11420968	Apr 29, 2039	DS DP		NCE	May 13, 2031
<u>SONROTOCLAX - BEQALZI</u>						
N 220711 002	11420968	Apr 29, 2039	DS DP		NCE	May 13, 2031
<u>SONROTOCLAX - BEQALZI</u>						
N 220711 003	11420968	Apr 29, 2039	DS DP		NCE	May 13, 2031
<u>SONROTOCLAX - BEQALZI</u>						
N 220711 004	11420968	Apr 29, 2039	DS DP		NCE	May 13, 2031
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	12569183	Apr 05, 2039	U-4456			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 001	9662312	Mar 29, 2030	U-4495		I-989	Apr 13, 2029
	9993461	Mar 29, 2030	U-3269			
	9993461	Mar 29, 2030	U-3993			
	9993461	Mar 29, 2030	U-4495			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 002	9662312	Mar 29, 2030	U-4495		I-989	Apr 13, 2029
	9993461	Mar 29, 2030	U-3269			
	9993461	Mar 29, 2030	U-3993			
	9993461	Mar 29, 2030	U-4495			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	12599610	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	12599610	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	12599610	May 29, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	12599610	May 29, 2033	DP			
<u>TADALAFIL - TADLIO</u>						
N 214522 001	12691120	Dec 24, 2038	DP U-3397			
	12697338	Dec 24, 2038	DP U-3397			
	>A> 12708626	Dec 24, 2038	DP U-3397			
	>A> 12721849	Dec 24, 2038	DP U-3397			
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	12616689	Dec 02, 2035	U-2582			
<u>TALETRECTINIB ADIPATE - IBTROZI</u>						
N 219713 001					ODE-544	Jun 11, 2032
<u>TAPINAROF - VTAMA</u>						
N 215272 001	10195160	May 23, 2036	DP			
	12569453	Dec 18, 2039	U-4048			
<u>TEBIPENEM PIVOXIL HYDROBROMIDE - UTEBZI</u>						
N 215960 001	10889587	Feb 06, 2038	DS DP U-4570		NCE	Jun 17, 2031
	12226403	Dec 15, 2037	DP U-4569		GAIN	Jun 17, 2036
<u>TECHNETIUM TC-99M LABELED CARBON - TECHNEGAS KIT</u>						
N 022335 001	7722856	Feb 24, 2031	U-4442			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 001	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 003	12539299	Nov 26, 2042	DP			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001					NPP	Mar 27, 2027
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	12629483	Aug 07, 2035	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	12629483	Aug 07, 2035	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	12629483	Aug 07, 2035	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	12605391	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	12605391	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	12605391	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	>A> 12691057	Apr 28, 2041	DP U-4194			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THIOTEPA - TEPADINA AND SODIUM CHLORIDE</u>						
N 208264 004	9931458	May 31, 2037	DP			
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 001	12622921	Aug 16, 2041	U-4530			
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 002	12622921	Aug 16, 2041	U-4530			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	12667576	Mar 12, 2038	U-4577			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 001	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 002	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 003	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 003	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 004	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 005	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 005	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 006	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 013	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	9474780	May 13, 2036	DS DP U-4374			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 013	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 014	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 015	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 016	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 017	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12616740	Jul 22, 2039	U-4502			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 017	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 018	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 019	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 020	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 021	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 022	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 022	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 023	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 024	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	9474780	May 13, 2036	DS DP U-4374			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 013	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 014	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 014	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 015	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 016	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 017	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 018	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 019	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 019	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 020	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 021	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 022	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	9474780	May 13, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 023	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	9474780	May 13, 2036	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 024	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	9474780	May 13, 2036	DS DP			
<u>TRABECTEDIN - EVDI</u>						
N 220837 001	12303506	Feb 18, 2043	DP			
<u>TRADIPITANT - NEREUS</u>						
N 220152 001	10772880	Mar 04, 2036	U-4396			
	10821099	Mar 04, 2036	U-4396			
	11324735	Mar 04, 2036	U-4396			
	12318375	Aug 09, 2036	U-4396			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 001	7199162	Oct 12, 2026	U-4142			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 002	7199162	Oct 12, 2026	U-4142			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	>A> 12679811	Mar 14, 2034	U-1849			
	>A> 12679811	Mar 14, 2034	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	>A> 12679811	Mar 14, 2034	U-1849			
	>A> 12679811	Mar 14, 2034	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	>A> 12679811	Mar 14, 2034	U-1849			
	>A> 12679811	Mar 14, 2034	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	>A> 12679811	Mar 14, 2034	U-1849			
	>A> 12679811	Mar 14, 2034	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 005	>A> 12679811	Mar 14, 2034	U-1849			
	>A> 12679811	Mar 14, 2034	U-3749			
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001	12662445	May 03, 2039	DS DP U-4262			
<u>TRIHEPTANOIN - DOJOLVI</u>						
N 213687 001	12551461	Nov 14, 2034	DP			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	12527798	Dec 05, 2037	U-3504			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE-425	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 002	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 003	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROSPIMUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 001	12558317	Oct 29, 2039	DP			
<u>TROSPIMUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 002	12558317	Oct 29, 2039	DP			
<u>TROSPIMUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 003	12558317	Oct 29, 2039	DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	8648087	Apr 17, 2034	DS DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	8648087	Apr 17, 2034	DS DP			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	12570664	Oct 17, 2036	U-4454		ODE-538	Apr 28, 2032
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	12569474	Jun 04, 2034	U-3876			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	12569474	Jun 04, 2034	U-3876			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	12569474	Jun 04, 2034	U-3876			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	12576080	Oct 19, 2035	U-1900			
	12653824	Oct 19, 2035	DP			
<u>VEPDEGESTRANT - VEPPANU</u>						
N 219835 001	10647698	Jan 30, 2038	DS DP		NCE	May 01, 2031
	10899742	Dec 01, 2037	U-4278			
	11597720	Dec 01, 2037	DS DP U-4278			
<u>VEPDEGESTRANT - VEPPANU</u>						
N 219835 002	10647698	Jan 30, 2038	DS DP		NCE	May 01, 2031
	10899742	Dec 01, 2037	U-4278			
	11597720	Dec 01, 2037	DS DP U-4278			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001					D-198	Jan 21, 2029
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002					D-198	Jan 21, 2029
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003					D-198	Jan 21, 2029
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	12576054	Jun 08, 2043	DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 001	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	12551483	Dec 06, 2044	DP			
	12582655	Dec 23, 2039	U-4145			
	12617775	Dec 06, 2044	DS DP			
	12643883	Dec 06, 2044	DS DP			
	12686672	Apr 30, 2045	DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 002	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	12551483	Dec 06, 2044	DP			
	12582655	Dec 23, 2039	U-4145			
	12617775	Dec 06, 2044	DS DP			
	12643883	Dec 06, 2044	DS DP			
	12686672	Apr 30, 2045	DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 003	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	12551483	Dec 06, 2044	DP			
	12582655	Dec 23, 2039	U-4145			
	12617775	Dec 06, 2044	DS DP			
	12643883	Dec 06, 2044	DS DP			
	12686672	Apr 30, 2045	DP			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	7332472	Oct 17, 2027	DS DP U-3056			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001	7977488	Apr 10, 2030	DS			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 002	7977488	Apr 10, 2030	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	12514906	Aug 01, 2036	DP U-3927			
	8198242	Jun 11, 2035	DS DP U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	12514906	Aug 01, 2036	DP U-3927			
	8198242	Jun 11, 2035	DS DP U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	12514906	Aug 01, 2036	DP U-3927			
	8198242	Jun 11, 2035	DS DP U-3927			
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					ODE-527	Mar 20, 2032
<u>ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET</u>						
N 216386 001	8481546	Jun 26, 2034	DS DP U-3555			
<u>ZIDESAMTINIB - JIDEYTRO</u>						
N 220185 001	11542278	May 05, 2041	DS DP		>A> NCE	Jul 22, 2031
	12043626	Sep 30, 2042	DS DP			
	12054498	May 05, 2041	U-4579			
	12630560	Sep 30, 2042	U-4579			
<u>ZIDESAMTINIB - JIDEYTRO</u>						
N 220185 002	11542278	May 05, 2041	DS DP		>A> NCE	Jul 22, 2031
	12043626	Sep 30, 2042	DS DP			
	12054498	May 05, 2041	U-4579			
	12630560	Sep 30, 2042	U-4579			
<u>ZIFTOMENIB - KOMZIFTI</u>						
N 220305 001	12521396	Jul 16, 2044	DP			
<u>ZOLIFLODACIN - NUZOLVENCE</u>						
N 219491 001	8658641	Jun 20, 2030	DS			
	8889671	Jan 21, 2034	DS	U-4369		
	9040528	Oct 13, 2029		U-4369		
	9187495	Jan 21, 2034	DS	U-4369		
	9540394	Jan 21, 2034		U-4369		
	9839641	Jan 21, 2034		U-4369		
<u>ZONISAMIDE - ZONISADE</u>						
N 214273 001	12685723	Aug 18, 2038	DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 46TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm